

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number
WO 01/10903 A2(51) International Patent Classification⁷: C07K 14/00

(21) International Application Number: PCT/US00/21878

(22) International Filing Date: 9 August 2000 (09.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/147,986 9 August 1999 (09.08.1999) US
60/160,807 21 October 1999 (21.10.1999) US(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
US 60/147,986 (CIP)
Filed on 9 August 1999 (09.08.1999)
US 60/160,807 (CIP)
Filed on 21 October 1999 (21.10.1999)

(71) Applicant (for all designated States except US): INCYTE GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043

(US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). YANG, Junming [CN/US]; 7125 Bark Lane, San Jose, CA 95129 (US).

(74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/10903 A2

(54) Title: PROTEASES AND PROTEASE INHIBITORS

(57) Abstract: The invention provides human proteases and protease inhibitors (PPIM) and polynucleotides which identify and encode PPIM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of PPIM.

PROTEASES AND PROTEASE INHIBITORS

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of proteases and protease
5 inhibitors and to the use of these sequences in the diagnosis, treatment, and prevention of cell
proliferative and autoimmune/inflammatory disorders.

BACKGROUND OF THE INVENTION

Proteolytic processing is an essential component of normal cell growth, differentiation,
10 remodeling, and homeostasis. The cleavage of peptide bonds within cells is necessary for the maturation
of precursor proteins to their active forms, the removal of signal sequences from targeted proteins, the
degradation of incorrectly folded proteins, and the controlled turnover of peptides within the cell.
Proteases participate in apoptosis, inflammation, and tissue remodeling during embryonic development,
wound healing, and normal growth. They are necessary components of bacterial, parasitic, and viral
15 invasion and replication within a host. Four principal categories of mammalian proteases have been
identified based on active site structure, mechanism of action, and overall three-dimensional structure.
(See Beynon, R.J. and J.S. Bond (1994) Proteolytic Enzymes: A Practical Approach, Oxford University
Press, New York NY, pp. 1-5.)

The serine proteases (SPs) are a large family of proteolytic enzymes that include the digestive
20 enzymes, trypsin and chymotrypsin; components of the complement cascade and of the blood-clotting
cascade; and enzymes that control the degradation and turnover of macromolecules of the extracellular
matrix. SPs are so named because of the presence of a serine residue found in the active catalytic site for
protein cleavage. The active site of all SPs is composed of a triad of residues including the
aforementioned serine, an aspartate, and a histidine residue. SPs have a wide range of substrate
25 specificities and can be subdivided into subfamilies on the basis of these specificities. The main sub-
families are trypases which cleave after arginine or lysine; aspases which cleave after aspartate;
chymases which cleave after phenylalanine or leucine; metases which cleavage after methionine; and
serases which cleave after serine. Clp protease is a unique member of the serine protease family as its
activity is controlled by a regulatory subunit that binds and hydrolyzes ATP. Clp protease was
30 originally found in plant chloroplasts but is believed to be widespread in both prokaryotic and eukaryotic
cells (Maurizi, M.R. et al. (1990) J. Biol. Chem. 265:12546-12552). SKD3, a mammalian homolog of
the bacterial Clp regulatory subunit, has recently been identified in mouse (Perier, F. et al. (1995) Gene
152:157-163).

Cysteine proteases are involved in diverse cellular processes ranging from the processing of
35 precursor proteins to intracellular degradation. Mammalian cysteine proteases include lysosomal

cathepsins and cytosolic calcium activated proteases, calpains. Of particular note, cysteine proteases are produced by monocytes, macrophages and other cells of the immune system which migrate to sites of inflammation and in their protective role secrete various molecules to repair damaged tissue. These cells may overproduce the same molecules and cause tissue destruction in certain disorders. In autoimmune diseases such as rheumatoid arthritis, the secretion of the cysteine protease, cathepsin C, degrades collagen, laminin, elastin and other structural proteins found in the extracellular matrix of bones. The cathepsin family of lysosomal proteases includes the cysteine proteases: cathepsins B, H, K, L, O₂, and S; and the aspartyl proteases; cathepsins D and G. Various members of this endosomal protease family are differentially expressed. Some, such as cathepsin D, have a ubiquitous tissue distribution while others, such as cathepsin L, are found only in monocytes, macrophages, and other cells of the immune system.

Aspartic proteases include bacterial penicillopepsin, mammalian pepsin, renin, chymosin, and certain fungal proteases. The characteristic active site residues of aspartic proteases are a pair of aspartic acid residues, for example, Asp33 and Asp213 in penicillopepsin. Aspartic proteases are also called acid proteases because the optimum pH for their activity is between 2 and 3. In this pH range, one of the aspartate residues is ionized and the other is neutral. A potent inhibitor of aspartic proteases is the hexapeptide pepstatin which, in the transition state, resembles normal substrates.

Carboxypeptidases A and B are the principal mammalian representatives of the metallo-protease family. Both are exopeptidases of similar structure and active site configuration. Carboxypeptidase A, like chymotrypsin, prefers C-terminal aromatic and aliphatic side chains of hydrophobic nature, whereas carboxypeptidase B is directed toward basic arginine and lysine residues. Active site components include zinc, which coordinates two glutamic acid and one histidine residues in the protein.

Ubiquitin proteases are associated with the ubiquitin conjugation system (UCS), a major pathway for the degradation of cellular proteins in eukaryotic cells and some bacteria. The UCS mediates the elimination of abnormal proteins and regulates the half-lives of important regulatory proteins that control cellular processes such as gene transcription and cell cycle progression. In the UCS pathway, proteins targeted for degradation are conjugated to a ubiquitin, a small heat stable protein. The ubiquitinated protein is then recognized and degraded by proteasome, a large, multisubunit proteolytic enzyme complex, and ubiquitin is released for reutilization by ubiquitin protease. The UCS is implicated in the degradation of mitotic cyclic kinases, oncoproteins, tumor suppressor genes such as p53, viral proteins, cell surface receptors associated with signal transduction, transcriptional regulators, and mutated or damaged proteins (Ciechanover, A. (1994) *Cell* 79:13-21). A murine proto-oncogene, Unp, encodes a nuclear ubiquitin protease whose overexpression leads to oncogenic transformation of NIH3T3 cells, and the human homolog of this gene is consistently elevated in small cell tumors and adenocarcinomas of the lung (Gray, D.A. (1995) *Oncogene* 10:2179-2183).

Protease inhibitors and other regulators of protease activity control the activity and effects of proteases. Protease inhibitors have been shown to control pathogenesis in animal models of proteolytic disorders (Murphy, G. (1991) Agents Actions Suppl. 35:69-76). Low levels of the cystatins, low molecular weight inhibitors of the cysteine proteases, correlate with malignant progression of tumors
5 (Calkins, C. et al (1995) Biol. Biochem. Hoppe Seyler 376:71-80).

The plasma inter- α -trypsin inhibitor family molecules are serine protease inhibitors (serpins) composed of a 240 kDa plasma protein complex of at least five different types of glycoproteins. These glycoproteins consist of four heavy (H) chains and one 30 kDa light (L) chain named H1, H2, H3, H4, and L, and are independently synthesized and proteolytically processed from precursor proteins (Daveau,
10 M. et al. (1998) Arch. Biochem. Biophys. 350:315-323; and Salier, J.P. et al. (1992) Mamm. Genome 2:233-239). The plasma inter- α -trypsin inhibitor light chains have sequence similarity to the Kunitz trypsin inhibitors which appear to be present in all vertebrates (Salier, J.P. (1990) Trends Biochem. Sci. 15:435-439). Some examples of the Kunitz trypsin inhibitors are tissue factor pathway inhibitor, which regulates tissue factor-induced coagulation, and protease nexin-2, which regulates serum coagulation
15 factor XIa. (Broze, G.J. (1995) Annu. Rev. Med. 46:103-112; and Wagner, S.L. et al. (1993) Brain Res. 626:90-98). The heavy chain precursors encode a signal peptide sequence and the mature chain. Other plasma inter- α -trypsin inhibitor heavy chains have been described in human and rodents (Bourguignon, J. et al. (1993) Eur. J. Biochem. 212:771-776; Salier, 1992, *supra*; and Salier, J.P. (1996) Biochem. J. 315:1-9). The expression of the rat plasma inter- α -trypsin inhibitor genes is regulated by inflammation
20 *in vivo*. The genes are predominantly expressed in the rat liver, but H2 and H3 mRNA is also present in brain, intestine, and stomach (Daveau, *supra*).

Kallistatins are members of the serine protease inhibitor family. Kallistatin forms a specific and covalently-linked complex with tissue kallikrein, which is a serine proteinase capable of cleaving kininogen to release vasoactive kinin. Components of the tissue kallikrein-kinin system include tissue
25 kallikrein, kallistatin, kininogen, kinin, bradykininB1 and B2 receptors, and kininases (Chao, J. and L. Chao (1995) Biol. Chem. Hoppe Seyler 376:705-713).

Proteases and protease inhibitory molecules may contain amino acid sequence motifs which determine protein-protein interactions, such as the potential metal-binding site of von Willebrand factor type A3 (vWFA3) motif, glycine-amino acid-serine-amino acid-serine. This motif is also required for
30 ligand interaction in the homologous I-type domains of integrins CR3 and LFA-1 (Huizinga, E.G. (1997) Structure 5:1147-1156).

Protease inhibitors play a major role in the regulation of the activity and effect of proteases. They have been shown to control pathogenesis in animal models of proteolytic disorders and in the treatment of HIV (Murphy, G. (1991) Agents Actions Suppl. 35:69-76; and Pakyz, A. and D. Israel
35 (1997) J. Am. Pharm. Assoc. (Wash.) NS37:543-551).

The discovery of new proteases and protease inhibitors and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative and autoimmune/inflammatory disorders.

5

SUMMARY OF THE INVENTION

The invention features purified polypeptides, proteases and protease inhibitors, referred to collectively as "PPIM" and individually as "PPIM-1," "PPIM-2," "PPIM-3," "PPIM-4," "PPIM-5," "PPIM-6," "PPIM-7," "PPIM-8," "PPIM-9," "PPIM-10," "PPIM-11," "PPIM-12," "PPIM-13," "PPIM-14," "PPIM-15," "PPIM-16," "PPIM-17," "PPIM-18," "PPIM-19," "PPIM-20," "PPIM-21," 10 "PPIM-22," "PPIM-23," "PPIM-24," "PPIM-25," "PPIM-26," and "PPIM-27." In one aspect, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, and d) an immunogenic 15 fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-27. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-27.

The invention further provides an isolated polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, b) a naturally occurring amino acid sequence having at least 90% 20 sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-27. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-27. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:28-54.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide comprising an amino acid sequence 30 selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1- 35 27. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In

another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-27. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-27.

The invention further provides an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions

whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

- 5 The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54, c) a
- 10 polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

- The invention further provides a composition comprising an effective amount of a polypeptide
- 15 comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, and d) an immunogenic fragment of an amino acid sequence selected
- 20 from the group consisting of SEQ ID NO:1-27, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-27. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional PPIM, comprising administering to a patient in need of such treatment the composition.

- 25 The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, c) a biologically active fragment of an amino acid sequence selected
- 30 from the group consisting of SEQ ID NO:1-27, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-27. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a
- 35 method of treating a disease or condition associated with decreased expression of functional PPIM,

comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, b) a naturally occurring
5 amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-27. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in
10 the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional PPIM, comprising administering to a patient in need of such treatment the composition.

15 The invention further provides a method of screening for a compound that specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, c) a biologically active fragment of an amino acid sequence selected
20 from the group consisting of SEQ ID NO:1-27, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-27. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

25 The invention further provides a method of screening for a compound that modulates the activity of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-27, c) a biologically active fragment of an amino
30 acid sequence selected from the group consisting of SEQ ID NO:1-27, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-27. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the
35 test compound with the activity of the polypeptide in the absence of the test compound, wherein a

change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:28-54, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54, ii) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54, ii) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

Table 1 shows polypeptide and nucleotide sequence identification numbers (SEQ ID NOs), clone identification numbers (clone IDs), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding PPIM.

Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods, algorithms, and searchable databases used for analysis of PPIM.

Table 3 shows selected fragments of each nucleic acid sequence; the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis; diseases, disorders, or conditions associated with these tissues; and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones
5 encoding PPIM were isolated.

Table 5 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

10 Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

15 It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings
20 as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in
25 connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"PPIM" refers to the amino acid sequences of substantially purified PPIM obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human,
30 and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of PPIM. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of PPIM either by directly interacting with PPIM or by acting on components of the biological pathway in which PPIM participates.

35 An "allelic variant" is an alternative form of the gene encoding PPIM. Allelic variants may

result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides.

- 5 Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

- “Altered” nucleic acid sequences encoding PPIM include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as PPIM or a polypeptide with at least one functional characteristic of PPIM. Included within this definition are
- 10 polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding PPIM, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding PPIM. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent PPIM. Deliberate
- 15 amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of PPIM is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include:
- 20 asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

- The terms “amino acid” and “amino acid sequence” refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic
- 25 molecules. Where “amino acid sequence” is recited to refer to a sequence of a naturally occurring protein molecule, “amino acid sequence” and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

- “Amplification” relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in
- 30 the art.

- The term “antagonist” refers to a molecule which inhibits or attenuates the biological activity of PPIM. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of PPIM either by directly interacting with PPIM or by acting on components of the biological pathway in which PPIM
- 35 participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind PPIM polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic PPIM, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution.

Compositions comprising polynucleotide sequences encoding PPIM or fragments of PPIM may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (PE Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
20	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
	Asp	Asn, Glu
	Cys	Ala, Ser
25	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
	Gly	Ala
	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
30	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
35	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the

side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide. Chemical
5 modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

10 A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

A "fragment" is a unique portion of PPIM or the polynucleotide encoding PPIM which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a
15 fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected
20 from the first 250 or 500 amino acids (or first 25% or 50% of a polypeptide) as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:28-54 comprises a region of unique polynucleotide sequence that
25 specifically identifies SEQ ID NO:28-54, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:28-54 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:28-54 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:28-54 and the region of SEQ ID NO:28-54 to which the fragment corresponds are routinely
30 determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-27 is encoded by a fragment of SEQ ID NO:28-54. A fragment of SEQ ID NO:1-27 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-27. For example, a fragment of SEQ ID NO:1-27 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-27. The precise length of a
35 fragment of SEQ ID NO:1-27 and the region of SEQ ID NO:1-27 to which the fragment corresponds

are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full-length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full-length" polynucleotide sequence encodes a "full-length" polypeptide sequence.

"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gort/bl2.html>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

35 *Matrix: BLOSUM62*

Reward for match: 1

Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

5 *Expect: 10*

Word Size: 11

Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the
10 length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

15 Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the
20 percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

25 Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with
30 polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (Apr-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

35 *Matrix: BLOSUM62*

Open Gap: 11 and Extension Gap: 1 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 3

5 *Filter: on*

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150
10 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

“Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for
15 chromosome replication, segregation and maintenance.

The term “humanized antibody” refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

“Hybridization” refers to the process by which a polynucleotide strand anneals with a
20 complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e.,
25 binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v)
30 SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target
35 sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for

nucleic acid hybridization are well known and can be found in Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C₀t or R₀t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of PPIM which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of PPIM which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of PPIM. For example, modulation may

cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of PPIM.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an PPIM may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of PPIM.

"Probe" refers to nucleic acid sequences encoding PPIM, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example

Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived
5 from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000
10 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program
15 (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public
20 from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful
25 in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This
30 artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant
35 nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding PPIM, or fragments thereof, or PPIM itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels

and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

"Transformation" describes a process by which exogenous DNA is introduced into a recipient
5 cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells
10 includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid
15 introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or *in vitro* fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic
20 organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants, and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook, J. et al. (1989), *supra*.

25 A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater
30 sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species
35 variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides

generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

The invention is based on the discovery of new human proteases and protease inhibitors (PPIM), the polynucleotides encoding PPIM, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative and autoimmune/inflammatory disorders.

Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding PPIM. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte clones in which nucleic acids encoding each PPIM were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. In some cases, GenBank sequence identifiers are also shown in column 5. The Incyte clones and GenBank cDNA sequences, where indicated, in column 5 were used to assemble the consensus nucleotide sequence of each PPIM and are useful as fragments in hybridization technologies.

The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3 shows potential phosphorylation sites; column 4 shows potential glycosylation sites; column 5 shows the amino acid residues comprising signature sequences and motifs; column 6 shows homologous sequences as identified by BLAST analysis; and column 7 shows analytical methods and in some cases, searchable databases to which the analytical methods were applied. The methods of column 7 were used to characterize each polypeptide through sequence homology and protein motifs.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding PPIM. The first column of Table 3 lists the nucleotide SEQ ID NOs. Column 2 lists fragments of the nucleotide sequences of column 1. These fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:28-54 and

to distinguish between SEQ ID NO:28-54 and related polynucleotide sequences. The polypeptides encoded by the selected fragments of SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, 5 SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, and SEQ ID NO:54 are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express PPIM as a fraction of total tissues expressing PPIM. Column 4 lists diseases, disorders, or conditions associated with those tissues expressing PPIM as a fraction of total tissues expressing PPIM. Column 5 lists the vectors used to subclone each cDNA 10 library. Of particular note is the expression of SEQ ID NO:28 in gastrointestinal tissue. Of particular note is the tissue-specific expression of SEQ ID NO:51. Over 83% of the tissues expressing SEQ ID NO:51 are derived from gastrointestinal tissue, particularly the liver.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding PPIM were isolated. Column 1 references the nucleotide SEQ ID 15 NOs, column 2 shows the cDNA libraries from which these clones were isolated, and column 3 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

SEQ ID NO:30 maps to chromosome 9 within the interval from 78.4 to 90.6 centiMorgans. This interval also contains a gene associated with cell proliferation.

SEQ ID NO:37 maps to chromosome 12 within the interval from 116.6 to 118.9 centiMorgans. 20 This interval also contains a gene associated with a neurological disorder.

SEQ ID NO:47 maps to chromosome 4 within the interval from 99.2 to 105.2 centiMorgans. This interval also contains a gene associated with cardiovascular disease.

The invention also encompasses PPIM variants. A preferred PPIM variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence 25 identity to the PPIM amino acid sequence, and which contains at least one functional or structural characteristic of PPIM.

The invention also encompasses polynucleotides which encode PPIM. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:28-54, which encodes PPIM. The polynucleotide sequences of SEQ 30 ID NO:28-54, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding PPIM. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least 35 about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence

encoding PPIM. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:28-54 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:28-54. Any one of the
5 polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of PPIM.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding PPIM, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the
10 invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring PPIM, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode PPIM and its variants are generally capable of
15 hybridizing to the nucleotide sequence of the naturally occurring PPIM under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding PPIM or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons
20 are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding PPIM and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode PPIM and PPIM
25 derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding PPIM or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing
30 to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:28-54 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the
35 embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA

polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (PE Biosystems, Foster City CA), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (PE Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (PE Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding PPIM may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library

does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, PE Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled.

10 Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode PPIM may be cloned in recombinant DNA molecules that direct expression of PPIM, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express PPIM.

15

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter PPIM-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

20

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Cramer, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of PPIM, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be

25

30

35 recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively,

fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding PPIM may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) *Nucleic Acids Symp. Ser.* 7:215-223; Horn, T. et al. (1980) *Nucleic Acids Symp. Ser.* 7:225-232.) Alternatively, PPIM itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) *Science* 269:202-204.) Automated synthesis may be achieved using the ABI 431 A peptide synthesizer (PE Biosystems). Additionally, the amino acid sequence of PPIM, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

In order to express a biologically active PPIM, the nucleotide sequences encoding PPIM or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding PPIM. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding PPIM. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding PPIM and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding PPIM and appropriate transcriptional and translational control

elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

- 5 A variety of expression vector/host systems may be utilized to contain and express sequences encoding PPIM. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco
- 10 mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; Scorer, C.A. et al. (1994) Bio/Technology 12:181-184; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO
- 15 J. 6:307-311; Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia
- 20 viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell
- 25 employed.

- In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding PPIM. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding PPIM can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid
- 30 (Life Technologies). Ligation of sequences encoding PPIM into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of PPIM are needed, e.g. for the production of antibodies,
- 35

vectors which direct high level expression of PPIM may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of PPIM. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, supra; and Scorer, supra.)

Plant systems may also be used for expression of PPIM. Transcription of sequences encoding PPIM may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, supra; Broglie, supra; and Winter, supra.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding PPIM may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses PPIM in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of PPIM in cell lines is preferred. For example, sequences encoding PPIM can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue

culture techniques appropriate to the cell type.

- Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk*⁻ and *apr*⁻ cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; 5 Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) 10 Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of 15 transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

- Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding PPIM is inserted within a marker gene sequence, transformed cells containing 20 sequences encoding PPIM can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding PPIM under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

- In general, host cells that contain the nucleic acid sequence encoding PPIM and that express 25 PPIM may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

- Immunological methods for detecting and measuring the expression of PPIM using either 30 specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on PPIM is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) 35 Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al.

(1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization
5 or PCR probes for detecting sequences related to polynucleotides encoding PPIM include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding PPIM, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6
10 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

15 Host cells transformed with nucleotide sequences encoding PPIM may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode PPIM may be designed to contain signal sequences which direct secretion
20 of PPIM through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the
25 protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

30 In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding PPIM may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric PPIM protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of PPIM activity. Heterologous protein and peptide moieties
35 may also facilitate purification of fusion proteins using commercially available affinity matrices. Such

moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the PPIM encoding sequence and the heterologous protein sequence, so that PPIM may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled PPIM may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

PPIM of the present invention or fragments thereof may be used to screen for compounds that specifically bind to PPIM. At least one and up to a plurality of test compounds may be screened for specific binding to PPIM. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of PPIM, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which PPIM binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express PPIM, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing PPIM or cell membrane fractions which contain PPIM are then contacted with a test compound and binding, stimulation, or inhibition of activity of either PPIM or the compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with PPIM, either in solution or affixed to a solid support, and detecting the binding of PPIM to the compound. Alternatively, the

assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

PPIM of the present invention or fragments thereof may be used to screen for compounds that
5 modulate the activity of PPIM. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for PPIM activity, wherein PPIM is combined with at least one test compound, and the activity of PPIM in the presence of a test compound is compared with the activity of PPIM in the absence of the test compound. A change in the activity of PPIM in the presence of the test compound is indicative of a
10 compound that modulates the activity of PPIM. Alternatively, a test compound is combined with an in vitro or cell-free system comprising PPIM under conditions suitable for PPIM activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of PPIM may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

15 In another embodiment, polynucleotides encoding PPIM or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent No. 5,175,383 and U.S. Patent No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and
20 grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D.
25 (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

30 Polynucleotides encoding PPIM may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

35 Polynucleotides encoding PPIM can also be used to create "knockin" humanized animals

(pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding PPIM is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with
 5 potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress PPIM, e.g., by secreting PPIM in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) *Biotechnol. Annu. Rev.* 4:55-74).

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between
 10 regions of PPIM and proteases and protease inhibitors. In addition, the expression of PPIM is closely associated with cell proliferation, inflammation, the immune response, and gastrointestinal, neurological, and reproductive tissue. Therefore, PPIM appears to play a role in cell proliferative and autoimmune/inflammatory disorders. In the treatment of disorders associated with increased PPIM expression or activity, it is desirable to decrease the expression or activity of PPIM. In the treatment of
 15 disorders associated with decreased PPIM expression or activity, it is desirable to increase the expression or activity of PPIM.

Therefore, in one embodiment, PPIM or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PPIM. Examples of such disorders include, but are not limited to, a cell proliferative disorder, such as actinic
 20 keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle,
 25 ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis,
 30 cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis,
 35 psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic

anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma.

In another embodiment, a vector capable of expressing PPIM or a fragment or derivative thereof
5 may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PPIM including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified PPIM in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PPIM including, but not limited to, those provided
10 above.

In still another embodiment, an agonist which modulates the activity of PPIM may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PPIM including, but not limited to, those listed above.

In a further embodiment, an antagonist of PPIM may be administered to a subject to treat or
15 prevent a disorder associated with increased expression or activity of PPIM. Examples of such disorders include, but are not limited to, those cell proliferative and autoimmune/inflammatory disorders described above. In one aspect, an antibody which specifically binds PPIM may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express PPIM.

20 In an additional embodiment, a vector expressing the complement of the polynucleotide encoding PPIM may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PPIM including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate
25 therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

30 An antagonist of PPIM may be produced using methods which are generally known in the art. In particular, purified PPIM may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind PPIM. Antibodies to PPIM may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab
35 expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally

preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with PPIM or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to PPIM have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of PPIM amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to PPIM may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce PPIM-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for PPIM may also be generated. For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin digestion

of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab)₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

5 Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between PPIM and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two
10 non-interfering PPIM epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for PPIM. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of PPIM-antibody complex divided by the
15 molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple PPIM epitopes, represents the average affinity, or avidity, of the antibodies for PPIM. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular PPIM epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12}
20 L/mole are preferred for use in immunoassays in which the PPIM-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of PPIM, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical
25 Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of PPIM-antibody
30 complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al., supra.)

In another embodiment of the invention, the polynucleotides encoding PPIM, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene
35 expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA,

PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding PPIM. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding PPIM. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

- 5 In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995) 10 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 15 25(14):2730-2736.)

- In another embodiment of the invention, polynucleotides encoding PPIM may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked 20 inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) *Science* 270:475-480; Bordignon, C. et al. (1995) *Science* 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) *Cell* 75:207-216; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:643-666; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:667-703), thalassemias, familial 25 hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) *Science* 270:404-410; Verma, I.M. and N. Somia (1997) *Nature* 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) *Nature* 335:395-396; Poeschla, E. et al. (1996) *Proc. Natl. Acad. Sci. USA.* 93:11395-11399), hepatitis B or C 30 virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in PPIM expression or regulation causes disease, the expression of PPIM from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic 35 deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in PPIM are treated by constructing mammalian expression vectors encoding PPIM and introducing these vectors by mechanical means into PPIM-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle
 5 delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) *Annu. Rev. Biochem.* 62:191-217; Ivics, Z. (1997) *Cell* 91:501-510; Boulay, J-L. and H. Récipon (1998) *Curr. Opin. Biotechnol.* 9:445-450).

Expression vectors that may be effective for the expression of PPIM include, but are not limited to, the pCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA),
 10 PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). PPIM may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) *Proc. Natl. Acad. Sci. USA* 89:5547-
 15 5551; Gossen, M. et al. (1995) *Science* 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) *Curr. Opin. Biotechnol.* 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and H.M. Blau, supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene
 20 encoding PPIM from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and
 25 A.J. Eb (1973) *Virology* 52:456-467), or by electroporation (Neumann, E. et al. (1982) *EMBO J.* 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to PPIM expression are treated by constructing a retrovirus vector consisting of (i) the
 30 polynucleotide encoding PPIM under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) *Proc. Natl. Acad. Sci.*
 35 *USA* 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate

vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) *J. Virol.* 61:1647-1650; Bender, M.A. et al. (1987) *J. Virol.* 61:1639-1646; Adam, M.A. and A.D. Miller (1988) *J. Virol.* 62:3802-3806; Dull, T. et al. (1998) *J. Virol.* 72:8463-8471; Zufferey, R. et al. (1998) *J. Virol.* 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) *J. Virol.* 71:7020-7029; Bauer, G. et al. (1997) *Blood* 89:2259-2267; Bonyhadi, M.L. (1997) *J. Virol.* 71:4707-4716; Ranga, U. et al. (1998) *Proc. Natl. Acad. Sci. USA* 95:1201-1206; Su, L. (1997) *Blood* 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding PPIM to cells which have one or more genetic abnormalities with respect to the expression of PPIM. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) *Transplantation* 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) *Annu. Rev. Nutr.* 19:511-544; and Verma, I.M. and N. Somia (1997) *Nature* 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding PPIM to target cells which have one or more genetic abnormalities with respect to the expression of PPIM. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing PPIM to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) *Exp. Eye Res.* 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction

and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding PPIM to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full-length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for PPIM into the alphavirus genome in place of the capsid-coding region results in the production of a large number of PPIM-coding RNAs and the synthesis of high levels of PPIM in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of PPIM into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme

molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding PPIM.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by
5 scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using
10 ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences
15 encoding PPIM. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of
20 the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

25 An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding PPIM. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular
30 chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased PPIM expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding PPIM may be therapeutically useful, and in the treatment of disorders associated with
35 decreased PPIM expression or activity, a compound which specifically promotes expression of the

polynucleotide encoding PPIM may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in
5 altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding PPIM is exposed to at least one test compound thus obtained. The sample may comprise, for
10 example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding PPIM are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding PPIM. The amount of hybridization may be quantified, thus forming the
15 basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al.
20 (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al.
25 (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using
30 methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

35 An additional embodiment of the invention relates to the administration of a composition which

generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of PPIM, antibodies to PPIM, and mimetics, agonists, antagonists, or inhibitors of PPIM.

The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising PPIM or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, PPIM or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example PPIM or fragments thereof, antibodies of PPIM, and agonists, antagonists or inhibitors of PPIM, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by

standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

10 The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μ g to 100,000 μ g, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind PPIM may be used for the diagnosis of disorders characterized by expression of PPIM, or in assays to monitor patients being treated with PPIM or agonists, antagonists, or inhibitors of PPIM. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for PPIM include methods which utilize the antibody and a label to detect PPIM in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring PPIM, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of PPIM expression. Normal or standard values for PPIM expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibody to PPIM under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by

various methods, such as photometric means. Quantities of PPIM expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding PPIM may be used for
5 diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of PPIM may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of PPIM, and to monitor regulation of PPIM levels during therapeutic intervention.

10 In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding PPIM or closely related molecules may be used to identify nucleic acid sequences which encode PPIM. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the
15 probe identifies only naturally occurring sequences encoding PPIM, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the PPIM encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:28-54 or from genomic sequences including promoters, enhancers, and introns of the PPIM gene.

20 Means for producing specific hybridization probes for DNAs encoding PPIM include the cloning of polynucleotide sequences encoding PPIM or PPIM derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups,
25 for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding PPIM may be used for the diagnosis of disorders associated with expression of PPIM. Examples of such disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed
30 connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate,
35 salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and an autoimmune/inflammatory

disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic
5 dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid
10 arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma. The polynucleotide sequences encoding PPIM may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR
15 technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered PPIM expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding PPIM may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide
20 sequences encoding PPIM may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding PPIM in the sample indicates the
25 presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of PPIM, a normal or standard profile for expression is established. This may be accomplished by combining body
30 fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding PPIM, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from
35 patients who are symptomatic for a disorder. Deviation from standard values is used to establish the

presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays
5 may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ
10 preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding PPIM may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding PPIM, or
15 a fragment of a polynucleotide complementary to the polynucleotide encoding PPIM, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences
20 encoding PPIM may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding PPIM are used to amplify DNA using the polymerase chain reaction
25 (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally,
30 sequence database analysis methods, termed *in silico* SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass
35 spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San

Diego CA).

Methods which may also be used to quantify the expression of PPIM include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described in Seilhamer, J.J. et al., "Comparative Gene Transcript Analysis," U.S. Patent No. 5,840,484, incorporated herein by reference. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, antibodies specific for PPIM, or PPIM or fragments thereof may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies,

or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of
5 pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to
10 that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The
15 normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at
20 <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present
25 invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present
30 invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the
35 polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-

dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, *supra*). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as

5 Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard

10 methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for PPIM to quantify the

15 levels of PPIM expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) *Anal. Biochem.* 270:103-111; Mendoze, L.G. et al. (1999) *Biotechniques* 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-

20 reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) *Electrophoresis* 18:533-537), so proteome toxicant signatures may be useful in the

25 analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological

30 sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

35 In another embodiment, the toxicity of a test compound is assessed by treating a biological

sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding PPIM may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, e.g., Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding PPIM on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal

associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to
5 that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, PPIM, its catalytic or immunogenic fragments, or
10 oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between PPIM and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds
15 having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with PPIM, or fragments thereof, and washed. Bound PPIM is then detected by methods well known in the art. Purified PPIM can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively,
20 non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding PPIM specifically compete with a test compound for binding PPIM. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PPIM.

25 In additional embodiments, the nucleotide sequences which encode PPIM may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding
30 description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, in particular U.S. Ser. No. 60/147,986 and U.S. Ser. No. 60/160,807, are hereby expressly incorporated by
35 reference.

EXAMPLES

I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, *supra*, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), pcDNA2.1 plasmid (Invitrogen, Carlsbad CA), or pINCY plasmid (Incyte Genomics, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by *in vivo* excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled

water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows.

Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (PE Biosystems) thermal cyclor or the PTC-200 thermal cyclor (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (PE Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (PE Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VI.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences

and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and PFAM to acquire annotation

5 using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the

10 GenBank databases (described above), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and

15 amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:28-54. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

IV. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene

20 and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much

25 faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum} \{ \text{length}(\text{Seq. 1}), \text{length}(\text{Seq. 2}) \}}$$

30

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a

35 score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every

mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding PPIM occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation, trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

V. Chromosomal Mapping of PPIM Encoding Polynucleotides

The cDNA sequences which were used to assemble SEQ ID NO:28-54 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:28-54 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 5). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO., to that map location.

The genetic map locations of SEQ ID NO:30, SEQ ID NO:37, and SEQ ID NO:47 are described in The Invention as ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. A disease associated with the public and Incyte sequences located within the indicated interval is also reported in the Invention.

VI. Extension of PPIM Encoding Polynucleotides

The full length nucleic acid sequences of SEQ ID NO:28-54 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other
5 primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

10 Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and β -
15 mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2:
20 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar,
25 Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested
30 with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with
35 Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E.*

coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC
10 DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (PE Biosystems).

In like manner, the polynucleotide sequences of SEQ ID NO:28-54 are used to obtain 5' regulatory sequences using the procedure above, along with oligonucleotides designed for such extension, and an appropriate genomic library.

15 VII. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:28-54 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National
20 Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ -³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human
25 genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under
30 conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

VIII. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing
35 photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra), mechanical

microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Skena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Skena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

Tissue or Cell Sample Preparation

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ μ l oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/ μ l RNase inhibitor, 500 μ M dATP, 500 μ M dGTP, 500 μ M dTTP, 40 μ M dCTP, 40 μ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 μ l 5X SSC/0.2% SDS.

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 µg.

5 Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated
10 with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incorporated herein by reference. 1 µl of the array element DNA, at an average concentration of 100 ng/µl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

15 Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

20 Hybridization

Hybridization reactions contain 9 µl of sample mixture consisting of 0.2 µg each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly
25 larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 µl of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

Detection

30 Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-
35 scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a

resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate
5 filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a
10 cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed,
15 the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a
20 linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot
25 is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

IX. Complementary Polynucleotides

Sequences complementary to the PPIM-encoding sequences, or any parts thereof, are used to
30 detect, decrease, or inhibit expression of naturally occurring PPIM. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of PPIM. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent
35 promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is

designed to prevent ribosomal binding to the PPIM-encoding transcript.

X. Expression of PPIM

Expression and purification of PPIM is achieved using bacterial or virus-based expression systems. For expression of PPIM in bacteria, cDNA is subcloned into an appropriate vector containing
5 an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express PPIM upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of
10 PPIM in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding PPIM by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA
15 transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, PPIM is synthesized as a fusion protein with, e.g., glutathione S-
20 transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from PPIM at
25 specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified PPIM obtained by these methods can be used directly in the assays shown in Examples XI and
30 XV.

XI. Demonstration of PPIM Activity

Protease activity of PPIM is measured by the hydrolysis of appropriate synthetic peptide substrates conjugated with various chromogenic molecules. The degree of hydrolysis is quantified by spectrophotometric (or fluorometric) absorption of the released chromophore (Beynon, R.J. and J.S.

Bond (1994) Proteolytic Enzymes: A Practical Approach, Oxford University Press, New York NY, pp.25-55). Peptide substrates are designed according to the category of protease activity as endopeptidase (serine, cysteine, aspartic proteases), aminopeptidase (leucine aminopeptidase), or carboxypeptidase (Carboxypeptidase A and B, procollagen C-proteinase). Chromogens commonly used
5 are 2-naphthylamine, 4-nitroaniline, and furylacrylic acid. Assays are performed at ambient temperature using an aliquot of PPIM and the appropriate substrate in a suitable buffer. Reactions are carried out in an optical cuvette and followed by the measurement of increase/decrease in absorbance of the chromogen released during hydrolysis of the peptide substrate. The change in absorbance is proportional to PPIM activity in the assay.

10 XII. Functional Assays

PPIM function is assessed by expressing the sequences encoding PPIM at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT plasmid (Life Technologies) and pCR3.1 plasmid (Invitrogen), both of which
15 contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector.
20 Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA
25 content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the
30 cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of PPIM on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding PPIM and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin
35 G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads

coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding PPIM and other genes of interest can be analyzed by northern analysis or microarray techniques.

5 XIII. Production of PPIM Specific Antibodies

PPIM substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the PPIM amino acid sequence is analyzed using LASERGENE software
10 (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A
15 peptide synthesizer (PE Biosystems) using Fmoc chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for anti-peptide and anti-PPIM activity by, for example, binding the peptide or PPIM to a substrate, blocking with 1% BSA, reacting
20 with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XIV. Purification of Naturally Occurring PPIM Using Specific Antibodies

Naturally occurring or recombinant PPIM is substantially purified by immunoaffinity chromatography using antibodies specific for PPIM. An immunoaffinity column is constructed by covalently coupling anti-PPIM antibody to an activated chromatographic resin, such as CNBr-activated
25 SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing PPIM are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PPIM (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/PPIM binding (e.g.,
30 a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and PPIM is collected.

XV. Identification of Molecules Which Interact with PPIM

PPIM, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) Candidate molecules

previously arrayed in the wells of a multi-well plate are incubated with the labeled PPIM, washed, and any wells with labeled PPIM complex are assayed. Data obtained using different concentrations of PPIM are used to calculate values for the number, affinity, and association of PPIM with the candidate molecules.

- 5 Alternatively, molecules interacting with PPIM are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989, Nature 340:245-246), or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

PPIM may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions
10 between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention.

- 15 Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Polypeptide SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	28	088718	LIVRNOT01	088718H1(LIVRNOT01), 151754F1 (FIBRAGT01), 151754R1 (FIBRAGT01), SCEA00861V1, SCEA01403V1, SCEA03107V1, SCEA01683V1
2	29	114551	TESTNOT01	1273531F1 (TESTTUT02), 1498122F1 (SINTBST01), 1686926F6 (PROSNOT15), 1922870R6 (BRSTTUT01), 2270121R6 (UTRSNOT02), 3227104F6 (COTRNOT01)
3	30	1261376	SYNORAT05	428341R6 (BLADNOT01), 488402R6 (HNT2AGT01), 1261376H1 (SYNORAT05), 1261376T6 (SYNORAT05), 1413230F6 (BRAINT012), 1448134F1 (PLACNOT02), 1869342F6 (SKINBIT01), 2263303H1 (UTRSNOT02), 2365444T6 (ADRENOT07), 2875019H1 (THYRNOT10), 2908347H1 (THYMNOT05), 3818352H1 (BONSTUT01), g3840298, g1965665, g848456
4	31	1299481	BRSTNOT07	1299481H1 (BRSTNOT07), 1302262F6 (PLACNOT02), 1596742X330D1 (BRAINT014), 1725693F6 (PROSNOT14), 2125677X306D3 (BRSTNOT07), SCHA02258V1, SCHA00613V1, g1477302
5	32	1873139	LEUKNOT02	003818R1 (HMCINOT01), 1873139F6 (LEUKNOT02), 1873139X325D1 (LEUKNOT02), 1873139X326V1 (LEUKNOT02), 1899870F6 (BLADTUT06), 2510118F6 (CONUTUT01)
6	33	1903112	OVARNOT07	1903112H1 (OVARNOT07), 1905330T6 (OVARNOT07), 2509325H1 (CONUTUT01), 2621121R6 (KERANOT02)
7	34	1993044	CORPNOT02	1858513F6 (PROSNOT18), 1993044H1 (CORPNOT02), 3733554F6 (SMCCNOS01), 4749046H1 (SMCRUNT01), 4960159H1 (TLYMNOT05), 5397428H1 (LIVRTUT13), SBCA07095F3
8	35	2292182	BRAINON01	2199554H1 (SPLNFET02), 2199554X305B1 (SPLNFET02), 2292182R6 (BRAINT01), 3480414T6 (OVARNOT11), 5427954H1 (THYMTUT03)
9	36	2331301	COLNNOT11	1253717H1 (LUNGFET03), 2331301H1 (COLNNOT11), 2331301R6 (COLNNOT11)
10	37	2517512	BRAITUT21	1222614R1 (COLNUT02), 1486943F6 (UCMCL5T01), 1486943T6 (UCMCL5T01), 1569195F1 (UTRSNOT05), 1813007F6 (PROSTUT12), 2517512H1 (BRAITUT21), 5847584H1 (BRAENOT04)
11	38	3489039	EPIGNOT01	2541141F6 (BONRTUT01), 3489039H1 (EPIGNOT01), 4871852H1 (COLDNOT01)

Table 1 (cont.)

Polypeptide SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
12	39	5432879	SPLNOT17	1429082F6 (SINTBST01), 1807480F6 (SINTNOT13), 2303440H1 (BRSTNOT05), 2669584F6 (ESOGTUT02), 3073745H1 (BONEUNT01), 3190142R6 (THYMNON04), 4693457H2 (BRAENOT02), 4774453H1 (BRAQNOT01), 5432879H1 (SPLNOT17), 9836070
13	40	5853753	FIBAUNT02	834033T1 (PROSNOT07), 1521711F6 (BLADTUT04), 1757751R6 (PITUNOT03), 2161634F6 (ENDCNOT02), SAEA01666R1, SCGA11716V1, SCGA05971V1, SCGA07285V1
14	41	411344	BRSTNOT01	411344F1 (BRSTNOT01), 411344H1 (BRSTNOT01), 411344R1 (BRSTNOT01), 1859850F6 (PROSNOT18), 2183379F6 (SINTNOT01), 2474963H1 (SMCANOT01), 2546619X300D1 (UTRSNOT11), 3728811H1 (SMCCNON03), 3932959H1 (PROSTUT09)
15	42	1256390	MENITUT03	1256390H1 (MENITUT03), SBAA04311F1, SBAA04104F1, SBAA03263F1, SBAA01188F1
16	43	1786774	BRAINOT10	857246H1 (NGANNOT01), 1786774F6 (BRAINOT10), 1786774H1 (BRAINOT10), 1810671T6 (PROSTUT12), 5202653H1 (STOMNOT08)
17	44	1911808	CONNTUT01	1255942F6 (MENITUT03), 1354692F6 (LUNGNOT09), 1354692T1 (LUNGNOT09), 1418156T1 (KIDNNOT09), 1436123F6 (PANCNOT08), 1498302T1 (SINTBST01), 1735923X304D1 (COLNNOT22), 1735923X318D4 (COLNNOT22), 1834236R6 (BRAINON01), 1911808F6 (CONNTUT01), 1911808H1 (CONNTUT01), 2360308H1 (LUNGFET05), 3075823H1 (BONEUNT01), 4106766H1 (BRSTTUT17), 5713020H1 (MASTTUT01)
18	45	1973875	UCMCL5T01	1220149R6 (NEUTGMT01), 1377281F1 (LUNGNOT10), 1377281T1 (LUNGNOT10), 1508502F6 (LUNGNOT14), 1973875H1 (UCMCL5T01), 5098879F6 (EPIMNON05)
19	46	2323917	OVARNOT02	1609987F6 (COLNTUT06), 2012426R6 (TESTNOT03), 2012426T6 (TESTNOT03), 2323917H1 (OVARNOT02), 2323917T6 (OVARNOT02), 4851027H1 (TESTNOT10)
20	47	2754960	THPIAZS08	039061R6 (HUVENOB01), 580098H1 (BRAVTXT05), 2025465H1 (KERANOT02), 2754960H1 (THPIAZS08), 2754960R6 (THPIAZS08), 2754960X11F1 (THPIAZS08), 2754960X15F1 (THPIAZS08), 2754960X310U1 (THPIAZS08), 2754960X50F1 (THPIAZS08), 3821989T6 (BONSTUT01), g3736615

Table 1 (cont.)

Polypeptide SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
21	48	3092341	BRSTNOT19	3092341H1 (BRSTNOT19), 3092341T6 (BRSTNOT19)
22	49	3658034	ENDPNOT02	2623516R6 (KERANOT02), 3658034F6 (ENDPNOT02), 3658034H1 (ENDPNOT02), 3658034T6 (ENDPNOT02), 5216522H1 (BRSTNOT35), 5590053H1 (ENDINOT02)
23	50	3883861	UTRSNOT05	858111H1 (NGANNOT01), 858233H1 (NGANNOT01), 1364808R1 (SCORNON02), 1861181F6 (PROSNOT19), 1906985T6 (OVARNOT07), 2687868H1 (LJUNGNOT23), 2687868X366D1 (LUNGNOT23), 2721116X369D1 (LUNGTUT10), 3883861H1 (UTRSNOT05), 5217169H1 (BRSTNOT35)
24	51	4993873	LIVRTUT11	4987943H1 (LIVRTUT10), 4993873H1 (LIVRTUT11), SCEA01665V1, SCEA00232V1, SXBC01625V1, SXBC01802V1, SCSA03627V1
25	52	5208004	BRAFNOT02	4696870F6 (BRALNOT01), 5208004H1 (BRAFNOT02)
26	53	5267783	BRAFDIT02	220636R1 (STOMNOT01), 679457R6 (UTRSNOT02), 1330537F6 (PANCNOT07), 1808720F6 (PROSTUT12), 1969475H1 (BRSTNOT04), 2697426F6 (UTRSNOT12), 2991180H1 (KIDNFET02), 3532849H1 (KIDNNOT25), 4992376F6 (LIVRTUT11), 5004695F6 (PROSTUT21), 5267783H1 (BRAFDIT02)
27	54	5583922	FIBAUNT01	726878R1 (SYNOOAT01), 956818X11 (KIDNNOT05), 1658964X12 (URETTUT01), 1658964X13 (URETTUT01), 2544879F6 (UTRSNOT11), 3748858H1 (UTRSNOT18), 4761921H1 (PLACNOT05), 5043801H1 (PLACFER01)

Table 2

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Homologous Sequence	Analytical Methods and Databases
1	444	S91 T244 T251 S277 T386 T38 S182 T263 T373 Y346	N36 N180 N197 N295	Signal_peptide: M1-A23 Serpins (serine protease inhibitors): M1-P441, L68-L444	g1397241 RASP1	Motifs BLAST-GenBank HMMER SPScan HMMER-PFAM BLIMPS-BLOCKS ProfileScan BLAST_PRODOR BLAST_DOMO
2	565	S9 S19 T343 T458 S5 S58 S82 S114 S184 S185 S295 T382 T432 T476 T495 T543 S2 S5 S12 S25 S42 T169 S307 T337 S352 T357 T426 S513 T523 Y220 Y514	N112 N494	Ubiquitin carboxyl-terminal hydrolases family 2: G226-L243, Y235-I549	g2746775 Similar to peptidase family C19 (ubiquitin carboxyl-terminal peptidase)	Motifs BLAST-GenBank HMMER-PFAM BLIMPS-BLOCKS BLAST_PRODOR BLAST_DOMO
3	589	T43 S71 S181 S200 S260 S304 S312 T506 T572 T40 S66	N55 N126 N136 N164 N167 N302 N501	Ubiquitin family signature: M37-K107 Ubiquitin-associated domain: Q541-S586	g3873621 Similar to ubiquitin family	Motifs BLAST-GenBank HMMER-PFAM
4	775	T305 T2 S27 S43 S67 S392 S611 S615 T647 S665 S710 S729 S759 S96 T106 S217 S288 S301 S316 S432 S438 T443 S575 T719 S723 Y334	N49 N215 N322 N387 N468 N487 N497 N504 N508 N568 N600	Ubiquitin carboxyl-terminal hydrolases family 2: G112-L129, G193-L202, V230-C244, Y354-V391, N380-S401 Ubiquitin hydrolase carboxyl-terminal thiolesterase: G112-K211	g2739431 Hematopoietic-specific IL-2 deubiquitinating enzyme	Motifs BLAST-GenBank HMMER-PFAM BLIMPS-BLOCKS BLAST_PRODOR BLAST_DOMO

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Homologous Sequence	Analytical Methods and Databases
5	351	S9 S41 S48 S194 S201 T203 T257 S278 T322 T324 S129 S162 S181 S194 S225 T226 S348 Y271	N46 N123 N317	Ubiquitin carboxyl-terminal hydrolases family 2: L49-L337	g5410230 Ubiquitin-specific protease 3	Motifs BLAST-GenBank HMMER-PFAM BLIMPS-BLOCKS BLAST-PRODOM BLAST-DOMO
6	136	T30 S104 Y98		Dipeptidyl serine protease iv: I9-S128 Serine family prolyl endopeptidase: M4-I136	g577284 Dipeptidyl peptidase IV	Motifs BLAST-GenBank BLAST-PRODOM BLAST-DOMO
7	396	S24 S139 T168 T177 S198 S223 S279 T369 S26 S60 S223 S292	N166	Ubiquitin carboxyl-terminal hydrolase: E74-I283	g2854121 BRCA1 associated protein 1	Motifs BLAST-GenBank BLIMPS-PRINTS BLAST-PRODOM BLAST-DOMO HMMER-PFAM
8	246	S87 Y65	N94 N156 N195 N225	Zinc-binding metalloprotease domain: R121-H133		Motifs HMMER-PFAM
9	262	T32 S78 S85 T89 S125 S26 S170 S244	N168	Inter-alpha-trypsin glycoprotein inhibitor precursor: T32-T197		Motifs BLAST-PRODOM
10	406	S18 S37 T80 S98 S112 S178 T292 S298 T320 T391 S105 S212 S220 Y213	N14 N56 N176 N318		g3309170 COP9 complex subunit 4	Motifs BLAST-GenBank

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Homologous Sequence	Analytical Methods and Databases
11	172	T117 S135 S146		signal peptide motif: M1-G13 ATP-binding kinase: I6-E164 AAA-protein family: P4-M69	g3875433 Similar to ATP binding protein	Motifs BLAST-GenBank SPScan BLAST-PRODOM BLAST-DOMO
12	517	S485 S4 T11 S128 T133 S155 S156 S171 S172 S278 T288 S485 S3 T57 T199 T204 S278 T455 S462 T480	N286	Ubiquitin carboxyl-terminal hydrolases family 2: K61-P256, F436-V481, S470-S491	g2459395 Ubiquitin protease	Motifs BLAST-GenBank HMMER-PFAM BLIMPS-BLOCKS BLAST-PRODOM
13	346	T237 S12 T64 T72 T124 T236 T261 S319 S150 T194 S226 T251 S319		Ubiquitin-activating enzyme signature: S297-344, 11-163, 19-189, 7-174, 9-192, R35-G170 Membrane protein: 11-249	g3647283 Ubiquitin activating enzyme	Motifs BLAST-GenBank HMMER BLAST-PRODOM BLAST-DOMO
14	151	T24 T47 S118 S61 Y131		Ubiquitin-conjugating enzymes: M1-D148 Active site: F58-M115	g4090259 Ubiquitin-conjugating enzyme E2	Motifs BLAST-GenBank HMMER-PFAM ProfileScan BLAST-PRODOM BLAST-DOMO
15	362	S199 S208 S212 S270 S281 T317 S327 S52 S122 T149	N120 N162 N175 N239	Signal peptide: M1-S26 Zinc carboxypeptidase: Y38-E320 Zinc binding region: E202-L258	g6013463 Carboxypeptidase homolog	Motifs BLAST-GenBank SPScan HMMER-PFAM ProfileScan BLAST-PRODOM BLAST-DOMO

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Homologous Sequence	Analytical Methods and Databases
16	123	S2 S9 T37 T46 T60 S112 T53 S112	N104	Kunitz type protease inhibitor active site region: C70-C120	g512802 Kunitz type protease inhibitor	Motifs BLAST-GenBank HMMER-PFAM ProfileScan BLAST-DOMO
17	983	S87 S461 S531 T761 T123 T143 S191 S445 S634 S660 T789 T820 S879 S886 S888 T890 T17 S158 T280 T398 T549 S598 S601 S687 Y268 Y688	N278 N427 N625 N884 N922	Ubiquitin carboxyl-terminal hydrolases family 2: G90-w107, Y336-I374	g1429371 Ubiquitin-specific protease	Motifs BLAST-GenBank HMMER-PFAM BLAST-DOMO
18	227	S49 T101 T131 T157 S166 S49 S144 S194 T199		Ubiquitin signature: K159-H179, A180-D200 (P value = 0.00032)	g9372 Ubiquitin (P value = 1.7e ⁻⁰⁸)	Motifs BLAST-GenBank BLIMPS-PRINTS
19	403	T47 S146 T261 T352 T381 S4 T119 S234 S291 S313	N117 N145 N232 N260 N289 N317	Ubiquitin carboxyl-terminal hydrolases family 2: G221-L238	g4731026 Nod1 activator of caspase-9 and NFkB	Motifs BLAST-GenBank HMMER-PFAM
20	372	T87 S291 S22 S197 T208 S343 T169 S185 S223 S260 T266	N188 N335	Ubiquitin carboxyl-terminal hydrolases family 2: A166-Q348 Active site: Y302-C320 Signal peptidase: V41-R55	g4469352 Ubiquitin specific protease UBP43	Motifs BLAST-GenBank HMMER-PFAM BLAST-DOMO
21	94	T9	N50		g3687497 Putative mitochondrial inner membrane protease subunit	Motifs BLAST-GenBank

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Homologous Sequence	Analytical Methods and Databases
22	248	S77 S135 S156 S183 S205 T3 S71 S72 T139	N47 N158	Alpha-2-macroglobulin family: T3-Y198 Complement precursor: E4-S206	g2073373 Alpha-2-macroglobulin protease inhibitor	Motifs BLAST-GenBank HMMER-PFAM BLAST-PRODOM
23	520	S166 S272 T301 S326 S379 S455 S56 T82 S136 S227 S498	N164 N355	Signal peptide: M1-R27 Peptidase M10: F39-S225 Matrixin domain: F128-G288 Neutral zinc metalloproteinase binding region: V237-L246 Hemopexin domain: I341-K400	g1731986 MMP-19 matrix metalloproteinase	Motifs BLAST-GenBank SIGPEPT SPScan HMMER-PFAM ProfileScan BLAST-PRODOM BLAST-DOMO
24	422	T188 S156 S306 T386 S130 T176 T226 T295 S357 S365	N94 N106 N169 N350	Signal peptide: M1-G26 Transmembrane domain: F398-N418 Serpins (serine protease inhibitors): P43-V420 Protease "bait" region: A371-G422	g425146 Kallistatin	Motifs BLAST-GenBank SIGPEPT SPScan HMMER HMMER-PFAM BLIMPS-BLOCKS ProfileScan BLAST-PRODOM BLAST-DOMO
25	114	S74 S16		Eukaryotic thiol (cysteine) protease active site: R71-S114		Motifs BLAST-GenBank ProfileScan

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Homologous Sequence	Analytical Methods and Databases
26	742	T167 S186 S308 S337 S343 T360 S439 S578 S92 S172 S239 T256 T278 S329 T414 S504 S633 T656 T708 Y28 Y107 Y356		Zinc carboxypeptidases, zinc-binding regions signatures: H32-W42		Motifs BLAST-GenBank
27	734	T83 S128 S151 S223 S233 T523 S574 T616 T665 T688 T34 S122 S203 S340 T546 S547 T703	N57 N210 N220 N318 N428 N472	Signal peptide: M1-G20 Zinc carboxypeptidases: H299-Y412, W421-Y678 Enkephalin convertase: P458-V687 Zinc binding region: E478-F529	g4322263 Metallocarboxy- peptidase CPX-1	Motifs BLAST-GenBank SIGPEPT SPScan HMMER-PFAM ProfileScan BLIMPS-PRINTS BLAST-PRODOM BLAST-DOMO

Table 3

Nucleotide SEQ ID NO:	Selected Fragment	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
28	164-208	Gastrointestinal (1.000)	Inflammation (0.500)	PBLUESCRIPT
29	57-101	Reproductive (0.274) Nervous (0.202) Cardiovascular (0.119) Gastrointestinal (0.119)	Cancer (0.524) Inflammation (0.273) Cell Proliferation(0.190)	PBLUESCRIPT
30	111-155	Nervous (0.222) Reproductive (0.194) Gastrointestinal (0.139)	Cancer (0.403) Inflammation (0.361)	PSPORT1
31	921-965	Nervous (0.300) Reproductive (0.200) Cardiovascular (0.100) Dermatologic (0.100) Developmental (0.100) Gastrointestinal (0.100) Hematopoietic/Immune (0.100)	Cancer (0.400) Cell Proliferation(0.300) Neurological (0.100)	pINCY
32	809-853	Hematopoietic/Immune (0.194) Reproductive (0.239) Gastrointestinal (0.164)	Cancer (0.403) Inflammation (0.269) Cell Proliferation(0.134)	pINCY
33	273-317	Reproductive (0.500) Cardiovascular (0.125) Dermatologic (0.125) Gastrointestinal (0.125) Hematopoietic/Immune (0.125)	Cancer (0.625) Cell Proliferation(0.125) Inflammation (0.125)	pINCY
34	55-99	Nervous (0.185) Cardiovascular (0.111) Gastrointestinal (0.111)	Cancer (0.352) Inflammation (0.204) Cell Proliferation(0.204)	pINCY
35	218-262	Gastrointestinal (0.313) Hematopoietic/Immune (0.250) Reproductive (0.188)	Cancer (0.630) Cell Proliferation(0.250)	PSPORT1
36	325-369	Developmental (0.500) Gastrointestinal (0.500)	Cancer (0.500) Cell Proliferation(0.500)	PSPORT1
37	99-143	Nervous (0.198) Reproductive (0.165) Cardiovascular (0.154)	Cancer (0.374) Inflammation (0.374) Cell Proliferation(0.154)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragment	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
38	1-46	Reproductive (0.278) Gastrointestinal (0.208) Cardiovascular (0.125)	Cancer (0.347) Inflammation (0.306) Cell Proliferation (0.153)	pINCY
39	109-153	Gastrointestinal (0.280) Hematopoietic/Immune (0.200) Musculoskeletal (0.120)	Inflammation (0.440) Cancer (0.280) Cell Proliferation (0.160)	pINCY
40	489-533	Nervous (0.209) Reproductive (0.203) Gastrointestinal (0.135)	Cancer (0.473) Cell Proliferation (0.243) Inflammation (0.264)	pINCY
41	589-633	Reproductive (0.229) Cardiovascular (0.200) Gastrointestinal (0.171) Nervous (0.171)	Cancer (0.314) Cell Proliferation (0.314) Inflammation/Trauma (0.372)	PBLUESCRIPT
42	649-693	Nervous (0.250) Reproductive (0.214) Cardiovascular (0.143)	Cancer (0.500) Inflammation/Trauma (0.321) Cell Proliferation (0.179)	pINCY
43	164-208	Nervous (0.333) Gastrointestinal (0.333) Reproductive (0.333)	Cancer (0.444) Inflammation/Trauma (0.444) Neurological (0.111)	pINCY
44	271-208	Reproductive (0.226) Developmental (0.151) Nervous (0.151)	Cancer (0.377) Inflammation/Trauma (0.358) Cell Proliferation (0.321)	pINCY
45	784-828	Reproductive (0.257) Hematopoietic/Immune (0.171) Nervous (0.171)	Cancer (0.486) Inflammation/Trauma (0.486) Cell Proliferation (0.143)	PBLUESCRIPT
46	219-263	Reproductive (0.444) Gastrointestinal (0.222) Nervous (0.222)	Inflammation/Trauma (0.666) Cancer (0.222)	PSPORT1
47	597-641	Reproductive (0.364) Cardiovascular (0.212) Nervous (0.152)	Cancer (0.545) Cell Proliferation (0.242) Inflammation/Trauma (0.273)	PSPORT1

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragment	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
48	271-315	Gastrointestinal (0.278) Reproductive (0.278) Cardiovascular (0.111) Hematopoietic/Immune (0.111) Nervous (0.111)	Cancer (0.444) Inflammation/Trauma (0.555) Cell Proliferation(0.167)	pINCY
49	217-261	Hematopoietic/Immune (0.364) Reproductive (0.273)	Cell Proliferation(0.364) Inflammation/Trauma (0.364) Cancer (0.182)	pINCY
50	164-208	Reproductive (0.333) Nervous (0.222) Gastrointestinal (0.167)	Cancer (0.611) Inflammation/Trauma (0.223)	pINCY
51	388-432	Gastrointestinal (0.833) Reproductive (0.166)	Cancer (0.666) Cell Proliferation(0.166)	pINCY
52	218-262	Nervous (0.750) Hematopoietic/Immune (0.250)	Inflammation/Trauma (0.500) Neurological (0.250)	pINCY
53	325-369	Reproductive (0.289) Nervous (0.253) Gastrointestinal (0.120)	Cancer (0.410) Inflammation/Trauma (0.386) Cell Proliferation(0.145)	pINCY
54	165-209	Reproductive (0.352) Urologic (0.185) Developmental (0.130)	Cancer (0.630) Cell Proliferation(0.167) Inflammation/Trauma (0.204)	pINCY

Table 4

Polynucleotide SEQ ID NO:	Library	Library Comment
28	LIVRNOT01	Library was constructed at Stratagene, using RNA isolated from the liver tissue of a 49-year-old male.
29	TESTNOT01	Library was constructed using RNA isolated from the testicular tissue of a 37-year-old Caucasian male, who died from liver disease. Patient history included cirrhosis, jaundice, and liver failure.
30	SYNORAT05	Library was constructed using RNA isolated from the knee synovial tissue of a 62-year-old female with rheumatoid arthritis.
31	BRSTNOT07	Library was constructed using RNA isolated from diseased breast tissue removed from a 43-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated mildly proliferative fibrocystic changes with epithelial hyperplasia, papillomatosis, and duct ectasia. Pathology for the associated tumor tissue indicated invasive grade 4, nuclear grade 3 mammary adenocarcinoma with extensive comedo necrosis. Family history included epilepsy, cardiovascular disease, and type II diabetes.
32	LEUKNOT02	Library was constructed using RNA isolated from white blood cells of a 45-year-old female with blood type O+. The donor tested positive for cytomegalovirus (CMV).
33	OVARNOT07	Library was constructed using RNA isolated from left ovarian tissue removed from a 28-year-old Caucasian female during a vaginal hysterectomy and removal of the fallopian tubes and ovaries. The tissue was associated with multiple follicular cysts, endometrium in a weakly proliferative phase, and chronic cervicitis of the cervix with squamous metaplasia. Family history included benign hypertension, hyperlipidemia, and atherosclerotic coronary artery disease.
34	CORPNOT02	Library was constructed using RNA isolated from diseased corpus callosum tissue removed from the brain of a 74-year-old Caucasian male who died from Alzheimer's disease.
35	BRAINON01	Library was constructed and normalized from 4.88 million independent clones from a brain tissue library. RNA was made from brain tissue removed from a 26-year-old Caucasian male during cranioplasty and excision of a cerebral meningeal lesion. Pathology for the associated tumor tissue indicated a grade 4 oligoastrocytoma in the right fronto-parietal part of the brain.
36	COLNNOT11	Library was constructed using RNA isolated from colon tissue removed from a 60-year-old Caucasian male during a left hemicolectomy.

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Library	Library Comment
37	BRAITUT21	Library was constructed using RNA isolated from brain tumor tissue removed from the midline frontal lobe of a 61-year-old Caucasian female during excision of a cerebral meningioma. Pathology indicated subfrontal meningothelial meningioma with no atypia. One ethmoid and mucosal tissue sample indicated meningioma. Family history included cerebrovascular disease, senile dementia, hyperlipidemia, benign hypertension, atherosclerotic coronary artery disease, congestive heart failure, and breast cancer.
38	EPIGNOT01	Library was constructed using RNA isolated from epiglottic tissue removed from a 71-year-old male during laryngectomy with right parathyroid biopsy. Pathology for the associated tumor tissue indicated recurrent grade 1 papillary thyroid carcinoma.
39	SPLNNOT17	Library was constructed using polyA RNA isolated from the spleen tissue of a 2-year-old Hispanic male who died from cerebral anoxia.
40	FIBAUNT02	Library was constructed using RNA isolated from untreated aortic adventitial fibroblasts removed from a 65-year-old Caucasian female.
41	BRSTNOT01	Library was constructed using RNA isolated from the breast tissue of a 56-year-old Caucasian female who died in a motor vehicle accident.
42	MENITUT03	Library was constructed using RNA isolated from brain meningioma tissue removed from a 35-year-old Caucasian female during excision of a cerebral meningioma lesion. Pathology indicated a benign neoplasm in the right cerebellopontine angle of the brain. Patient history included hypothyroidism. Family history included myocardial infarction and breast cancer.
43	BRAINOT10	Library was constructed using RNA isolated from diseased cerebellum tissue removed from the brain of a 74-year-old Caucasian male, who died from Alzheimer's disease.
44	CONNTUT01	Library was constructed using RNA isolated from a soft tissue tumor removed from the clival area of the skull of a 30-year-old Caucasian female. Pathology indicated chondroid chordoma with neoplastic cells reactive for keratin.
45	UCMCL5T01	Library was constructed using RNA isolated from mononuclear cells obtained from the umbilical cord blood of 12 individuals. The cells were cultured for 12 days with IL-5 before RNA was obtained from the pooled lysates.
46	OVARNOT02	Library was constructed using RNA isolated from ovarian tissue removed from a 59-year-old Caucasian female who died of a myocardial infarction. Patient history included cardiomyopathy, coronary artery disease, previous myocardial infarctions, hypercholesterolemia, hypotension, and arthritis.

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Library	Library Comment
47	THPIAZS08	This subtracted THP-1 promonocyte cell line library was constructed using 5.76 million clones from a 5-aza-2'-deoxycytidine (AZ) treated THP-1 cell library. Starting RNA was made from THP-1 promonocyte cells treated for three days with 0.8 micromolar AZ. The hybridization probe for subtraction was derived from a similarly constructed library, made from RNA isolated from untreated THP-1 cells. 5.76 million clones from the AZ-treated THP-1 cell library were then subjected to two rounds of subtractive hybridization with 5 million clones from the untreated THP-1 cell library. Subtractive hybridization conditions were based on the methodologies of Swaroop et al. (1991) Nucleic Acids Res. 19:1954; and Bonaldo et al. (1996) Genome Research 6:791. THP-1 (ATCC TIB 202) is a human promonocyte line derived from peripheral blood of a 1-year-old Caucasian male with acute monocytic leukemia.
48	BRSTNOT19	Library was constructed using RNA isolated from breast tissue removed from a 67-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated residual invasive lobular carcinoma. The focus of residual invasive carcinoma was positive for both estrogen and progesterone. Patient history included depressive disorder and benign large bowel neoplasm. Family history included cerebrovascular disease, benign hypertension, congestive heart failure, and lung cancer.
49	ENDPNOT02	Library was constructed using RNA isolated from pulmonary artery endothelial cells removed from a 10-year-old Caucasian male. The cells were treated with TNF alpha and IL-1 beta 10ng/ml each for 20 hours.
50	UTRSNOT05	Library was constructed using RNA isolated from the uterine tissue of a 45-year-old Caucasian female during a total abdominal hysterectomy and total colectomy. Pathology for the associated tumor tissue indicated multiple leiomyomas of the myometrium and a grade 2 colonic adenocarcinoma of the cecum. Patient history included multiple sclerosis and mitral valve disorder. Family history included type I diabetes, cerebrovascular disease, atherosclerotic coronary artery disease, malignant skin neoplasm, hypertension, and malignant neoplasm of the colon.

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Library	Library Comment
51	LIVRTUT11	Library was constructed using 1.1 micrograms of polyA RNA isolated from a treated C3A hepatocyte cell line which is a derivative of Hep G2, a cell line derived from a hepatoblastoma removed from a 15-year-old Caucasian male. The cells were treated with phenobarbital (PB), 1mM for 48 hours. cDNA synthesis was initiated using a NotI-anchored oligo(dT) primer. Double-stranded cDNA was blunted, ligated to EcoRI adaptors, digested with NotI, size-selected, and cloned into the NotI and EcoRI sites of the pINCY vector (Incyte).
52	BRAFNOT02	The library was constructed using RNA isolated from superior frontal cortex tissue removed from a 35-year-old Caucasian male who died from cardiac failure. Pathology indicated moderate leptomeningeal fibrosis and multiple microinfarctions of the cerebral neocortex. Patient history included dilated cardiomyopathy, congestive heart failure, cardiomegaly, and an enlarged spleen and liver.
53	BRAFDIT02	The library was constructed using RNA isolated from diseased right frontal lobe tissue removed from the brain of a 57-year-old Caucasian male, who died from a cerebrovascular accident. Patient history included Huntington's disease and emphysema.
54	FIBAUNT01	Library was constructed using RNA isolated from untreated aortic adventitial fibroblasts obtained from a 48-year-old Caucasian male.

Table 5

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	PE Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	PE Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	PE Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and, if applicable, Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322.	Score=10-50 bits for PFAM hits, depending on individual protein families

Table 5 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score \geq GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

5 a) an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, and SEQ ID
10 NO:27,

b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27,

c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27, and

d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27.

30 2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, and SEQ
35 ID NO:27.

3. An isolated polynucleotide encoding a polypeptide of claim 1.
4. An isolated polynucleotide encoding a polypeptide of claim 2.
5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, and SEQ ID NO:54.
6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
7. A cell transformed with a recombinant polynucleotide of claim 6.
8. A transgenic organism comprising a recombinant polynucleotide of claim 6.
9. A method for producing a polypeptide of claim 1, the method comprising:
- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
- b) recovering the polypeptide so expressed.
10. An isolated antibody which specifically binds to a polypeptide of claim 1.
11. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:
- a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, and SEQ ID NO:54,
- b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a

- polynucleotide sequence selected from the group consisting of SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, and SEQ ID NO:54,
- c) a polynucleotide sequence complementary to a),
 - d) a polynucleotide sequence complementary to b), and
 - e) an RNA equivalent of a)-d).

12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.

13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
- b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

30

16. A composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

17. A composition of claim 16, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4,

SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27.

5

18. A method for treating a disease or condition associated with decreased expression of functional PPIM, comprising administering to a patient in need of such treatment the composition of claim 16.

10

19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

15

20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

20

21. A method for treating a disease or condition associated with decreased expression of functional PPIM, comprising administering to a patient in need of such treatment a composition of

claim 20.

22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

25

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

30

24. A method for treating a disease or condition associated with overexpression of functional PPIM, comprising administering to a patient in need of such treatment a composition of claim 23.

25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

35

- a) combining the polypeptide of claim 1 with at least one test compound under suitable

conditions, and

b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

5 26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,

b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound,
10 and

c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

15

27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:

a) exposing a sample comprising the target polynucleotide to a compound, and
20 b) detecting altered expression of the target polynucleotide.

28. A method for assessing toxicity of a test compound, said method comprising:

a) treating a biological sample containing nucleic acids with the test compound;
b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at
25 least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
c) quantifying the amount of hybridization complex; and
30 d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

SEQUENCE LISTING

<110> INCYTE GENOMICS, INC.

YUE, Henry
 TANG, Y. Tom
 BANDMAN, Olga
 LAL, Preeti
 BAUGHN, Mariah R.
 AZIMZAI, Yalda
 LU, Dyung Aina M.
 YANG, Junming

<120> PROTEASES AND PROTEASE INHIBITORS

<130> PF-0727 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/147,986; 60/160,807

<151> 1999-08-09; 1999-10-21

<160> 54

<170> PERL Program

<210> 1

<211> 444

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 088718CD1

<400> 1

Met	Lys	Val	Val	Pro	Ser	Leu	Leu	Leu	Ser	Val	Leu	Leu	Ala	Gln
1				5					10					15
Val	Trp	Leu	Val	Pro	Gly	Leu	Ala	Pro	Ser	Pro	Gln	Ser	Pro	Glu
				20					25					30
Thr	Pro	Ala	Pro	Gln	Asn	Gln	Thr	Ser	Arg	Val	Val	Gln	Ala	Pro
				35					40					45
Arg	Glu	Glu	Glu	Glu	Asp	Glu	Gln	Glu	Ala	Ser	Glu	Glu	Lys	Ala
				50					55					60
Gly	Glu	Glu	Glu	Lys	Ala	Trp	Leu	Met	Ala	Ser	Arg	Gln	Gln	Leu
				65					70					75
Ala	Lys	Glu	Thr	Ser	Asn	Phe	Gly	Phe	Ser	Leu	Leu	Arg	Lys	Ile
				80					85					90
Ser	Met	Arg	His	Asp	Gly	Asn	Met	Val	Phe	Ser	Pro	Phe	Gly	Met
				95					100					105
Ser	Leu	Ala	Met	Thr	Gly	Leu	Met	Leu	Gly	Ala	Thr	Gly	Pro	Thr
				110					115					120
Glu	Thr	Gln	Ile	Lys	Arg	Gly	Leu	His	Leu	Gln	Ala	Leu	Lys	Pro
				125					130					135
Thr	Lys	Pro	Gly	Leu	Leu	Pro	Ser	Leu	Phe	Lys	Gly	Leu	Arg	Glu
				140					145					150
Thr	Leu	Ser	Arg	Asn	Leu	Glu	Leu	Gly	Leu	Ser	Gln	Gly	Ser	Phe
				155					160					165
Ala	Phe	Ile	His	Lys	Asp	Phe	Asp	Val	Lys	Glu	Thr	Phe	Phe	Asn
				170					175					180
Leu	Ser	Lys	Arg	Tyr	Phe	Asp	Thr	Glu	Cys	Val	Pro	Met	Asn	Phe
				185					190					195
Arg	Asn	Ala	Ser	Gln	Ala	Lys	Arg	Leu	Met	Asn	His	Tyr	Ile	Asn
				200					205					210
Lys	Glu	Thr	Arg	Gly	Lys	Ile	Pro	Lys	Leu	Phe	Asp	Glu	Ile	Asn
				215					220					225
Pro	Glu	Thr	Lys	Leu	Ile	Leu	Val	Asp	Tyr	Ile	Leu	Phe	Lys	Gly

Lys	Trp	Leu	Thr	Pro	Phe	Asp	Pro	Val	Phe	Thr	Glu	Val	Asp	Thr	230	235	240
				245					250						255		
Phe	His	Leu	Asp	Lys	Tyr	Lys	Thr	Ile	Lys	Val	Pro	Met	Met	Tyr	260	265	270
				275					280						285		
Gly	Ala	Gly	Lys	Phe	Ala	Ser	Thr	Phe	Asp	Lys	Asn	Phe	Arg	Cys	290	295	300
				305					310						315		
His	Val	Leu	Lys	Leu	Pro	Tyr	Gln	Gly	Asn	Ala	Thr	Met	Leu	Val	320	325	330
				335					340						345		
Val	Leu	Met	Glu	Lys	Met	Gly	Asp	His	Leu	Ala	Leu	Glu	Asp	Tyr	350	355	360
				365					370						375		
Leu	Thr	Thr	Asp	Leu	Val	Glu	Thr	Trp	Leu	Arg	Asn	Met	Lys	Thr	380	385	390
				395					400						405		
Arg	Asn	Met	Glu	Val	Phe	Phe	Pro	Lys	Phe	Lys	Leu	Asp	Gln	Lys	410	415	420
				425					430						435		
Tyr	Glu	Met	His	Glu	Leu	Leu	Arg	Gln	Met	Gly	Ile	Arg	Arg	Ile			
				440													
Phe	Ser	Pro	Phe	Ala	Asp	Leu	Ser	Glu	Leu	Ser	Ala	Thr	Gly	Arg			
				445					450								
Asn	Leu	Gln	Val	Ser	Arg	Val	Leu	Gln	Arg	Thr	Val	Ile	Glu	Val			
				455					460								
Asp	Glu	Arg	Gly	Thr	Glu	Ala	Val	Ala	Gly	Ile	Leu	Ser	Glu	Ile			
				465					470								
Thr	Ala	Tyr	Ser	Met	Pro	Pro	Val	Ile	Lys	Val	Asp	Arg	Pro	Phe			
				475					480								
His	Phe	Met	Ile	Tyr	Glu	Glu	Thr	Ser	Gly	Met	Leu	Leu	Phe	Leu			
				485					490								
Gly	Arg	Val	Val	Asn	Pro	Thr	Leu	Leu									

<210> 2

<211> 565

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 114551CD1

<400> 2

Met	Ser	Gly	Arg	Ser	Lys	Arg	Glu	Ser	Arg	Gly	Ser	Thr	Arg	Gly	1	5	10	15
				20					25						30			
Lys	Arg	Glu	Ser	Glu	Ser	Arg	Gly	Ser	Ser	Gly	Arg	Val	Lys	Arg				
				35					40						45			
Glu	Arg	Asp	Arg	Glu	Arg	Glu	Pro	Glu	Ala	Ala	Ser	Ser	Arg	Gly				
				50					55						60			
Ser	Pro	Val	Arg	Val	Lys	Arg	Glu	Phe	Glu	Pro	Ala	Ser	Ala	Arg				
				65					70						75			
Glu	Ala	Pro	Ala	Ser	Val	Val	Pro	Phe	Val	Arg	Val	Lys	Arg	Glu				
				80					85						90			
Arg	Glu	Val	Asp	Glu	Asp	Ser	Glu	Pro	Glu	Arg	Glu	Val	Arg	Ala				
				95					100						105			
Lys	Asn	Gly	Arg	Val	Asp	Ser	Glu	Asp	Arg	Arg	Ser	Arg	His	Cys				
				110					115						120			
Pro	Tyr	Leu	Asp	Thr	Ile	Asn	Arg	Ser	Val	Leu	Asp	Phe	Asp	Phe				
				125					130						135			
Glu	Lys	Leu	Cys	Ser	Ile	Ser	Leu	Ser	His	Ile	Asn	Ala	Tyr	Ala				
				140					145						150			
Cys	Leu	Val	Cys	Gly	Lys	Tyr	Phe	Gln	Gly	Arg	Gly	Leu	Lys	Ser				
				155					160						165			
His	Ala	Tyr	Ile	His	Ser	Val	Gln	Phe	Ser	His	His	Val	Phe	Leu				
				170					175						180			
Asn	Leu	His	Thr	Leu	Lys	Phe	Tyr	Cys	Leu	Pro	Asp	Asn	Tyr	Glu				
				185					190						195			
Ile	Ile	Asp	Ser	Ser	Leu	Glu	Asp	Ile	Thr	Tyr	Val	Leu	Lys	Pro				
				200					205						210			
Thr	Phe	Thr	Lys	Gln	Gln	Ile	Ala	Asn	Leu	Asp	Lys	Gln	Ala	Lys				

Leu	Ser	Arg	Ala	Tyr	Asp	Gly	Thr	Thr	Tyr	Leu	Pro	Gly	Ile	Val
				215					220					225
Gly	Leu	Asn	Asn	Ile	Lys	Ala	Asn	Asp	Tyr	Ala	Asn	Ala	Val	Leu
				230					235					240
Gln	Ala	Leu	Ser	Asn	Val	Pro	Pro	Leu	Arg	Asn	Tyr	Phe	Leu	Glu
				245					250					255
Glu	Asp	Asn	Tyr	Lys	Asn	Ile	Lys	Arg	Pro	Pro	Gly	Asp	Ile	Met
				260					265					270
Phe	Leu	Leu	Val	Gln	Arg	Phe	Gly	Glu	Leu	Met	Arg	Lys	Leu	Trp
				275					280					285
Asn	Pro	Arg	Asn	Phe	Lys	Ala	His	Val	Ser	Pro	His	Glu	Met	Leu
				290					295					300
Gln	Ala	Val	Val	Leu	Cys	Ser	Lys	Lys	Thr	Phe	Gln	Ile	Thr	Lys
				305					310					315
Gln	Gly	Asp	Gly	Val	Asp	Phe	Leu	Ser	Trp	Phe	Leu	Asn	Ala	Leu
				320					325					330
His	Ser	Ala	Leu	Gly	Gly	Thr	Lys	Lys	Lys	Lys	Lys	Thr	Ile	Val
				335					340					345
Thr	Asp	Val	Phe	Gln	Gly	Ser	Met	Arg	Ile	Phe	Thr	Lys	Lys	Leu
				350					355					360
Pro	His	Pro	Asp	Leu	Pro	Ala	Glu	Glu	Lys	Glu	Gln	Leu	Leu	His
				365					370					375
Asn	Asp	Glu	Tyr	Gln	Glu	Thr	Met	Val	Glu	Ser	Thr	Phe	Met	Tyr
				380					385					390
Leu	Thr	Leu	Asp	Leu	Pro	Thr	Ala	Pro	Leu	Tyr	Lys	Asp	Glu	Lys
				395					400					405
Glu	Gln	Leu	Ile	Ile	Pro	Gln	Val	Pro	Leu	Phe	Asn	Ile	Leu	Ala
				410					415					420
Lys	Phe	Asn	Gly	Ile	Thr	Glu	Lys	Glu	Tyr	Lys	Thr	Tyr	Lys	Glu
				425					430					435
Asn	Phe	Leu	Lys	Arg	Phe	Gln	Leu	Thr	Lys	Leu	Pro	Pro	Tyr	Leu
				440					445					450
Ile	Phe	Cys	Ile	Lys	Arg	Phe	Thr	Lys	Asn	Asn	Phe	Phe	Val	Glu
				455					460					465
Lys	Asn	Pro	Thr	Ile	Val	Asn	Phe	Pro	Ile	Thr	Asn	Val	Asp	Leu
				470					475					480
Arg	Glu	Tyr	Leu	Ser	Glu	Glu	Val	Gln	Ala	Val	His	Lys	Asn	Thr
				485					490					495
Thr	Tyr	Asp	Leu	Ile	Ala	Asn	Ile	Val	His	Asp	Gly	Lys	Pro	Ser
				500					505					510
Glu	Gly	Ser	Tyr	Arg	Ile	His	Val	Leu	His	His	Gly	Thr	Gly	Lys
				515					520					525
Trp	Tyr	Glu	Leu	Gln	Asp	Leu	Gln	Val	Thr	Asp	Ile	Leu	Pro	Gln
				530					535					540
Met	Ile	Thr	Leu	Ser	Glu	Ala	Tyr	Ile	Gln	Ile	Trp	Lys	Arg	Arg
				545					550					555
Asp	Asn	Asp	Glu	Thr	Asn	Gln	Gln	Gly	Ala					
				560					565					

<210> 3

<211> 589

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1261376CD1

<400> 3

Met	Ala	Glu	Ser	Gly	Glu	Ser	Gly	Gly	Pro	Pro	Gly	Ser	Gln	Asp
1				5					10					15
Ser	Ala	Ala	Gly	Ala	Glu	Gly	Ala	Gly	Ala	Pro	Ala	Ala	Ala	Ala
				20					25					30
Ser	Ala	Asp	Ala	Lys	Ile	Met	Lys	Val	Thr	Val	Lys	Thr	Pro	Lys
				35					40					45
Glu	Lys	Glu	Glu	Phe	Ala	Val	Pro	Glu	Asn	Ser	Ser	Val	Gln	Gln
				50					55					60
Phe	Lys	Glu	Glu	Ile	Ser	Lys	Arg	Phe	Lys	Ser	His	Thr	Asp	Gln

	65		70		75
Leu Val Leu Ile	Phe Ala Gly Lys Ile	Leu Lys Asp Gln Asp	Thr		
	80		85		90
Leu Ser Gln His	Gly Ile His Asp Gly	Leu Thr Val His Leu	Val		
	95		100		105
Ile Lys Thr Gln	Asn Arg Pro Gln Asp	His Ser Ala Gln Gln	Thr		
	110		115		120
Asn Thr Ala Gly	Ser Asn Val Thr Thr	Ser Ser Thr Pro Asn	Ser		
	125		130		135
Asn Ser Thr Ser	Gly Ser Ala Thr Ser	Asn Pro Phe Gly Leu	Gly		
	140		145		150
Gly Leu Gly Gly	Leu Ala Gly Leu Ser	Ser Leu Gly Leu Asn	Thr		
	155		160		165
Thr Asn Phe Ser	Glu Leu Gln Ser Gln	Met Gln Arg Gln Leu	Leu		
	170		175		180
Ser Asn Pro Glu	Met Met Val Gln Ile	Met Glu Asn Pro Phe	Val		
	185		190		195
Gln Ser Met Leu	Ser Asn Pro Asp Leu	Met Arg Gln Leu Ile	Met		
	200		205		210
Ala Asn Pro Gln	Met Gln Gln Leu Ile	Gln Arg Asn Pro Glu	Ile		
	215		220		225
Ser His Met Leu	Asn Asn Pro Asp Ile	Met Arg Gln Thr Leu	Glu		
	230		235		240
Leu Ala Arg Asn	Pro Ala Met Met Gln	Glu Met Met Arg Asn	Gln		
	245		250		255
Asp Arg Ala Leu	Ser Asn Leu Glu Ser	Ile Pro Gly Gly Tyr	Asn		
	260		265		270
Ala Leu Arg Arg	Met Tyr Thr Asp Ile	Gln Glu Pro Met Leu	Ser		
	275		280		285
Ala Ala Gln Glu	Gln Phe Gly Gly Asn	Pro Phe Ala Ser Leu	Val		
	290		295		300
Ser Asn Thr Ser	Ser Gly Glu Gly Ser	Gln Pro Ser Arg Thr	Glu		
	305		310		315
Asn Arg Asp Pro	Leu Pro Asn Pro Trp	Ala Pro Gln Thr Ser	Gln		
	320		325		330
Ser Ser Ser Ala	Ser Ser Gly Thr Ala	Ser Thr Val Gly Gly	Thr		
	335		340		345
Thr Gly Ser Thr	Ala Ser Gly Thr Ser	Gly Gln Ser Thr Thr	Ala		
	350		355		360
Pro Asn Leu Val	Pro Gly Val Gly Ala	Ser Met Phe Asn Thr	Pro		
	365		370		375
Gly Met Gln Ser	Leu Leu Gln Gln Ile	Thr Glu Asn Pro Gln	Leu		
	380		385		390
Met Gln Asn Met	Leu Ser Ala Pro Tyr	Met Arg Ser Met Met	Gln		
	395		400		405
Ser Leu Ser Gln	Asn Pro Asp Leu Ala	Ala Gln Met Met Leu	Asn		
	410		415		420
Asn Pro Leu Phe	Ala Gly Asn Pro Gln	Leu Gln Glu Gln Met	Arg		
	425		430		435
Gln Gln Leu Pro	Thr Phe Leu Gln Gln	Met Gln Asn Pro Asp	Thr		
	440		445		450
Leu Ser Ala Met	Ser Asn Pro Arg Ala	Met Gln Ala Leu Leu	Gln		
	455		460		465
Ile Gln Gln Gly	Leu Gln Thr Leu Ala	Thr Glu Ala Pro Gly	Leu		
	470		475		480
Ile Pro Gly Phe	Thr Pro Gly Leu Gly	Ala Leu Gly Ser Thr	Gly		
	485		490		495
Gly Ser Ser Gly	Thr Asn Gly Ser Asn	Ala Thr Pro Ser Glu	Asn		
	500		505		510
Thr Ser Pro Thr	Ala Gly Thr Thr Glu	Pro Gly His Gln Gln	Phe		
	515		520		525
Ile Gln Gln Met	Leu Gln Ala Leu Ala	Gly Val Asn Pro Gln	Leu		
	530		535		540
Gln Asn Pro Glu	Val Arg Phe Gln Gln	Gln Leu Glu Gln Leu	Ser		
	545		550		555
Ala Met Gly Phe	Leu Asn Arg Glu Ala	Asn Leu Gln Ala Leu	Ile		
	560		565		570

Ala Thr Gly Gly Asp Ile Asn Ala Ala Ile Glu Arg Leu Leu Gly
 575 580 585
 Ser Gln Pro Ser

<210> 4
 <211> 775
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1299481CD1

<400> 4
 Met Thr Ile Val Asp Lys Ala Ser Glu Ser Ser Asp Pro Ser Ala
 1 5 10 15
 Tyr Gln Asn Gln Pro Gly Ser Ser Glu Ala Val Ser Pro Gly Asp
 20 25 30
 Met Asp Ala Gly Ser Ala Ser Trp Gly Ala Val Ser Ser Leu Asn
 35 40 45
 Asp Val Ser Asn His Thr Leu Ser Leu Gly Pro Val Pro Gly Ala
 50 55 60
 Val Val Tyr Ser Ser Ser Ser Val Pro Asp Lys Ser Lys Pro Ser
 65 70 75
 Pro Gln Lys Asp Gln Ala Leu Gly Asp Gly Ile Ala Pro Pro Gln
 80 85 90
 Lys Val Leu Phe Pro Ser Glu Lys Ile Cys Leu Lys Trp Gln Gln
 95 100 105
 Thr His Arg Val Gly Ala Gly Leu Gln Asn Leu Gly Asn Thr Cys
 110 115 120
 Phe Ala Asn Ala Ala Leu Gln Cys Leu Thr Tyr Thr Pro Pro Leu
 125 130 135
 Ala Asn Tyr Met Leu Ser His Glu His Ser Lys Thr Cys His Ala
 140 145 150
 Glu Gly Phe Cys Met Met Cys Thr Met Gln Ala His Ile Thr Gln
 155 160 165
 Ala Leu Ser Asn Pro Gly Asp Val Ile Lys Pro Met Phe Val Ile
 170 175 180
 Asn Glu Met Arg Arg Ile Ala Arg His Leu Arg Phe Gly Asn Gln
 185 190 195
 Glu Asp Ala His Glu Phe Leu Gln Tyr Thr Val Asp Ala Met Gln
 200 205 210
 Lys Ala Cys Leu Asn Gly Ser Asn Lys Leu Asp Arg His Thr Gln
 215 220 225
 Ala Thr Thr Leu Val Cys Gln Ile Phe Gly Gly Tyr Leu Arg Ser
 230 235 240
 Arg Val Lys Cys Leu Asn Cys Lys Gly Val Ser Asp Thr Phe Asp
 245 250 255
 Pro Tyr Leu Asp Ile Thr Leu Glu Ile Lys Ala Ala Gln Ser Val
 260 265 270
 Asn Lys Ala Leu Glu Gln Phe Val Lys Pro Glu Gln Leu Asp Gly
 275 280 285
 Glu Asn Ser Tyr Lys Cys Ser Lys Cys Lys Lys Met Val Pro Ala
 290 295 300
 Ser Lys Arg Phe Thr Ile His Arg Ser Ser Asn Val Leu Thr Leu
 305 310 315
 Ser Leu Lys Arg Phe Ala Asn Phe Thr Gly Gly Lys Ile Ala Lys
 320 325 330
 Asp Val Lys Tyr Pro Glu Tyr Leu Asp Ile Arg Pro Tyr Met Ser
 335 340 345
 Gln Pro Asn Gly Glu Pro Ile Val Tyr Val Leu Tyr Ala Val Leu
 350 355 360
 Val His Thr Gly Phe Asn Cys His Ala Gly His Tyr Phe Cys Tyr
 365 370 375
 Ile Lys Ala Ser Asn Gly Leu Trp Tyr Gln Met Asn Asp Ser Ile
 380 385 390
 Val Ser Thr Ser Asp Ile Arg Ser Val Leu Ser Gln Gln Ala Tyr

Val Leu Phe Tyr	395	Ile Arg Ser His Asp	400	Val Lys Asn Gly Gly	405
	410		415		420
Leu Thr His Pro	425	Thr His Ser Pro Gly	430	Gln Ser Ser Pro Arg	435
Val Ile Ser Gln	440	Arg Val Val Thr Asn	445	Lys Gln Ala Ala Pro	450
Phe Ile Gly Pro	455	Gln Leu Pro Ser His	460	Met Ile Lys Asn Pro	465
His Leu Asn Gly	470	Thr Gly Pro Leu Lys	475	Asp Thr Pro Ser Ser	480
Met Ser Ser Pro	485	Asn Gly Asn Ser Ser	490	Val Asn Arg Ala Ser	495
Val Asn Ala Ser	500	Ala Ser Val Gln Asn	505	Trp Ser Val Asn Arg	510
Ser Val Ile Pro	515	Glu His Pro Lys Lys	520	Gln Lys Ile Thr Ile	525
Ile His Asn Lys	530	Leu Pro Val Arg Gln	535	Cys Gln Ser Gln Pro	540
Leu His Ser Asn	545	Ser Leu Glu Asn Pro	550	Thr Lys Pro Val Pro	555
Ser Thr Ile Thr	560	Asn Ser Ala Val Gln	565	Ser Thr Ser Asn Ala	570
Thr Met Ser Val	575	Ser Ser Lys Val Thr	580	Lys Pro Ile Pro Arg	585
Glu Ser Cys Ser	590	Gln Pro Val Met Asn	595	Gly Lys Ser Lys Leu	600
Ser Ser Val Leu	605	Val Pro Tyr Gly Ala	610	Glu Ser Ser Glu Asp	615
Asp Glu Glu Ser	620	Lys Gly Leu Gly Lys	625	Glu Asn Gly Ile Gly	630
Ile Val Ser Ser	635	His Ser Pro Gly Gln	640	Asp Ala Glu Asp Glu	645
Ala Thr Pro His	650	Glu Leu Gln Glu Pro	655	Met Thr Leu Asn Gly	660
Asn Ser Ala Asp	665	Ser Asp Ser Asp Pro	670	Lys Glu Asn Gly Leu	675
Pro Asp Gly Ala	680	Ser Cys Gln Gly Gln	685	Pro Ala Leu His Ser	690
Asn Pro Phe Ala	695	Lys Ala Asn Gly Leu	700	Pro Gly Lys Leu Met	705
Ala Pro Leu Leu	710	Ser Leu Pro Glu Asp	715	Lys Ile Leu Glu Thr	720
Arg Leu Ser Asn	725	Lys Leu Lys Gly Ser	730	Thr Asp Glu Met Ser	735
Pro Gly Ala Glu	740	Arg Gly Pro Pro Glu	745	Asp Arg Asp Ala Glu	750
Gln Pro Gly Ser	755	Pro Ala Ala Glu Ser	760	Leu Glu Glu Pro Asp	765
Ala Ala Ser Leu	770	Phe Pro Phe Ser Glu	775	Gly	

<210> 5

<211> 351

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1873139CD1

<400> 5

Met Asn Ala Ile Leu	1	Gln Ser Leu Ser Asn	10	Ile Glu Gln Phe Cys	15
Cys Tyr Phe Lys Glu	20	Leu Pro Ala Val Glu	25	Leu Arg Asn Gly Lys	30
Thr Ala Gly Arg Arg	35	Thr Tyr His Thr Arg	40	Ser Gln Gly Asp Asn	45

```

Asn Val Ser Leu Val Glu Glu Phe Arg Lys Thr Leu Cys Ala Leu
    50      55      60
Trp Gln Gly Ser Gln Thr Ala Phe Ser Pro Glu Ser Leu Phe Tyr
    65      70      75
Val Val Trp Lys Ile Met Pro Asn Phe Arg Gly Tyr Gln Gln Gln
    80      85      90
Asp Ala His Glu Phe Met Arg Tyr Leu Leu Asp His Leu His Leu
    95     100     105
Glu Leu Gln Gly Gly Phe Asn Gly Val Ser Arg Ser Ala Ile Leu
   110     115     120
Gln Glu Asn Ser Thr Leu Ser Ala Ser Asn Lys Cys Cys Ile Asn
   125     130     135
Gly Ala Ser Thr Val Val Thr Ala Ile Phe Gly Gly Ile Leu Gln
   140     145     150
Asn Glu Val Asn Cys Leu Ile Cys Gly Thr Glu Ser Arg Lys Phe
   155     160     165
Asp Pro Phe Leu Asp Leu Ser Leu Asp Ile Pro Ser Gln Phe Arg
   170     175     180
Ser Lys Arg Ser Lys Asn Gln Glu Asn Gly Pro Val Cys Ser Leu
   185     190     195
Arg Asp Cys Leu Arg Ser Phe Thr Asp Leu Glu Glu Leu Asp Glu
   200     205     210
Thr Glu Leu Tyr Met Cys His Lys Cys Lys Lys Lys Gln Lys Ser
   215     220     225
Thr Lys Lys Phe Trp Ile Gln Lys Leu Pro Lys Val Leu Cys Leu
   230     235     240
His Leu Lys Arg Phe His Trp Thr Ala Tyr Leu Arg Asn Lys Val
   245     250     255
Asp Thr Tyr Val Glu Phe Pro Leu Arg Gly Leu Asp Met Lys Cys
   260     265     270
Tyr Leu Leu Glu Pro Glu Asn Ser Gly Pro Glu Ser Cys Leu Tyr
   275     280     285
Asp Leu Ala Ala Val Val Val His His Gly Ser Gly Val Gly Ser
   290     295     300
Gly His Tyr Thr Ala Tyr Ala Thr His Glu Gly Arg Trp Phe His
   305     310     315
Phe Asn Asp Ser Thr Val Thr Leu Thr Asp Glu Glu Thr Val Val
   320     325     330
Lys Ala Lys Ala Tyr Ile Leu Phe Tyr Val Glu His Gln Ala Lys
   335     340     345
Ala Gly Ser Asp Lys Leu
    350

```

<210> 6
 <211> 136
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1903112CD1

```

<400> 6
Met Ala Leu Met Gln Arg Ser Asp Ile Phe Arg Val Ala Ile Ala
    1      5      10      15
Gly Ala Pro Val Thr Leu Trp Ile Phe Tyr Asp Thr Gly Tyr Thr
    20      25      30
Glu Arg Tyr Met Gly His Pro Asp Gln Asn Glu Gln Gly Tyr Tyr
    35      40      45
Leu Gly Ser Val Ala Met Gln Ala Glu Lys Phe Pro Ser Glu Pro
    50      55      60
Asn Arg Leu Leu Leu Leu His Gly Phe Leu Asp Glu Asn Val His
    65      70      75
Phe Ala His Thr Ser Ile Leu Leu Ser Phe Leu Val Arg Ala Gly
    80      85      90
Lys Pro Tyr Asp Leu Gln Ile Tyr Pro Gln Glu Arg His Ser Ile
    95     100     105
Arg Val Pro Glu Ser Gly Glu His Tyr Glu Leu His Leu Leu His

```

				110						115					120
Tyr	Leu	Gln	Glu	Asn	Leu	Gly	Ser	Arg	Ile	Ala	Ala	Leu	Lys	Val	
				125					130					135	
Ile															

<210> 7
 <211> 396
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1993044CD1

<400> 7

Met	Ser	Leu	Gly	Trp	Leu	Glu	Arg	Pro	Pro	Ala	Leu	Ser	Arg	Ala	
1				5					10					15	
Ala	Gly	Asp	Gly	Ala	Arg	Arg	Leu	Ser	Gly	Ser	Met	Arg	Gly	Asp	
				20					25					30	
Val	Trp	Leu	Thr	Ser	Ser	Ala	Ala	Gly	Leu	Leu	Arg	Ser	Val	Ala	
				35					40					45	
Gly	Gly	Ser	Trp	Cys	Gly	Gly	Gln	Leu	Arg	Ala	Arg	Gly	Gly	Ser	
				50					55					60	
Gly	Arg	Cys	Val	Ala	Arg	Ala	Met	Thr	Gly	Asn	Ala	Gly	Glu	Trp	
				65					70					75	
Cys	Leu	Met	Glu	Ser	Asp	Pro	Gly	Val	Phe	Thr	Glu	Leu	Ile	Lys	
				80					85					90	
Gly	Phe	Gly	Cys	Arg	Gly	Ala	Gln	Val	Glu	Glu	Ile	Trp	Ser	Leu	
				95					100					105	
Glu	Pro	Glu	Asn	Phe	Glu	Lys	Leu	Lys	Pro	Val	His	Gly	Leu	Ile	
				110					115					120	
Phe	Leu	Phe	Lys	Trp	Gln	Pro	Gly	Glu	Glu	Pro	Ala	Gly	Ser	Val	
				125					130					135	
Val	Gln	Asp	Ser	Arg	Leu	Asp	Thr	Ile	Phe	Phe	Ala	Lys	Gln	Val	
				140					145					150	
Ile	Asn	Asn	Ala	Cys	Ala	Thr	Gln	Ala	Ile	Val	Ser	Val	Leu	Leu	
				155					160					165	
Asn	Cys	Thr	His	Gln	Asp	Val	His	Leu	Gly	Glu	Thr	Leu	Ser	Glu	
				170					175					180	
Phe	Lys	Glu	Phe	Ser	Gln	Ser	Phe	Asp	Ala	Ala	Met	Lys	Gly	Leu	
				185					190					195	
Ala	Leu	Ser	Asn	Ser	Asp	Val	Ile	Arg	Gln	Val	His	Asn	Ser	Phe	
				200					205					210	
Ala	Arg	Gln	Gln	Met	Phe	Glu	Phe	Asp	Thr	Lys	Thr	Ser	Ala	Lys	
				215					220					225	
Glu	Glu	Asp	Ala	Phe	His	Phe	Val	Ser	Tyr	Val	Pro	Val	Asn	Gly	
				230					235					240	
Arg	Leu	Tyr	Glu	Leu	Asp	Gly	Leu	Arg	Glu	Gly	Pro	Ile	Asp	Leu	
				245					250					255	
Gly	Ala	Cys	Asn	Gln	Asp	Asp	Trp	Phe	Ser	Ala	Val	Arg	Pro	Val	
				260					265					270	
Ile	Glu	Lys	Arg	Ile	Gln	Lys	Tyr	Ser	Glu	Gly	Glu	Ile	Arg	Phe	
				275					280					285	
Asn	Leu	Met	Ala	Ile	Val	Ser	Asp	Arg	Lys	Met	Ile	Tyr	Glu	Gln	
				290					295					300	
Lys	Ile	Ala	Glu	Leu	Gln	Arg	Gln	Leu	Ala	Glu	Glu	Glu	Pro	Met	
				305					310					315	
Asp	Thr	Asp	Gln	Gly	Asn	Ser	Met	Leu	Ser	Ala	Ile	Gln	Ser	Glu	
				320					325					330	
Val	Ala	Lys	Asn	Gln	Met	Leu	Ile	Glu	Glu	Glu	Val	Gln	Lys	Leu	
				335					340					345	
Lys	Arg	Tyr	Lys	Ile	Glu	Asn	Ile	Arg	Arg	Lys	His	Asn	Tyr	Leu	
				350					355					360	
Pro	Phe	Ile	Met	Glu	Leu	Leu	Lys	Thr	Leu	Ala	Glu	His	Gln	Gln	
				365					370					375	
Leu	Ile	Pro	Leu	Val	Glu	Lys	Ala	Lys	Glu	Lys	Gln	Asn	Ala	Lys	
				380					385					390	

Lys Ala Gln Glu Thr Lys
395

<210> 8
<211> 246
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2292182CD1

<400> 8
Met Ala Gly Ala Pro Asp Glu Arg Arg Arg Gly Pro Ala Ala Gly
1 5 10 15
Glu Gln Leu Gln Gln Gln His Val Ser Cys Gln Val Phe Pro Glu
20 25 30
Arg Leu Ala Gln Gly Asn Pro Gln Gln Gly Phe Phe Ser Ser Phe
35 40 45
Phe Thr Ser Asn Gln Lys Cys Gln Leu Arg Leu Leu Lys Thr Leu
50 55 60
Glu Thr Asn Pro Tyr Val Lys Leu Leu Leu Asp Ala Met Lys His
65 70 75
Ser Gly Cys Ala Val Asn Lys Asp Arg His Phe Ser Cys Glu Asp
80 85 90
Cys Asn Gly Asn Val Ser Gly Gly Phe Asp Ala Ser Thr Ser Gln
95 100 105
Ile Val Leu Cys Gln Asn Asn Ile His Asn Gln Ala His Met Asn
110 115 120
Arg Val Val Thr His Glu Leu Ile His Ala Phe Asp His Cys Arg
125 130 135
Ala His Val Asp Trp Phe Thr Asn Ile Arg His Leu Ala Cys Ser
140 145 150
Glu Val Arg Ala Ala Asn Leu Ser Gly Asp Cys Ser Leu Val Asn
155 160 165
Glu Ile Phe Arg Leu His Phe Gly Leu Lys Gln His His Gln Thr
170 175 180
Cys Val Arg Asp Arg Ala Thr Leu Ser Ile Leu Ala Val Arg Asn
185 190 195
Ile Ser Lys Glu Val Ala Lys Lys Ala Val Asp Glu Val Phe Glu
200 205 210
Ser Cys Phe Asn Asp His Glu Pro Phe Gly Arg Ile Pro His Asn
215 220 225
Lys Thr Tyr Ala Arg Tyr Ala His Arg Asp Phe Glu Asn Arg Asp
230 235 240
Arg Tyr Tyr Ser Asn Ile
245

<210> 9
<211> 262
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2331301CD1

<400> 9
Met Glu Val Tyr Ile Arg His Leu Glu Lys Val Leu Arg Arg Tyr
1 5 10 15
Val Gln Arg Leu Gln Trp Leu Leu Ser Gly Ser Arg Arg Leu Phe
20 25 30
Gly Thr Val Leu Glu Ser Lys Val Cys Ile Leu Leu Asp Thr Ser
35 40 45
Gly Ser Met Gly Pro Tyr Leu Gln Gln Val Lys Thr Glu Leu Val
50 55 60
Leu Leu Ile Trp Glu Gln Leu Arg Lys Cys Cys Asp Ser Phe Asn
65 70 75
Leu Leu Ser Phe Ala Glu Ser Leu Gln Ser Trp Gln Asp Thr Leu

80	85	90
Val Glu Thr Thr Asp Ala Ala Cys His	Glu Ala Met Gln Trp Val	
95	100	105
Thr His Leu Gln Ala Gln Gly Ser Thr	Ser Ile Leu Gln Ala Leu	
110	115	120
Leu Lys Ala Phe Ser Phe His Asp Leu	Glu Gly Leu Tyr Leu Leu	
125	130	135
Thr Asp Gly Lys Pro Asp Thr Ser Cys	Ser Leu Val Leu Asn Glu	
140	145	150
Val Gln Lys Leu Arg Glu Lys Arg Asp	Val Lys Val His Thr Ile	
155	160	165
Ser Leu Asn Cys Ser Asp Arg Ala Ala	Val Glu Phe Leu Arg Lys	
170	175	180
Leu Ala Ser Phe Thr Gly Gly Arg Tyr	His Cys Pro Val Gly Glu	
185	190	195
Asp Thr Leu Ser Lys Ile His Ser Leu	Leu Thr Lys Gly Phe Ile	
200	205	210
Asn Glu Lys Asp Arg Thr Leu Pro Pro	Phe Glu Gly Asp Asp Leu	
215	220	225
Arg Ile Leu Ala Gln Glu Ile Thr Lys	Ala Arg Ser Phe Leu Trp	
230	235	240
Gln Ala Gln Ser Phe Arg Ser Gln Leu	Gln Lys Lys Asn Asp Ala	
245	250	255
Glu Pro Lys Val Thr Leu Ser		
260		

<210> 10

<211> 406

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2517512CD1

<400> 10

Met Ala Ala Ala Val Arg Gln Asp Leu Ala Gln Leu Met Asn Ser	
1 5 10 15	
Ser Gly Ser His Lys Asp Leu Ala Gly Lys Tyr Arg Gln Ile Leu	
20 25 30	
Glu Lys Ala Ile Gln Leu Ser Gly Ala Glu Gln Leu Glu Ala Leu	
35 40 45	
Lys Ala Phe Val Glu Ala Met Val Asn Glu Asn Val Ser Leu Val	
50 55 60	
Ile Ser Arg Gln Leu Leu Thr Asp Phe Cys Thr His Leu Pro Asn	
65 70 75	
Leu Pro Asp Ser Thr Ala Lys Glu Ile Tyr His Phe Thr Leu Glu	
80 85 90	
Lys Ile Gln Pro Arg Val Ile Ser Phe Glu Glu Gln Val Ala Ser	
95 100 105	
Ile Arg Gln His Leu Ala Ser Ile Tyr Glu Lys Glu Glu Asp Trp	
110 115 120	
Arg Asn Ala Ala Gln Val Leu Val Gly Ile Pro Leu Glu Thr Gly	
125 130 135	
Gln Lys Gln Tyr Asn Val Asp Tyr Lys Leu Glu Thr Tyr Leu Lys	
140 145 150	
Ile Ala Arg Leu Tyr Leu Glu Asp Asp Pro Val Gln Ala Glu	
155 160 165	
Ala Tyr Ile Asn Arg Ala Ser Leu Leu Gln Asn Glu Ser Thr Asn	
170 175 180	
Glu Gln Leu Gln Ile His Tyr Lys Val Cys Tyr Ala Arg Val Leu	
185 190 195	
Asp Tyr Arg Arg Lys Phe Ile Glu Ala Ala Gln Arg Tyr Asn Glu	
200 205 210	
Leu Ser Tyr Lys Thr Ile Val His Glu Ser Glu Arg Leu Glu Ala	
215 220 225	
Leu Lys His Ala Leu His Cys Thr Ile Leu Ala Ser Ala Gly Gln	
230 235 240	

Gln	Arg	Ser	Arg	Met	Leu	Ala	Thr	Leu	Phe	Lys	Asp	Glu	Arg	Cys
				245					250					255
Gln	Gln	Leu	Ala	Ala	Tyr	Gly	Ile	Leu	Glu	Lys	Met	Tyr	Leu	Asp
				260					265					270
Arg	Ile	Ile	Arg	Gly	Asn	Gln	Leu	Gln	Glu	Phe	Ala	Ala	Met	Leu
				275					280					285
Met	Pro	His	Gln	Lys	Ala	Thr	Thr	Ala	Asp	Gly	Ser	Ser	Ile	Leu
				290					295					300
Asp	Arg	Ala	Val	Ile	Glu	His	Asn	Leu	Leu	Ser	Ala	Ser	Lys	Leu
				305					310					315
Tyr	Asn	Asn	Ile	Thr	Phe	Glu	Glu	Leu	Gly	Ala	Leu	Leu	Glu	Ile
				320					325					330
Pro	Ala	Ala	Lys	Ala	Glu	Lys	Ile	Ala	Ser	Gln	Met	Ile	Thr	Glu
				335					340					345
Gly	Arg	Met	Asn	Gly	Phe	Ile	Asp	Gln	Ile	Asp	Gly	Ile	Val	His
				350					355					360
Phe	Glu	Thr	Arg	Glu	Ala	Leu	Pro	Thr	Trp	Asp	Lys	Gln	Ile	Gln
				365					370					375
Ser	Leu	Cys	Phe	Gln	Val	Asn	Asn	Leu	Leu	Glu	Lys	Ile	Ser	Gln
				380					385					390
Thr	Ala	Pro	Glu	Trp	Thr	Ala	Gln	Ala	Met	Glu	Ala	Gln	Met	Ala
				395					400					405

Gln

<210> 11

<211> 172

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3489039CD1

<400> 11

Met	Leu	Leu	Pro	Asn	Ile	Leu	Leu	Thr	Gly	Thr	Pro	Gly	Val	Gly
				5					10					15
Lys	Thr	Thr	Leu	Gly	Lys	Glu	Leu	Ala	Ser	Lys	Ser	Gly	Leu	Lys
				20					25					30
Tyr	Ile	Asn	Val	Gly	Asp	Leu	Ala	Arg	Glu	Glu	Gln	Leu	Tyr	Asp
				35					40					45
Gly	Tyr	Asp	Glu	Glu	Tyr	Asp	Cys	Pro	Ile	Leu	Asp	Glu	Asp	Arg
				50					55					60
Val	Val	Asp	Glu	Leu	Asp	Asn	Gln	Met	Arg	Glu	Gly	Gly	Val	Ile
				65					70					75
Val	Asp	Tyr	His	Gly	Cys	Asp	Phe	Phe	Pro	Glu	Arg	Trp	Phe	His
				80					85					90
Ile	Val	Phe	Val	Leu	Arg	Thr	Asp	Thr	Asn	Val	Leu	Tyr	Glu	Arg
				95					100					105
Leu	Glu	Thr	Arg	Gly	Tyr	Asn	Glu	Lys	Lys	Leu	Thr	Asp	Asn	Ile
				110					115					120
Gln	Cys	Glu	Ile	Phe	Gln	Val	Leu	Tyr	Glu	Glu	Ala	Thr	Ala	Ser
				125					130					135
Tyr	Lys	Glu	Glu	Ile	Val	His	Gln	Leu	Pro	Ser	Asn	Lys	Pro	Glu
				140					145					150
Glu	Leu	Glu	Asn	Asn	Val	Asp	Gln	Ile	Leu	Lys	Trp	Ile	Glu	Gln
				155					160					165
Trp	Ile	Lys	Asp	His	Asn	Ser								
				170										

<210> 12

<211> 517

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5432879CD1

<400> 12

Met	Leu	Ser	Ser	Arg	Ala	Glu	Ala	Ala	Met	Thr	Ala	Ala	Asp	Arg
1				5					10					15
Ala	Ile	Gln	Arg	Phe	Leu	Arg	Thr	Gly	Ala	Ala	Val	Arg	Tyr	Lys
				20					25					30
Val	Met	Lys	Asn	Trp	Gly	Val	Ile	Gly	Gly	Ile	Ala	Ala	Ala	Leu
				35					40					45
Ala	Ala	Gly	Ile	Tyr	Val	Ile	Trp	Gly	Pro	Ile	Thr	Glu	Arg	Lys
				50					55					60
Lys	Arg	Arg	Lys	Gly	Leu	Val	Pro	Gly	Leu	Val	Asn	Leu	Gly	Asn
				65					70					75
Thr	Cys	Phe	Met	Asn	Ser	Leu	Leu	Gln	Gly	Leu	Ser	Ala	Cys	Pro
				80					85					90
Ala	Phe	Ile	Arg	Trp	Leu	Glu	Glu	Phe	Thr	Ser	Gln	Tyr	Ser	Arg
				95					100					105
Asp	Gln	Lys	Glu	Pro	Pro	Ser	His	Gln	Tyr	Leu	Ser	Leu	Thr	Leu
				110					115					120
Leu	His	Leu	Leu	Lys	Ala	Leu	Ser	Cys	Gln	Glu	Val	Thr	Asp	Asp
				125					130					135
Glu	Val	Leu	Asp	Ala	Ser	Cys	Leu	Leu	Asp	Val	Leu	Arg	Met	Tyr
				140					145					150
Arg	Trp	Gln	Ile	Ser	Ser	Phe	Glu	Glu	Gln	Asp	Ala	His	Glu	Leu
				155					160					165
Phe	His	Val	Ile	Thr	Ser	Ser	Leu	Glu	Asp	Glu	Arg	Asp	Arg	Gln
				170					175					180
Pro	Arg	Val	Thr	His	Leu	Phe	Asp	Val	His	Ser	Leu	Glu	Gln	Gln
				185					190					195
Ser	Glu	Ile	Thr	Pro	Lys	Gln	Ile	Thr	Cys	Arg	Thr	Arg	Gly	Ser
				200					205					210
Pro	His	Pro	Thr	Ser	Asn	His	Trp	Lys	Ser	Gln	His	Pro	Phe	His
				215					220					225
Gly	Arg	Leu	Thr	Ser	Asn	Met	Val	Cys	Lys	His	Cys	Glu	His	Gln
				230					235					240
Ser	Pro	Val	Arg	Phe	Asp	Thr	Phe	Asp	Ser	Leu	Ser	Leu	Ser	Ile
				245					250					255
Pro	Ala	Ala	Thr	Trp	Gly	His	Pro	Leu	Thr	Leu	Asp	His	Cys	Leu
				260					265					270
His	His	Phe	Ile	Ser	Ser	Glu	Ser	Val	Arg	Asp	Val	Val	Cys	Asp
				275					280					285
Asn	Cys	Thr	Lys	Ile	Glu	Ala	Lys	Gly	Thr	Leu	Asn	Gly	Glu	Lys
				290					295					300
Val	Glu	His	Gln	Arg	Thr	Thr	Phe	Val	Lys	Gln	Leu	Lys	Leu	Gly
				305					310					315
Lys	Leu	Pro	Gln	Cys	Leu	Cys	Ile	His	Leu	Gln	Arg	Leu	Ser	Trp
				320					325					330
Ser	Ser	His	Gly	Thr	Pro	Leu	Lys	Arg	His	Glu	His	Val	Gln	Phe
				335					340					345
Asn	Glu	Phe	Leu	Met	Met	Asp	Ile	Tyr	Lys	Tyr	His	Leu	Leu	Gly
				350					355					360
His	Lys	Pro	Ser	Gln	His	Asn	Pro	Lys	Leu	Asn	Lys	Asn	Pro	Gly
				365					370					375
Pro	Thr	Leu	Glu	Leu	Gln	Asp	Gly	Pro	Gly	Ala	Pro	Thr	Pro	Val
				380					385					390
Leu	Asn	Gln	Pro	Gly	Ala	Pro	Lys	Thr	Gln	Ile	Phe	Met	Asn	Gly
				395					400					405
Ala	Cys	Ser	Pro	Ser	Leu	Leu	Pro	Thr	Leu	Ser	Ala	Pro	Met	Pro
				410					415					420
Phe	Pro	Leu	Pro	Val	Val	Pro	Asp	Tyr	Ser	Ser	Ser	Thr	Tyr	Leu
				425					430					435
Phe	Arg	Leu	Met	Ala	Val	Val	Val	His	His	Gly	Asp	Met	His	Ser
				440					445					450
Gly	His	Phe	Val	Thr	Tyr	Arg	Arg	Ser	Pro	Pro	Ser	Ala	Arg	Asn
				455					460					465
Pro	Leu	Ser	Thr	Ser	Asn	Gln	Trp	Leu	Trp	Val	Ser	Asp	Asp	Thr
				470					475					480
Val	Arg	Lys	Ala	Ser	Leu	Gln	Glu	Val	Leu	Ser	Ser	Ser	Ala	Tyr
				485					490					495

Leu Leu Phe Tyr Glu Arg Val Leu Ser Arg Met Gln His Gln Ser
 500 505 510
 Gln Glu Cys Lys Ser Glu Glu
 515

<210> 13

<211> 346

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5853753CD1

<400> 13

Met Val Glu Lys Glu Glu Ala Gly Gly Gly Ile Ser Glu Glu Glu
 1 5 10 15
 Ala Ala Gln Tyr Asp Arg Gln Ile Arg Leu Trp Gly Leu Glu Ala
 20 25 30
 Gln Lys Arg Leu Arg Ala Ser Arg Val Leu Leu Val Gly Leu Lys
 35 40 45
 Gly Leu Gly Ala Glu Ile Ala Lys Asn Leu Ile Leu Ala Gly Val
 50 55 60
 Lys Gly Leu Thr Met Leu Asp His Glu Gln Val Thr Pro Glu Asp
 65 70 75
 Pro Gly Ala Gln Phe Leu Ile Arg Thr Gly Ser Val Gly Arg Asn
 80 85 90
 Arg Ala Glu Ala Ser Leu Glu Arg Ala Gln Asn Leu Asn Pro Met
 95 100 105
 Val Asp Val Lys Val Asp Thr Glu Asp Ile Glu Lys Lys Pro Glu
 110 115 120
 Ser Phe Phe Thr Gln Phe Asp Ala Val Cys Leu Thr Cys Cys Ser
 125 130 135
 Arg Asp Val Ile Val Lys Val Asp Gln Ile Cys His Lys Asn Ser
 140 145 150
 Ile Lys Phe Phe Thr Gly Asp Val Phe Gly Tyr His Gly Tyr Thr
 155 160 165
 Phe Ala Asn Leu Gly Glu His Glu Phe Val Glu Glu Lys Thr Lys
 170 175 180
 Val Ala Lys Val Ser Gln Gly Val Glu Asp Gly Pro Asp Thr Lys
 185 190 195
 Arg Ala Lys Leu Asp Ser Ser Glu Thr Thr Met Val Lys Lys Lys
 200 205 210
 Val Val Phe Cys Pro Val Lys Glu Ala Leu Glu Val Asp Trp Ser
 215 220 225
 Ser Glu Lys Ala Lys Ala Ala Leu Lys Arg Thr Thr Ser Asp Tyr
 230 235 240
 Phe Leu Leu Gln Val Leu Leu Lys Phe Arg Thr Asp Lys Gly Arg
 245 250 255
 Asp Pro Ser Ser Asp Thr Tyr Glu Glu Asp Ser Glu Leu Leu Leu
 260 265 270
 Gln Ile Arg Asn Asp Val Leu Asp Ser Leu Gly Ile Ser Pro Asp
 275 280 285
 Leu Leu Pro Glu Asp Phe Val Arg Tyr Cys Phe Ser Glu Met Ala
 290 295 300
 Pro Val Cys Ala Val Val Gly Gly Ile Leu Ala Gln Glu Ile Val
 305 310 315
 Lys Ala Leu Ser Gln Arg Asp Pro Pro His Asn Asn Phe Phe Phe
 320 325 330
 Phe Asp Gly Met Lys Gly Asn Gly Ile Val Glu Cys Leu Gly Pro
 335 340 345

Lys

<210> 14

<211> 151

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 411344CD1

<400> 14

Met	Ala	Ser	Met	Gln	Lys	Arg	Leu	Gln	Lys	Glu	Leu	Leu	Ala	Leu
1				5					10					15
Gln	Asn	Asp	Pro	Pro	Pro	Gly	Met	Thr	Leu	Asn	Glu	Lys	Ser	Val
				20					25					30
Gln	Asn	Ser	Ile	Thr	Gln	Trp	Ile	Val	Asp	Met	Glu	Gly	Ala	Pro
				35					40					45
Gly	Thr	Leu	Tyr	Glu	Gly	Glu	Lys	Phe	Gln	Leu	Leu	Phe	Lys	Phe
				50					55					60
Ser	Ser	Arg	Tyr	Pro	Phe	Asp	Ser	Pro	Gln	Val	Met	Phe	Thr	Gly
				65					70					75
Glu	Asn	Ile	Pro	Val	His	Pro	His	Val	Tyr	Ser	Asn	Gly	His	Ile
				80					85					90
Cys	Leu	Ser	Ile	Leu	Thr	Glu	Asp	Trp	Ser	Pro	Ala	Leu	Ser	Val
				95					100					105
Gln	Ser	Val	Cys	Leu	Ser	Ile	Ile	Ser	Met	Leu	Ser	Ser	Cys	Lys
				110					115					120
Glu	Lys	Arg	Arg	Pro	Pro	Asp	Asn	Ser	Phe	Tyr	Val	Arg	Thr	Cys
				125					130					135
Asn	Lys	Asn	Pro	Lys	Lys	Thr	Lys	Trp	Trp	Tyr	His	Asp	Asp	Thr
				140					145					150

Cys

<210> 15

<211> 362

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1256390CD1

<400> 15

Met	Leu	Val	Pro	Gly	Gly	Leu	Gly	Tyr	Asp	Arg	Ser	Leu	Ala	Gln
1				5					10					15
His	Arg	Gln	Glu	Ile	Val	Asp	Lys	Ser	Val	Ser	Pro	Trp	Ser	Leu
				20					25					30
Glu	Thr	Tyr	Ser	Tyr	Asn	Ile	Tyr	His	Pro	Met	Gly	Glu	Ile	Tyr
				35					40					45
Glu	Trp	Met	Arg	Glu	Ile	Ser	Glu	Lys	Tyr	Lys	Glu	Val	Val	Thr
				50					55					60
Gln	His	Phe	Leu	Gly	Val	Thr	Tyr	Glu	Thr	His	Pro	Met	Tyr	Tyr
				65					70					75
Leu	Lys	Ile	Ser	Gln	Pro	Ser	Gly	Asn	Pro	Lys	Lys	Ile	Ile	Trp
				80					85					90
Met	Asp	Cys	Gly	Ile	His	Ala	Arg	Glu	Trp	Ile	Ala	Pro	Ala	Phe
				95					100					105
Cys	Gln	Trp	Phe	Val	Lys	Glu	Ile	Leu	Gln	Asn	His	Lys	Asp	Asn
				110					115					120
Ser	Ser	Ile	Arg	Lys	Leu	Leu	Arg	Asn	Leu	Asp	Phe	Tyr	Val	Leu
				125					130					135
Pro	Val	Leu	Asn	Ile	Asp	Gly	Tyr	Ile	Tyr	Thr	Trp	Thr	Thr	Asp
				140					145					150
Arg	Leu	Trp	Arg	Lys	Ser	Arg	Ser	Pro	His	Asn	Asn	Gly	Thr	Cys
				155					160					165
Phe	Gly	Thr	Asp	Leu	Asn	Arg	Asn	Phe	Asn	Ala	Ser	Trp	Cys	Ser
				170					175					180
Ile	Gly	Ala	Ser	Arg	Asn	Cys	Gln	Asp	Gln	Thr	Phe	Cys	Gly	Thr
				185					190					195
Gly	Pro	Val	Ser	Glu	Pro	Glu	Thr	Lys	Ala	Val	Ala	Ser	Phe	Ile
				200					205					210
Glu	Ser	Lys	Lys	Asp	Asp	Ile	Leu	Cys	Phe	Leu	Thr	Met	His	Ser
				215					220					225

Tyr	Gly	Gln	Leu	Ile	Leu	Thr	Pro	Tyr	Gly	Tyr	Thr	Lys	Asn	Lys
				230					235					240
Ser	Ser	Asn	His	Pro	Glu	Met	Ile	Gln	Val	Gly	Gln	Lys	Ala	Ala
				245					250					255
Asn	Ala	Leu	Lys	Ala	Lys	Tyr	Gly	Thr	Asn	Tyr	Arg	Val	Gly	Ser
				260					265					270
Ser	Ala	Asp	Ile	Leu	Tyr	Ala	Ser	Ser	Gly	Ser	Ser	Arg	Asp	Trp
				275					280					285
Ala	Arg	Asp	Ile	Gly	Ile	Pro	Phe	Ser	Tyr	Thr	Phe	Glu	Leu	Arg
				290					295					300
Asp	Ser	Gly	Thr	Tyr	Gly	Phe	Val	Leu	Pro	Glu	Ala	Gln	Ile	Gln
				305					310					315
Pro	Thr	Cys	Glu	Glu	Thr	Met	Glu	Ala	Val	Leu	Ser	Val	Leu	Asp
				320					325					330
Asp	Val	Tyr	Ala	Lys	His	Trp	His	Ser	Asp	Ser	Ala	Gly	Arg	Val
				335					340					345
Thr	Ser	Ala	Thr	Met	Leu	Leu	Gly	Leu	Leu	Val	Ser	Cys	Met	Ser
				350					355					360

Leu Leu

<210> 16

<211> 123

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1786774CD1

<400> 16

Met	Ser	Gly	Glu	Glu	Leu	Ser	Glu	Ser	Thr	Pro	Glu	Pro	Gln	Lys
1				5					10					15
Glu	Ile	Ser	Glu	Ser	Leu	Ser	Val	Thr	Arg	Asp	Gln	Asp	Glu	Asp
				20					25					30
Asp	Lys	Ala	Pro	Glu	Pro	Thr	Trp	Ala	Asp	Asp	Leu	Pro	Ala	Thr
				35					40					45
Thr	Ser	Ser	Glu	Ala	Thr	Thr	Thr	Pro	Arg	Pro	Leu	Leu	Ser	Thr
				50					55					60
Pro	Val	Asp	Gly	Ala	Glu	Asp	Pro	Arg	Cys	Leu	Glu	Ala	Leu	Lys
				65					70					75
Pro	Gly	Asn	Cys	Gly	Glu	Tyr	Val	Val	Arg	Trp	Tyr	Tyr	Asp	Lys
				80					85					90
Gln	Val	Asn	Ser	Cys	Ala	Arg	Phe	Trp	Phe	Ser	Gly	Cys	Asn	Gly
				95					100					105
Ser	Gly	Asn	Arg	Phe	Asn	Ser	Glu	Lys	Glu	Cys	Gln	Glu	Thr	Cys
				110					115					120

Ile Gln Gly

<210> 17

<211> 983

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1911808CD1

<400> 17

Met	Ala	Pro	Arg	Leu	Gln	Leu	Glu	Lys	Ala	Ala	Trp	Arg	Trp	Ala
1				5					10					15
Glu	Thr	Val	Arg	Pro	Glu	Glu	Val	Ser	Gln	Glu	His	Ile	Glu	Thr
				20					25					30
Ala	Tyr	Arg	Ile	Trp	Leu	Glu	Pro	Cys	Ile	Arg	Gly	Val	Cys	Arg
				35					40					45
Arg	Asn	Cys	Lys	Gly	Asn	Pro	Asn	Cys	Leu	Val	Gly	Ile	Gly	Glu
				50					55					60
His	Ile	Trp	Leu	Gly	Glu	Ile	Asp	Glu	Asn	Ser	Phe	His	Asn	Ile

Asp	Asp	Pro	Asn	Cys	Glu	Arg	Arg	Lys	Lys	Asn	Ser	Phe	Val	Gly	65	70	75
				80					85					90			
Leu	Thr	Asn	Leu	Gly	Ala	Thr	Cys	Tyr	Val	Asn	Thr	Phe	Leu	Gln			
				95					100					105			
Val	Trp	Phe	Leu	Asn	Leu	Glu	Leu	Arg	Gln	Ala	Leu	Tyr	Leu	Cys			
				110					115					120			
Pro	Ser	Thr	Cys	Ser	Asp	Tyr	Met	Leu	Gly	Asp	Gly	Ile	Gln	Glu			
				125					130					135			
Glu	Lys	Asp	Tyr	Glu	Pro	Gln	Thr	Ile	Cys	Glu	His	Leu	Gln	Tyr			
				140					145					150			
Leu	Phe	Ala	Leu	Leu	Gln	Asn	Ser	Asn	Arg	Arg	Tyr	Ile	Asp	Pro			
				155					160					165			
Ser	Gly	Phe	Val	Lys	Ala	Leu	Gly	Leu	Asp	Thr	Gly	Gln	Gln	Gln			
				170					175					180			
Asp	Ala	Gln	Glu	Phe	Ser	Lys	Leu	Phe	Met	Ser	Leu	Leu	Glu	Asp			
				185					190					195			
Thr	Leu	Ser	Asn	Gln	Lys	Asn	Pro	Asp	Val	Arg	Asn	Ile	Val	Gln			
				200					205					210			
Gln	Gln	Phe	Cys	Gly	Glu	Tyr	Ala	Tyr	Val	Thr	Val	Cys	Asn	Gln			
				215					220					225			
Cys	Gly	Arg	Glu	Ser	Lys	Leu	Leu	Ser	Lys	Phe	Tyr	Glu	Leu	Glu			
				230					235					240			
Leu	Asn	Ile	Gln	Gly	His	Lys	Gln	Leu	Thr	Asp	Cys	Ile	Ser	Glu			
				245					250					255			
Phe	Leu	Lys	Glu	Glu	Lys	Leu	Glu	Gly	Asp	Asn	Arg	Tyr	Phe	Cys			
				260					265					270			
Glu	Asn	Cys	Gln	Ser	Lys	Gln	Asn	Ala	Thr	Arg	Lys	Ile	Arg	Leu			
				275					280					285			
Leu	Ser	Leu	Pro	Cys	Thr	Leu	Asn	Leu	Gln	Leu	Met	Arg	Phe	Val			
				290					295					300			
Phe	Asp	Arg	Gln	Thr	Gly	His	Lys	Lys	Lys	Leu	Asn	Thr	Tyr	Ile			
				305					310					315			
Gly	Phe	Ser	Glu	Ile	Leu	Asp	Met	Glu	Pro	Tyr	Val	Glu	His	Lys			
				320					325					330			
Gly	Gly	Ser	Tyr	Val	Tyr	Glu	Leu	Ser	Ala	Val	Leu	Ile	His	Arg			
				335					340					345			
Gly	Val	Ser	Ala	Tyr	Ser	Gly	His	Tyr	Ile	Ala	His	Val	Lys	Asp			
				350					355					360			
Pro	Gln	Ser	Gly	Glu	Trp	Tyr	Lys	Phe	Asn	Asp	Glu	Asp	Ile	Glu			
				365					370					375			
Lys	Met	Glu	Gly	Lys	Lys	Leu	Gln	Leu	Gly	Ile	Glu	Glu	Asp	Leu			
				380					385					390			
Ala	Glu	Pro	Ser	Lys	Ser	Gln	Thr	Arg	Lys	Pro	Lys	Cys	Gly	Lys			
				395					400					405			
Gly	Thr	His	Cys	Ser	Arg	Asn	Ala	Tyr	Met	Leu	Val	Tyr	Arg	Leu			
				410					415					420			
Gln	Thr	Gln	Glu	Lys	Pro	Asn	Thr	Thr	Val	Gln	Val	Pro	Ala	Phe			
				425					430					435			
Leu	Gln	Glu	Leu	Val	Asp	Arg	Asp	Asn	Ser	Lys	Phe	Glu	Glu	Trp			
				440					445					450			
Cys	Ile	Glu	Met	Ala	Glu	Met	Arg	Lys	Gln	Ser	Val	Asp	Lys	Gly			
				455					460					465			
Lys	Ala	Lys	His	Glu	Glu	Val	Lys	Glu	Leu	Tyr	Gln	Arg	Leu	Pro			
				470					475					480			
Ala	Gly	Ala	Glu	Pro	Tyr	Glu	Phe	Val	Ser	Leu	Glu	Trp	Leu	Gln			
				485					490					495			
Lys	Trp	Leu	Asp	Glu	Ser	Thr	Pro	Thr	Lys	Pro	Ile	Asp	Asn	His			
				500					505					510			
Ala	Cys	Leu	Cys	Ser	His	Asp	Lys	Leu	His	Pro	Asp	Lys	Ile	Ser			
				515					520					525			
Ile	Met	Lys	Arg	Ile	Ser	Glu	Tyr	Ala	Ala	Asp	Ile	Phe	Tyr	Ser			
				530					535					540			
Arg	Tyr	Gly	Gly	Gly	Pro	Arg	Leu	Thr	Val	Lys	Ala	Leu	Cys	Lys			
				545					550					555			
Glu	Cys	Val	Val	Glu	Arg	Cys	Arg	Ile	Leu	Arg	Leu	Lys	Asn	Gln			
				560					565					570			

```

Leu Asn Glu Asp Tyr Lys Thr Val Asn Asn Leu Leu Lys Ala Ala
575 580 585
Val Lys Gly Ser Asp Gly Phe Trp Val Gly Lys Ser Ser Leu Arg
590 595 600
Ser Trp Arg Gln Leu Ala Leu Glu Gln Leu Asp Glu Gln Asp Gly
605 610 615
Asp Ala Glu Gln Ser Asn Gly Lys Met Asn Gly Ser Thr Leu Asn
620 625 630
Lys Asp Glu Ser Lys Glu Glu Arg Lys Glu Glu Glu Glu Leu Asn
635 640 645
Phe Asn Glu Asp Ile Leu Cys Pro His Gly Glu Leu Cys Ile Ser
650 655 660
Glu Asn Glu Arg Arg Leu Val Ser Lys Glu Ala Trp Ser Lys Leu
665 670 675
Gln Gln Tyr Phe Pro Lys Ala Pro Glu Phe Pro Ser Tyr Lys Glu
680 685 690
Cys Cys Ser Gln Cys Lys Ile Leu Glu Arg Glu Gly Glu Glu Asn
695 700 705
Glu Ala Leu His Lys Met Ile Ala Asn Glu Gln Lys Thr Ser Leu
710 715 720
Pro Asn Leu Phe Gln Asp Lys Asn Arg Pro Cys Leu Ser Asn Trp
725 730 735
Pro Glu Asp Thr Asp Val Leu Tyr Ile Val Ser Gln Phe Phe Val
740 745 750
Glu Glu Trp Arg Lys Phe Val Arg Lys Pro Thr Arg Cys Ser Pro
755 760 765
Val Ser Ser Val Gly Asn Ser Ala Leu Leu Cys Pro His Gly Gly
770 775 780
Leu Met Phe Thr Phe Ala Ser Met Thr Lys Glu Asp Ser Lys Leu
785 790 795
Ile Ala Leu Ile Trp Pro Ser Glu Trp Gln Met Ile Gln Lys Leu
800 805 810
Phe Val Val Asp His Val Ile Lys Ile Thr Arg Ile Glu Val Gly
815 820 825
Asp Val Asn Pro Ser Glu Thr Gln Tyr Ile Ser Glu Pro Lys Leu
830 835 840
Cys Pro Glu Cys Arg Glu Gly Leu Leu Cys Gln Gln Gln Arg Asp
845 850 855
Leu Arg Glu Tyr Thr Gln Ala Thr Ile Tyr Val His Lys Val Val
860 865 870
Asp Asn Lys Lys Val Met Lys Asp Ser Ala Pro Glu Leu Asn Val
875 880 885
Ser Ser Ser Glu Thr Glu Glu Asp Lys Glu Glu Ala Lys Pro Asp
890 895 900
Gly Glu Lys Asp Pro Asp Phe Asn Gln Ile Met His Ala Phe Ser
905 910 915
Val Ala Pro Phe Asp Gln Asn Leu Ser Ile Asp Gly Lys Ile Leu
920 925 930
Ser Asp Asp Cys Ala Thr Leu Gly Thr Leu Gly Val Ile Pro Glu
935 940 945
Ser Val Ile Leu Leu Lys Ala Asp Glu Pro Ile Ala Asp Tyr Ala
950 955 960
Ala Met Asp Asp Val Met Gln Val Cys Met Pro Glu Glu Gly Phe
965 970 975
Lys Gly Thr Gly Leu Leu Gly His
980

```

<210> 18

<211> 227

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1973875CD1

<400> 18

Met Gly Asn Cys Val Gly Arg Gln Arg Arg Glu Arg Pro Ala Ala

1	5	10	15
Pro Gly His Pro Arg Lys Arg Ala Gly Arg Asn Glu Pro Leu Lys			
	20	25	30
Lys Glu Arg Leu Lys Trp Lys Ser Asp Tyr Pro Met Thr Asp Gly			
	35	40	45
Gln Leu Arg Ser Lys Arg Asp Glu Phe Trp Asp Thr Ala Pro Ala			
	50	55	60
Phe Glu Gly Arg Lys Glu Ile Trp Asp Ala Leu Lys Ala Ala Ala			
	65	70	75
Tyr Ala Ala Glu Ala Asn Asp His Glu Leu Ala Gln Ala Ile Leu			
	80	85	90
Asp Gly Ala Ser Ile Thr Leu Pro His Gly Thr Leu Cys Glu Cys			
	95	100	105
Tyr Asp Glu Leu Gly Asn Arg Tyr Gln Leu Pro Ile Tyr Cys Leu			
	110	115	120
Ser Pro Pro Val Asn Leu Leu Leu Glu His Thr Glu Glu Glu Ser			
	125	130	135
Leu Glu Pro Pro Glu Pro Pro Pro Ser Val Arg Arg Glu Phe Pro			
	140	145	150
Leu Lys Val Arg Leu Ser Thr Gly Lys Asp Val Arg Leu Ser Ala			
	155	160	165
Ser Leu Pro Asp Thr Val Gly Gln Leu Lys Arg Gln Leu His Ala			
	170	175	180
Gln Glu Gly Ile Glu Pro Ser Trp Gln Arg Trp Phe Phe Ser Gly			
	185	190	195
Lys Leu Leu Thr Asp Arg Thr Arg Leu Gln Glu Thr Lys Ile Gln			
	200	205	210
Lys Asp Phe Val Ile Gln Val Ile Ile Asn Gln Pro Pro Pro Pro			
	215	220	225

Gln Asp

<210> 19

<211> 403

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2323917CD1

<400> 19

Met Glu Lys Ser Gln Lys Ile Asn Pro Phe Ile Leu His Ile Leu			
1	5	10	15
Gln Glu Val Asp Glu Glu Ile Lys Lys Gly Leu Ala Ala Gly Ile			
	20	25	30
Thr Leu Asn Ile Ala Gly Asn Asn Arg Leu Val Pro Val Glu Arg			
	35	40	45
Val Thr Gly Glu Asp Phe Trp Ile Leu Ser Lys Ile Leu Lys Asn			
	50	55	60
Cys Leu Tyr Ile Asn Gly Leu Asp Val Gly Tyr Asn Leu Leu Cys			
	65	70	75
Asp Val Gly Ala Tyr Tyr Ala Ala Lys Leu Leu Gln Lys Gln Leu			
	80	85	90
Asn Leu Ile Tyr Leu Asn Leu Met Phe Asn Asp Ile Gly Pro Glu			
	95	100	105
Gly Gly Glu Leu Ile Ala Lys Val Leu His Lys Asn Arg Thr Leu			
	110	115	120
Lys Tyr Leu Arg Met Thr Gly Asn Lys Ile Glu Asn Lys Gly Gly			
	125	130	135
Met Phe Phe Ala Ala Met Leu Gln Ile Asn Ser Ser Leu Glu Lys			
	140	145	150
Leu Asp Leu Gly Asp Cys Asp Leu Gly Met Gln Ser Val Ile Ala			
	155	160	165
Phe Ala Thr Val Leu Thr Gln Asn Gln Ala Ile Lys Ala Ile Asn			
	170	175	180
Leu Asn Arg Pro Ile Leu Tyr Gly Glu Gln Glu Glu Ser Thr Val			
	185	190	195

His Val Gly Leu Met Leu Lys Glu Asn His Cys Leu Val Ala Leu
 200 205 210
 His Met Cys Lys His Asp Ile Lys Asn Ser Gly Ile Gln Gln Leu
 215 220 225
 Cys Asp Ala Leu Tyr Leu Asn Ser Ser Leu Arg Tyr Leu Asp Val
 230 235 240
 Ser Cys Asn Lys Ile Thr His Asp Gly Met Val Tyr Leu Ala Asp
 245 250 255
 Val Leu Lys Ser Asn Thr Thr Leu Glu Val Ile Asp Leu Ser Phe
 260 265 270
 Asn Arg Ile Glu Asn Ala Gly Ala Asn Tyr Leu Ser Glu Thr Leu
 275 280 285
 Thr Ser His Asn Arg Ser Leu Lys Ala Leu Ser Val Val Ser Asn
 290 295 300
 Asn Ile Glu Gly Glu Gly Leu Val Ala Leu Ser Gln Ser Met Lys
 305 310 315
 Thr Asn Leu Thr Phe Ser His Ile Tyr Ile Trp Gly Asn Lys Phe
 320 325 330
 Asp Glu Ala Thr Cys Ile Ala Tyr Ser Asp Leu Ile Gln Met Gly
 335 340 345
 Cys Leu Lys Pro Asp Asn Thr Asp Val Glu Pro Phe Val Val Asp
 350 355 360
 Gly Arg Val Tyr Leu Ala Glu Val Ser Asn Gly Leu Lys Lys His
 365 370 375
 Tyr Tyr Trp Thr Ser Thr Tyr Gly Glu Ser Tyr Asp His Ser Ser
 380 385 390
 Asn Ala Gly Phe Ala Leu Val Pro Val Gly Gln Gln Pro
 395 400

<210> 20

<211> 372

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2754960CD1

<400> 20

Met Ser Lys Ala Phe Gly Leu Leu Arg Gln Ile Cys Gln Ser Ile
 1 5 10 15
 Leu Ala Glu Ser Ser Gln Ser Pro Ala Asp Leu Glu Glu Lys Lys
 20 25 30
 Glu Glu Asp Ser Asn Met Lys Arg Glu Gln Pro Arg Glu Arg Pro
 35 40 45
 Arg Ala Trp Asp Tyr Pro His Gly Leu Val Gly Leu His Asn Ile
 50 55 60
 Gly Gln Thr Cys Cys Leu Asn Ser Leu Ile Gln Val Phe Val Met
 65 70 75
 Asn Val Asp Phe Thr Arg Ile Leu Lys Arg Ile Thr Val Pro Arg
 80 85 90
 Gly Ala Asp Glu Gln Arg Arg Ser Val Pro Phe Gln Met Leu Leu
 95 100 105
 Leu Leu Glu Lys Met Gln Asp Ser Arg Gln Lys Ala Val Arg Pro
 110 115 120
 Leu Glu Leu Ala Tyr Cys Leu Gln Lys Cys Asn Val Pro Leu Phe
 125 130 135
 Val Gln His Asp Ala Ala Gln Leu Tyr Leu Lys Leu Trp Asn Leu
 140 145 150
 Ile Lys Asp Gln Ile Thr Asp Val His Leu Val Glu Arg Leu Gln
 155 160 165
 Ala Leu Tyr Thr Ile Arg Val Lys Asp Ser Leu Ile Cys Val Asp
 170 175 180
 Cys Ala Met Glu Ser Ser Arg Asn Ser Ser Met Leu Thr Leu Pro
 185 190 195
 Leu Ser Leu Phe Asp Val Asp Ser Lys Pro Leu Lys Thr Leu Glu
 200 205 210
 Asp Ala Leu His Cys Phe Phe Gln Pro Arg Glu Leu Ser Ser Lys

Ser	Lys	Cys	Phe	Cys	Glu	Asn	Cys	Gly	Lys	Lys	Thr	Arg	Gly	Lys	225
				230					235						240
Gln	Val	Leu	Lys	Leu	Thr	His	Leu	Pro	Gln	Thr	Leu	Thr	Ile	His	245
				245					250						255
Leu	Met	Arg	Phe	Ser	Ile	Arg	Asn	Ser	Gln	Thr	Arg	Lys	Ile	Cys	260
				260					265						270
His	Ser	Leu	Tyr	Phe	Pro	Gln	Ser	Leu	Asp	Phe	Ser	Gln	Ile	Leu	275
				275					280						285
Pro	Met	Lys	Arg	Glu	Ser	Cys	Asp	Ala	Glu	Glu	Gln	Ser	Gly	Gly	290
				290					295						300
Gln	Tyr	Glu	Leu	Phe	Ala	Val	Ile	Ala	His	Val	Gly	Met	Ala	Asp	305
				305					310						315
Ser	Gly	His	Tyr	Cys	Val	Tyr	Ile	Arg	Asn	Ala	Val	Asp	Gly	Lys	320
				320					325						330
Trp	Phe	Cys	Phe	Asn	Asp	Ser	Asn	Ile	Cys	Leu	Val	Ser	Trp	Glu	335
				335					340						345
Asp	Ile	Gln	Cys	Thr	Tyr	Gly	Asn	Pro	Asn	Tyr	His	Trp	Gln	Glu	350
				350					355						360
Thr	Ala	Tyr	Leu	Leu	Val	Tyr	Met	Lys	Met	Glu	Cys				365
				365					370						

<210> 21

<211> 94

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3092341CD1

<400> 21

Met	Leu	Arg	Gly	Val	Leu	Gly	Lys	Thr	Phe	Arg	Leu	Val	Gly	Tyr	
1				5					10					15	
Thr	Ile	Gln	Tyr	Gly	Cys	Ile	Ala	His	Cys	Ala	Phe	Glu	Tyr	Val	
				20					25					30	
Gly	Gly	Val	Val	Met	Val	Pro	Met	Gly	His	Val	Trp	Leu	Glu	Gly	
				35					40					45	
Asp	Asn	Leu	Gln	Asn	Ser	Thr	Asp	Ser	Arg	Cys	Tyr	Gly	Pro	Ile	
				50					55					60	
Pro	Tyr	Gly	Leu	Ile	Arg	Gly	Arg	Ile	Phe	Phe	Lys	Ile	Trp	Leu	
				65					70					75	
Leu	Ser	Asp	Phe	Gly	Phe	Leu	Arg	Ala	Ser	Pro	Asn	Gly	His	Arg	
				80					85					90	
Phe	Ser	Asp	Asp												

<210> 22

<211> 248

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3658034CD1

<400> 22

Met	Asn	Thr	Glu	Arg	Thr	Asn	Ile	Gln	Val	Thr	Val	Thr	Gly	Pro	
1				5					10					15	
Ser	Ser	Pro	Ser	Pro	Val	Lys	Phe	Leu	Ile	Asp	Thr	His	Asn	Arg	
				20					25					30	
Leu	Leu	Leu	Gln	Thr	Ala	Glu	Leu	Ala	Val	Val	Gln	Pro	Thr	Ala	
				35					40					45	
Val	Asn	Ile	Ser	Ala	Asn	Gly	Phe	Gly	Phe	Ala	Ile	Cys	Gln	Leu	
				50					55					60	
Asn	Val	Val	Tyr	Asn	Val	Lys	Ala	Ser	Gly	Ser	Ser	Arg	Arg	Arg	
				65					70					75	
Arg	Ser	Ile	Gln	Asn	Gln	Glu	Ala	Phe	Asp	Leu	Asp	Val	Ala	Val	
				80					85					90	

Lys	Glu	Asn	Lys	Asp	Asp	Leu	Asn	His	Val	Asp	Leu	Asn	Val	Cys
				95					100					105
Thr	Ser	Phe	Ser	Gly	Pro	Gly	Arg	Ser	Gly	Met	Ala	Leu	Met	Glu
				110					115					120
Val	Asn	Leu	Leu	Ser	Gly	Phe	Met	Val	Pro	Ser	Glu	Ala	Ile	Ser
				125					130					135
Leu	Ser	Glu	Thr	Val	Lys	Lys	Val	Glu	Tyr	Asp	His	Gly	Lys	Leu
				140					145					150
Asn	Leu	Tyr	Leu	Asp	Ser	Val	Asn	Glu	Thr	Gln	Phe	Cys	Val	Asn
				155					160					165
Ile	Pro	Ala	Val	Arg	Asn	Phe	Lys	Val	Ser	Asn	Thr	Gln	Asp	Ala
				170					175					180
Ser	Val	Ser	Ile	Val	Asp	Tyr	Tyr	Glu	Pro	Arg	Arg	Gln	Ala	Val
				185					190					195
Arg	Ser	Tyr	Asn	Ser	Glu	Val	Lys	Leu	Ser	Ser	Cys	Asp	Leu	Cys
				200					205					210
Ser	Asp	Val	Gln	Gly	Cys	Arg	Pro	Cys	Glu	Asp	Gly	Ala	Ser	Gly
				215					220					225
Ser	His	His	His	Ser	Ser	Val	Ile	Phe	Ile	Phe	Cys	Phe	Lys	Leu
				230					235					240
Leu	Tyr	Phe	Met	Glu	Leu	Trp	Leu							
				245										

<210> 23

<211> 520

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3883861CD1

<400> 23

Met	Val	Ala	Arg	Val	Gly	Leu	Leu	Leu	Arg	Ala	Leu	Gln	Leu	Leu
1				5					10					15
Leu	Trp	Gly	His	Leu	Asp	Ala	Gln	Pro	Ala	Glu	Arg	Gly	Gly	Gln
				20					25					30
Glu	Leu	Arg	Lys	Glu	Ala	Glu	Ala	Phe	Leu	Glu	Lys	Tyr	Gly	Tyr
				35					40					45
Leu	Asn	Glu	Gln	Val	Pro	Lys	Ala	Pro	Thr	Ser	Thr	Arg	Phe	Ser
				50					55					60
Asp	Ala	Ile	Arg	Ala	Phe	Gln	Trp	Val	Ser	Gln	Leu	Pro	Val	Ser
				65					70					75
Gly	Val	Leu	Asp	Arg	Ala	Thr	Leu	Arg	Gln	Met	Thr	Arg	Pro	Arg
				80					85					90
Cys	Gly	Val	Thr	Asp	Thr	Asn	Ser	Tyr	Ala	Ala	Trp	Ala	Glu	Arg
				95					100					105
Ile	Ser	Asp	Leu	Phe	Ala	Arg	His	Arg	Thr	Lys	Met	Arg	Arg	Lys
				110					115					120
Lys	Arg	Phe	Ala	Lys	Gln	Gly	Asn	Lys	Trp	Tyr	Lys	Gln	His	Leu
				125					130					135
Ser	Tyr	Arg	Leu	Val	Asn	Trp	Pro	Glu	His	Leu	Pro	Glu	Pro	Ala
				140					145					150
Val	Arg	Gly	Ala	Val	Arg	Ala	Ala	Phe	Gln	Leu	Trp	Ser	Asn	Val
				155					160					165
Ser	Ala	Leu	Glu	Phe	Trp	Glu	Ala	Pro	Ala	Thr	Gly	Pro	Ala	Asp
				170					175					180
Ile	Arg	Leu	Thr	Phe	Phe	Gln	Gly	Asp	His	Asn	Asp	Gly	Leu	Gly
				185					190					195
Asn	Ala	Phe	Asp	Gly	Pro	Gly	Gly	Ala	Leu	Ala	His	Ala	Phe	Leu
				200					205					210
Pro	Arg	Arg	Gly	Glu	Ala	His	Phe	Asp	Gln	Asp	Glu	Arg	Trp	Ser
				215					220					225
Leu	Ser	Arg	Arg	Arg	Gly	Arg	Asn	Leu	Phe	Val	Val	Leu	Ala	His
				230					235					240
Glu	Ile	Gly	His	Thr	Leu	Gly	Leu	Thr	His	Ser	Pro	Ala	Pro	Arg
				245					250					255
Ala	Leu	Met	Ala	Pro	Tyr	Tyr	Lys	Arg	Leu	Gly	Arg	Asp	Ala	Leu

Leu Ser Trp Asp	260	Val Leu Ala Val	265	Gln Ser Leu Tyr Gly	270
Asp	275	Val Ala Val Gln	280	Lys	285
Pro Leu Gly Gly	290	Leu Pro Gly Lys Leu	295	Phe	300
Thr Asp Phe Glu	305	Thr Trp Asp Ser Tyr	310	Arg Arg	315
Pro Glu Thr Gln	320	Pro Lys Tyr Cys	325	His Ser Ser Phe Asp	330
Ile Thr Val Asp	335	Arg Gln Gln Gln Leu	340	Tyr Ile Phe Lys Gly	345
His Phe Trp Glu	350	Val Ala Ala Asp Gly	355	Asn Val Ser Glu Pro	360
Pro Leu Gln Glu	365	Arg Trp Val Gly Leu	370	Pro Pro Asn Ile Glu	375
Ala Ala Val Ser	380	Leu Asn Asp Gly Asp	385	Phe Tyr Phe Phe Lys	390
Gly Arg Cys Trp	395	Arg Phe Arg Gly Pro	400	Lys Pro Val Trp Gly	405
Pro Gln Leu Cys	410	Arg Ala Gly Gly Leu	415	Pro Arg His Pro Asp	420
Ala Leu Phe Phe	425	Pro Leu Arg Arg	430	Leu Ile Leu Phe Lys	435
Ala Arg Tyr Tyr	440	Val Leu Ala Arg Gly	445	Gly Leu Gln Val Glu	450
Tyr Tyr Pro Arg	455	Ser Leu Gln Asp Trp	460	Gly Gly Ile Pro Glu	465
Val Ser Gly Ala	470	Leu Pro Arg Pro Asp	475	Gly Ser Ile Ile Phe	480
Arg Asp Asp Arg	485	Tyr Trp Arg Leu Asp	490	Gln Ala Lys Leu Gln	495
Thr Thr Ser Gly	500	Arg Trp Ala Thr Glu	505	Leu Pro Trp Met Gly	510
Trp His Ala Asn	515	Ser Gly Ser Ala Leu	520	Phe	

<210> 24

<211> 422

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4993873CD1

<400> 24

Met Gly Pro Ala Trp	1	Leu Trp Leu Leu Gly	10	Thr Gly Ile Leu Ala	15
Ser Val His Cys Gln	20	Pro Leu Leu Ala His	25	Gly Asp Lys Ser Leu	30
Gln Gly Pro Gln Pro	35	Pro Arg His Gln Leu	40	Ser Glu Pro Ala Pro	45
Ala Tyr His Arg Ile	50	Thr Pro Thr Ile Thr	55	Asn Phe Ala Leu Arg	60
Leu Tyr Lys Glu Leu	65	Ala Ala Asp Ala Pro	70	Gly Asn Ile Phe Phe	75
Ser Pro Val Ser Ile	80	Ser Thr Thr Leu Ala	85	Leu Leu Ser Leu Gly	90
Ala Gln Ala Asn Thr	95	Ser Ala Leu Ile Leu	100	Glu Gly Leu Gly Phe	105
Asn Leu Thr Glu Thr	110	Pro Glu Ala Asp Ile	115	His Gln Gly Phe Arg	120
Ser Leu Leu His Thr	125	Leu Ala Leu Pro Ser	130	Pro Lys Leu Glu Leu	135
Lys Val Gly Asn Ser	140	Leu Phe Leu Asp Lys	145	Arg Leu Lys Pro Arg	150
Gln His Tyr Leu Asp	155	Ser Ile Lys Glu Leu	160	Tyr Gly Ala Phe Ala	165

Phe	Ser	Ala	Asn	Phe	Thr	Asp	Ser	Val	Thr	Thr	Gly	Arg	Gln	Ile
				170					175					180
Asn	Asp	Tyr	Leu	Arg	Arg	Gln	Thr	Tyr	Gly	Gln	Val	Val	Asp	Cys
				185					190					195
Leu	Pro	Glu	Phe	Ser	Gln	Asp	Thr	Phe	Met	Val	Leu	Ala	Asn	Tyr
				200					205					210
Ile	Phe	Phe	Lys	Ala	Lys	Trp	Lys	His	Pro	Phe	Ser	Arg	Tyr	Gln
				215					220					225
Thr	Gln	Lys	Gln	Ala	Ser	Phe	Phe	Val	Asp	Glu	Arg	Thr	Ser	Leu
				230					235					240
Gln	Val	Pro	Met	Met	His	Gln	Lys	Glu	Met	His	Arg	Phe	Leu	Tyr
				245					250					255
Asp	Gln	Asp	Leu	Ala	Cys	Thr	Val	Leu	Gln	Ile	Glu	Tyr	Arg	Gly
				260					265					270
Asn	Ala	Leu	Ala	Leu	Leu	Val	Leu	Pro	Asp	Pro	Gly	Lys	Met	Lys
				275					280					285
Gln	Val	Glu	Ala	Ala	Leu	Gln	Pro	Gln	Thr	Leu	Arg	Lys	Trp	Gly
				290					295					300
Gln	Leu	Leu	Leu	Pro	Ser	Leu	Leu	Asp	Leu	His	Leu	Pro	Arg	Phe
				305					310					315
Ser	Ile	Ser	Gly	Thr	Tyr	Asn	Leu	Glu	Asp	Ile	Leu	Pro	Gln	Ile
				320					325					330
Gly	Leu	Thr	Asn	Ile	Leu	Asn	Leu	Glu	Ala	Asp	Phe	Ser	Gly	Val
				335					340					345
Thr	Gly	Gln	Leu	Asn	Lys	Thr	Ile	Ser	Lys	Val	Ser	His	Lys	Ala
				350					355					360
Met	Val	Asp	Met	Ser	Glu	Lys	Gly	Thr	Glu	Ala	Gly	Ala	Ala	Ser
				365					370					375
Gly	Leu	Leu	Ser	Gln	Pro	Pro	Ser	Leu	Asn	Thr	Met	Ser	Asp	Pro
				380					385					390
His	Ala	His	Phe	Asn	Arg	Pro	Phe	Leu	Leu	Leu	Trp	Glu	Val	Val
				395					400					405
Thr	Thr	Gln	Ser	Leu	Leu	Phe	Leu	Gly	Lys	Val	Val	Asn	Pro	Val
				410					415					420

Ala Gly

<210> 25
 <211> 114
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5208004CD1

Met	Arg	Trp	Arg	Gln	Arg	Ser	Phe	Leu	Leu	Arg	Leu	Phe	Leu	Gly
1				5					10					15
Ser	Leu	Arg	Gly	Gly	Gln	His	His	Pro	Pro	Leu	Thr	Leu	Pro	Ser
				20					25					30
Ala	Ser	Ser	Leu	Pro	Phe	Ser	Thr	Leu	Ser	Leu	Leu	Leu	Ala	Ser
				35					40					45
Ser	Leu	Ser	Cys	Cys	Leu	Val	Ser	Pro	Cys	Pro	Lys	Thr	Pro	Gly
				50					55					60
Ser	Phe	Val	Leu	Leu	Pro	Trp	Pro	Pro	Pro	Arg	Arg	Arg	Ser	Gln
				65					70					75
Ala	Pro	Ser	Pro	Pro	Arg	Gly	Ile	His	Thr	Thr	Gly	Ser	Cys	Trp
				80					85					90
Gly	Trp	Gly	Ser	Pro	Ala	Gly	Phe	Leu	Met	Pro	Cys	Ala	Gln	Gly
				95					100					105
Ser	Ala	Ala	Val	Ile	Phe	Gly	Leu	Ser						
				110										

<210> 26
 <211> 742
 <212> PRT
 <213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5267783CD1

<400> 26

Met	Pro	Ala	Gly	Gly	Lys	Gly	Ser	His	Pro	Ser	Ser	Thr	Pro	Gln
1				5					10					15
Arg	Val	Pro	Asn	Arg	Leu	Ile	His	Glu	Lys	Ser	Pro	Tyr	Leu	Leu
				20					25					30
Gln	His	Ala	Tyr	Asn	Pro	Val	Asp	Trp	Tyr	Pro	Trp	Gly	Glu	Glu
				35					40					45
Ala	Phe	Asp	Lys	Ala	Arg	Lys	Glu	Asn	Lys	Pro	Ile	Phe	Leu	Ser
				50					55					60
Val	Gly	Tyr	Ser	Thr	Cys	His	Trp	Cys	His	Met	Met	Glu	Glu	Glu
				65					70					75
Ser	Phe	Gln	Asn	Glu	Glu	Ile	Gly	Arg	Leu	Leu	Ser	Glu	Asp	Phe
				80					85					90
Val	Ser	Val	Lys	Val	Asp	Arg	Glu	Glu	Arg	Pro	Asp	Val	Asp	Lys
				95					100					105
Val	Tyr	Met	Thr	Phe	Val	Gln	Ala	Thr	Ser	Ser	Gly	Gly	Gly	Trp
				110					115					120
Pro	Met	Asn	Val	Trp	Leu	Thr	Pro	Asn	Leu	Gln	Pro	Phe	Val	Gly
				125					130					135
Gly	Thr	Tyr	Phe	Pro	Pro	Glu	Asp	Gly	Leu	Thr	Arg	Val	Gly	Phe
				140					145					150
Arg	Thr	Val	Leu	Leu	Arg	Ile	Arg	Glu	Gln	Trp	Lys	Gln	Asn	Lys
				155					160					165
Asn	Thr	Leu	Leu	Glu	Asn	Ser	Gln	Arg	Val	Thr	Thr	Ala	Leu	Leu
				170					175					180
Ala	Arg	Ser	Glu	Ile	Ser	Val	Gly	Asp	Arg	Gln	Leu	Pro	Pro	Ser
				185					190					195
Ala	Ala	Thr	Val	Asn	Asn	Arg	Cys	Phe	Gln	Gln	Leu	Asp	Glu	Gly
				200					205					210
Tyr	Asp	Glu	Glu	Tyr	Gly	Gly	Phe	Ala	Glu	Ala	Pro	Lys	Phe	Pro
				215					220					225
Thr	Pro	Val	Ile	Leu	Ser	Phe	Leu	Phe	Ser	Tyr	Trp	Leu	Ser	His
				230					235					240
Arg	Leu	Thr	Gln	Asp	Gly	Ser	Arg	Ala	Gln	Gln	Met	Ala	Leu	His
				245					250					255
Thr	Leu	Lys	Met	Met	Ala	Asn	Gly	Gly	Ile	Arg	Asp	His	Val	Gly
				260					265					270
Gln	Gly	Phe	His	Arg	Tyr	Ser	Thr	Asp	Arg	Gln	Trp	His	Val	Pro
				275					280					285
His	Phe	Glu	Lys	Met	Leu	Tyr	Asp	Gln	Ala	Gln	Leu	Ala	Val	Ala
				290					295					300
Tyr	Ser	Gln	Ala	Phe	Gln	Leu	Ser	Gly	Asp	Glu	Phe	Tyr	Ser	Asp
				305					310					315
Val	Ala	Lys	Gly	Ile	Leu	Gln	Tyr	Val	Ala	Arg	Ser	Leu	Ser	His
				320					325					330
Arg	Ser	Gly	Gly	Phe	Tyr	Ser	Ala	Glu	Asp	Ala	Asp	Ser	Pro	Pro
				335					340					345
Glu	Arg	Gly	Gln	Arg	Pro	Lys	Glu	Gly	Ala	Tyr	Tyr	Val	Trp	Thr
				350					355					360
Val	Lys	Glu	Val	Gln	Gln	Leu	Leu	Pro	Glu	Pro	Val	Leu	Gly	Ala
				365					370					375
Thr	Glu	Pro	Leu	Thr	Ser	Gly	Gln	Leu	Leu	Met	Lys	His	Tyr	Gly
				380					385					390
Leu	Thr	Glu	Ala	Gly	Asn	Ile	Ser	Pro	Ser	Gln	Asp	Pro	Lys	Gly
				395					400					405
Glu	Leu	Gln	Gly	Gln	Asn	Val	Leu	Thr	Val	Arg	Tyr	Ser	Leu	Glu
				410					415					420
Leu	Thr	Ala	Ala	Arg	Phe	Gly	Leu	Asp	Val	Glu	Ala	Val	Arg	Thr
				425					430					435
Leu	Leu	Asn	Ser	Gly	Leu	Glu	Lys	Leu	Phe	Gln	Ala	Arg	Lys	His
				440					445					450
Arg	Pro	Lys	Pro	His	Leu	Asp	Ser	Lys	Met	Leu	Ala	Ala	Trp	Asn
				455					460					465

Gly	Leu	Met	Val	Ser	Gly	Tyr	Ala	Val	Thr	Gly	Ala	Val	Leu	Gly	
				470					475					480	
Gln	Asp	Arg	Leu	Ile	Asn	Tyr	Ala	Thr	Asn	Gly	Ala	Lys	Phe	Leu	
				485					490					495	
Lys	Arg	His	Met	Phe	Asp	Val	Ala	Ser	Gly	Arg	Leu	Met	Arg	Thr	
				500					505					510	
Cys	Tyr	Thr	Gly	Pro	Gly	Gly	Thr	Val	Glu	His	Ser	Asn	Pro	Pro	
				515					520					525	
Cys	Trp	Gly	Phe	Leu	Glu	Asp	Tyr	Ala	Phe	Val	Val	Arg	Gly	Leu	
				530					535					540	
Leu	Asp	Leu	Tyr	Glu	Ala	Ser	Gln	Glu	Ser	Ala	Trp	Leu	Glu	Trp	
				545					550					555	
Ala	Leu	Arg	Leu	Gln	Asp	Thr	Gln	Asp	Arg	Leu	Phe	Trp	Asp	Ser	
				560					565					570	
Gln	Gly	Gly	Gly	Tyr	Phe	Cys	Ser	Glu	Ala	Glu	Leu	Gly	Ala	Gly	
				575					580					585	
Leu	Pro	Leu	Arg	Leu	Lys	Asp	Asp	Gln	Asp	Gly	Ala	Glu	Pro	Ser	
				590					595					600	
Ala	Asn	Ser	Val	Ser	Ala	His	Asn	Leu	Leu	Arg	Leu	His	Gly	Phe	
				605					610					615	
Thr	Gly	His	Lys	Asp	Trp	Met	Asp	Lys	Cys	Val	Cys	Leu	Leu	Thr	
				620					625					630	
Ala	Phe	Ser	Glu	Arg	Met	Arg	Arg	Val	Pro	Val	Ala	Leu	Pro	Glu	
				635					640					645	
Met	Val	Arg	Ala	Leu	Ser	Ala	Gln	Gln	Gln	Thr	Leu	Lys	Gln	Ile	
				650					655					660	
Val	Ile	Cys	Gly	Asp	Arg	Gln	Ala	Lys	Asp	Thr	Lys	Ala	Leu	Val	
				665					670					675	
Gln	Cys	Val	His	Ser	Val	Tyr	Ile	Pro	Asn	Lys	Val	Leu	Ile	Leu	
				680					685					690	
Ala	Asp	Gly	Asp	Pro	Ser	Ser	Phe	Leu	Ser	Arg	Gln	Leu	Pro	Phe	
				695					700					705	
Leu	Ser	Thr	Leu	Arg	Arg	Leu	Glu	Asp	Gln	Ala	Thr	Ala	Tyr	Val	
				710					715					720	
Cys	Glu	Asn	Gln	Ala	Cys	Ser	Val	Pro	Ile	Thr	Asp	Pro	Cys	Glu	
				725					730					735	
Leu	Arg	Lys	Leu	Leu	His	Pro									
				740											

<210> 27
 <211> 734
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5583922CD1

<400> 27

Met	Trp	Gly	Leu	Leu	Leu	Ala	Leu	Ala	Ala	Phe	Ala	Pro	Ala	Val	
1				5					10					15	
Gly	Pro	Ala	Leu	Gly	Ala	Pro	Arg	Asn	Ser	Val	Leu	Gly	Leu	Ala	
				20					25					30	
Gln	Pro	Gly	Thr	Thr	Lys	Val	Pro	Gly	Ser	Thr	Pro	Ala	Leu	His	
				35					40					45	
Ser	Ser	Pro	Ala	Gln	Pro	Pro	Ala	Glu	Thr	Ala	Asn	Gly	Thr	Ser	
				50					55					60	
Glu	Gln	His	Val	Arg	Ile	Arg	Val	Ile	Lys	Lys	Lys	Lys	Val	Ile	
				65					70					75	
Met	Lys	Lys	Arg	Lys	Lys	Leu	Thr	Leu	Thr	Arg	Pro	Thr	Pro	Leu	
				80					85					90	
Val	Thr	Ala	Gly	Pro	Leu	Val	Thr	Pro	Thr	Pro	Ala	Gly	Thr	Leu	
				95					100					105	
Asp	Pro	Ala	Glu	Lys	Gln	Glu	Thr	Gly	Cys	Pro	Pro	Leu	Gly	Leu	
				110					115					120	
Glu	Ser	Leu	Arg	Val	Ser	Asp	Ser	Arg	Leu	Glu	Ala	Ser	Ser	Ser	
				125					130					135	
Gln	Ser	Phe	Gly	Leu	Gly	Pro	His	Arg	Gly	Arg	Leu	Asn	Ile	Gln	

Ser Gly Leu Glu Asp	Gly Asp Leu Tyr	Asp Gly Ala Trp Cys	Ala
140	145	150	
155	160	165	
Glu Glu Gln Asp	Asp Pro Trp Phe	Gln Val Asp Ala Gly	His
170	175	180	
Pro Thr Arg Phe	Ser Gly Val Ile Thr	Gln Gly Ser Asn Ser	Val
185	190	195	
Trp Arg Tyr Asp	Trp Val Thr Ser Tyr	Lys Val Gln Phe Ser	Asn
200	205	210	
Asp Ser Arg Thr	Trp Trp Gly Ser Arg	Asn His Ser Ser Gly	Met
215	220	225	
Asp Ala Val Phe	Pro Ala Asn Ser Asp	Pro Glu Thr Pro Val	Leu
230	235	240	
Asn Leu Leu Pro	Glu Pro Gln Val Ala	Arg Phe Ile Arg Leu	Leu
245	250	255	
Pro Gln Thr Trp	Leu Gln Gly Gly Ala	Pro Cys Leu Arg Ala	Glu
260	265	270	
Ile Leu Ala Cys	Pro Val Ser Asp Pro	Asn Asp Leu Phe Leu	Glu
275	280	285	
Ala Pro Ala Ser	Gly Ser Ser Asp Pro	Leu Asp Phe Gln His	His
290	295	300	
Asn Tyr Lys Ala	Met Arg Lys Leu Met	Lys Gln Val Gln Glu	Gln
305	310	315	
Cys Pro Asn Ile	Thr Arg Ile Tyr Ser	Ile Gly Lys Ser Tyr	Gln
320	325	330	
Gly Leu Lys Leu	Tyr Val Met Glu Met	Ser Asp Lys Pro Gly	Glu
335	340	345	
His Glu Leu Gly	Glu Pro Glu Val Arg	Tyr Val Ala Gly Met	His
350	355	360	
Gly Asn Glu Ala	Leu Gly Arg Glu Leu	Leu Leu Leu Met	Gln
365	370	375	
Phe Leu Cys His	Glu Phe Leu Arg Gly	Asn Pro Arg Val Thr	Arg
380	385	390	
Leu Leu Ser Glu	Met Arg Ile His Leu	Leu Pro Ser Met Asn	Pro
395	400	405	
Asp Gly Tyr Glu	Ile Ala Tyr His Arg	Gly Ser Glu Leu Val	Gly
410	415	420	
Trp Ala Glu Gly	Arg Trp Asn Asn Gln	Ser Ile Asp Leu Asn	His
425	430	435	
Asn Phe Ala Asp	Leu Asn Thr Pro Leu	Trp Glu Ala Gln Asp	Asp
440	445	450	
Gly Lys Val Pro	His Ile Val Pro Asn	His His Leu Pro Leu	Pro
455	460	465	
Thr Tyr Tyr Thr	Leu Pro Asn Ala Thr	Val Ala Pro Glu Thr	Arg
470	475	480	
Ala Val Ile Lys	Trp Met Lys Arg Ile	Pro Phe Val Leu Ser	Ala
485	490	495	
Asn Leu His Gly	Gly Glu Leu Val Val	Ser Tyr Pro Phe Asp	Met
500	505	510	
Thr Arg Thr Pro	Trp Ala Ala Arg Glu	Leu Thr Pro Thr Pro	Asp
515	520	525	
Asp Ala Val Phe	Arg Trp Leu Ser Thr	Val Tyr Ala Gly Ser	Asn
530	535	540	
Leu Ala Met Gln	Asp Thr Ser Arg Arg	Pro Cys His Ser Gln	Asp
545	550	555	
Phe Ser Val His	Gly Asn Ile Ile Asn	Gly Ala Asp Trp His	Thr
560	565	570	
Val Pro Gly Ser	Met Asn Asp Phe Ser	Tyr Leu His Thr Asn	Cys
575	580	585	
Phe Glu Val Thr	Val Glu Leu Ser Cys	Asp Lys Phe Pro His	Glu
590	595	600	
Asn Glu Leu Pro	Gln Glu Trp Glu Asn	Asn Lys Asp Ala Leu	Leu
605	610	615	
Thr Tyr Leu Glu	Gln Val Arg Met Gly	Ile Ala Gly Val Val	Arg
620	625	630	
Asp Lys Asp Thr	Glu Leu Gly Ile Ala	Asp Ala Val Ile Ala	Val
635	640	645	

Asp	Gly	Ile	Asn	His	Asp	Val	Thr	Thr	Ala	Trp	Gly	Gly	Asp	Tyr
				650					655					660
Trp	Arg	Leu	Leu	Thr	Pro	Gly	Asp	Tyr	Met	Val	Thr	Ala	Ser	Ala
				665					670					675
Glu	Gly	Tyr	His	Ser	Val	Thr	Arg	Asn	Cys	Arg	Val	Thr	Phe	Glu
				680					685					690
Glu	Gly	Pro	Phe	Pro	Cys	Asn	Phe	Val	Leu	Thr	Lys	Thr	Pro	Lys
				695					700					705
Gln	Arg	Leu	Arg	Glu	Leu	Leu	Ala	Ala	Gly	Ala	Lys	Val	Pro	Pro
				710					715					720
Asp	Leu	Arg	Arg	Arg	Leu	Glu	Arg	Leu	Arg	Gly	Gln	Lys	Asp	
				725					730					

<210> 28

<211> 2080

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 088718CB1

<400> 28

tgaaggactt	ttccaggacc	caaggccaca	cactggaagt	cttgcagctg	aagggaggca	60
ctccttggcc	tccgcagccg	atcacatgaa	gggtggtgcc	agtctcctgc	tctccgtcct	120
cctggcacag	gtgtggctgg	taccggctt	ggccccaggt	cctcagtcgc	cagagacccc	180
agccccctag	aaccagacca	gcagggtagt	gcaggctccc	agggaggaag	aggaagatga	240
gcaggaggcc	agcgaggaga	aggccggtga	ggaagagaaa	gcctggctga	tggccagcag	300
gcagcagctt	gccaaggaga	cttcaaactt	cggattcagc	ctgctgcgaa	agatctccat	360
gaggcacgat	ggcaacatgg	tcttctctcc	atctggcatg	tccttggcca	tgacaggctt	420
gatgctgggg	gccacagggc	cgactgaaac	ccagatcaag	agagggctcc	acttgcaggc	480
cctgaagccc	accaagcccc	ggctcctgcc	tccctctttt	aagggactca	gagagacctt	540
ctcccccaac	ctggaactgg	gcctctcaca	ggggagtttt	gccttcatcc	acaaggattt	600
tgatgtcaaa	gagactttct	tcaatttatc	caagaggtat	tttgatacag	agtgcgtgcc	660
tatgaatttt	cgcaatgcct	cacaggccaa	aaggctcatg	aatcattaca	ttaacaaaga	720
gactcggggg	aaaattccca	aactgtttga	tgagattaat	cctgaaacca	aattaatctt	780
tgtcgattac	atcttgttca	aagggaatg	gttgaccccc	tttgacctg	tcttcaccga	840
agtcgacact	ttccacctgg	acaagtacaa	gaccattaag	gtgcccata	tgtagcgtgc	900
aggcaagttt	gcctccacct	ttgacaagaa	ttttcgttgt	catgtcctca	aactgcccta	960
ccaaggaaat	gccaccatgc	tgggtggtct	catggagaaa	atgggtgacc	acctcgccct	1020
tgaagactac	ctgaccacag	acttggtgga	gacatggctc	agaaacatga	aaaccagaaa	1080
catggaagtt	tcttttccga	agttcaagct	agatcagaag	tatgagatgc	atgagctgct	1140
taggcagatg	ggaatcagaa	gaatcttctc	accttttgct	gaccttagtg	aactctcagc	1200
tactggaaga	aatctccaag	tatccagggt	tttacaagaa	acagtgattg	aagttgatga	1260
aaggggcact	gaggcagtg	caggaatctt	gtcagaaaat	actgcttatt	ccatgcctcc	1320
tgctacaaa	gtggaccggc	catttcattt	catgatctat	gaagaaacct	ctggaatgct	1380
tctgtttctg	ggcagggtgg	tgaatccgac	tctcctataa	ttcaggacat	gcataagcaa	1440
cttcgtgctg	tagtagatgc	tgaatctgag	gtatcaaaca	cacacaggat	accagcaatg	1500
gatggcaggg	gagagtgttc	cttttgttct	taactagttt	aggggtttct	caaataaata	1560
cagtagtccc	cacttatctg	agggggatac	attcaaagac	ccccagcaga	tgccatgaaac	1620
ggtggacagt	gctgaacctt	atatataatt	tttctacac	atacatacct	atgataaagt	1680
ttaattttata	aattaggcac	agtaagagat	taacaataat	aacaacatta	agtaaaatga	1740
gttacttgaa	cgcaagcact	gcaataccat	aacagtcaaa	ctgattatag	agaaggctac	1800
taagtgtactc	atgggcgagg	agcatagaca	gtgtggagac	attgggcaag	gggagaattc	1860
acatcctggg	tgggacagag	caggacgatg	caagattcca	tcccactact	cagaatggca	1920
tgctgcttaa	gactttttaga	ttgtttattt	ctggaatttt	tcatttaattg	tttttggacc	1980
atggttgacc	atggttaact	gagactgcag	aaagcaaaac	catggataag	ggaggactac	2040
tacaaaagca	ttaaattgat	acatatattt	taaaaaaaa			2080

<210> 29

<211> 2225

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 114551CB1

```

<400> 29
gtgcttggcg cctgcgctgg acgactcggc cggtagtgga gatgtccggc cggctctaagc 60
gggagtcctc cgggtccact cgcgggaagc gagagtcctga gtcgcggggc agctccggtc 120
gcgtcaagcg ggagcgcgat cgggagcggg agcctgaggg ggcgagctcc cggggcagcc 180
ctgtgcgcgt gaagcgggag ttcgagccgg cgagcgcgcg cgaggccccg gcttctgttg 240
tcccgtttgt gcgggtgaag cgggagcgcg aggtcgatga ggactcggag cctgagcggg 300
aggtgcgagc aaagaatggc cgagtggatt ctgaggaccg gaggagccgc cactgcccgt 360
acctggacac cattaacagg agtgtgctgg actttgactt tgagaaactg tgttctatct 420
ccctctcaca catcaatgct tatgcctgtc tgggtgtgtg caagtacttt caaggccggg 480
gtttgaagtc tcacgcctac attcacagtg tccagtttag ccaccatgtt ttcctcaacc 540
tccacaccct caagttttac tgccttccag acaactatga gatcatcgat tccctattgg 600
aggatatcac gtatgtgttg aagcccactt tcacaaagca gcaaattgca aacttggaca 660
agcaagccaa attgtccggg gcatatgatg gtaccactta cctgccgggt attgtgggac 720
tgaataacat aaaggccaat gattatgcca acgctgtcct tcaggctcta tctaattgtc 780
ctcctctccg gaactacttt ctggaagaag acaattataa gaacatcaaa cgtcctccag 840
gggatatcat gttcttgttg gtccagcggt ttggagagct gatgagaaaag ctctggaacc 900
ctcgaaattt caaggcacat gtgtctcccc atgagatgct tcaggcagtt gtagtttga 960
gtaagaagac ttttcagatc accaaacaag gatagtgcg tgaactttct tcttggtttc 1020
tgaatgctct gcactcagct ctggggggca caaagaagaa aaagaagact attgtgactg 1080
atgttttcca ggggtccatg aggatcttca ctaaaaagct tccccatcct gatctgccag 1140
cagaagaaaa agagcagttg ctccataatg acgagtacca ggagacaatg gtggagtcca 1200
cttttatgta cctgacgctg gaccttecta ctgccccctt ctacaaggac gagaaggagc 1260
agctcatcat tccccagtg ccactcttca acatcctggc taagttcaat ggcacactg 1320
agaaggaaata taagacttac aaggagaact ttctgaagcg cttccagctt accaagttgc 1380
ctccatatct aatcttttgt atcaagagat tcactaagaa caacttcttt gttgagaaga 1440
atccaactat tgtcaatttc cctattacaa atgtggatct gagagaatac ttgtctgaag 1500
aagtacaagc agtacacaag aataccacct atgacctcat tgccaacatc gtgcatgacg 1560
gcaagccctc cgagggtccc taccggatcc acgtgcttca tcatgggaca ggcaaatggt 1620
atgaattaca agacctccag gtgactgaca tcttccccca gatgatcaca ctgtcagagg 1680
cttacattca gatttgggaag aggcgagata atgatgaaac caaccagcag ggggcttgaa 1740
ggaggcgctt agggctttgc tccaagggc tgtggctgat gatggtaaat aagaacacag 1800
aagctgtagc tgaacacagg ctggctgggt ggcttcctag gccagcccag cttgtatggg 1860
ttctggctac accagagcac caagagccca cttgcctggg atggccccac actgtcactc 1920
agctgttctt tgatcatttt tttctagatt gatgtcctt tctcccatgc attgagctcc 1980
catctagctt cagcagggca gaaccttct ccagatgtgt gtaacttatg tctttagtat 2040
ctgggagtag ttgaagaaca gataattcct tccaaacatc aagccttggg attcttggag 2100
caagcagaaa gccagtaact tcgctctgtt agaggtggag gattttctta tggttcccc 2160
catttcctga tttgtatttt tagatggatt aaatagtctc ctgtttttaa accaaaaaaa 2220
aaaaa 2225

```

```

<210> 30
<211> 3287
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 1261376CB1

```

```

<400> 30
caggcgcgtt acccggcggt ctccgcgcgg cgcggcgcaa gggacgtggg ggaaggggca 60
gggaggagga agcgggtggc gctgcggatg tccgtgtgag cgagcggcgc ctgaacacac 120
ggcggtctgc gagcgctga cccgggcctg cgcagagacc tgcaccgagc tccggggccc 180
cacaccgct acggtggccc tgcgcccggt gctactgagg cggcgtgctc tgcattcttc 240
gctgtccagg cctgcgggct ctgggtgtct tgggtcctc cttgtctgcc tgctccctcc 300
tgcttgcttg agtcaccgcc gccgcgcggc ccacagccat ggccgagagt ggtgaaagcg 360
gggttccctc gggctcccag gatagcgccg cggagccga aggtgctggc gcccccgcg 420
ccgtgcctc cgcggacgcc aaaatcatga aagtcaccgt gaagaccccg aaggaaaagg 480
aggaattcgc cgtgcccag aatagctccg tccagcagtt taaggaagaa atctctaacc 540
gttttaaate acatactgac caacttgtgt tgatatttgc tggaaaaatt ttgaaagatc 600
aagatacctt gagtcagcat ggaattcatg atggacttac tgttcacctt gtcattaaaa 660
cacaaaacag gctcaggat cattcagctc agcaaacaaa tacagctgga agcaatgtta 720
ctacatcatc aactccta atgttaactc catctggttc tgctactagc aaccttttg 780
gttttaggtg ccttggggga cttgcaggtc tgagttagct gggtttgaat actaccaact 840
tctctgaact acagagtcag atgcagcgac aacttttgtc taacctgaa atgatggtc 900
agatcatgga aaatcccttt gttcagagca tgctctcaaa tctgacctg atgagacgt 960
taattatggc caatccacaa atgcagcagt tgatacagag aaatccagaa attagtcata 1020

```

tgttgaataa	tccagatata	atgagacaaa	cgttggaaact	tgccaggaat	ccagcaatga	1080
tgcaggagat	gatgaggaa	caggaccgag	ctttgagcaa	cctagaaagc	atcccagggg	1140
gatataatgc	tttaaggcgc	atgtacacag	atattcagga	accaatgctg	agtgtctgcac	1200
aagagcagtt	tggtggtaat	ccattttgctt	cotttggtgag	caatacatcc	tctggtgaag	1260
gtagtcaacc	ttcccgtaaca	gaaaatagag	atccactacc	caatccatgg	gctccacaga	1320
cttcccagag	ttcatcagct	tccagcggca	ctgccagcac	tgtgggtggc	actactggta	1380
gtactgccag	tggcacttct	gggcagagta	ctactgcgcc	aaatttgggtg	cctgggagtag	1440
gagctagtat	gttcaacaca	ccaggaatgc	agagcttgtt	gcaacaaata	actgaaaacc	1500
cacaacttat	gcaaaacatg	ttgtctgccc	cctacatgag	aagcatgatg	cagtcactaa	1560
gccagaatcc	tgaccttgc	gcacagatga	tgctgaataa	tcccctattt	gctggaaatc	1620
ctcagcttca	agaacaaatg	agacaacagc	tcccactttt	cctccaacaa	atgcagaatc	1680
ctgatacact	atcagcaatg	tcaaacccta	gagcaatgca	ggccttgtta	cagattcagc	1740
aggggtttaca	gacatttagc	acgggaagccc	cgggcctcat	cccaggggtt	actcctggct	1800
tgggggcatt	aggaagcact	ggaggctctt	caggaaactaa	tggatctaac	gccacacctt	1860
gtgaaaacac	aagtcccaca	gcaggaacca	ctgaacctgg	acatcagcag	tttattcagc	1920
agatgcttca	ggctcttgc	ggagtaaatc	ctcagctaca	gaatccagaa	gtcagatttc	1980
agcaacaact	ggaacaactc	agtgcattgg	gatttttgaa	ccgtgaagca	aacttgcaag	2040
ctctaatagc	aacaggaggt	gatatcaatg	cagctattga	aagggttact	ggctcccagc	2100
catcatagca	gcatttctgt	atcttgaaaa	aatgtaattt	atttttgata	acggctctta	2160
aactttaaaa	tacctgcttt	atttcatttt	gactcttgga	attctgtgct	gttataaaca	2220
aacccaatat	gatgcatttt	aagggtggagt	acagtaagat	gtgtgggttt	ttctgtattt	2280
ttcttttctg	gaacagtggg	aattaaggct	actgcatgca	tcacttctgc	atttattgta	2340
attttttaaa	aacatcacct	tttatagttg	ggtgaccaga	ttttgtctcg	catctgtcca	2400
gtttatttgc	tttttaaaaca	ttagcctatg	gtagtaattt	atgtagaata	aaagcattaa	2460
aaagaagcaa	atcatttgca	ctctataatt	tgtggtacag	tattgcttat	tgtgactttg	2520
gcatgcattt	ttgcaaacaa	tgctgtaaga	tttatactac	tgataatttt	gttttatttg	2580
tatacaatat	agagtatgca	catttgggac	tgcatctctg	gaaacatact	gcaataggct	2640
ctctgagcaa	aacacctgta	actaaaaaag	tgaagataag	aaaatactct	taaagctgag	2700
tatttccctaa	ttgtatagaa	tcttacagca	tctttgacaa	acatctccca	gcaaaagtgc	2760
cgggttagtca	ggtttggtga	aaatacagta	gaaaagctga	ttctgggtta	ctctttaagg	2820
acaattaatt	gtacagacac	ataatgtaac	attgtctcaa	cattcattca	cagattgact	2880
gtaaattacc	ttaatctttg	tgcagactga	aggaacactg	tagtataccc	caaagtgcac	2940
ttgcctagga	cttctcagct	tctcccatag	gtagtttaac	aggcattaaa	atttghtaatt	3000
gaaatgttgc	tttcaactgaa	aaagtgtctt	gatgtttcag	ttatttttaa	tcgccataaa	3060
aaaaatagaac	tatcttttgg	gtttatctgt	tttctcatgc	acaggcaata	cacaaattta	3120
aatgagtttg	tgagccaatt	gtttctgaag	tgttttggtg	gttctattaa	gaaatagtta	3180
aattttgtgc	ttttcagagc	ctcagagaca	gggggacgcg	gtgccggggt	ggggcagcgg	3240
aatctgtcct	ggatggggcc	agcttaataa	atactggcaa	ccaagat		3287

<210> 31
 <211> 2412
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1299481CB1

<400> 31						
gggctgtgtg	cgccggcggc	ggcggcggcc	gagggggatg	gagcagcgc	cgagccgggt	60
cagagttgaa	caatgaccat	agttgacaaa	gcttctgaat	cttcagaccc	atcagcctat	120
cagaatcagc	ctggcagctc	cgaggcagtc	tcacctggag	acatggatgc	aggttctgcc	180
agctgggggtg	ctgtgtcttc	attgaatgat	gtgtcaaatc	acacactttc	tttaggacca	240
gtacctgggtg	ctgtagttaa	ttcgagtcca	tctgtacctg	ataaatcaaa	accatcacca	300
caaaaggatc	aagccctagg	tgatggcatc	gctcctccac	agaaagttct	tttcccatct	360
gagaagattt	gtcttaagt	gcaacaaact	catagagttg	gagctggggt	ccagaatttg	420
ggcaataacc	gttttgccaa	tgcagcactg	cagtgtttta	cctacacacc	acctcttgcc	480
aattacatgc	tatcacatga	acactccaaa	acatgtcatg	cagaaggctt	ttgtatgatg	540
tgtacaatgc	aagcacatat	taccagga	ctcagtaatc	ctggggacgt	tattaaacca	600
atgtttgtca	tcaatgagat	gcggcgtata	gctaggcacc	tccgttttgg	aaaccaagaa	660
gatgcccatg	aattccttca	atacactggt	gatgctatgc	agaaagcatg	cttgaatggc	720
agcaataaat	tagacagaca	caccagggcc	accactcttg	tttgtcagat	tttgtaggag	780
tacctaagat	ctagagtcaa	atgttttaaa	tgcaagggcg	tttcagatac	ttttgatcca	840
tatcttgata	taacattgga	gataaaggct	gctcagagtg	tcaacaaggc	attggagcag	900
tttgtgaagc	cggaacagct	tgatggagaa	aactcgtaca	agtgcagcaa	gtgtaaaaag	960
atggttccag	cttcaaagag	gttccactatc	catagatcct	ctaattgtct	tacactttct	1020
ctgaaacggt	ttgcaaattt	taccggtgga	aaaattgcta	aggatgtgaa	ataccctgag	1080

tatcttgata	ttcggccata	tatgtctcaa	cccaacggag	agccaattgt	ctacgtcttg	1140
tatgcagtg	tggccacac	tggttttaat	tgccatgctg	gccattactt	ctgctacata	1200
aaagctagca	atggcctctg	gtatcaaagt	aatgactcca	ttgtatctac	cagtgtatatt	1260
agatcgggtac	tcagccaaca	agcctatgtg	ctcttttata	tcagggtccca	tgatgtgaaa	1320
aatggagggtg	aacttactca	tcccacccat	agccccggcc	agtcctctcc	ccgccccgtc	1380
atcagtcagc	gggttggtcac	caacaaacag	gctgcgccag	gctttatcgg	accacagctt	1440
ccctctcaca	tgataaagaa	tccacctcac	ttaaatggga	ctggaccatt	gaaagacacg	1500
ccaagcagtt	ccatgtcgag	tcctaacggg	aattccagtg	tcaacagggc	tagtctgttt	1560
aatgcttcag	cttctgtcca	aaactgggtca	gttaatatgt	cctcagtgat	cccagaacat	1620
cctaagaaac	aaaaaattac	aatcagttat	cacaacaagt	tgctgttctg	ccagtgtcag	1680
tctcaacctc	accttcatag	taattctttg	gagaacccta	ccaagcccg	tccctcttct	1740
accattacca	attctgcagt	acagtctacc	tccaacgcac	ctacgatgtc	agtttctagt	1800
aaagtaacca	aaccgatccc	ccgcagtgaa	tctgtctccc	agcccggtat	gaatggcaaa	1860
tccaagctga	actccagcgt	gctggtgcc	cttggtgccg	agtcctctga	ggactctgac	1920
gaggagtcaa	aggggctggg	caaggagaat	gggattggta	cgattgtgag	ctcccactct	1980
cccgcccaag	atgccgaaga	tgaggaggcc	actccgcacg	agcttcaaga	acccatgacc	2040
ctaaacggtg	ctaatagtgc	agacagcgac	agtgaaccga	aagaaaacgg	cctagcgctc	2100
gatggtgcca	gctgccaaag	cgagcctgcc	ctgcactcag	aaaatccctt	tgctaaggca	2160
aacggtcttc	ctggaaagt	gatgcctgct	cctttgctgt	ctctcccaga	agacaaaatc	2220
ttagagacct	tcagggttag	caacaaactg	aaaggctcga	cggatgaaat	gagtgcacct	2280
ggagcagaga	ggggccctcc	cgaggaccgc	gacgcgcagc	ctcagcctgg	cagccccgcc	2340
gccgaatccc	tgaggagacc	agatgcggcc	gcaagcttat	tccccttag	tgagggttaa	2400
ttttagcttg	ca					2412

<210> 32
 <211> 2286
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1873139CB1

<400> 32						
gaaaacccgg	cgctccggaag	cccgtgcttt	ctttgacgca	agggctcgag	acgcagccgc	60
cgctccggaag	gcgcccggct	agaagcgaca	ccagacggag	cctccggagt	tctccgccc	120
ccacctcgcc	gggtcctgga	gccgcagtc	tcccagctgc	cctcctcggtg	gccatggagt	180
gtccacacct	gagctccagc	gtctgcattg	ctccggactc	agccaagttc	cccaacgggt	240
ccccgtcgct	ctgggtgctgc	agcgttatcg	ctgtgatgat	ttgttggtta	atgacaccaa	300
gctgggactg	gtacagaaaag	tcagagaaca	cttacagaac	ttggaaaact	cagctttcac	360
agctgacagg	cataagaaaa	gaaaactttt	ggaaaactca	acactaaaca	gcaagttatt	420
aaaagttaa	ggaagcacca	ctgccatttg	tgccacaggc	cttcggaatt	tggggaacac	480
atgtttcatg	aatgccatcc	ttcagtcact	cagtaacatt	gagcagtttt	gctgtttatt	540
caaagaactg	cccgcctggt	agttaaggaa	tgggaaaaca	gcaggaaggc	ggacatacca	600
caccaggagc	caaggggata	acaatgtgtc	tttggtagaa	gagtttagaa	agacactctg	660
tgctttatgg	caaggcagcc	agactgcatt	tagcccagag	tccttatttt	atgttgtttg	720
gaagattatg	ccaaacttta	ggggctatca	acagcaggac	gccccatga	tcatgcgcta	780
ccttttggtg	cacctacact	tggaacttca	gggcgggttc	aacgggtgtt	cccgctcagc	840
aattctgcag	gagaattcta	ctctgtctgc	aagtaacaag	tggtgcataa	atggagcatc	900
tactgttgtc	acggctatat	tcggaggcat	tctccaaaat	gagggttaac	gcctcatatg	960
tgggacagaa	tctagaaaag	ttgatccatt	cctagacctt	tcattagata	ttccaagtca	1020
gttcagaagt	aagcgctcta	agaatcaaga	aaatggacca	gtttgttcgt	tacgagattg	1080
tcttcgcagt	tttacgcact	tagaagaact	tgatgagaca	gagttatata	tgtgccataa	1140
atgcaaaaag	aaacaaaagt	ccacaaaaaa	gttttggtat	caaaaactac	ccaaggtgct	1200
atgcttacat	ttgaaaagat	ttcattggac	agcatattta	agaaaataag	ttgatacata	1260
cgtagaattt	ccactgagag	gcctagacat	gaaatgtcac	ttactagagc	ctgagaacag	1320
tggcccggag	agctgcctgt	atgacctcgc	cgctgtgggtg	gtgcaccatg	gttcgggggt	1380
tggttctgga	cattacacag	catacgcaac	tcacgaaggc	cgctggttcc	acttcaatga	1440
cagtactgta	acactgactg	acgaggagac	tgtggtgaag	gcgaaggcct	acatcctttt	1500
ctacgtggaa	caccaggcca	aagctggatc	ggataaaact	taatacctcc	tccaaatcat	1560
cattaccgaa	ccataccaga	gaaacatttc	cagtttttcca	caaatacttg	atacaagatt	1620
taatttcatt	atgcactttt	caatttccta	ttttggattt	agttttgtca	atggtagtga	1680
cttactgaac	atgggcacca	actaattttg	ttgttgttct	accagaaaac	ctcagcagat	1740
gttttgattt	gctgcttttag	ttgtaataat	tcaattttta	taggtagtgt	taagaactta	1800
gtcttatttg	actttttttat	tttatgttaa	ggttttcagt	tctcactttt	aggcacattt	1860
acatcaatgc	ttttgttctc	ctcacatgct	tgaagcaaga	tgtgttctct	atgtgtgaaga	1920
gcgacacac	tgctgtctgc	ctttccacag	ctataatgga	catcagggtg	actctaaatc	1980

```

aaggatcatg tgtgcacaat acttgtggcc cacaaaattt cacaatgact gctgaggaat 2040
cattcttttt gctgtataaa tataacaaag ggcatactta agtagaccag gtaattactg 2100
cttgtctctc aaggctgctg tctttatcag cactaactaa ataaatttgt tgggttcagtt 2160
gtacttgttc tgcaaataca agaattactc tctttgttgg tttttttggg tttggggcat 2220
acttgtttgc ggggaggtaa gatgggagta aagaccaa atcatgtaatg tttaaaaaaa 2280
aaaaaa

```

<210> 33
 <211> 873
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1903112CB1

```

<400> 33
taaaaacatt tatcatcttt gaaagcactc ttacgagact tttattcatc agaatcagtg 60
aaatgttttc ctttttttga caggggtcaaa tagaaattga cgatcagggtg gaaggactcc 120
aatatctagc ttctcgatat gatttcattg acttagatcg tgtgggcac caccgctggg 180
cctatggagg atacctctcc ctgatggcat taatgcagag gtcagatata ttcagggttg 240
ctattgctgg ggccccagtc actctgtgga tcttctatga tacaggatac accgaacggt 300
atatgggtca cctgaccag aatgaacagg gctattactt aggatctgtg gccatgcaag 360
cagaaaagtt cccctctgaa ccaaatcgtt tactgtctct acatggtttc ctggatgaga 420
atgtccattt tgcacatacc agtatattac tgagtttttt agtgagggtc ggaaagccat 480
atgattttaca gatctatcct caggagagac acagcataag agttcctgaa tcggggagaac 540
attatgaact gcatcttttg cactaccttc aagaaaacct tggatcacgt attgctgtc 600
taaaagtgat ataattttga cctgtgtaga actctctggt atacactggc tatttaacca 660
aatgaggagg tttaatcaat agaaaacaca gaattgatca tcacattttg atacctgcca 720
tgtaacatct actcctgaaa ataaatgtgg tgccatgcag gggctctacg tttgtggtag 780
taatctaata ccttaacccc acatgctcaa aatcaaatga tacatattcc tgagagacc 840
agcaatacca taagaattac taaaaaaaaa aaa 873

```

<210> 34
 <211> 1658
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1993044CB1

```

<400> 34
ggaagagttt cgatgtctct aggggtggcta gagcgtcttc ccgcgctcag tcgcgctgca 60
ggtgagcgcg cccgagggct gtcgggaagt atgcgggggt acgtgtggtt gacgagctcg 120
ggcgcggttt tgctgagatc tgtggccggc gccagctggt gcggggggca gctgagagcg 180
agagggtgat cggggcggtg tgtggccagg gccatgacgg gcaatgccgg ggagtgggtc 240
ctcatggaaa gcgaccccg ggtcttcacc gagctcatta aaggattcgg ttgccgagga 300
gccccagtag aagaaatatg gagtttagag cctgagaatt ttgaaaaatt aaagccagtt 360
catgggttaa ttttctttt caagtggcag ccaggagaag aaccagcagg ctctgtggtt 420
caggactccc gacttgacac gatatttttt gctaagcagg taattaataa tgcttgtgct 480
actcaagcca tagtgagtgt gttactgaac tgtaccaccc aggatgtcca tttaggcgag 540
acattatcag agtttaaaga attttcacaa agttttgatg cagctatgaa aggcttgcca 600
ctgagcaatt cagatgtgat tgcacaagta cacaacagtt tcgccagaca gcaaatgttt 660
gaatttgata cgaagacatc agcaaaagaa gaagatgctt ttcactttgt cagttatgtt 720
cctgttaatg ggagactgta tgaattagat ggattaagag aaggaccgat tgatttaggt 780
gcatgcaatc aagatgattg gttcagtgca gtaaggcctg tcatagaaaa aaggatacaa 840
aagtacagtg aaggtgaaat tcgatttaat ttaatggcca ttgtgtctga cagaaaaatg 900
atatatgagc agaagatagc agagttacaa agacaacttg cagaggagga acccatggat 960
acagatcaag gtaatagtat gtttaagtgt attcagtcag aagttgccaa aaatcagatg 1020
cttattgaag aagaagtaca gaaattaaaa agatacaaga ttgagaatat cagaaggaag 1080
cataattatc tgcctttcat tatggaattg ttaaagactt tagcagaaca ccagcagtta 1140
ataccactag tagaaaaggc aaaagaaaaa cagaacgcaa agaaagctca ggaaaccaa 1200
tgaagatgtt ttcagatatg tacacatttc tgcttctgca catattttca tggaaacat 1260
tatgtataaa gaacttagag caacatccta attggctcag tgcacgtttg gcaatagtgc 1320
cagcctgtct tgtctttaat gcatggattc ataaacttct tcctacctc catcatgtgc 1380
atgtagtgca tattaatga aagtgatatt aagaatgctt tcccaaattc cattatttga 1440

```

```

catttgaggt cctgaccact gtttaagttt tcttgggttg tcttaactaa ccattaatgg 1500
aggcctgaga aaatggcgcc aaacggatta ttgctttaat ctgtaaatct aaaataacgt 1560
aacaattttg cacattgggc agatccttgg attaaaccgg gttgggtcta atttgcttcc 1620
tccatccata accgggaaaa aaaattccgg gttttccc 1658

```

```

<210> 35
<211> 1255
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 2292182CB1

```

```

<400> 35
gcctaacgtc ttcagccag ccaggtgccc cttcttccct gcgaggaggag ggctggggcg 60
gtcgcgttgg cgggaggagg gttaccttcc ccagtctcgc tctggccgcc tgagccagga 120
ggaagcagcg gcgaggtctg cgggaggcat ggcgaggagc ccggacgagc gccggcgggg 180
ccccgcggca ggggagcagc tgccagcaga acacgtctct tgccaggtct tccccgagcg 240
tctggcccag gggaatcccc agcaagggtt cttctccagc ttcttcacca gcaaccagaa 300
gtgccagctt aggtcctctg agacgtctga gacaaatcca tatgtcaaac ttctgcttga 360
tgctatgaaa cactcaggtt gtgctgttaa caaagataga cacttttctt gcgaagactg 420
taatggaaat gtcagtggag gttttgatgc ttcaacatct cagatagttt tgtgccagaa 480
taatatccat aatcaggccc atatgaacag agtgggtcac cagagctta ttcatgcatt 540
tgatcattgt cgtgcccatg tgcactgggt caccaacatc agacatttgg cgtgctcaga 600
ggttcgagct gctaaccctt gtggagactg ctcacttgct aatgaaatat tcaggttaca 660
ttttggatta aaacaacacc accagacttg tgtgcgagac agagccactc tttctatcct 720
ggctgttagg aatatcagca aagaagtagc taaaaaggct gttgatgaag tttttgaatc 780
ttgtttcaat gaccatgaac cttttggaag gatcccatat aacaagactt atgcaagata 840
tgctcacaga gactttgaaa accgtgatcg gtattattca aatatatgag cacaatgaca 900
tttttatatt acagagcttc catcatcatg aagaaaaaaa aatttgggtc tcaagtgaac 960
aaacatataa aatgtaaaca atccctacaa tccagataaa acagagaaga ctgtgattct 1020
agcatattat cagaaaaagt aactatggca aaaaatgaaa ctgctttaaa ctccaaggca 1080
gaaattgtat ctttatagct aaccatttag taaataaata cattacattt ttgtatttta 1140
gtcatttggt tttattacat gtgattattt taaaatttga ttatgaaacc tgtgaagtgt 1200
gctcttccat gatgttgata ggtgaccact gttggtattt acattaaatg taaag 1255

```

```

<210> 36
<211> 1139
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 2331301CB1

```

```

<400> 36
tgcttttaaa aaaaaaaaaa gcttctaate ctctggggaa agatctgctt ctttccccat 60
ttgatgcaat gaaataccgt gtgactcttc ccagcgttg agatccatgg agtgggtgaga 120
cacatccagt ggacgcccag ggagatggag gtgtacatca ggcacttgga gaaggtgtta 180
aggcgctatg tccagaggct gcagtggctg ctgtccggga gcccgccgact gtttggcacc 240
gttttgagga gcaaagtatg catattgctg gacacgtcag ggtccatggg cccctacctg 300
cagcaggtga agacagagct ggttttgctg atttgggaac agctgcggaa gtgctgtgac 360
agttttaacc tgctcagctt tgcagagagc cttcagtcac ggcaggacac gctggtggag 420
accacagatg cagcgtgtca tgaggctatg caatgggtga cccacctgca agctcagggc 480
agcacctcca tcttgcaagc attgctgaaa gctttcagtt tccatgatct ggaaggattg 540
tacctcctga ccgacggaaa gccagacaca agctgcagcc ttgtcctaaa tgaagtccaa 600
aaactcaggg agaaaagaga tgtgaaagtg cacaccattt ccttgaactg ctgagacaga 660
gcggcggttg agttcctgag aaagctggct tccctcaccg gcggacgcta tcaactgcct 720
gtgggtgagg acacactctc caaaattcac agcctgctga ccaaaggctt catcaatgaa 780
aaggatcgca cattgccacc atttgaagga gatgatttaa ggatcctggc ccaggaaatc 840
accaaggcca gaagcttctc ctggcaggcc caatccttca gatcccaact ccagaagaaa 900
aatgatgcag aaccaaagggt cactcttctc tagagaagtg ttctcagaaa agtcatcctg 960
caaaggacca ctactgagc aaatctcagc cccgagggca ggatgggatg aaatgctgtg 1020
acctgcagga aacatgattc ctggtaccag gactctcttg aagctgagga aggaaagact 1080
ttgtcttttg tgtgaggggc cattcccggg tcttaatcta actctccagc cctgtccgg 1139

```

<210> 37
<211> 1753
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2517512CB1

<400> 37
gtggcggact agcccaggct cccacacccg acgctctggc ccacacagac gctactctgt 60
agcatctcag gttccctctg gctgcactct ggaggaccac actcggtttc tttttggctg 120
ccagaggccc ccgcatccac cgctgagctg ggagaaagat ggcggcagcc gtgcgacagg 180
atattggccc gctcatgaat tcgagcggct ctcataaaga tctggctggc aagtatcgtc 240
agatcctgga aaaagccatt cagttatctg gagcagaaca actagaagct ttgaaagctt 300
ttgtggaagc aatggtaaat gagaatgtca gtctcgtgat ctgcggcag ttgctgactg 360
atttttgcac acatcttcct aacttgccct atagcacagc caaagaaatc tatcacttca 420
ccttgaaaaa gatccagcct agagtcattt catttgagga gcaggttgct tccataagac 480
agcatcttgc atctatatat gagaaagaag aagattggag aaatgcagcc caagtgttgg 540
tggaattcc tttggaacaa ggacaaaaac agtacaatgt agattataaa ctggagactt 600
acttgaagat tgctaggcta tatctggagg atgatgatcc agtccaggca gaggcttaca 660
taaatcgagc atcgttgctt cagaatgaat caaccaatga acaattacag atacattata 720
aggatatgcta tgcacgtggt cttgattata gaagaaaatt cattgaagct gcacaaaggt 780
acaatgagct ctcttacaag acaatagttc acgaaagtga aagactagag gccttaaaac 840
atgctttgca ctgtacgata ttagcatcag cagggcagca gcgttctcgg atgctagcta 900
ctctttttaa ggatgaaagg tgccagcaac ttgctgccta tgggatccta gagaaaatgt 960
atctagatag gatcatcaga ggaaatcaac ttcaagaatt tgctgccatg ctgatgcctc 1020
accaaaaagc aactacagct gatggttcca gcactcttga cagagctggt attgaacaca 1080
atattgtgtc tgcaagcaaa ttatataata atattacctt cgaagaactt ggagctcttt 1140
tagagatccc tgcagctaag gcgaaaaaga tagcatctca aatgataacc gaaggacgta 1200
tgaatggatt tattgaccag attgatggaa tagttcattt tgaaacacga gaagccctgc 1260
caacgtggga taagcagatc caatcacttt gtttccaagt aagccatgga agcccagatg gctcagtga 1320
ttagtcaaac agcaccagaa tggacagcac aagccatgga agcccagatg gctcagtga 1380
tccttgacga acttctgtgc acatgacatc tttttccatg ttgtgcagat cagtttccat 1440
atctccaaag catttgcatc atgaccttat acatttcaat ccccttttatg ctggattccg 1500
tttaagaag acattattag agcaggaagt acaagcattt aaaatattga ttctccat 1560
atctcagggt ctctgtgtat taagctaact cagatgtttt gaaagctttt tctttaaaca 1620
gaggtgaaat atctgtggct aaaaagtgtg agatttgtga taactttgta gtcattgtaa 1680
acttaagtgc ttcattgcct tccaaatgtg gttattctaa taaatggaga aatgagccaa 1740
aaaaaaaaaaa aaa 1753

<210> 38
<211> 580
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3489039CB1

<400> 38
cgaggcggcc gaagccgtcg cggcggggac catgttgctt ccgaacatcc tgetcaccgg 60
tacaccaggg gttggaaaaa ccacactagg caaagaactt gcgtcaaaat caggactgaa 120
atacattaat gtgggtgatt tagctcgaga agagcaattg tatgatggct atgatgaaga 180
gtatgactgt cccatttttag atgaagacag agtagttgat gagttagata accaaatgag 240
agaaggtgga gttattgttg attaccatgg ttgtgatctt ttcctgaac gctggtttca 300
tatagttttt gtgctgagaa cagataccaa tgtattgtac gaaagacttg aaacaagggg 360
ttataatgag aagaaactaa cagacaatat tcagtgtgag atttttcaag ttctttatga 420
agaagccaca gcattcctaca aggaagaaat cgtgcacatg ctgcccagta ataaaccaga 480
agagctagaa aataatgtag atcagatctt gaaatggatt gagcagtgga tcaaagatca 540
taactcttga cttataaggc tagctactta ataatacact 580

<210> 39
<211> 2186
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5432879CB1

<400> 39
gtccggcgccg ggcggcgccg gtagcgagg agacgggttc aggcctccgg tgcggctgca 60
atgctgagct cccggggccga ggcggcgatg accgcgcccg acagggccat ccagcgcttc 120
ctgcggaaccg gggcgggcgt cagatataaa gtcatgaaga actggggagt tatagggtga 180
attgctgctg ctcttgacgc aggaatatat gttatttggg gtcccattac agaaagaaag 240
aagcgtagaa aagggttgt gcctggcctt gttatttag ggaacacctg cttcatgaac 300
tccctgctac aaggcctgtc tgctgtcct gctttcatca ggtggctgga agagtccacc 360
tcccagttact ccagggatca gaaggagccc cctcacacc agtatttatc cttaacactc 420
ttgcaacctc tgaagcctt gtctgcccga gaagtactg atgatgaggt cttagatgca 480
agctgcttgg tggatgtctt aagaatgtac aatatgttgc agatggcaga tctcatcatt tgaagaacag 540
gatgctcacg aattattcca tgctattacc tcgtcattgg aagatgagcg agaccgccag 600
cctcggtgca cacatttgtt tgatgtgcat tccctggagc agcagtcaga aataactccc 660
aaacaaatta cctgcgcgac aagaggggtca cctcacccc catccaatca ctggaagtct 720
caacatcctt ttcattggaag actcactagt aatatgttgc gcaaacactg tgaacaccag 780
agtcctgttc gatttgatgc ctttgatagc ctttactaa gtattccagc cgccacatgg 840
ggtaacccat tgaccctgga ccaactgcct caccacttca tctcatcaga atcagtgcgg 900
gatgttgtgt gtgacaactg tacaaagatt gaagccaagg gaacgttgaa cggggaaaag 960
gtggaacacc agaggaccac ttttggttaa cagttaaaac tagggaagct cctcagttgt 1020
ctctgcaccc acctacagcg gctgagctgg tccagccacg gcacgcctc gaagcggcat 1080
gagcagctgc agttcaatga gtctctgatg atggacattt acaagtacca cctccttgga 1140
cataaaccta gtcaacacaa ccttaaactg aacaagaacc cagggcctac actggagctg 1200
caggatgggc cgggagcccc ctcccactct ttattgcaa cgctgtcagc gccgatgccc 1260
atttttatga atggcgctg cgactacagc tctccacat acctcttccg gctgatggca 1320
ttccctctcc cagttgttcc cgactacagc catgcaactc ggacactttg tcaattaccg acgggtcccc 1440
gttgctgtcc accatggaga ctcaactagc aatcagtggt tgtgggtctc cgatgacact 1500
ccttctgcca ggaacctctt ggaggctcct tctccagcg cctacctgtt gttctacgag 1560
gtccgcaagg ccagcctgca gcaccagagc caggagtgc aagtctgaaga atgactgtgc 1620
cgctgccttt ccaggatgca gatggcactg tctgcaactgt ccaggaaaaa agtaaaactg 1680
cctcctgcaa ggctagagct gccccactag agccttccag ccttctgtgt tgttctaaga 1740
tactgttgcg tgtgcaagcg agccccactg cacaccaaac caggctcctt gaacagctc 1800
gcaggctcca cctgggagcc ctggtgtgtt taattaaaag aactcagatt cttgaagcca ccgttttcat 1860
gttcatgtgt ctgatacagg taattaaaag cagaggggag gtacctttgt ctaatacaacg tttccactta 1920
ttttactcat attgtaatgt taggtgttct cagaggggag aaaaattgtg acaagaatta atgaaattat 2040
gatcttttat ttttaataag caggcccata tttcacttcc gattgctttt gtagcacgtc 2100
taaaggcaac aatttagaag aggtactca aaggatagca agagaacagg taaatgatgc 2160
cattgtgaaa tttccttcc tctatg 2186
ctaaagaaca ccttctttt

<210> 40
<211> 2522
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5853753CB1

<400> 40
ctccggggcgt gctgccggcg gcggtaggtg gcgcgcgggt ccggcgggcg gttggcttga 60
gcgggaccgg agctgaggca ggaagagccg gcgccatggt ggagaaggag gaggctggcg 120
gcggcattag cgaggaggag gcggcacagt atgaccggca gatccgctg tggggactgg 180
aggcccagaa acggtgcgg gcctctcggg tgcttcttgt cggttgaaa ggacttgggg 240
ctgaaattgc caagaatctc atcttggcag gagtgaagg actgaccatg ctggatcacg 300
aacaggtaac tccagaagat cccggagctc agttcttgat tcgtactggg tctgttggcc 360
gaaatagggc tgaagcctct ttggagcgag ctgagaatct caaccccatg gtggatgtga 420
aggtggacac tgaggatata gagaagaaac cagagtcatt tttcactcaa ttcgatgctg 480
tgtgtgtgac ttgctgtccc agggatgtca tagttaaagt tgaccagatc tgtcacaaaa 540
atagcatcaa gttctttaca ggagatgttt ttggctacca tggatacaca tttgccaatc 600
taggagagca tgagtttcta gaggagaaaa cttaaagttgc caaagttagc caaggagtag 660
aagatgggac cgacaccaag agagcaaaaac ttgattcttc tgagacaacg atggtaaaaa 720
agaaggtggt cttctgcctt ccttgagggt ggactggagc agtgagaaag 780
caaaggctgc tctgaagcgc acgacctccg actactttct ccttcaagtg ctcttaaaag 840


```

tccgtacaga taaaggaaga gatccagtt ctgatacata tgaggaagat tctgagttgt 900
tgctccagat acgaaatgat gtgcttgact cactgggtat tagtcctgac ctgcttctctg 960
aggactttgt caggtactgc ttctccgaga tggccccagt gtgtgcggtg gttggaggga 1020
ttttggcaca ggaaattgtg aaggccctgt ctccagcgga cctcctcac aacaacttct 1080
tcttcttcga tggcatgaag gggaatggga ttgtggagtg ccttggcccc aagtgaactc 1140
aagatttggc agccccagag atgccaaactg cagcatgccc acctgtattc cctgtcccc 1200
tccttcataa aggcattctc aggcgaaggaa aactgaagtc attggccccg taaaaacat 1260
ttcttgcaac gaaggaggtg gtgcccagct gctgcttccc atcaccagca gctgctcgac 1320
aagggggcgca ggggtgctgt ctttgttcca gcactgttca ggctgectgt catcccgggc 1380
ctgccagctc ccttgagtga tgagcacttc caagcaccoc tctgccccct ctctgtcctt 1440
atgctgtccc ggccctcgcca gccctctggg gcattgtggg agatgectgc caggaatgag 1500
caagctctgt tgctcgggag cctcttgtca ccttcttggg ctatttcccc acctgatacc 1560
ttatagagaa aagtgtgaat tcaggtggag agtaggcccc ggccccatga ggcaccagt 1620
gaagcacagc tccaagttca gacaggtgcc cttagagagg aaaaccatga caggcaaatg 1680
catttctctt ggagtgtgag acctgacaa acaacagggtg gcatctggtg tgctgttctt 1740
gagttttcgt ttaggattag ttgagttcca gctgggtttt gggagaaagg agatgctacc 1800
aagtcttggg tgtagggcg agacctgca agttgagtat tagagagctt gtctttcaag 1860
gcaggttccc ggggcttcag ggctaggagg gaggagcctg cctttttaac agaaccacc 1920
tcacatggcg ctcaagtcac tcagaggctg ttgcatttca ggctatggtt ggtcctttgt 1980
ttacctcta aaccacagct gtttgtgttt cacatatgtt gtgaattttc cttggttctt 2040
tttaaaggaa tgataataaa gttacttgc ttaggatttg cttgtttttc ttccacttca 2100
gaagcttctg agagggaaatg ggatgatcct accagttgcc ttttcagacc tgaggctcta 2160
actcaagaga ttctctctc cctcaccat cctgcccacc atttttctg ggtgatgcag 2220
caagagttaa attgttcaca ttctagaatg tgtagaagct tctggctcca gttgtctaat 2280
ggataattca gctaaatagt ggctattttc agtggaaga attataataa taaagggaag 2340
tcaaaagtga tgcttcatat gccccaaagt ccacagccgc tacgggtcac agcttttatt 2400
ggaagaccag gtttgecttg atgcagccaa agtgcgttcc agttcaccc 2460
gtgtttcttc tttatgtaaa ttgtgtgatg tttcaataaa tcagtctctt tcttaaaaaa 2520
aa 2522

```

<210> 41
 <211> 2167
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 411344CB1

```

<400> 41
cgccgggtct ggggggatgg ttccatcatg gcgtaaatgc agaaacgact acagaaagaa 60
ctgttggctt tgcaaaatga cccacctcct ggaatgacct taaatgagaa gagtgttcaa 120
aattcaatta cacagtggat tgtagacatg gaaggtgcac caggtagctt atatgaagg 180
gaaaaatttc aacttctatt taaatttagt agtcgatata cttttgactc tctcagggtc 240
atgtttactg gtgaaaatat tcctgttcat cctcatgttt atagcaatgg tcatatctgt 300
ttatccattc taacagaaga ctgggtcccc gcgctctcag tccaatcagt ttgtcttagc 360
attattagca tgctttccag ctgcaaggaa aagagacgac caccggataa ttctttttat 420
gtgcgaacat gtaacaagaa tccaaagaaa acaaaatggg ggtatcatga tgatacttgt 480
tgatgccact gttatcatcc tctagcaga actagtcct actgagaaaa tgagcacttt 540
gatcattcag tctttgaact ttaacctttg actggaagtg acctataggc aatgaagact 600
acttctcttt actgcatttt tactcgtgtg cattctgggc gcatgttgat cgctggttca 660
gtccaggcaa ctgacatgct tttattagtc atacagtatt aatgcagggtg tcaggaaatg 720
tcaaatataa ttccattttt tatttttatt tttttaagct tttggaaaag ctcagggtcc 780
tcatgtattg tgcaataaca atgacttctt tggcggtttt ggtacgttca ttgccggcaa 840
tgggcggtgt aacaggaaaa gttttcatta actcctgcca ttcaatgatt aatgcatgat 900
agggcctatg aaatgaactt actggttata gtgggaatat aaataaagtg agggatccaa 960
cattacttta aaagtcaccc caactgttta tatttgatt ctatgcactg tgatcctaag 1020
gttaacagca tgaattaaca tgcgtcttta aaggactgta atgaaagatc attgcatatt 1080
tattgaattg tttatatcta ctgtcaagtt gttttgacat ggaagatttt caagtaacat 1140
tgccagagag gtacagtatg ttatccctat ggtgaaaata aattaatttg ttgtatatag 1200
ttcctcaatc tctgaagtaa aggtatgagt aatatagggt atgaatggtt taatcaaggc 1260
tttattttgg aagtaagaaa aatggcagtg atgattaaat tgctgcagtc cataatttgg 1320
gctgtttatt tgtacattaa agattttttc caagtaagtt acactctgtt aacttctctg 1380
tagccatcag catgagccct actgcctaaa cactatttca tttatttatg tttggaaacc 1440
ccgtaaacat ttttgtttgc aatcttgttt ctttgtttat aagtcaagtt tgaatgttac 1500
aatactttta ttgaaacttt tgtaagttt tttcttgtaa attttcttta cttgtgagta 1560
tcactttgtc ctttaactct gtaccctaaa ataagaaata catttttgac agaggcttaa 1620

```

tgttttaaca	aaagagtgtg	gacattttta	ttttaaaatt	taggcaaaag	tcactatcaa	1680
atggttgctt	atgtgtctca	cacagccata	tagtttttcc	tggagggttt	tgttttgttg	1740
ttgttgaaaa	gactttgctt	acagctagat	gaaactttct	atagaaaaaa	aaaattgttg	1800
aaaggtccag	ttctcagtac	catgtgagtt	aatgatacta	caactaagtt	ctttttaaaa	1860
agtgattaat	gtattttata	aattaccttt	tcacatatgc	aaaatctgtt	tctactacaa	1920
tgttattttt	actaatgcct	tattgtggca	ctctttttga	aacatcctgc	agtgaatata	1980
tgaatcaatt	tgggctttaa	actgaaagcc	agttgggctg	aaagggttga	aatacgtacc	2040
ccagtaaaaac	cattcaatcc	ataattggta	aataatattt	taaaaatggt	tttaatccgt	2100
atagatgaca	ttttgtagct	ttggacatgg	tggttaattaa	ggggcattaa	ttttacactc	2160
caaggta						2167

<210> 42
 <211> 1826
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1256390CB1

<220>
 <221> unsure
 <222> 1755
 <223> a, t, c, g, or other

<400> 42						
ccccgcctt	tctatagcat	agttctcttt	aggtggaatg	attcctataa	gatttctcat	60
tattaaatca	tgcatttttc	aagatggaat	caatctttga	tttaattctaa	gctgatattc	120
tcatttggtta	gaagaacaac	ctacatgcta	gagagagagg	aggaaatata	cccacgacca	180
cacagccagt	tagtatccag	ttggtgctgg	actccagcca	ggtgtcctgc	ctcatggtag	240
ttaaatgata	tatagaaaag	gtaaaatttt	aaagaaatat	ttattaatat	attcctataa	300
aacatttttaa	aggtaaccac	ataaaaaatgg	ttattttttc	cattccaaag	taaagtctaa	360
gcatgtttat	taatgaagca	gtacttctga	ttagtatatg	acattctgaa	gttaattaaa	420
ctcattgcac	taaatgtgtc	ttccttggtg	tagtggagga	tttgaggatt	ggaatataga	480
gtagagtgtc	tgcttaagcc	tctgcttgaa	accctttatc	ttttggggat	gctggttcct	540
ggagggtctgg	gatatgatag	atccttagcc	caacacagac	aagagattgt	ggacaagtca	600
gtgagtccat	ggagcctgga	gacgtattcc	tataacatat	accaccccat	gggagagatc	660
tatgagtggga	tgagagagat	cagtgaagaag	tacaaggaag	tggtgacaca	gcatttccta	720
ggagtgcact	atgagaccca	ccccatgtat	tatctgaaga	tcagccaacc	atctggtaat	780
cccaagaaaa	tcatttggat	ggactgtgga	attcacgcca	gagaatggat	tgctcctgct	840
ttttgccaat	ggttcgtcaa	agaaattcta	caaaaccata	aagacaactc	aagtatacgc	900
aagctcctta	ggaacctgga	cttctatgtc	cttccagttc	ttaacataga	tggttatatc	960
tacacttggga	caactgatcg	tctttggagg	aaatcccgtt	caccccataa	taatggcaca	1020
tgttttggga	cggatctcaa	tcgaaatttc	aatgcattct	ggtgtagtat	tggtgcctct	1080
agaaactgcc	aagatcaaac	attctgtggg	acagggccag	tgtctgaacc	agagactaaa	1140
gctgttgcca	gcttcataga	gagcaagaag	gatgatattt	tgtgcttctc	gaccatgcac	1200
tcttatgggc	agtttaattct	cacacettac	ggctacacca	aaaataaaatc	aagtaaccac	1260
ccagaaatga	ttcaagttgg	acagaaggca	gcaaattgcat	tgaaagcaaa	gtatgggaacc	1320
aattatagag	ttggatcgag	tgcagatatt	ttatatgcct	catcagggtc	ttcaagagat	1380
tgggcccag	acattgggat	tcccttctca	tatacgtttg	agctgaggga	cagtgggaaca	1440
tatgggtttg	ttctgccaga	agctcagatc	cagcccacct	gtgaggagac	catggaggct	1500
gtgctgtcag	tcctggatga	tgtgtatgcg	aaacactggc	actcggacag	tgctggaagg	1560
gtgacatctg	ccactatgct	gctgggcctg	ctgggtgtct	gcatgtctct	tctctaagtg	1620
cattctgccc	aggtcttttt	ctgccagaaa	ttccccttta	tttttctccc	tagtaaagtc	1680
tttctttgat	actaattctg	acattacctg	tgggaattttt	gctgacttcc	acagattttt	1740
ttttctctcc	ttctntaact	gtttgtacac	actttaatgt	aataatttac	agacttgtgt	1800
agtgaatag	gatattacat	gccctg				1826

<210> 43
 <211> 1371
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1786774CB1

<400> 43

```

gcaaaaattg tttcaaaaaa tttgtgagga ttttgattcc tatctcgttc aaatTTTTTgg 60
ttcatcgtca cctcaacctg gatttgggat gtcaggggaa gaactcagtg aatctactcc 120
agagcctcaa aaagaaattt ctgagtcatt gagtgtcacc agagaccagg atgaagatga 180
taaggctcca gagccaacgt gggtgatga tctgcctgcc actacctcat ctgagggccac 240
caccaccccc aggccactgc tcagcacccc tgtggatggg gcagaggatc ctgatgtttt 300
ggaagccttg aagcctggaa actgtggtga atatgtggtt cgatggtatt atgacaaaca 360
gggtcaactct tgtgccgat tttggttcag tggctgtaat ggctcaggaa atagattcaa 420
cagtgaaaag gaatgtcaag aaacctgcat tcaaggatga gcaagtaaat tggcctgtct 480
ctatcaaaaag catagaactc cctaatttcc acataattcac ccaatacaaa tacagcata 540
tatttgagtg tatactgagt atttacaact tatacatgta attgaattct cactacagcc 600
ctaggatgta catattatta accacttata taggtaagaa agctgaggct ctgagaagtt 660
tagtaacttg tcaactgtca cccaactaaa aagtttcaga gctgaggatt tagacttaga 720
gctgtgtaac ttcaatacac agactctatc tacttcacaa cctgcaatgt gattctgatt 780
cctttgaattc ctgttgatg tactatgtca gctcaaaccc ctacctgtgt cacttttgta 840
acctccaccc actcacctcc ctaacctctt tatgtccctc acagtagcaa gatgtagggtg 900
ataggaagga cttcgggtgtg agaattagaa atgatgtaaa tgtttacgca ggagtgtctgg 960
gataggagtc gggatggtga gggtagttag atttttgctt cacttgccct gaaagtggta 1020
atagggagaa accaatctga ttacaatta cttaaatgta tcacagactg tcaactttgta 1080
ttcctccaac atgtttggtg acaagtgcct aatgtatggt aaaataaaga aggtttttat 1140
acctttccat taaaatatgt cagtgggccc ttccatttta tggagtggaa tgggaaggcc 1200
cttgacagcc aggaaccact tgaagctggc atccactctt gaacagagag tattaagac 1260
aggattcaca ctgaaaagtg agccaccaa ttgaaatgcg agtaatggag agtaacggag 1320
aatcgcttga cctgggaag cagaggttgc agagagccgg gattgcccc 1371

```

<210> 44

<211> 3634

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1911808CB1

<400> 44

```

gcgccggcag tggcgcgcac aggtgattga ctggccagct gcctgaagga gcgccaggtc 60
ctccttgctg gcagggtggcg aagcccatg gggcgccggt gcagaccgcg gcggcggtcg 120
cgccgggtctg gctcgggagg cgttcctggg gccaaaggcca tggccccgcg gctgcagctg 180
gagaaggcgg cctggcgctg ggccggagacg gtgcggcccg aggaggtgtc gcaggagcat 240
atcgagaccg cttaccgcat ctggctggag cctgcattc gcggcggtgtg cacagcaaac 300
tgcaaaaggaa atccgaattg cttgggtggg attggtgagc atatttgggt agagaaaata 360
gatgaaaata gttttcataa catcgatgat cccaactgtg agaggagaaa aaagaactca 420
tttgtggggc tgactaacct tggagccact tgttatgtca acacatttct tcaagtgtgg 480
ttttctcaact tggagcttcg gcaggcactc tacttatgtc caagcacttg tagtgactac 540
atgctgggag acggcatcca agaagaaaaa gattatgagc ctcaaacaaat ttgtgagcat 600
ctccagtgact tgtttgcctt gttgcaaaac agtaataggc gatacattga tccatcagga 660
tttgttaaag ccttgggcct ggacactgga caacagcagg atgtcagaag attttcaaag 720
ctctttatgt ctctattgga agatactttg tctaaccaaa agaattcaga tgtgcgcaat 780
attgttcaac agcagttctg tggagaatat gcectatgtaa ctgtttgcaa ccagtgtggc 840
agagagtcta agctttgtc aaaattttat gagctggagt taaatatcca aggccacaaa 900
cagttaacag attgtatctc ggaatttttg aaggaagaaa aattagaagg agacaatcgc 960
tatttttgcg agaactgtca aagcaaacag aatgcaacaa gaaagattcg acttcttagc 1020
cttcttgca ctctgaactt gcagctaatg cgttttgtct ttgacaggca aactggacat 1080
aagaaaaagc tgaataccta cattggcttc tcagaaaattt tggatatgga gccttatgtg 1140
gaacataaag gtgggtccta cgtgtatgaa ctccagcgag tctcatataa cagaggagtg 1200
agtgttatt ctggccacta catcgccac gtgaaagatc cacagtctgg tgaatggtat 1260
aagtttaatg atgaagacat agaaaagatg gaggggaaga aattacaact agggattgag 1320
gaagatctag cagaaccttc taagtctcag acacgtaaac ccaagtgtgg gccctatgag 1380
cattgctctc gaaatgcata tatgttgggt tatagactgc aaactcaaga aaagcccaac 1440
actactgttc aagttccagc ctttcttcaa gagctggtag atcgggataa ttccaaattt 1500
gaggagtgggt gtattgaaat ggctgagatg cgtaagcaaa gtgtggataa agggaaaagca 1560
aaacacgaag aggttaagga gctgtaccaa aggttacctg ctggagctgc gccctatgag 1620
tttgtctctc tggaatggct tggaaatgac ttctatagta caacacctac caaacctatt 1680
gataatcacg cttgectgtg ttcccatgac aagcttcacc cggataaaat atcaattatg 1740
aagaggatat ctgaatatgc agctgacatt ttctatagta gatatggagg aggtccaaga 1800
ctaactgtga aagccctgtg taaggaatgt gtagtagaac gttgtcgcac attgcgtctg 1860
aagaaccaac taaatgaaga ttataaaact gttaataatc tgctgaaagc agcagtaaaag 1920

```

```

ggcagcgtatg gatttttgggt ggggaagtcc tccttgcgga gttggcgcca gctagctctt 1980
gaacagctgg atgagcaaga tggatgatgca gaacaaagca acggaaagat gaacggtagc 2040
accttaataa aagatgaatc aaaggaagaa agaaaagaag aggaggaatt aaattttaat 2100
gaagatatcc tgtgtccaca tggtagttaa tgcataatctg aaaatgaaag aaggcttggt 2160
tctaaagagg cttggagcaa actgcagcag tactttccaa aggtctctga gtttccaagt 2220
tacaaagagt gctgttcaca gtgcaagatt ttagaaagag aaggggaaga aaatgaagcc 2280
ttacataaga tgattgcaaa cgagcaaaag acttctctcc caaatttggt ccaggataaa 2340
aacagaccgt gtctcagtaa ctggccagag gatacggatg tcctctacat cgtgtctcag 2400
ttctttgtag aagagtggcg gaaatttggt agaaagccta caagatgcag ccctgtgtca 2460
tcagttggga acagtgtctt tttgtgtccc cacggggggc tcattgtttac atttgcttcc 2520
atgaccaaaag aagattctaa acttatagct ctcatatggc ccagtgaagt gcaaattgata 2580
caaaagctct ttgtttgtga tcatgttaatt aaaatcacga gaattgaagt gggagatgta 2640
aacccttcag aaacacagta tatttctgag cccaaactct gtccagaatg cagagaaggc 2700
ttatttgtgc agcagcagag ggacctgcgt gaatacactc aagccaccat ctatgtccat 2760
aaagtgtgtg ataataaaaa ggtgatgaag gattcggtct cggaactgaa tgtgagtagt 2820
tctgaaacag aggaggacaa ggaagaagct aaaccagatg gagaaaaaga tccagatttt 2880
aatcaaatca tgcatgcatt ttcagttgct ccttttgacc agaatttgct aattgatgga 2940
aagattttaa gtgatgactg tgccacccta ggcaccttg gcgtcattcc tgaatctgtc 3000
attttattga aggtgtatga accaattgca gattatgctg caatggatga tgtcatgcaa 3060
gtttgtatgc cagaagaagg gtttaaagggt actggtcttc ttggacatta atctttgaat 3120
acttgctgac tgctaagaaa tgaccagagg ggaagaggag ttgacatgt tagggcata 3180
aagcaaaagt ggattttaaga attaaacctt tccaaagggc ttccaaatcca 3240
ttcaaacgtg actgtcccaa atgccttatg tcaataaagg cagattgcac tgatggacat 3300
cagacttgaa ggaaatgttt ccaattttat atttaagggg ggtggtgggt gggagggggc 3360
aagtaagac ggaacaagtt tagtagcagt aatagtaaat catgtttaca tatgagattt 3420
atagtcgtgg gaggggaata aagttctggt atatttctct gctcgagttt cataccagat 3480
gcgttggtcc ataaaggatt gtatcaagta gatgggacaa cattctgttc tgaacgaaaa 3540
gtaattttag agacataacc tgcttaccaa tgctgtctt tgattcatat tctactttca 3600
ataaagcatg aaagtgaaga acttgtaaaa aaaa 3634

```

<210> 45
 <211> 1661
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1973875CB1

```

<400> 45
ctcgagccga ttcggtctga ggcggactgg tctcggccg ggcaccgtcg cgggcccccc 60
tgccccggcc acctgggacc gtgctgggga gtctgccact tccctctctc ccctggcccc 120
caaagttttg gcggaccatc cgtgggggtc gagcgcgcgc cgggggggag atcggggagc 180
gccgatgccc gggcgcccg agccattgac ccgggacgcc gccgtccgct gagcagccga 240
ccaccccgcc gctccgggtg catggggact ggctgaggag ccagcatggg caactgctgt 300
gggagacagc gccgggagag gccggcagcc ccgggacacc cccgcaagcg agcaggacgc 360
aatgagcccc tgaagaaaga gcggcttaag tggaaagagcg actaccccat gactgacggg 420
cagctgcgga gcaaacggga tgagtctggt gacacagcgc ctgccttcga gggccgcaag 480
gagatctggg atgccctcaa ggctgccgcc tatgtgtctg aagccaacga ccacgagctg 540
gcccaggcca tcttgatgg agccagcatc accctgcctc atggcaccct ctgtgaatgc 600
tacgatgagc tgggcaatcg ctaccagctg cccatctact gcctgtcacc gccggtgaac 660
ctgtctgtgg agcacacgga ggaggagagc ctggagcccc ccgagcctcc acccagctgt 720
cgccgtgagt tcccgtgaa ggtgcgcctg tccacgggca aggacgtgag gctcagcgcc 780
agcctgcccc acacagtggg gcagctcaag aggcagctgc acgcccagga gggcatcgag 840
ccatcgtggc agcgggtggtt cttctccggg aagctgtctc cagaccgcac acgggtccag 900
gagaccaaga tccagaaaga ttttgtcatc cagggtcatc tcaaccagcc cccaccacc 960
caggatgat gggccccagg acccctggga agaggcccc cctggagcac taggccccca 1020
ccctgtctgt gcttccagt gctgtcattt tcttcagggg ccctccccctc ggtgtggctg 1080
gtgggtgagc cgtgaaggga cctgtccttt cagggcaacta cgcgccacca gttcccggta 1140
cccagggagc aggcagccac acacgggcct tgcaaccttg tcagagaaaa ggccaacagg 1200
gccccaccc tgccgtgtct cgaagcagc ttcagaccac aagggccaac caggagcccc 1260
ctggagccca gatctgtcat ctggtgtgct cagctgtgct cactctggtt ttctgtctag 1320
ggtctgaagc agctgtgtc tccctctct gccccatcc cctggctctc ccctgggcac 1380
agtgccactc ccttggaagg gagggaaaca cccgtgagcc ccagggttg ggaagcctga 1440
ggcgggctc tgccctctcc tgcccccagc acaattggga gagatgaggc ggggtgggta 1500
ggctgggct gtcgtggcag ggtctgcaca gggccatgtc ctggctgtaa cccaggcagt 1560
gggaggtctg cagcctggtc atggcctcca cagcaggtcc ctgtggacag acatatctgc 1620

```

atatttatca ataaagcctt ttgctccttc aaaaaaaaaa a

1661

<210> 46
 <211> 1910
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2323917CB1

<400> 46
 gtactccgcg cgcagccctg gcggtccagc gccaatctcc agaattctggt ctccagaaac 60
 attattctaa tctgtgtatg gaaaaatccc agaaaattaa tccttttata ttgcataac 120
 tccaagaagt ggatgaagaa attaaaaagg ggctagcagc aggaatcaca ttaaacattg 180
 ctggtaacaa tcgcttagtg ccagtagaaa gagttacagg tgaagatttt tggattcttt 240
 ccaaaatttt aaagaattgt ctgtatatta atgggttgga tgttgatat aaccttctat 300
 gtgatgttgg tgcatactat gctgcgaaac tgcttcagaa acaacttaac ctcatctact 360
 taaacctcat gtttaatgat attgggcccg aagggtggaga attgattgct aaagtgtac 420
 ataagaatcg gactctgaaa tacctaagaa tgactggaaa caaattgaa aataaagggtg 480
 gaatgttttt tgctgcaatg ctgcaaatta attcatcatt agagaaatta gatctgggtg 540
 actgtgatct gggaatgcaa agtgtgatag catttgctac agtactaact caaaaccaag 600
 caattaaggc aataaaccta aaccgacctt tactgtacgg tgaacaggaa gagtctacag 660
 tccatgtagg cctcatgttg aaagaaaatc actgtcttgt tgcactacac atgtgtaagc 720
 atgatataaa aaacagtggg atacaacagt tatgtgatgc actgtatctg aacagtagcc 780
 tgcgctacct tgatgtcagc tgcaacaaaa taactcatga tgggaatggtg tatttggtcg 840
 atgtactgaa aagcaacact accctggaag taatagatct ttctttaac agaatagaaa 900
 atgcaggcgc aaactatctc agtgaaactc ttacttcaca caacaggagt cttaaagcgt 960
 tgtcagtagt cagcaacaac atagaggagg aaggacttgt tgcactttca caatcaatga 1020
 aaacaaatct cactttctct catatctaca tttggggaaa caaatttgat gaggctacgt 1080
 gtatagcata ttcagactta attcaaatgg gttgtctaaa accagacaat acagatgtgg 1140
 agccatttgt ggtagatgga cgtgtatata ttgcagaagt ctccaatggc cttaaaaagc 1200
 attattattg gacatcaact tatggagaat cttatgacca ctcatctaat gcagggtttg 1260
 ctcttgttcc agtaggtcaa cagccatgaa aaagtagctg taaaataatt ttcatacact 1320
 tgtcttattg tttcacagag ataatattc tatagcctat tttcttttat aaattaaaac 1380
 aagttacttt tttcaaatgt gtaaaagata atgactgtat taaacttgtt ataactgtca 1440
 aaaaaaaaaa aaagggggcg gccccgatta gtgagctcgt ccccgcggtt atttactccc 1500
 ggggccccgt cccctggggg ggggttaacca gtctttccgc caaggggtgtg gtccgtgata 1560
 tacaggcgctc ttggaaagag aagtcgtgct gtccctgggc tcttcttctg gtccggagggc 1620
 attttactcg tctgtccccg ctggtgtaat atagtaccgc cacgcgtgtg gtccgtggta 1680
 tgttggaat aagtgttggg tggagtctcg ctgggtgttg gacgtaggta gatccctgca 1740
 gacgtttctca tatcggttg gcgttggtcg tggccccgct tcccggtggt gtgttgctga 1800
 ggtagtgggtg ttgcacctgt atttatattg gtccctccgc cgcgcggggt ggaggcggtg 1860
 ttggtttagt agctcgtggc ggtgtgtgtg ttcctcaacc cacacacaat 1910

<210> 47
 <211> 2162
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2754960CB1

<400> 47
 gacagcgcaa ccgcactcca gcctggacga cagaatgaga ctccgtctca aaaaaaaaaa 60
 aaaaaaaaaa aagcgagggc tggaagtctg gagcaggtgc gcggtgcaa cggcagccgc 120
 gggaagctcg ggccggcagc gtttccccgc acgctggcgc ccagctcccg ggcgggagc 180
 cgtgtgaagt ttcgctttcc attcagtggg aaacgaaagc tgggcggggg gccacgagcg 240
 cggggccaga ccaaggcggg cccggagcgg aacttcgggc ccagctcggg ccccggtcca 300
 gtccccgact ggaactcagc agcggaggct ggacgcttgc atggcgcttg agagattcca 360
 tctgtcctgg ctacataag cgcttctctg aagtgaagtc gtgctgtcct gaacgcgggc 420
 caggcagctg cggcctgggg gttttggagt gatcacgaat gagcaaggcg tttgggctcc 480
 tgaggcaaat ctgtcagtc atcttggtg agtctcgcga gtccccggca gatcttgaag 540
 aaaagaagga agaagacagc aacatgaaga gagagcagcc cagagagcgt cccagggcct 600
 gggactaccc tcatggcctg gttggtttac acaacattgg acagacctgc tgccttaact 660
 ccttgattca ggtgttcgta atgaatgtgg acttcaccag gatattgaag aggatcacgg 720

```

tgcccagggg agctgacgag cagaggagaa gcgtcccttt ccagatgctt ctgctgctgg 780
agaagatgca ggacagccgg cagaaagcag tgcggccctt ggagctggcc tactgcctgc 840
agaagtgcaa cgtgcccttg tttgtccaac atgatgctgc ccaactgtac ctcaaactct 900
ggaacctgat taaggaccag atcactgatg tgcacttggg ggagagactg caggccctgt 960
atacgatccg ggtgaaggac tccttgattt gcgttgactg tgccatggag agtagcagaa 1020
acagcagcat gctcacccct ccactttctc tttttgatgt ggactcaaag cccctgaaga 1080
cactggagga cgccctgcac tgcttcttcc agcccaggga gttatcaagc aaaagcaagt 1140
gcttctgtga gaactgtggg aagaagaccc gtgggaaaca ggtcttgaag ctgacccatt 1200
tgccccagac cctgacaatc cacctcatgc gattctccat caggaattca cagacgagaa 1260
agatctgcca ctccctgtac ttccccaga gcttggattt cagccagatc cttccaatga 1320
agcgagagtc ttgtgatgct gaggagcagt ctggagggca gtatgagctt tttgctgtga 1380
ttgcgcacgt gggaatggca gactccggtc attactgtgt ctacatccgg aatgctgtgg 1440
atggaaaatg gttctgcttc aatgactcca atatttgctt ggtgtcctgg gaagacatcc 1500
agtgtacata cggaaatcct aactaccaat ggcaggaaac tgcatatctt ctgggtttaca 1560
tgaagatgga gtgctaattg aaatgcccac aaccttcaga gattgacacg ctgtcatttt 1620
ccatttccgt tcctggatct acggagtctt ctaagagatt ttgcaatgag gagaagcatt 1680
gttttcaaac tataatactg agccttattt ataattaggg atattatcaa aatatgtaac 1740
catgaggccc ctcaggctct gatcagtcag aatggatgct ttcaccagca gaccggcca 1800
tgtggctgct cggtccctggg tgctcgctgc tgtgcaagac attagccctt tagttatgag 1860
cctgtgggaa cttcaggggt tcccagtggt gagagcagtg gcagtgaggag gcactctggg 1920
gccaaagggt agtggcaggg ggtatttcag tattatacaa ctgctgtgac cagacttgta 1980
tactggctga atatcagtcg tgtttgtaat ttttcacttt gagaaccaac attaatcca 2040
tatgaatcaa gtgttttgta actgctatcc atttattcag caaatattta ttgatcatct 2100
cttctccata agatagtgtg ataaacacag tcatgaataa agttattttc cacaaaaaaa 2160
aa 2162

```

<210> 48

<211> 578

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3092341CB1

<400> 48

```

gaaaggccca cctgtgtcct ggttgagggt ctccagggtt ctttggggcc cgaggaattt 60
cagacctgaa caatcagggt gacaacttct tgtgactttg ggtattctga aattactcat 120
cttgactcta ctgtgcctgg atgtagctgt gtgttttggt tgtatcctgt tcatggccaa 180
tgggtgcaga gtctacatag aactatgctt cgtgggtgtt tggggaaaac ctttcgactt 240
gttggctata ctattcaata tggctgtata gctcattgtg cttttgaata cgttgggtgt 300
gttgtcatgg tgccaatggg tcatgttttg ttagaagggt acaatctaca gaattctaca 360
gattccaggt gctatggacc tattccatat ggactaataa gaggacgaat cttctttaag 420
atttggcttc tgagtgattt tggattttta cgtggccagcc ctaatggcca cagattttct 480
gatgattagt aagcatttat tcttttgact tgattattgt ctccttttca tgtgaattta 540
ttactccctg tgaaccgtg tacttaccac taaactat 578

```

<210> 49

<211> 1300

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3658034CB1

<400> 49

```

agggaatccc aattatgagg cggetaagca ggcaaagaaa tagcttgggt ggttttgcatt 60
ctactcagga taccactgtg gctttaaagg ctgtctgaat ttgcagccct aatgaatata 120
gaaaggacaa atatccaagt gaccgtgacg gggcctagct caccaagtc tgtaaagttt 180
ctgattgaca cacacaaccg cttactcctt gagacagcag agcttgctgt ggtacagcca 240
acggcagtta atatttccgc aaatggtttt ggatttgcta tttgtcagct caatgttgta 300
tataatgtga aggttcttgg gtcttctaga agacgaagat ctatccaaaa tcaagaagcc 360
tttgatttag atgttgctgt aaaagaaaat aaagatgac tcaatcatgt ggatttgaat 420
gtgtgtacaa gcttttcggg cccgggtagg agtggcatgg ctcttatgga agttaaccta 480
ttaagtggct ttatgggtgc ttcagaagca atttctctga gcgagacagt gaagaaagtg 540
gaatatgac atggaaaact caacctctat ttagattctg taaatgaaac ccagttttgt 600

```

gttaatat	ctgctgtg	aaacttta	gtttcaa	ccaagatg	ttcagtgt	660
atagtgg	actatgag	aaggagac	gcggtgag	gttacaac	tgaagtga	720
ctgtctct	gtgacctt	cagtgatg	cagggctg	gtccttgt	ggatggag	780
tcaggtccc	atcatcact	ttcagtcatt	tttatttt	gtttcaag	tctgtact	840
atggaact	ggctgtg	tatttttaa	ggactctg	taacacta	atttccag	900
gtcacatg	attgtttt	tttcgtag	gaatactg	tctatttt	aaaaagag	960
ttttttct	ctatgggt	gcagggat	tgtacaac	gtcctagc	gtatagct	1020
atagattt	tcacctga	tttggtgt	agatcaga	gaatgcag	gtgtgtct	1080
attttccc	ctcaaaat	tttagaatt	ttttggag	gtttgttt	tccagaata	1140
aggattact	ttagaatag	tattctct	attttgtg	agaaatga	ctagattct	1200
aagcattat	acacatcc	gtttgctta	agatggatt	ccctggga	gggagaaa	1260
agccagcag	aggagctt	tctgttcc	tcccacct			1300

<210> 50
 <211> 2241
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3883861CB1

<400> 50						
gctccccg	ccgggctg	ccggaggc	cgagatgg	gcgcgcgt	gcctcctg	60
gcgcgcct	cagctgtac	tgtggggc	cctggacg	cagcccgc	agcgcggg	120
ccaggagct	cgcaaggag	cggaggcat	cctagaga	tacggata	tcaatga	180
ggctcccaa	gctcccact	ccactcgat	cagcgatg	atcagagc	ttcagtgg	240
gtcccagta	cctgtcagc	gcgtgttg	ccgcgccac	ctgcgccag	tgactcgt	300
ccgctgcgg	gttacagata	ccaacagt	tgcggcct	gctgagag	tcagtact	360
gtttgctag	caccggacca	aaatgagg	taagaaac	tttgcaag	aaggtaac	420
atggtaca	cagcacct	cctaccgc	ggtgaact	cctgagcat	tgccggag	480
ggcagttcg	ggcgccgt	gcgcgcct	ccagtgtg	agcaacgt	cagcgtgg	540
gttttggg	gccccagca	caggcccc	tgacatcc	ctcacctt	tccaaggg	600
ccacaacga	gggctggg	atgccttt	tggcccag	ggcgccct	cgcacgct	660
cctgcccc	cgcgccga	cgcacttc	ccaagatg	cgttgttc	tgagccgc	720
ccgcgggc	aacctgtt	tggtgctg	gcacgagat	ggtcacac	ttggcctc	780
ccactgcgc	gcgcgcgc	cgctcatg	gccctact	aagaggct	gccgcgac	840
gctgctcag	tgggacgac	tgctggcc	gcagagct	tatgggag	ccctaggg	900
ctcagtgcc	gtccagct	caggaaag	gttactgac	tttgagac	gggactct	960
cagccccc	ggaaggcg	ctgaaacg	ggccctaa	tactgccac	cttcttgc	1020
tgccatcact	gtagacagg	aacagca	gtacattt	aaagggag	atttctgg	1080
gggtggcag	gatggca	tctcagag	ccgtccact	caggaaag	gggtcggg	1140
gcccccca	attgaggct	cggcagtg	attgaatg	ggagattt	acttctta	1200
agggggct	tgctggag	tccggggc	tggggtct	cacagctg	ctctgcgc	1260
ccgggcagg	ggcctgccc	gccatcct	cgccgcct	ttcttccc	ctctgcgc	1320
cctcactct	ttcaagggt	cccgtact	cgtgctgg	cgaggggg	tgcaagtg	1380
gcccactac	ccccgaag	tgcaggact	gggaggcat	cctgaggag	tcagcggc	1440
cctgcccag	cccgatgg	ccatcatct	cttccgag	gaccgctac	ggcgcccg	1500
ccaggccaa	ctgcaggca	ccacctcg	ccgtgggc	accgagct	cctggatg	1560
ctgctggca	gccaaact	ggagcgcct	gttctga	cacctctc	cctcagaa	1620
tgggtggt	ctcagggca	aatcatgt	cccacccc	gggcagaa	cctcttag	1680
gcctctgag	ccctctgc	aagaccgg	agcaaagc	ccatctgg	gtctgtct	1740
ctttgttct	tgaagaat	agcattgt	ttgtctgt	ccaccatg	gaggtggg	1800
tgggtcaat	cttaggaaa	gcaaaaa	gtcccagat	ccttggcc	ttctccag	1860
gacttctat	ctccccag	ctttgttt	tgggtaaa	gtacagtt	tttcaag	1920
taacagcact	gggatcca	cagggggat	aaaaactc	cagagaa	cgagacc	1980
ttgcaagact	gtgcccct	cctcaggac	ccctggct	gttcttga	aacggtgt	2040
tatttagtca	gaggcccc	cccagga	catggatg	gatgaagg	caggcgtc	2100
caacctcaga	ggcccttt	ggggtcagg	cacagagt	gagggag	gatgcagg	2160
taccagtc	tggctttt	tctggggct	gaataaag	gtgccttc	ctgggtgg	2220
gagaggcag	aaaaaaaa	a				2241

<210> 51
 <211> 1860
 <212> DNA
 <213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4993873CB1

<400> 51

```
agaattgacc tgacaaatat tgaccaggtt gctgtgatct tcaaacacca ttttctgtg 60
ggtagagggtg atgcagtgtc gaagacctgg gcccctgctc agtgcccttg ctctagaatg 120
ggtccagctt ggcttttggt actgggaaca gggatcctgg cctctgtcca ctgtcagccc 180
cttcttgccc atggagataa aagtctgcag gggcctcaac ccccaggca tcagctctca 240
gagccagccc ccgcctacca cagaatcaca cccaccatta ccaattttgc tttgcgtttg 300
tataaagagc tggcagcaga cgcctccgga aacatcttct tctcgccagt gagcatctcc 360
accacctgtg ccctgtctct tcttggggcc caagctaaca cctcagctct gatcctggag 420
ggcctgggat tcaacctcac agaaacctct aaactcgaaac taaaagttag aaactccctg 540
ctcctccaca cccttgccct gccagcccc cactatttgg acagcatcaa ggagctttat 600
ttcctagaca agcgactaaa gcctcggcag gattctgtta caactgggag gcagattaat 660
ggagcttttg cttttctctg caacttcaca gtctgtggact gcctcccgga gttcagccag 720
gactatttga gaaggcaaac atacgggcaa ttcttcaaag ccaagtggaa gcacctttc 780
gacacgttca tgggtcttgc caattacatc tctctcaaag ccaagtggaa gcacctttc 780
agtcgtacc agaccagaa gcaggcaagt ttctttgtgg atgagaggac ttctctccag 840
gtcccatga tgcacaaaaa ggaaatgcac agattcctct atgaccagga tttggcttgc 900
actgtcctcc agatagaata cagaggaaat gccttgccgc tgctggtctt ccctgacctg 960
gggaaaaatga agcaggtgga ggctgctctg cagccacaga ccctgagaaa atggggccaa 1020
ttgctcctgc ccagctgtt ggatttgcac ttgccaagggt tttcaatttc tggacatat 1080
aacctggaag acatacttcc ccaaattggt ctcaccaaca tactcaactt agaagctgac 1140
ttctcaggag tcaactgggca gctcaacaaa accatctcca aggtgtcaca caaggcgatg 1200
gtggacatga gtgagaaggg gaccgaggcc gggcctgctt caggcctcct ctcccagccc 1260
ccatctctga acacctatgc agaccacatc gggcacttca acaggccttt cctcttgcct 1320
ctttgggagg tcaccaccca gagcttactc ttctgggaa aagttgtcaa ccagttgca 1380
gggtaaccat ggtgggaggc caggagttat cttatctcat cctggaccaa acagataggc 1440
cagaaccagc ctgcctcctg gggctgctat gtggttcagt taatcagtg gccaagattc 1500
taataaagtt gacctgggt tctgtgaaaa aaaaaaaaag aacaaccaac gcataaagtt 1560
gcggcgtaaa ggatgctgaa agcaaatacc ccggtttgcc cgtccaaatt taacataagg 1620
ggggggccgg cagtacagaa ggtccctcag agtggtgttg atggcgtcg actgattggc 1680
ggggggggcg agagagttt tacgcatctt tgcacgtgtt agcaccggg gggggggggc 1740
ccataggagc ccgagagctg gaggttgggt ttgcgcgggc actcttgggg ggggtgttat 1800
gaccgacttt tagtggcaca aactgtgggg cttctcatat gtgtgcgcgc gcttctgttt 1860
```

<210> 52

<211> 550

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5208004CB1

<400> 52

```
ggcgggtggc tggaggacac ggtgtaggcc ttgccgtgt ctgggttctt cgccactgca 60
ggagcaggac tgtttctgga aacactgggc tgctggtgac ccgtcaaact tctcccacaa 120
attctgaatc cgagaaagtg aaggaaggat ggtggggaag tgaggaggca ggagcagagg 180
ccacagggac cgaccagaga tgcggtggag acagaggagc ttcttctca ggctgtttct 240
gggaagcctg agaggcggcc agcaccacc tccgctcact ctcccctcag cctcttcgct 300
tcccttctca accctttctc tctctctcgc ctcttccctt tcttctgtgc ttgttagtcc 360
ctgtcccaaa actcctggct cctttgttct gctgcccgtg cccccacca ggaggaggtc 420
tcaggcacca tccccccac gagggatcca cacaacagg tcatgctggg gctgggggag 480
ccccgctggg ttctgatgc cttgtgcaca ggaagtgtc gcagtcattt ttggactctc 540
ctgaatgtgt
```

<210> 53

<211> 2597

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5267783CB1


```

<400> 53
gacctggttgg gccgcgtcct ttctgtgccc cgcgcggtg caggcctcgc cgcgagccgc 60
aggtgtcctg gagtctggcc caggacctgg cccacagga gtcccagcag gggtagctcc 120
tcccgggaca aggaccgaag tgcgacggtc agtagttcag tgcccagcgc tgctggaggg 180
aaaggaagcc atccttcac taccacccag agggccccca accgcctgat ccacgagaag 240
tcaccatacc tcctacaaca tgcctacaat cctgtggact ggtacccctg gggagaggaa 300
gacctcgaca aggccaggaa ggaaaacaag ccgattttcc tctcagtcgg gtactccacc 360
tgccactggt gccacatgat ggaagaggag tcttccaga atgaggagat tggccgctcg 420
ctcagtgagg actttgtgag tgtgaaggta gacctgagg agcggcctga cgtggacaag 480
gtgtacatga cgttcgtgca ggccaccagc agcggcgggg gctggcccat gaatgtgtgg 540
ctgactccca acctccagcc ctttgtcggg ggcacctatt tccctcctga ggatggcttg 600
acctcgagtc gcttcgcac agtgttgctg agaatacgag aacagtggaa acagaacaag 660
aacacctgc tagaaaatag ccagcgtgtc accactgccc tgctggcccc atcagagatc 720
agcgtgggtg accgccagct gccgccctct gccgccaccg tgaacaatcg ctgcttccag 780
cagctggatg agggctatga tgaggaaatc ggtggcttcg ctgaggcccc caagtttccc 840
acgcgggtga tctgagctt cctgtctcc tactggctca gccatcgact gactcaggat 900
ggctctcggg cccagcagat ggcttgcac accctgaaaa tgatggctaa cgggggcatc 960
cgggaccatg tggggcaggg ctttccaccg tactccacag accgccagtg gcacgtccct 1020
cactttgaga agatgctcta tgaccaggca cagctcgtg tggcctattc caggccttc 1080
cagctctctg gtgatgaatt ctactctgac gtggccaaag gcatcctgca gtacgtggct 1140
cggagcctga gccaccggtc cggaggcttc tatagcgag aagatgcaga ctgccccca 1200
gagcggggcc agcggcccaa agagggcgcc tactatgtgt ggacggctaa agaggttcag 1260
cagctcctcc cggagcctgt gttgggtgcc accgagccgc tgacctcagg ccagctccc 1320
atgaagcact acggcctcac agaggtgggt aacatcagcc ccagtcagg ccccaagggg 1380
gagctgcagg gccagaatgt gctgaccgtc cggtaactgc tggagctgac tgctgcccgc 1440
tttggcttgg atgtggaggc cgtgcggacc ttgctcaatt cagggctgga gaagctcttc 1500
caggccccga agcatcggcc caagccgcac ctggacagca agatgctggc tgcttggat 1560
ggcttgatgg tgtcaggcta tgcgtgact ggggctgtcc tgggccaaga cagctgac 1620
aactatgcca ccaatgggtc caagttcctg aagcggcaca tgtttgatgt ggccagtggc 1680
cgctgatgc ggacctgcta caccggccct ggggggactg tggagcacag caaccaccc 1740
tgctggggct tcctggagga ctacgccttc gtggtgcggg gcttctgcgg tgcaggacac 1800
gctcaccagg agagtgcgtg gctcagtggt gctctgcggc aggtgagct ccagcgccaa 1860
ctcttttggg actcccagg gtctgaagga cgaccaggat ggagcagagc cagcgccaa 1920
ctgccccctg gtctcgaagg gcatggcttc acgggccaca aggactggat tcccggtggc 1980
gcccacaacc tgctccggct tcccgagcgc atgcgtcgtg tcccggtggc gttgcccag 2040
gtgtgcctat tgaccgcctt ccagcagcag acctcaagc agatcgtgat ctgtggagac 2100
atggtccgcg cctctcagc ggccctggtg cagtgcgtcc actctgtcta cattcctaac 2160
cgtcaggcca aggaacacaa tggggacccc tgcagcttcc tgtcccgcca gctgccttc 2220
aaggtgctga ttctggctga ggaagaccag gccatgcat atgtgtgtga gaatcaagc 2280
ctgagtaccc tccgacggt tccctgcgaa ttacgaaaac tactacatcc atgactgaga 2340
tgctcagtc ccactactga tccctgcgaa ttacgaaaac tactacatcc atgactgaga 2400
caacccccct ggggtggggc tggccatccc tgagcaccct gccaccagg 2460
gcagggccct atagaacctg ccccccttgg gacccactc gtgtcccggt 2520
atactactg gtaaaaaaa aaaaaaa 2580
gtaaaaaaa aaaaaaa 2597

```

```

<210> 54
<211> 2385
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 5583922CB1

```

```

<400> 54
gaccgacccg ccacccgcgc tagcccgccg gcccttggea ctcaatcccc gccatgtggg 60
ggctcctgct cgccttgccc gccttcgcgc cggcgtcgg cccggtctgt ggggcgcca 120
ggaactcggg gctgggcctc gcgcagccgc ggaccaccaa ggtcccaggc tcgaccccg 180
cctgcatag cagcccgcca cagccgcggc cggagacagc taacgggacc tcagaacagc 240
atgtccggat tcgagtcac aagaagaaaa aggtcattat gaagaagcgg aagaagctaa 300
ctctaactcg cccaccccca ctggtgactg ccgggcccc tgtgacccc actccagcag 360
ggacctcga ccccgctgag cagctgttc tcctttgggt cttggaccac 420
tgcgagtttc agatagccgg cttgagcat ccagcagcca gtcctttggg gatggagcct 480
accgaggacg gctcaacatt cagtcaggcc tggaggacgg cgatctatat gatggagcct 540
ggtgtgctga ggagcaggac gccgatccat ggtttcaggg ggagcgtggg caccacccc 600
gcttctcggg tgttatcaca cagggcagta actctgtctg gaggtatgac tgggtcacat 660

```

catacaaggt	ccagttcagc	aatgacagtc	ggacctggtg	gggaagtagg	aaccacagca	720
gtgggatgga	cgcagtattt	cctgccaatt	cagacccaga	aactccagtg	ctgaacctcc	780
tgccggagcc	ccaggtggcc	cgcttcattc	gcctgctgcc	ccagacctgg	ctccagggag	840
gcgcgccttg	cctccgggca	gagatcctgg	cctgcccagt	ctcagacccc	aatgacctat	900
tccttgaggc	ccctgcgtcg	ggatcctctg	accctctaga	ctttcagcat	cacaattaca	960
aggccatgag	gaagctgatg	aagcaggtae	aagagcaatg	ccccaacatc	acccgcatct	1020
acagcattgg	gaagagctac	cagggcctga	agctgtatgt	gatggaaatg	tcggacaagc	1080
ctggggagca	tgagctgggg	gagcctgagg	tgcgctacgt	ggctggcatg	catgggaacg	1140
aggccctggg	gcgggagttg	cttctgctcc	tgatgcagtt	cctgtgccat	gagttcctgc	1200
gagggaaccc	acgggtgacc	cgctgctct	ctgagatgcg	cattcacctg	ctgccctcca	1260
tgaacctga	tggtatgag	atcgctacc	accggggttc	agagctgggtg	ggctgggccc	1320
agggccgctg	gaacaaccag	agcatcgatc	ttaaccataa	ttttgctgac	ctcaacacac	1380
cactgtggga	agcacaggac	gatgggaagg	tgccccacat	cgtccccaac	catcacctgc	1440
cattgcccac	ttactacacc	ctgcccattg	ccaccgtggc	tctgaaaacg	cgggcagtaa	1500
tcaagtggat	gaagcggatc	ccctttgtgc	taagtgccaa	cctccaacggg	ggtgagctcg	1560
tggtgtccta	cccattcgac	atgactcgca	ccccgtgggc	tgcccgcgag	ctcacgcca	1620
caccagatga	tgctgtgttt	cgctggctca	gcactgtcta	tgctggcagt	aatctggcca	1680
tgaggacac	cagccgccga	ccctgccaca	gccaggactt	ctccgtgcac	ggcaacatca	1740
tcaacggggc	tgactggcac	acgggtcccc	ggagcatgaa	tgacttcagc	tacctacaca	1800
ccaactgctt	tgaggctact	gtggagctgt	cctgtgacaa	gttccctcac	gagaatgaat	1860
tgccccagga	gtgggagaa	aacaaagacg	ccctcctcac	ctacctggag	caggtgcgca	1920
tgggcattgc	aggagtgggtg	agggacaagg	acacggagct	tgggattgct	gacgtgtca	1980
ttgccgtgga	tgggattaac	catgacgtga	ccacggcgtg	gggcggggat	tattggcgtc	2040
tgctgacccc	aggggactac	atgggtgactg	ccagtgccga	gggctaccat	tcagtgcac	2100
ggaactgtcg	ggtcaccttt	gaagagggcc	ccttcccctg	caatttcgtg	ctaccaaga	2160
ctcccaaaca	gaggctgcgc	gagctgctgg	cagctggggc	caaggtgccc	ccggaccttc	2220
gcaggcgcc	ggagcggcta	aggggacaga	aggattgata	cctgcggttt	aagagcccta	2280
gggcaggctg	gacctgtcaa	gacgggaagg	ggaagagtag	agagggaggg	acaaagtgag	2340
gaaaaggtgc	tcattaaagc	taccgggcac	cttaaaaaaa	aaaaa		2385

SEQUENCE LISTING

<110> INCYTE GENOMICS, INC.
 YUE, Henry
 TANG, Y. Tom
 BANDMAN, Olga
 LAL, Preeti
 BAUGHN, Mariah R.
 AZIMZAI, Valda
 LU, Dzung Aina M.
 YANG, Junming

<120> PROTEASES AND PROTEASE INHIBITORS

<130> PF-0727 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/147,986; 60/160,807

<151> 1999-08-09; 1999-10-21

<160> 54

<170> PERL Program

<210> 1

<211> 444

<212> PRT

<213> Homo sapiens

<220>

<221> misc.feature

<223> Incyte ID No: 088718CD1

<400> 1

Met	Lys	Val	Val	Pro	Ser	Leu	Leu	Leu	Ser	Val	Leu	Leu	Ala	Gln
1				5					10					15
Val	Trp	Leu	Val	Pro	Gly	Leu	Ala	Pro	Ser	Pro	Gln	Ser	Pro	Glu
				20					25					30
Thr	Pro	Ala	Pro	Gln	Asn	Gln	Thr	Ser	Arg	Val	Val	Gln	Ala	Pro
				35					40					45
Arg	Glu	Glu	Glu	Glu	Asp	Glu	Gln	Glu	Ala	Ser	Glu	Glu	Lys	Ala
				50					55					60
Gly	Glu	Glu	Glu	Lys	Ala	Trp	Leu	Met	Ala	Ser	Arg	Gln	Gln	Leu
				65					70					75
Ala	Lys	Glu	Thr	Ser	Asn	Phe	Gly	Phe	Ser	Leu	Leu	Arg	Lys	Ile
				80					85					90
Ser	Met	Arg	His	Asp	Gly	Asn	Met	Val	Phe	Ser	Pro	Phe	Gly	Met
				95					100					105
Ser	Leu	Ala	Met	Thr	Gly	Leu	Met	Leu	Gly	Ala	Thr	Gly	Pro	Thr
				110					115					120
Glu	Thr	Gln	Ile	Lys	Arg	Gly	Leu	His	Leu	Gln	Ala	Leu	Lys	Pro
				125					130					135
Thr	Lys	Pro	Gly	Leu	Leu	Pro	Ser	Leu	Phe	Lys	Gly	Leu	Arg	Glu
				140					145					150
Thr	Leu	Ser	Arg	Asn	Leu	Glu	Leu	Gly	Leu	Ser	Gln	Gly	Ser	Phe
				155					160					165
Ala	Phe	Ile	His	Lys	Asp	Phe	Asp	Val	Lys	Glu	Thr	Phe	Phe	Asn
				170					175					180
Leu	Ser	Lys	Arg	Tyr	Phe	Asp	Thr	Glu	Cys	Val	Pro	Met	Asn	Phe
				185					190					195
Arg	Asn	Ala	Ser	Gln	Ala	Lys	Arg	Leu	Met	Asn	His	Tyr	Ile	Asn
				200					205					210
Lys	Glu	Thr	Arg	Gly	Lys	Ile	Pro	Lys	Leu	Phe	Asp	Glu	Ile	Asn
				215					220					225
Pro	Glu	Thr	Lys	Leu	Ile	Leu	Val	Asp	Tyr	Ile	Leu	Phe	Lys	Gly

Lys	Trp	Leu	Thr	Pro	Phe	Asp	Pro	Val	Phe	Thr	Glu	Val	Asp	Thr	230
															245
Phe	His	Leu	Asp	Lys	Tyr	Lys	Thr	Ile	Lys	Val	Pro	Met	Met	Tyr	245
															260
Gly	Ala	Gly	Lys	Phe	Ala	Ser	Thr	Phe	Asp	Lys	Asn	Phe	Arg	Cys	260
															275
His	Val	Leu	Cys	Leu	Pro	Tyr	Gln	Gly	Asn	Ala	Thr	Met	Leu	Val	275
															290
Val	Leu	Met	Glu	Lys	Met	Gly	Asp	His	Leu	Ala	Leu	Glu	Asp	Tyr	290
															305
Leu	Thr	Thr	Asp	Leu	Val	Glu	Thr	Trp	Leu	Arg	Asn	Met	Lys	Thr	305
															320
Arg	Asn	Met	Glu	Val	Phe	Phe	Pro	Lys	Phe	Lys	Leu	Asp	Gln	Lys	320
															335
Tyr	Glu	Met	His	Glu	Leu	Leu	Arg	Gln	Met	Gly	Ile	Arg	Arg	Ile	335
															350
Phe	Ser	Pro	Phe	Ala	Asp	Leu	Ser	Glu	Leu	Ser	Ala	Thr	Gly	Arg	350
															365
Asn	Leu	Gln	Val	Ser	Arg	Val	Leu	Gln	Arg	Thr	Val	Ile	Glu	Val	365
															380
Asp	Glu	Arg	Gly	Thr	Glu	Ala	Val	Ala	Gly	Ile	Leu	Ser	Glu	Ile	380
															395
Thr	Ala	Tyr	Ser	Met	Pro	Pro	Val	Ile	Lys	Val	Asp	Arg	Pro	Phe	395
															410
His	Phe	Met	Ile	Tyr	Glu	Glu	Thr	Ser	Gly	Met	Leu	Leu	Phe	Leu	410
															425
Gly	Arg	Val	Val	Asn	Pro	Thr	Leu	Leu							425
															440

<210> 2

<211> 565

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 114551CD1

<400> 2

Met	Ser	Gly	Arg	Ser	Lys	Arg	Glu	Ser	Arg	Gly	Ser	Thr	Arg	Gly	1
															5
Lys	Arg	Glu	Ser	Glu	Ser	Arg	Gly	Ser	Ser	Gly	Arg	Val	Lys	Arg	10
															20
Glu	Arg	Asp	Arg	Glu	Arg	Glu	Pro	Glu	Ala	Ala	Ser	Ser	Arg	Gly	25
															35
Ser	Pro	Val	Arg	Val	Lys	Arg	Glu	Phe	Glu	Pro	Ala	Ser	Ala	Arg	40
															50
Glu	Ala	Pro	Ala	Ser	Val	Val	Pro	Phe	Val	Arg	Val	Lys	Arg	Glu	55
															65
Arg	Glu	Val	Asp	Glu	Asp	Ser	Glu	Pro	Glu	Arg	Glu	Val	Arg	Ala	70
															80
Lys	Asn	Gly	Arg	Val	Asp	Ser	Glu	Asp	Arg	Arg	Ser	Arg	His	Cys	85
															95
Pro	Tyr	Leu	Asp	Thr	Ile	Asn	Arg	Ser	Val	Leu	Asp	Phe	Asp	Phe	100
															110
Glu	Lys	Leu	Cys	Ser	Ile	Ser	Leu	Ser	His	Ile	Asn	Ala	Tyr	Ala	115
															125
Cys	Leu	Val	Cys	Gly	Lys	Tyr	Phe	Gln	Gly	Arg	Gly	Leu	Lys	Ser	130
															140
His	Ala	Tyr	Ile	His	Ser	Val	Gln	Phe	Ser	His	His	Val	Phe	Leu	145
															155
Asn	Leu	His	Thr	Lys	Lys	Phe	Tyr	Cys	Leu	Pro	Asp	Asn	Tyr	Glu	160
															170
Ile	Ile	Asp	Ser	Ser	Leu	Glu	Asp	Ile	Thr	Tyr	Val	Leu	Lys	Pro	175
															185
Thr	Phe	Thr	Lys	Gln	Gln	Ile	Ala	Asn	Leu	Asp	Lys	Gln	Ala	Lys	190
															200

```

Leu Ser Arg Ala Tyr Asp Gly Thr Thr Tyr Leu Pro Gly Ile Val
215 220 225
Gly Leu Asn Asn Ile Lys Ala Asn Asp Tyr Ala Asn Ala Val Leu
230 235 240
Gln Ala Leu Ser Asn Val Pro Pro Leu Arg Asn Tyr Phe Leu Glu
245 250 255
Glu Asp Asn Tyr Lys Asn Ile Lys Arg Pro Pro Gly Asp Ile Met
260 265 270
Phe Leu Leu Val Gln Arg Phe Gly Glu Leu Met Arg Lys Leu Trp
275 280 285
Asn Pro Arg Asn Phe Lys Ala His Val Ser Pro His Glu Met Leu
290 295 300
Gln Ala Val Val Leu Cys Ser Lys Lys Thr Phe Gln Ile Thr Lys
305 310 315
Gln Gly Asp Gly Val Asp Phe Leu Ser Trp Phe Leu Asn Ala Leu
320 325 330
His Ser Ala Leu Gly Gly Thr Lys Lys Lys Lys Lys Thr Ile Val
335 340 345
Thr Asp Val Phe Gln Gly Ser Met Arg Ile Phe Thr Lys Lys Leu
350 355 360
Pro His Pro Asp Leu Pro Ala Glu Glu Lys Glu Gln Leu Leu His
365 370 375
Asn Asp Glu Tyr Gln Glu Thr Met Val Glu Ser Thr Phe Met Tyr
380 385 390
Leu Thr Leu Asp Leu Pro Thr Ala Pro Leu Tyr Lys Asp Glu Lys
395 400 405
Glu Gln Leu Ile Ile Pro Gln Val Pro Leu Phe Asn Ile Leu Ala
410 415 420
Lys Phe Asn Gly Ile Thr Glu Lys Glu Tyr Lys Thr Tyr Lys Glu
425 430 435
Asn Phe Leu Lys Arg Phe Gln Leu Thr Lys Leu Pro Pro Tyr Leu
440 445 450
Ile Phe Cys Ile Lys Arg Phe Thr Lys Asn Asn Phe Phe Val Glu
455 460 465
Lys Asn Pro Thr Ile Val Asn Phe Pro Ile Thr Asn Val Asp Leu
470 475 480
Arg Glu Tyr Leu Ser Glu Glu Val Gln Ala Val His Lys Asn Thr
485 490 495
Thr Tyr Asp Leu Ile Ala Asn Ile Val His Asp Gly Lys Pro Ser
500 505 510
Glu Gly Ser Tyr Arg Ile His Val Leu His His Gly Thr Gly Lys
515 520 525
Trp Tyr Glu Leu Gln Asp Leu Gln Val Thr Asp Ile Leu Pro Gln
530 535 540
Met Ile Thr Leu Ser Glu Ala Tyr Ile Gln Ile Trp Lys Arg Arg
545 550 555
Asp Asn Asp Glu Thr Asn Gln Gln Gly Ala
560 565

```

<210> 3

<211> 589

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1261376CD1

<400> 3

```

Met Ala Glu Ser Gly Glu Ser Gly Gly Pro Pro Gly Ser Gln Asp
1 5 10 15
Ser Ala Ala Gly Ala Glu Gly Ala Gly Ala Pro Ala Ala Ala Ala
20 25 30
Ser Ala Asp Ala Lys Ile Met Lys Val Thr Val Lys Thr Pro Lys
35 40 45
Glu Lys Glu Glu Phe Ala Val Pro Glu Asn Ser Ser Val Gln Gln
50 55 60
Phe Lys Glu Glu Ile Ser Lys Arg Phe Lys Ser His Thr Asp Gln

```

				65					70					75
Leu	Val	Leu	Ile	Phe	Ala	Gly	Lys	Ile	Leu	Lys	Asp	Gln	Asp	Thr
				80					85					90
Leu	Ser	Gln	His	Gly	Ile	His	Asp	Gly	Leu	Thr	Val	His	Leu	Val
				95					100					105
Ile	Lys	Thr	Gln	Asn	Arg	Pro	Gln	Asp	His	Ser	Ala	Gln	Gln	Thr
				110					115					120
Asn	Thr	Ala	Gly	Ser	Asn	Val	Thr	Thr	Ser	Ser	Thr	Pro	Asn	Ser
				125					130					135
Asn	Ser	Thr	Ser	Gly	Ser	Ala	Thr	Ser	Asn	Pro	Phe	Gly	Leu	Gly
				140					145					150
Gly	Leu	Gly	Gly	Leu	Ala	Gly	Leu	Ser	Ser	Leu	Gly	Leu	Asn	Thr
				155					160					165
Thr	Asn	Phe	Ser	Glu	Leu	Gln	Ser	Gln	Met	Gln	Arg	Gln	Leu	Leu
				170					175					180
Ser	Asn	Pro	Glu	Met	Met	Val	Gln	Ile	Met	Glu	Asn	Pro	Phe	Val
				185					190					195
Gln	Ser	Met	Leu	Ser	Asn	Pro	Asp	Leu	Met	Arg	Gln	Leu	Ile	Met
				200					205					210
Ala	Asn	Pro	Gln	Met	Gln	Gln	Leu	Ile	Gln	Arg	Asn	Pro	Glu	Ile
				215					220					225
Ser	His	Met	Leu	Asn	Asn	Pro	Asp	Ile	Met	Arg	Gln	Thr	Leu	Glu
				230					235					240
Leu	Ala	Arg	Asn	Pro	Ala	Met	Met	Gln	Glu	Met	Met	Arg	Asn	Gln
				245					250					255
Asp	Arg	Ala	Leu	Ser	Asn	Leu	Glu	Ser	Ile	Pro	Gly	Gly	Tyr	Asn
				260					265					270
Ala	Leu	Arg	Arg	Met	Tyr	Thr	Asp	Ile	Gln	Glu	Pro	Met	Leu	Ser
				275					280					285
Ala	Ala	Gln	Glu	Gln	Phe	Gly	Gly	Asn	Pro	Phe	Ala	Ser	Leu	Val
				290					295					300
Ser	Asn	Thr	Ser	Ser	Gly	Glu	Gly	Ser	Gln	Pro	Ser	Arg	Thr	Glu
				305					310					315
Asn	Arg	Asp	Pro	Leu	Pro	Asn	Pro	Trp	Ala	Pro	Gln	Thr	Ser	Gln
				320					325					330
Ser	Ser	Ser	Ala	Ser	Ser	Gly	Thr	Ala	Ser	Thr	Val	Gly	Gly	Thr
				335					340					345
Thr	Gly	Ser	Thr	Ala	Ser	Gly	Thr	Ser	Gly	Gln	Ser	Thr	Thr	Ala
				350					355					360
Pro	Asn	Leu	Val	Pro	Gly	Val	Gly	Ala	Ser	Met	Phe	Asn	Thr	Pro
				365					370					375
Gly	Met	Gln	Ser	Leu	Leu	Gln	Gln	Ile	Thr	Glu	Asn	Pro	Gln	Leu
				380					385					390
Met	Gln	Asn	Met	Leu	Ser	Ala	Pro	Tyr	Met	Arg	Ser	Met	Met	Gln
				395					400					405
Ser	Leu	Ser	Gln	Asn	Pro	Asp	Leu	Ala	Ala	Gln	Met	Met	Leu	Asn
				410					415					420
Asn	Pro	Leu	Phe	Ala	Gly	Asn	Pro	Gln	Leu	Gln	Glu	Gln	Met	Arg
				425					430					435
Gln	Gln	Leu	Pro	Thr	Phe	Leu	Gln	Gln	Met	Gln	Asn	Pro	Asp	Thr
				440					445					450
Leu	Ser	Ala	Met	Ser	Asn	Pro	Arg	Ala	Met	Gln	Ala	Leu	Leu	Gln
				455					460					465
Ile	Gln	Gln	Gly	Leu	Gln	Thr	Leu	Ala	Thr	Glu	Ala	Pro	Gly	Leu
				470					475					480
Ile	Pro	Gly	Phe	Thr	Pro	Gly	Leu	Gly	Ala	Leu	Gly	Ser	Thr	Gly
				485					490					495
Gly	Ser	Ser	Gly	Thr	Asn	Gly	Ser	Asn	Ala	Thr	Pro	Ser	Glu	Asn
				500					505					510
Thr	Ser	Pro	Thr	Ala	Gly	Thr	Thr	Glu	Pro	Gly	His	Gln	Gln	Phe
				515					520					525
Ile	Gln	Gln	Met	Leu	Gln	Ala	Leu	Ala	Gly	Val	Asn	Pro	Gln	Leu
				530					535					540
Gln	Asn	Pro	Glu	Val	Arg	Phe	Gln	Gln	Gln	Leu	Glu	Gln	Leu	Ser
				545					550					555
Ala	Met	Gly	Phe	Leu	Asn	Arg	Glu	Ala	Asn	Leu	Gln	Ala	Leu	Ile
				560					565					570

Ala Thr Gly Gly Asp Ile Asn Ala Ala Ile Glu Arg Leu Leu Gly
 575 580 585
 Ser Gln Pro Ser

<210> 4
 <211> 775
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1299481CD1

<400> 4
 Met Thr Ile Val Asp Lys Ala Ser Glu Ser Ser Asp Pro Ser Ala
 1 5 10 15
 Tyr Gln Asn Gln Pro Gly Ser Ser Glu Ala Val Ser Pro Gly Asp
 20 25 30
 Met Asp Ala Gly Ser Ala Ser Trp Gly Ala Val Ser Ser Leu Asn
 35 40 45
 Asp Val Ser Asn His Thr Leu Ser Leu Gly Pro Val Pro Gly Ala
 50 55 60
 Val Val Tyr Ser Ser Ser Ser Val Pro Asp Lys Ser Lys Pro Ser
 65 70 75
 Pro Gln Lys Asp Gln Ala Leu Gly Asp Gly Ile Ala Pro Pro Gln
 80 85 90
 Lys Val Leu Phe Pro Ser Glu Lys Ile Cys Leu Lys Trp Gln Gln
 95 100 105
 Thr His Arg Val Gly Ala Gly Leu Gln Asn Leu Gly Asn Thr Cys
 110 115 120
 Phe Ala Asn Ala Ala Leu Gln Cys Leu Thr Tyr Thr Pro Pro Leu
 125 130 135
 Ala Asn Tyr Met Leu Ser His Glu His Ser Lys Thr Cys His Ala
 140 145 150
 Glu Gly Phe Cys Met Met Cys Thr Met Gln Ala His Ile Thr Gln
 155 160 165
 Ala Leu Ser Asn Pro Gly Asp Val Ile Lys Pro Met Phe Val Ile
 170 175 180
 Asn Glu Met Arg Arg Ile Ala Arg His Leu Arg Phe Gly Asn Gln
 185 190 195
 Glu Asp Ala His Glu Phe Leu Gln Tyr Thr Val Asp Ala Met Gln
 200 205 210
 Lys Ala Cys Leu Asn Gly Ser Asn Lys Leu Asp Arg His Thr Gln
 215 220 225
 Ala Thr Thr Leu Val Cys Gln Ile Phe Gly Gly Tyr Leu Arg Ser
 230 235 240
 Arg Val Lys Cys Leu Asn Cys Lys Gly Val Ser Asp Thr Phe Asp
 245 250 255
 Pro Tyr Leu Asp Ile Thr Leu Glu Ile Lys Ala Ala Gln Ser Val
 260 265 270
 Asn Lys Ala Leu Glu Gln Phe Val Lys Pro Glu Gln Leu Asp Gly
 275 280 285
 Glu Asn Ser Tyr Lys Cys Ser Lys Cys Lys Lys Met Val Pro Ala
 290 295 300
 Ser Lys Arg Phe Thr Ile His Arg Ser Ser Asn Val Leu Thr Leu
 305 310 315
 Ser Leu Lys Arg Phe Ala Asn Phe Thr Gly Gly Lys Ile Ala Lys
 320 325 330
 Asp Val Lys Tyr Pro Glu Tyr Leu Asp Ile Arg Pro Tyr Met Ser
 335 340 345
 Gln Pro Asn Gly Glu Pro Ile Val Tyr Val Leu Tyr Ala Val Leu
 350 355 360
 Val His Thr Gly Phe Asn Cys His Ala Gly His Tyr Phe Cys Tyr
 365 370 375
 Ile Lys Ala Ser Asn Gly Leu Trp Tyr Gln Met Asn Asp Ser Ile
 380 385 390
 Val Ser Thr Ser Asp Ile Arg Ser Val Leu Ser Gln Gln Ala Tyr

	395								400						405
Val	Leu	Phe	Tyr	Ile	Arg	Ser	His	Asp	Val	Lys	Asn	Gly	Gly	Glu	
	410								415						420
Leu	Thr	His	Pro	Thr	His	Ser	Pro	Gly	Gln	Ser	Ser	Pro	Arg	Pro	
	425								430						435
Val	Ile	Ser	Gln	Arg	Val	Val	Thr	Asn	Lys	Gln	Ala	Ala	Pro	Gly	
	440								445						450
Phe	Ile	Gly	Pro	Gln	Leu	Pro	Ser	His	Met	Ile	Lys	Asn	Pro	Pro	
	455								460						465
His	Leu	Asn	Gly	Thr	Gly	Pro	Leu	Lys	Asp	Thr	Pro	Ser	Ser	Ser	
	470								475						480
Met	Ser	Ser	Pro	Asn	Gly	Asn	Ser	Ser	Val	Asn	Arg	Ala	Ser	Pro	
	485								490						495
Val	Asn	Ala	Ser	Ala	Ser	Val	Gln	Asn	Trp	Ser	Val	Asn	Arg	Ser	
	500								505						510
Ser	Val	Ile	Pro	Glu	His	Pro	Lys	Lys	Gln	Lys	Ile	Thr	Ile	Ser	
	515								520						525
Ile	His	Asn	Lys	Leu	Pro	Val	Arg	Gln	Cys	Gln	Ser	Gln	Pro	Asn	
	530								535						540
Leu	His	Ser	Asn	Ser	Leu	Glu	Asn	Pro	Thr	Lys	Pro	Val	Pro	Ser	
	545								550						555
Ser	Thr	Ile	Thr	Asn	Ser	Ala	Val	Gln	Ser	Thr	Ser	Asn	Ala	Ser	
	560								565						570
Thr	Met	Ser	Val	Ser	Ser	Lys	Val	Thr	Lys	Pro	Ile	Pro	Arg	Ser	
	575								580						585
Glu	Ser	Cys	Ser	Gln	Pro	Val	Met	Asn	Gly	Lys	Ser	Lys	Leu	Asn	
	590								595						600
Ser	Ser	Val	Leu	Val	Pro	Tyr	Gly	Ala	Glu	Ser	Ser	Glu	Asp	Ser	
	605								610						615
Asp	Glu	Glu	Ser	Lys	Gly	Leu	Gly	Lys	Glu	Asn	Gly	Ile	Gly	Thr	
	620								625						630
Ile	Val	Ser	Ser	His	Ser	Pro	Gly	Gln	Asp	Ala	Glu	Asp	Glu	Glu	
	635								640						645
Ala	Thr	Pro	His	Glu	Leu	Gln	Glu	Pro	Met	Thr	Leu	Asn	Gly	Ala	
	650								655						660
Asn	Ser	Ala	Asp	Ser	Asp	Ser	Asp	Pro	Lys	Glu	Asn	Gly	Leu	Ala	
	665								670						675
Pro	Asp	Gly	Ala	Ser	Cys	Gln	Gly	Gln	Pro	Ala	Leu	His	Ser	Glu	
	680								685						690
Asn	Pro	Phe	Ala	Lys	Ala	Asn	Gly	Leu	Pro	Gly	Lys	Leu	Met	Pro	
	695								700						705
Ala	Pro	Leu	Leu	Ser	Leu	Pro	Glu	Asp	Lys	Ile	Leu	Glu	Thr	Phe	
	710								715						720
Arg	Leu	Ser	Asn	Lys	Leu	Lys	Gly	Ser	Thr	Asp	Glu	Met	Ser	Ala	
	725								730						735
Pro	Gly	Ala	Glu	Arg	Gly	Pro	Pro	Glu	Asp	Arg	Asp	Ala	Glu	Pro	
	740								745						750
Gln	Pro	Gly	Ser	Pro	Ala	Ala	Glu	Ser	Leu	Glu	Glu	Pro	Asp	Ala	
	755								760						765
Ala	Ala	Ser	Leu	Phe	Pro	Phe	Ser	Glu	Gly						
	770								775						

<210> 5

<211> 351

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1873139CD1

<400> 5

Met	Asn	Ala	Ile	Leu	Gln	Ser	Leu	Ser	Asn	Ile	Glu	Gln	Phe	Cys	
1				5					10					25	
Cys	Tyr	Phe	Lys	Glu	Leu	Pro	Ala	Val	Glu	Leu	Arg	Asn	Gly	Lys	
				20					25					30	
Thr	Ala	Gly	Arg	Arg	Thr	Tyr	His	Thr	Arg	Ser	Gln	Gly	Asp	Asn	
				35					40					45	


```

Asn Val Ser Leu Val Glu Glu Phe Arg Lys Thr Leu Cys Ala Leu
50 55 60
Trp Gln Gly Ser Gln Thr Ala Phe Ser Pro Glu Ser Leu Phe Tyr
65 70 75
Val Val Trp Lys Ile Met Pro Asn Phe Arg Gly Tyr Gln Gln Gln
80 85 90
Asp Ala His Glu Phe Met Arg Tyr Leu Leu Asp His Leu His Leu
95 100 105
Glu Leu Gln Gly Gly Phe Asn Gly Val Ser Arg Ser Ala Ile Leu
110 115 120
Gln Gln Asn Ser Thr Leu Ser Ala Ser Asn Lys Cys Cys Ile Asn
125 130 135
Gly Ala Ser Thr Val Val Thr Ala Ile Phe Gly Gly Ile Leu Gln
140 145 150
Asn Glu Val Asn Cys Leu Ile Cys Gly Thr Glu Ser Arg Lys Phe
155 160 165
Asp Pro Phe Leu Asp Leu Ser Leu Asp Ile Pro Ser Gln Phe Arg
170 175 180
Ser Lys Arg Ser Lys Asn Gln Glu Asn Gly Pro Val Cys Ser Leu
185 190 195
Arg Asp Cys Leu Arg Ser Phe Thr Asp Leu Glu Glu Leu Asp Glu
200 205 210
Thr Glu Leu Tyr Met Cys His Lys Cys Lys Lys Lys Gln Lys Ser
215 220 225
Thr Lys Lys Phe Trp Ile Gln Lys Leu Pro Lys Val Leu Cys Leu
230 235 240
His Leu Lys Arg Phe His Trp Thr Ala Tyr Leu Arg Asn Lys Val
245 250 255
Asp Thr Tyr Val Glu Phe Pro Leu Arg Gly Leu Asp Met Lys Cys
260 265 270
Tyr Leu Leu Glu Pro Glu Asn Ser Gly Pro Glu Ser Cys Leu Tyr
275 280 285
Asp Leu Ala Ala Val Val Val His His Gly Ser Gly Val Gly Ser
290 295 300
Gly His Tyr Thr Ala Tyr Ala Thr His Glu Gly Arg Trp Phe His
305 310 315
Phe Asn Asp Ser Thr Val Thr Leu Thr Asp Glu Glu Thr Val Val
320 325 330
Lys Ala Lys Ala Tyr Ile Leu Phe Tyr Val Glu His Gln Ala Lys
335 340 345
Ala Gly Ser Asp Lys Leu
350

```

<210> 6

<211> 136

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1903112CD1

<400> 6

```

Met Ala Leu Met Gln Arg Ser Asp Ile Phe Arg Val Ala Ile Ala
1 5 10 15
Gly Ala Pro Val Thr Leu Trp Ile Phe Tyr Asp Thr Gly Tyr Thr
20 25 30
Glu Arg Tyr Met Gly His Pro Asp Gln Asn Glu Gln Gly Tyr Tyr
35 40 45
Leu Gly Ser Val Ala Met Gln Ala Glu Lys Phe Pro Ser Glu Pro
50 55 60
Asn Arg Leu Leu Leu Leu His Gly Phe Leu Asp Glu Asn Val His
65 70 75
Phe Ala His Thr Ser Ile Leu Leu Ser Phe Leu Val Arg Ala Gly
80 85 90
Lys Pro Tyr Asp Leu Gln Ile Tyr Pro Gln Glu Arg His Ser Ile
95 100 105
Arg Val Pro Glu Ser Gly Glu His Tyr Glu Leu His Leu Leu His

```

	110		115		120
Tyr	Leu	Gln	Glu	Asn	Leu
	125	Gly	Ser	Arg	Ile
Ile				Ala	Ala
				Leu	Lys
				Val	135

<210> 7
 <211> 396
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Inocyte ID No: 1993044CD1

<400> 7
 Met Ser Leu Gly Trp Leu Glu Arg Pro Pro Ala Leu Ser Arg Ala
 1 5 10 15
 Ala Gly Asp Gly Ala Arg Arg Leu Ser Gly Ser Met Arg Gly Asp
 20 25 30
 Val Trp Leu Thr Ser Ser Ala Ala Gly Leu Leu Arg Ser Val Ala
 35 40 45
 Gly Gly Ser Trp Cys Gly Gly Gln Leu Arg Ala Arg Gly Gly Ser
 50 55 60
 Gly Arg Cys Val Ala Arg Ala Met Thr Gly Asn Ala Gly Glu Trp
 65 70 75
 Cys Leu Met Glu Ser Asp Pro Gly Val Phe Thr Glu Leu Ile Lys
 80 85 90
 Gly Phe Gly Cys Arg Gly Ala Gln Val Glu Glu Ile Trp Ser Leu
 95 100 105
 Glu Pro Glu Asn Phe Glu Lys Leu Lys Pro Val His Gly Leu Ile
 110 115 120
 Phe Leu Phe Lys Trp Gln Pro Gly Glu Glu Pro Ala Gly Ser Val
 125 130 135
 Val Gln Asp Ser Arg Leu Asp Thr Ile Phe Phe Ala Lys Gln Val
 140 145 150
 Ile Asn Asn Ala Cys Ala Thr Gln Ala Ile Val Ser Val Leu Leu
 155 160 165
 Asn Cys Thr His Gln Asp Val His Leu Gly Glu Thr Leu Ser Glu
 170 175 180
 Phe Lys Glu Phe Ser Gln Ser Phe Asp Ala Ala Met Lys Gly Leu
 185 190 195
 Ala Leu Ser Asn Ser Asp Val Ile Arg Gln Val His Asn Ser Phe
 200 205 210
 Ala Arg Gln Gln Met Phe Glu Phe Asp Thr Lys Thr Ser Ala Lys
 215 220 225
 Glu Glu Asp Ala Phe His Phe Val Ser Tyr Val Pro Val Asn Gly
 230 235 240
 Arg Leu Tyr Glu Leu Asp Gly Leu Arg Glu Gly Pro Ile Asp Leu
 245 250 255
 Gly Ala Cys Asn Gln Asp Asp Trp Phe Ser Ala Val Arg Pro Val
 260 265 270
 Ile Glu Lys Arg Ile Gln Lys Tyr Ser Glu Gly Glu Ile Arg Phe
 275 280 285
 Asn Leu Met Ala Ile Val Ser Asp Arg Lys Met Ile Tyr Glu Gln
 290 295 300
 Lys Ile Ala Glu Leu Gln Arg Gln Leu Ala Glu Glu Glu Pro Met
 305 310 315
 Asp Thr Asp Gln Gly Asn Ser Met Leu Ser Ala Ile Gln Ser Glu
 320 325 330
 Val Ala Lys Asn Gln Met Leu Ile Glu Glu Glu Val Gln Lys Leu
 335 340 345
 Lys Arg Tyr Lys Ile Glu Asn Ile Arg Arg Lys His Asn Tyr Leu
 350 355 360
 Pro Phe Ile Met Glu Leu Leu Lys Thr Leu Ala Glu His Gln Gln
 365 370 375
 Leu Ile Pro Leu Val Glu Lys Ala Lys Glu Lys Gln Asn Ala Lys
 380 385 390

Lys Ala Gln Glu Thr Lys
395

<210> 8

<211> 246

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2292182CD1

<400> 8

Met	Ala	Gly	Ala	Pro	Asp	Glu	Arg	Arg	Arg	Gly	Pro	Ala	Ala	Gly	
1				5					10					15	
Glu	Gln	Leu	Gln	Gln	Gln	His	Val	Ser	Cys	Gln	Val	Phe	Pro	Glu	
			20						25					30	
Arg	Leu	Ala	Gln	Gly	Asn	Pro	Gln	Gln	Gly	Phe	Phe	Ser	Ser	Phe	
			35						40					45	
Phe	Thr	Ser	Asn	Gln	Lys	Cys	Gln	Leu	Arg	Leu	Leu	Lys	Thr	Leu	
			50						55					60	
Glu	Thr	Asn	Pro	Tyr	Val	Lys	Leu	Leu	Leu	Asp	Ala	Met	Lys	His	
			65						70					75	
Ser	Gly	Cys	Ala	Val	Asn	Lys	Asp	Arg	His	Phe	Ser	Cys	Glu	Asp	
			80						85					90	
Cys	Asn	Gly	Asn	Val	Ser	Gly	Gly	Phe	Asp	Ala	Ser	Thr	Ser	Gln	
			95						100					105	
Ile	Val	Leu	Cys	Gln	Asn	Asn	Ile	His	Asn	Gln	Ala	His	Met	Asn	
			110						115					120	
Arg	Val	Val	Thr	His	Glu	Leu	Ile	His	Ala	Phe	Asp	His	Cys	Arg	
			125						130					135	
Ala	His	Val	Asp	Trp	Phe	Thr	Asn	Ile	Arg	His	Leu	Ala	Cys	Ser	
			140						145					150	
Glu	Val	Arg	Ala	Ala	Asn	Leu	Ser	Gly	Asp	Cys	Ser	Leu	Val	Asn	
			155						160					165	
Glu	Ile	Phe	Arg	Leu	His	Phe	Gly	Leu	Lys	Gln	His	His	Gln	Thr	
			170						175					180	
Cys	Val	Arg	Asp	Arg	Ala	Thr	Leu	Ser	Ile	Leu	Ala	Val	Arg	Asn	
			185						190					195	
Ile	Ser	Lys	Glu	Val	Ala	Lys	Lys	Ala	Val	Asp	Glu	Val	Phe	Glu	
			200						205					210	
Ser	Cys	Phe	Asn	Asp	His	Glu	Pro	Phe	Gly	Arg	Ile	Pro	His	Asn	
			215						220					225	
Lys	Thr	Tyr	Ala	Arg	Tyr	Ala	His	Arg	Asp	Phe	Glu	Asn	Arg	Asp	
			230						235					240	
Arg	Tyr	Tyr	Ser	Asn	Ile										
				245											

<210> 9

<211> 262

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2331301CD1

<400> 9

Met	Glu	Val	Tyr	Ile	Arg	His	Leu	Glu	Lys	Val	Leu	Arg	Arg	Tyr	
1				5					10					15	
Val	Gln	Arg	Leu	Gln	Trp	Leu	Leu	Ser	Gly	Ser	Arg	Arg	Leu	Phe	
			20						25					30	
Gly	Thr	Val	Leu	Glu	Ser	Lys	Val	Cys	Ile	Leu	Leu	Asp	Thr	Ser	
			35						40					45	
Gly	Ser	Met	Gly	Pro	Tyr	Leu	Gln	Gln	Val	Lys	Thr	Gln	Leu	Val	
			50						55					60	
Leu	Leu	Ile	Trp	Glu	Gln	Leu	Arg	Lys	Cys	Cys	Asp	Ser	Phe	Asn	
			65						70					75	
Leu	Leu	Ser	Phe	Ala	Glu	Ser	Leu	Gln	Ser	Trp	Gln	Asp	Thr	Ile	

	80		85		90
Val Glu Thr Thr Asp	Ala Ala Cys His	Glu Ala Met Gln Trp	Val		
	95		100		105
Thr His Leu Gln Ala	Gln Gly Ser Thr	Ser Ile Leu Gln Ala	Leu		
	110		115		120
Leu Lys Ala Phe Ser	Phe His Asp Leu	Glu Gly Leu Tyr Leu	Leu		
	125		130		135
Thr Asp Gly Lys Pro	Asp Thr Ser Cys	Ser Leu Val Leu Asn	Glu		
	140		145		150
Val Gln Lys Leu Arg	Glu Lys Arg Asp	Val Lys Val His Thr	Ile		
	155		160		165
Ser Leu Asn Cys Ser	Asp Arg Ala Ala	Val Glu Phe Leu Arg	Lys		
	170		175		180
Leu Ala Ser Phe Thr	Gly Gly Arg Tyr	His Cys Pro Val Gly	Glu		
	185		190		195
Asp Thr Leu Ser Lys	Ile His Ser Leu	Leu Thr Lys Gly Phe	Ile		
	200		205		210
Asn Glu Lys Asp Arg	Thr Leu Pro Pro	Phe Glu Gly Asp Asp	Leu		
	215		220		225
Arg Ile Leu Ala Gln	Glu Ile Thr Lys	Ala Arg Ser Phe Leu	Trp		
	230		235		240
Gln Ala Gln Ser Phe	Arg Ser Gln Leu	Gln Lys Lys Asn Asp	Ala		
	245		250		255
Glu Pro Lys Val Thr	Leu Ser				
	260				

<210> 10

<211> 406

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2517512CD1

<400> 10

Met Ala Ala Ala Val	Arg Gln Asp Leu	Ala Gln Leu Met Asn	Ser
1	5	10	15
Ser Gly Ser His Lys	Asp Leu Ala Gly	Lys Tyr Arg Gln Ile	Leu
	20	25	30
Glu Lys Ala Ile Gln	Leu Ser Gly Ala	Glu Gln Leu Glu Ala	Leu
	35	40	45
Lys Ala Phe Val Glu	Ala Met Val Asn	Glu Asn Val Ser Leu	Val
	50	55	60
Ile Ser Arg Gln Leu	Thr Asp Phe Cys	Thr His Leu Pro	Asn
	65	70	75
Leu Pro Asp Ser Thr	Ala Lys Glu Ile	Tyr His Phe Thr	Leu
	80	85	90
Lys Ile Gln Pro Arg	Val Ile Ser Phe	Glu Gln Val Ala	Ser
	95	100	105
Ile Arg Gln His Leu	Ala Ser Ile Tyr	Glu Lys Glu Glu Asp	Trp
	110	115	120
Arg Asn Ala Ala Gln	Val Leu Val Gly	Ile Pro Leu Glu Thr	Gly
	125	130	135
Gln Lys Gln Tyr Asn	Val Asp Tyr Lys	Leu Glu Thr Tyr	Leu
	140	145	150
Ile Ala Arg Leu Tyr	Leu Glu Asp Asp	Asp Pro Val Gln	Ala
	155	160	165
Ala Tyr Ile Asn Arg	Ala Ser Leu Leu	Gln Asn Glu Ser	Thr
	170	175	180
Glu Gln Leu Gln Ile	His Tyr Lys Val	Cys Tyr Ala Arg	Val
	185	190	195
Asp Tyr Arg Arg Lys	Phe Ile Glu Ala	Ala Gln Arg Tyr	Asn
	200	205	210
Leu Ser Tyr Lys Thr	Ile Val His Glu	Ser Glu Arg Leu	Glu
	215	220	225
Leu Lys His Ala Leu	His Cys Thr Ile	Leu Ala Ser Ala	Gly
	230	235	240

Gln	Arg	Ser	Arg	Met	Leu	Ala	Thr	Leu	Phe	Lys	Asp	Glu	Arg	Cys	
				245					250					255	
Gln	Gln	Leu	Ala	Ala	Tyr	Gly	Ile	Leu	Glu	Lys	Met	Tyr	Leu	Asp	
				260					265					270	
Arg	Ile	Ile	Arg	Gly	Asn	Gln	Leu	Gln	Glu	Phe	Ala	Ala	Met	Leu	
				275					280					285	
Met	Pro	His	Gln	Lys	Ala	Thr	Thr	Ala	Asp	Gly	Ser	Ser	Ile	Leu	
				290					295					300	
Asp	Arg	Ala	Val	Ile	Glu	His	Asn	Leu	Leu	Ser	Ala	Ser	Lys	Leu	
				305					310					315	
Tyr	Asn	Asn	Ile	Thr	Phe	Glu	Glu	Leu	Gly	Ala	Leu	Leu	Glu	Ile	
				320					325					330	
Pro	Ala	Ala	Lys	Ala	Glu	Lys	Ile	Ala	Ser	Gln	Met	Ile	Thr	Glu	
				335					340					345	
Gly	Arg	Met	Asn	Gly	Phe	Ile	Asp	Gln	Ile	Asp	Gly	Ile	Val	His	
				350					355					360	
Phe	Glu	Thr	Arg	Glu	Ala	Leu	Pro	Thr	Trp	Asp	Lys	Gln	Ile	Gln	
				365					370					375	
Ser	Leu	Cys	Phe	Gln	Val	Asn	Asn	Leu	Leu	Glu	Lys	Ile	Ser	Gln	
				380					385					390	
Thr	Ala	Pro	Glu	Trp	Thr	Ala	Gln	Ala	Met	Glu	Ala	Gln	Met	Ala	
				395					400					405	

Gln

<210> 11
 <211> 172
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3489039CD1

Met	Leu	Leu	Pro	Asn	Ile	Leu	Leu	Thr	Gly	Thr	Pro	Gly	Val	Gly	
				5					10					15	
Lys	Thr	Thr	Leu	Gly	Lys	Glu	Leu	Ala	Ser	Lys	Ser	Gly	Leu	Lys	
				20					25					30	
Tyr	Ile	Asn	Val	Gly	Asp	Leu	Ala	Arg	Glu	Glu	Gln	Leu	Tyr	Asp	
				35					40					45	
Gly	Tyr	Asp	Glu	Glu	Tyr	Asp	Cys	Pro	Ile	Leu	Asp	Glu	Asp	Arg	
				50					55					60	
Val	Val	Asp	Glu	Leu	Asp	Asn	Gln	Met	Arg	Glu	Gly	Gly	Val	Ile	
				65					70					75	
Val	Asp	Tyr	His	Gly	Cys	Asp	Phe	Phe	Pro	Glu	Arg	Trp	Phe	His	
				80					85					90	
Ile	Val	Phe	Val	Leu	Arg	Thr	Asp	Thr	Asn	Val	Leu	Tyr	Glu	Arg	
				95					100					105	
Leu	Glu	Thr	Arg	Gly	Tyr	Asn	Glu	Lys	Lys	Leu	Thr	Asp	Asn	Ile	
				110					115					120	
Gln	Cys	Glu	Ile	Phe	Gln	Val	Leu	Tyr	Glu	Glu	Ala	Thr	Ala	Ser	
				125					130					135	
Tyr	Lys	Glu	Glu	Ile	Val	His	Gln	Leu	Pro	Ser	Asn	Lys	Pro	Glu	
				140					145					150	
Glu	Leu	Glu	Asn	Asn	Val	Asp	Gln	Ile	Leu	Lys	Trp	Ile	Glu	Gln	
				155					160					165	
Trp	Ile	Lys	Asp	His	Asn	Ser									
				170											

<210> 12
 <211> 517
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5432879CD1

<400> 12

Met	Leu	Ser	Ser	Arg	Ala	Glu	Ala	Ala	Met	Thr	Ala	Ala	Asp	Arg
1				5					10					15
Ala	Ile	Gln	Arg	Phe	Leu	Arg	Thr	Gly	Ala	Ala	Val	Arg	Tyr	Lys
				20					25					30
Val	Met	Lys	Asn	Trp	Gly	Val	Ile	Gly	Gly	Ile	Ala	Ala	Ala	Leu
				35					40					45
Ala	Ala	Gly	Ile	Tyr	Val	Ile	Trp	Gly	Pro	Ile	Thr	Glu	Arg	Lys
				50					55					60
Lys	Arg	Arg	Lys	Gly	Leu	Val	Pro	Gly	Leu	Val	Asn	Leu	Gly	Asn
				65					70					75
Thr	Cys	Phe	Met	Asn	Ser	Leu	Leu	Gln	Gly	Leu	Ser	Ala	Cys	Pro
				80					85					90
Ala	Phe	Ile	Arg	Trp	Leu	Glu	Glu	Phe	Thr	Ser	Gln	Tyr	Ser	Arg
				95					100					105
Asp	Gln	Lys	Glu	Pro	Pro	Ser	His	Gln	Tyr	Leu	Ser	Leu	Thr	Leu
				110					115					120
Leu	His	Leu	Leu	Lys	Ala	Leu	Ser	Cys	Gln	Glu	Val	Thr	Asp	Asp
				125					130					135
Glu	Val	Leu	Asp	Ala	Ser	Cys	Leu	Leu	Asp	Val	Leu	Arg	Met	Tyr
				140					145					150
Arg	Trp	Gln	Ile	Ser	Ser	Phe	Glu	Glu	Gln	Asp	Ala	His	Glu	Leu
				155					160					165
Phe	His	Val	Ile	Thr	Ser	Ser	Leu	Glu	Asp	Glu	Arg	Asp	Arg	Gln
				170					175					180
Pro	Arg	Val	Thr	His	Leu	Phe	Asp	Val	His	Ser	Leu	Glu	Gln	Gln
				185					190					195
Ser	Glu	Ile	Thr	Pro	Lys	Gln	Ile	Thr	Cys	Arg	Thr	Arg	Gly	Ser
				200					205					210
Pro	His	Pro	Thr	Ser	Asn	His	Trp	Lys	Ser	Gln	His	Pro	Phe	His
				215					220					225
Gly	Arg	Leu	Thr	Ser	Asn	Met	Val	Cys	Lys	His	Cys	Glu	His	Gln
				230					235					240
Ser	Pro	Val	Arg	Phe	Asp	Thr	Phe	Asp	Ser	Leu	Ser	Leu	Ser	Ile
				245					250					255
Pro	Ala	Ala	Thr	Trp	Gly	His	Pro	Leu	Thr	Leu	Asp	His	Cys	Leu
				260					265					270
His	His	Phe	Ile	Ser	Ser	Glu	Ser	Val	Arg	Asp	Val	Val	Cys	Asp
				275					280					285
Asn	Cys	Thr	Lys	Ile	Glu	Ala	Lys	Gly	Thr	Leu	Asn	Gly	Glu	Lys
				290					295					300
Val	Glu	His	Gln	Arg	Thr	Thr	Phe	Val	Lys	Gln	Leu	Lys	Leu	Gly
				305					310					315
Lys	Leu	Pro	Gln	Cys	Leu	Cys	Ile	His	Leu	Gln	Arg	Leu	Ser	Trp
				320					325					330
Ser	Ser	His	Gly	Thr	Pro	Leu	Lys	Arg	His	Glu	His	Val	Gln	Phe
				335					340					345
Asn	Glu	Phe	Leu	Met	Met	Asp	Ile	Tyr	Lys	Tyr	His	Leu	Leu	Gly
				350					355					360
His	Lys	Pro	Ser	Gln	His	Asn	Pro	Lys	Leu	Asn	Lys	Asn	Pro	Gly
				365					370					375
Pro	Thr	Leu	Glu	Leu	Gln	Asp	Gly	Pro	Gly	Ala	Pro	Thr	Pro	Val
				380					385					390
Leu	Asn	Gln	Pro	Gly	Ala	Pro	Lys	Thr	Gln	Ile	Phe	Met	Asn	Gly
				395					400					405
Ala	Cys	Ser	Pro	Ser	Leu	Leu	Pro	Thr	Leu	Ser	Ala	Pro	Met	Pro
				410					415					420
Phe	Pro	Leu	Pro	Val	Val	Pro	Asp	Tyr	Ser	Ser	Ser	Thr	Tyr	Leu
				425					430					435
Phe	Arg	Leu	Met	Ala	Val	Val	Val	His	His	Gly	Asp	Met	His	Ser
				440					445					450
Gly	His	Phe	Val	Thr	Tyr	Arg	Arg	Ser	Pro	Pro	Ser	Ala	Arg	Asn
				455					460					465
Pro	Leu	Ser	Thr	Ser	Asn	Gln	Trp	Leu	Trp	Val	Ser	Asp	Asp	Thr
				470					475					480
Val	Arg	Lys	Ala	Ser	Leu	Gln	Glu	Val	Leu	Ser	Ser	Ser	Ala	Tyr
				485					490					495

<220>
 <221> misc_feature
 <223> Incyte ID No: 4993873CB1

<400> 51
 agaatggacc tgacaaatat tgaccagggtt gctgtgatct tcaaacacca ttttctgtgt 60
 ggtagagggtg atgacagtgt gaagacotgt gccctgtctc agtgcctttg ctctagaatg 120
 ggtccagctt ggttttggt actgggaaca gggatcctgg cctctgtcca ctgtcagccc 180
 ctctcttgcc atggagataa aggtcttgcg ggccctcaac cccccaggca ttagctctca 240
 gagccagccc ccgctacca cagatcaac ccaccatta ccaattttgc ttgtcgtttg 300
 tataaagagc tggcagraga cgcctccgga aacatcttct tctgcaggt gagcatctcc 360
 accacccctg ccctgtctct caagctaaca cctcagctct gatcctggag 420
 ggctctgggt tcaacctcac agaacccct gaagccgaca tccaccaggg ctcccgaggc 480
 ctctctacca cccttgccct gccacgccc aaactcgaa taaaagttag aaactccctg 540
 ttcttagaca agcgactaaa gctctggcag cactatttgg acagcatcaa ggagctttat 600
 ggagcctttg cttttctgtg caactcaca gattctgtta caactgggag gcagattaat 660
 gactatttga gaaggcaaac atacgggcaa gtctgtgact gctctccgga gttcagccag 720
 gacaggttca tgggtcttgc caattacat ctctcctcag ccagtgga gaccccttct 780
 agtctgtacc agacccagaa gcaggcaagt ttctttgtgt atgagaggac tctctccag 840
 gtcccccata tgcacccaaa ggaattycac agattctct atgacaggga tttgtgttgc 900
 actgtctctc agatagata cagaggaaat gcttggcgc ccttgagaaa atggggccaa 1020
 gggaaactga agcaggttga ggctgtctct cagccacaga ccttgagaaa atggggccaa 1080
 ttctctctgc ccagtctgtt ggatttgcac ttgcccaggg tttaaatctc tggaaacat 1140
 aacctggaag acatacttcc ccaaatttgt ctcaccaaca accatctcca aggtgtcaca caagctgac 1200
 ttctcagga tcactgggca gctcaacaaa ggggtctct caggctctct ctccagccc 1260
 gtggacatga gtgagaagg agacccacat gcmaactca acaggcctt ctctctgtct 1320
 cctctcttga acacccatgt caccacccc gagcttact tctctgggaa aagtgttcaa 1380
 ctttggagg ggtggggggc caggagtatt ctatctctat crtggacca acagataggc 1440
 cagacccagc ctgcctctgt ggtgtgtat ttgttccagt gtgttccagt taateaggt 1500
 taataaagtt gaccttgggt tctgtgaaaa gaaaaaaaag cctcaacatt gccataagg 1560
 ggggggttaa ggalgtgaa agcaaatacc cgggtttgct agtgcgtt atggccgtct 1620
 gggggggcgg cagtacagaa ggtccctcag agtgcgtt atggccgtct 1680
 gggggggcgg agagagtttt tacgcctctt tgcacgtt agcaacccgg 1740
 ccataaggcc ccggagctg gaggttctt ttgcgcgggc actcttgggg 1800
 gaccgacttt tagtggcacc aactgtgggg cttctctat gtgtgcgcgc gcttctgttt 1860

<210> 52
 <211> 550
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5208004CB1

<400> 52
 ggcygggtggc tggaggacac ggtgtaggcc ttgcctgtgt ctgggttctt cggcaactga 60
 ggagcaggac tgtttctgga aacactgggc tgcctgtgac ccgtcaaac tctccacaa 120
 attctgaatc cgagaaagt aaggaaggat ggtggggag ttaggaggga gtagcagg 180
 ccacagggac agaccagaga tgcqgtggag acagaggagc ttctctctca gtagcagg 240
 gggaagcctg agaggcggcc aycacacccc tccgtcact ctccctcag cctctctgct 300
 tccctctca acccttctc tctctctcgc ccttccctt tcttctgtc ttgttagtcc 360
 ctgtcccaaa actctgtgct cctttgttct gctgcctgg cccccacca ggaggaggtc 420
 ttaggcacca tccccccac gaggatctca cacaacagg tcatgtctgg gctggggag 480
 ccccgctggg ttcttgatgc cttgtgcaca ggyaagtgt gcagtcatt ttggactctc 540
 ctgaatgtgt

<210> 53
 <211> 2597
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5267783CB1

gttaatat	ctgctgtgag	aaacatttaa	gtttcaata	ccccagatgc	ttcagtgctc	660
atagtggatt	actatggagc	aaggagacag	goggtgagaa	gttacaactc	tgaagtgaag	720
ctgtctctct	gtgacatttt	cagtgatgtc	caggtgtguc	gtccttctga	ggatggagct	780
lcaggctccc	atcateactc	ttcagtcatt	tttattttct	gtttcaagct	tctgtacttt	840
atggacattt	ggctgtgatt	tttttttaaa	ggactctgtg	taacactaac	atttcagta	900
gtcacatgtg	attgttttgt	tttcgtagaa	gaatactgtc	tcatttttgg	aaaaagattt	960
ttttttcttt	ctatgggggt	gcagggatgg	tgtacaacag	gtcctagcat	gtatagctgc	1020
atagatttct	tcacctgctc	tttgtgtgga	agalcagaa	gaatgcagtt	gtgtgtctat	1080
attttccctc	ctcaaaatct	tttagaattt	ttttggaggt	gtttgttttc	tcacagaata	1140
aggtattact	ttagaatagg	tattctctct	atlttctgaa	agaaatgaa	ctagattctt	1200
aagcattatt	acacatccat	gtttgtttaa	agatggattt	ccctgggaat	gggagaaaac	1260
agccagcagg	aggagcttca	tctgttctct	ttccacctcc			1320

<210> 50
 <211> 2241
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3883861CB1

<400> 50						
gtcccccgag	ccgggtgtgca	ccggaggcgg	cgagatggtc	gcgcgcgtcg	gootctctgt	60
ggcgcgcctg	cagctgtctac	tytggygcra	cctggacgcc	cagcccgggg	agcgcggagg	120
ccaggagctg	cgcaaggagg	cggaggcatt	cctagagaag	tacggatacc	tcaatgaaca	180
ggtccccaaa	gtccccacct	ccactcgatt	cagcgatgcc	atcagagcgt	ttcagtgggt	240
gtccccagta	cctgtcagcg	gogtqtggga	ccgcgcaccc	ctgcgcacaga	tgaactctcc	300
ccgctcgggg	gttacagata	ccaacagtta	tggggcctgg	gctgagagga	tcagtgaact	360
gtttgtctaga	caacgggacc	aaatgagggc	laagaaacgc	tttgcaaaagc	aaggtaacaa	420
atggtacaag	cagcaacctct	cctaccgctc	ggtgaactgg	cctgagcctc	tgcgggagcc	480
ggcagttcgg	ggcgcgcgtg	ggcgcgcctt	ccagtttgtg	agcaangtct	cagcgtctga	540
gtttctgggg	gccccagcca	caggccccgc	tgaactccgg	ctcaactctc	tccaaagggg	600
cccccacgat	gggctgggca	atgcctttga	tggcccaggg	ggcgcctctg	cgcacgcctt	660
cctgccccgc	cgccggggaag	cgcaacttga	ccaagatgag	cgtctgtccc	lgagcccgcc	720
ccgcgggggc	aaacctgttgc	tgggtcctgg	gcacagagat	ggtcacacgc	ttggcctcac	780
ccactcggcc	ggcgcgcggg	cgtctcctgg	ccctctctac	aagagggctg	ggcgcgcagc	840
gctgctcagc	tgggaacagc	tgttggcctg	gcagagcctg	tatgggaagc	ccctaggggg	900
ctcagtgccc	gtccagctcc	caggaaagct	gttcaactgac	tttgagacct	gggactctta	960
cagcccccaa	ggaaggcgcc	ctgaaacgca	gggccttaaa	tactgcaact	attctctaga	1020
tgcctcact	gtagacagcg	aacagcaact	gtacattttt	aaaggggagc	atttctggga	1080
ggtgpcagct	gatgggaacg	lctcagagcc	cgttccactg	caggaaagat	gggtcgggct	1140
gccccccaac	attgaggtct	cggcagtgct	attgaatgat	ggagatttct	acttcttcaa	1200
aggggggtga	tgttgagggt	tcgggggccc	caagccagtg	tggggtctcc	caacagtctg	1260
ccgggcaggg	ggcctgcctc	gcactcctga	ogccgccttc	ttcttccctc	ctctgcgcgc	1320
cctctctctc	ttcaagggtg	cccgctacta	cgtgctggcc	cgggggggac	tgcaggtgga	1380
gcctactctc	ccccgaagtc	tgcaggactg	gggagggcct	cctgagggag	tcagccagcc	1440
cctgcccagg	cccgatggct	ccatctctct	cttccagatc	gaccgctact	ggcgccctga	1500
ccaggccaaa	clgcaggcaa	ccactctggg	cccgctgggc	accgagctgc	cctggatggg	1560
ctgctggcat	gccaactcgg	ggagcgccct	gttctgaagg	caactctctc	cctcagaaac	1620
tgggtgtgct	ctcagggcaa	aatcalttcc	cccccccccc	gggcagaaac	cctctllaga	1680
gcctctgagt	ccctctgcag	aagaccgggc	agcaaaagct	ccatctggaa	gtctgtctgc	1740
ctttgttctc	tgaagaaatg	agcatttgtc	lgtctgtctc	ccaccacatg	gaagtggggg	1800
tgggataaat	cttaggaaaa	gcaaaaaagg	gtcccagatc	ccttggccct	ttctccagag	1860
gacttctatc	ctcccagggc	ctttgttctc	tgggtanaag	gtacagtctc	tttcaagagg	1920
taacagcact	gggatcccaag	caggpggatg	aaaaactcag	cagagaaatt	cgagaccatt	1980
ttgcaagact	gtgcctctct	cctcaggagc	ccttggtctc	gttctlgaaa	aagggtgtca	2040
tattttagta	gaggcccccac	ccccagggaag	catggatggg	gatgaaggca	caggcgtctc	2100
caactctaga	ggccclltgt	ggggtcaagg	cacagagtg	gagggagact	gatgcaggcc	2160
taccagctcc	tggctttttg	tctggggctg	gaataaagag	gtgccttcag	ctgggtgggccc	2220
gagaggcaag	aaaaaaaaaa	a				2241

<210> 51
 <211> 1860
 <212> DNA
 <213> Homo sapiens


```

tgcccagggg agctgacgag cagaggagaa ggtcccttt ccagatgctt ctgctgctgg 780
agaagatgca ggacagccgg cagaaagcag tgcggccctt ggagctggcc tactgootgc 810
agaagtgcna cgtgcccctt tttgncnaa atgafgtgtg ccaactgtac ctcaaaactct 900
ggaaacctgat taaggaccag atcaactgat tgcacttggg ggagagactg caggccctgt 960
atacgaatccg ggtgaaggaa locttyattt ccactttctc ttttggatgt ggcattggag agtagcagaa 1020
acagcagcat gctcaccctc tgetttctcc agcccaggga gttatcaagc cccctgaaga 1080
cactggagga cgccttgac gaactgtggg aagaagacc cgtgggaaca gtttctgag ctgaccactt 1200
gcttctgtga cctgacactt caactcatgc gattctecat caggaattca cagacagaaa 1260
tgccccagac cctgacactt ttccccaga gcttggatbt cagccagatc ctccaatga 1320
agatctgcca ctccctgtac ttgtgatgct gaggagcagt ctggagggca gtatgagctt tttgctgtga 1380
agcyagagtc ttgtgatgct ggaatggca gactccggtc attactgtgt ctactccgg aatgctgtgg 1440
ttgggcacgt atggaaaetg gttctgtctt aatgactcca atatttgcct ggtgtctgg gaagacatcc 1500
atgtaaccta gtaaatctt cctgacactt aaactacact aacttccaga hgcatactt ctggtttaca 1560
tgagatggga gtgctaattg tctggatct ataggagatt ctgaagtgg gattgacacg ctgtcatttt 1620
ccatttccgt tctggatct tatataactg ataattaggg atattatcaa gatgacacg gaggagcatt 1680
gttttcaaac ctcaggctct cggctcctgg tctcagctc ataccagca aatattatca aatattatca 1740
catgaggccc ctcaggctct cggctcctgg tctcagctc ataccagca aatattatca aatattatca 1800
tgtgctgct tctcagctc cggctcctgg tctcagctc ataccagca aatattatca aatattatca 1860
cctgtgggaa cttcaggggt tcccagtggt gtagcagtg gcagtgagg gcagtgagg 1920
gcaaaaggtc agtggcaggg ggtatttcag tattatacaa clgctgtgac cagacttgta 1980
tactggctga atatcagtc actgctatcc ttttactttt caaatattta ttgatcatct 2040
takgaatcaa gtatbtgtg ataacacag tcatgaataa agttattttt ccaaaaaaaa 2100
cttctccata agatagtgtg
aa

```

<210> 48
 <211> 578
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3092341CB1

```

<400> 48
gaaaggccca cctgtgtctt cctgtgtctt cctcaggtt ctttggggcc cgaggaattt 60
cagacctgaa caatecagtg gacaacttct tgtgactttg ggtattctga aattactcat 120
cttgactcta ctgtgecttg atgtagctgt cgtttttgtg tctatccctg tcatggccaa 180
tggtggcaga gtctacatag aactatgctt cgtgtgtgtc tggggaaaac ctttcgactt 240
gttggctata ctattcaata tggctgtata gctcattgtg cttttgaata cgttgggtgt 300
gttctcatgg tgccaatggg loatgttttg ttggaagggt acaatctaca gaattctaca 360
gattccaggt gctatggacc tattccatat ggactaataa gaggacgaat cttotttaag 420
atttggcltc tgaatgattt tggattttta cgtgcccgc ccaatggcca cagattttct 480
gatgattagt aagcatttat tcttttgaat tgattattgt ctccttttca tctgaattta 540
tactccctgt tgaaccctgt tacttaccaa taactctt

```

<210> 49
 <211> 1300
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3658034CR1

```

<400> 49
agggaaatcc aattatgagg cggctaagca ggcaaaagaa tagtttgggt ggttttgcac 60
ctactccgga taccactgtg gclbbaagv ctgtctgaat tgcagccctt aatgaataca 120
gaaaggacaa atatccaagt gaccgtgacg gggcctagct caccagctcc tgtaaaagttt 180
ctgattgaca cacaacaacc atactnctt cagacagcag ggtacagcca ggtacagcca 240
acggcagtta atatttccgc aaatggtttt ggatttgcta tttgtcagct caatgtttga 300
tataatgtga aggtttcttg gtctctctaga agaagaagat ctatccaaa taaagaagcc 360
tttgatttag atgttgcctg aaaaagaaat aaagatgctc tcaatcatgt ggatttgaat 420
gtgtgtacaa gcttttccgg cccgggtagg agtggcatgg ctcttatgga agttaccca 480
ttaagtggct tcatggtgct tttagagcca atttctctga gcgagacagt gaagaaagt 540
gaatatgato atggaaaact caactcttat ttagattctg taaatgaacc ccagtttllgt 600

```

atatttatca ataaagccct ttgctctcttc aaaaaaaaaa #

1661

<210> 46
 <211> 1910
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2323917CB1

<400> 46
 gtactccggc ogcagccctg ggggtccagc ggaatctctc agaatctcgt ctccagaaac 60
 attattctaa tctgtgtatg gaaaaatccc agaaatttaa tccctttata ttgcataaac 120
 tccaagaagt ggatgaagaa attaaaaggg ggcctagcagc aggaatcaca ttaaacattg 180
 ctggtaacaa tgccttagtg ccagtagaaa gaggtaacagg tgaagatttt tggattcttt 240
 ccaaaatttt aaagaattgt ctgtatatta gctgcgaaac tgcttcagaa accacttaac ctcatctact 300
 gtgatgttgg tgcatactat gctgcgaaac aaggtcggaa attgatttgc aaagtgttac 420
 tazacctcat gtttaattgt taactaagaa tgaactgaaa canaattgaa aataaaggtg 480
 ataagaatcg gactctgaaa taactaagaa ctgcattatt agagaaatta gatctgggtg 540
 gaattttttt tgcgtgaaag ctgcattatt cacttctact agtactaac ctcaaacctg 600
 actgtgatct gggaatgcaa agtctgatag cacttctact tgaactaac agtactaac 660
 caattaaagg tccatgtagg cctcatgttg aaagaataac tgaactaac agtactaac 720
 atgatataaa aaacagtggt atacaacagt tgaactaac agtactaac agtactaac 780
 tgcctacact tgaatgtagc tgaactaac agtactaac agtactaac agtactaac 840
 atgtactgaa aagcaaacct accctggagc taatagatct ttcctttaac agaatagaaa 900
 atgcaggcgc aaactatctc agtgaactc ttaactcaca caacaggagt cttaagcgt 960
 tgcctagctc cagcaacaac atagaggagc aaggacttgt tgaacttcaa caatcaatga 1020
 aaacaaactc cactttctct catatctaca ttgggggaaa caaatttgat gaggtctagt 1080
 gtatagcata ttcagactta attcaaatgg gttgtctaaa accagcaaat acagatgttg 1140
 agccatttgt ggtgatgga cgtgtatctc ttgcagaagt ctccaatgga cttaaaaago 1200
 attattattg gacatcaact batggagaat tatggagaa aaagttagctg taaatcaatt ttccttttat 1260
 ctcttgttcc ttcacacagc atlaactatc atgactgtat taaactttgt atnaacttca 1320
 tgccttattg aagttacttt tttcaaatgt gtaaaagata atgactgtat taaactttgt atnaacttca 1380
 aaaaaaaaca aaagggggag gcccgatta gtaaaagata atgactgtat taaactttgt atnaacttca 1440
 gggggccggc ccttggggg ggggttaaca atgactgtat taaactttgt atnaacttca 1500
 tacaggcgtc ttggaaagag aagtcgtgct gtaaaagata atgactgtat taaactttgt atnaacttca 1560
 atttlaactc tctgtccccc ctggtgtact gtaaaagata atgactgtat taaactttgt atnaacttca 1620
 tgttggaaat aagtgtttgg ttgagtcctg ctggtgtact gtaaaagata atgactgtat taaactttgt atnaacttca 1680
 gacgttctca tatcggcttg ggtttggctg ctggtgtact gtaaaagata atgactgtat taaactttgt atnaacttca 1740
 ggtagtgttg ttgcacctgt atttatattg ggtttgttgg gtaaaagata atgactgtat taaactttgt atnaacttca 1800
 ttggttttgg agtctgtggc ggtttgttgg gtaaaagata atgactgtat taaactttgt atnaacttca 1860
 1910

<210> 47
 <211> 2162
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2754960CB1

<400> 47
 gacagcgcaa cgcactcca gctggacga cagaalaga cccgtctcca aaaaaaaaaa 60
 aaaaaaaaca aagcgagggc tggaaegtct gaggcaggtg ggggtgcaa cggcagccgc 120
 gggaaagctg ggcggcagg gtttccccc ccagctccc ccagctccc ccagctccc 180
 cgtctgaagt ttctgttttc attcagtgga aaacgaaagc tggggggggg gccacgagcg 240
 cggggccaga ccaaggcggg ccgggagcgg ccagctccgt ccagctccgt ccagctccgt 300
 gtcctgaagt ggaactcagc agcgggagct ggaactcagc atggcgtttg agagattcca 360
 tctgtccttg ctacataag cgttctctgg aagtgaagtc gtgtgtctct gaacgggggc 420
 caggcagctg cggcctgggg gtttggaggt gtttggaggt gtttggaggt gtttggaggt 480
 tggagcaaat ctgtcagtc atcttggctg agtctctgca gttcctggca gatcttgaag 540
 aaaaagaagg aagaagacagc aacatgaaga gaggagagcc agagagagcc agagagagcc 600
 gggactaccc tcatggcctg gttgggttac aacacattgg acagacctgc tgccttaact 660
 ccttqatlea ggtgttctga atgaalgtgg acttcaaccc gatattgaag aggatccagg 720

ggcagcgatg	gattttgggt	ggggangtcc	teettgogga	gttgggagca	gctagctctt	1980
gaacagctgg	atgagcaaga	tggtgatgca	gaacaaagca	acggaaagat	gaacggtagc	2040
accttaata	agatgaatc	aaaygaagaa	agaaaagaa	aggaggaatt	aatTTTTaat	2100
gaagatattc	tgtgtccaca	tggtgagtta	tgcatactct	aaaktgaag	aaggtctgtt	2160
tctaaagagg	cttggagcaa	actgcagcag	tactttccaa	aggtccctga	gtttcccaagt	2220
tacaaagagt	gctgttcaca	gtgcaagatt	ttggaagag	aaggggagaa	aatgaagctc	2280
ttacataaga	tgattgcaaa	cgagcaaaa	acttctctcc	caaatttgtt	ccaggataaa	2340
aacagaccgt	gtctcagtaa	ctggccagag	galacggatg	teetctacat	ctgtgtctcg	2400
ttcttlttag	aagagtggcg	gaaatttgtt	agaaagccta	caagatgcag	ccctgtgtca	2460
tcagttggga	acagtgtctc	tttgtgtccn	caogggggcc	tcagtgttac	atttgettcc	2520
atgacccaa	agattctaa	acttatagct	ctcatatggc	ccagttagtg	gcaaatgata	2580
caaaagctct	ttgttgttga	toatglaatt	aaactcaoya	gaattgaagt	gggagatgta	2640
aaccccttcag	aaacacagta	tattttctgag	cccaaactct	gtccagaatg	caggaagggc	2700
ttatttgtctc	agcagcagag	ggaacttgcg	gaatacactc	aagccaccat	ctatgtccat	2760
aaagtctgtg	ataataaaaa	ggtgatgaag	gattcggtct	cggaaetgaa	tgtgaatagt	2820
tctgaacacg	aggaagacaa	gggaagaagt	aaaccagatg	gagaaaaaga	tccagatttt	2880
aatcaaatca	tgcatgcatt	ttcagttgct	ccctttgacc	agaatttgtc	aattgatgga	2940
agatattttaa	gtgatgactg	tgccacccta	ggcacccttg	gcgtcattcc	tgaatctgtc	3000
attctatttg	aggtgatgta	accaattgca	gattatgctg	caattgagta	tgcatgcaa	3060
gtttgtatgc	caggaagag	gtttaaaggt	actggtcttc	ttggacatta	atctttgaat	3120
acttgctgac	tgttaagaaa	tgaccagagg	ggaagaggag	tttgacatgt	tayggatm	3180
aagcaaaagt	ggatttaaga	attaaaccat	tacatgcccc	ttccaaaaga	cagaaatcca	3240
ttcaaacgtg	actgtcccaa	algccttatg	tcactaaag	cagatttgcac	tgatggacat	3300
cagacttgaa	ggaaatgttt	ccaattttat	atttaagggg	gggtggtggg	gggagggggc	3360
aagttaagac	ggaaacagtt	taytaycagt	aattagtaaat	catgtttaca	tatgagattt	3420
atagtctgtg	gagggggaata	aagtctctgt	atatctctct	gctcagatct	cataccagat	3480
gcttltgttc	ataaaggttt	gtatcaagta	gatgggacaa	cattctgtct	tgaacgaaaa	3540
gtaatttttag	agacataacc	tgcttaccaa	tgctgtctct	tgattcatat	ctantttca	3600
ataaagcatg	aaagtgaaga	acttgtaaaa	aaaa			3634

<210> 45
 <211> 1661
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1973875CB1

<400> 45	ctcagagcga	ttcggctcga	ggcggactgg	tctcggcccg	ggcaccgtcg	cgggccccc	60
	tgcccccgc	acctgggacc	glcctgggga	gtctgcact	tccctctctc	ccctggcccg	120
	caaaattttg	gggaccccat	cgctggggct	gagcgccccc	ccggggggag	atcggggagc	180
	gcccagatgc	gggcccgggg	agccalttgc	ccgggagcgc	gcccctcgtc	gagcagccga	240
	ccacccccgc	gcccctgggt	catggggaet	ggctgagggg	ccagcatggg	caactgcgtg	300
	ggggagacag	gcccgggag	gcccggcagc	ccgggacacc	cccgcaagcg	agcaggagcg	360
	aattgagcccc	tgaagaaaga	ggggttbaag	tggaaagagc	actaacccat	gaatgaaggg	420
	cagctgcggga	gcaaacggga	tgagttctgg	gacacagcgc	ctgcttcga	gggcccgaag	480
	gaatctgtgg	atgcctccaa	ggctgcggcc	tatgtgtctg	aagccaaagc	ccacgagctg	540
	gcccaggcca	tccctggatg	agccagcacc	acctgcctc	atggcaccct	ctgtgaatgc	600
	taagatgagc	tgggcaatcg	ctaccagctg	cccatctart	gcccgttacc	ggcggtagac	660
	ctgctgtctg	agcacacgga	ggaggagagc	ctggagcccc	ccgagcctcc	acccagcgtg	720
	cgccgtaggt	tcccgtgaa	ggtgcgcctg	tccacgggca	aggacgtgag	gctcagcgcc	780
	agcctgcerc	acacagtggt	gcagctcaag	aggcagctgc	acgcccagga	gggcatcgag	840
	ccatcgttgc	agcgttgggt	cttctccggg	aagrtgtctc	cagaccgcac	acggctccag	900
	gagaccaaga	tccagaaaga	ttttgtcact	caggtcatca	tcaaccagcc	ccaccaccac	960
	caggaactgat	gggcccacgg	acccctggga	agagggcccc	cttggagcac	tagggcccca	1020
	ccctgtctgt	gecttccagt	gctgtcattt	tcttcagggg	ccctccccc	ggtgtggctg	1080
	gtgggttagc	cgtaagggga	ccctgacctt	aggggactta	cgcccccaca	gttccgggta	1140
	cccgaggagc	aggcagccac	acacggggct	tgcacacttg	tcaagaaaaa	ggcgaacagc	1200
	gcctccacc	tgcctgtctc	ccgaagagag	ctcagaccac	aagggccaac	caggaaggcc	1260
	ctggagccca	gctctgtcat	ctgggtgctg	cagctgtgct	cactctgggt	ttctgtctag	1320
	ggtctgaagc	agctgtgtgc	tccctccctc	gcccccatcc	ccctggctctc	ccctggggac	1380
	agtgccactc	cccttggaggt	gaggggaaca	cccgtagacc	ccagggtctg	ggagacctga	1440
	ggcgggctct	tgcctctccc	tgcctccagc	acaattggca	gaatagaggg	aggtagtggc	1500
	cggctgggct	gtcgtggcag	ggctctgcac	ggccatgtc	ctggctgtaa	ccaggcagt	1560
	gggaggtctg	cagcctgggt	atggcctccc	cagcaggtcc	ctgtggacag	acatatctgc	1620

<400> 43

gcacaaattg	tttcaaaaaa	tttgtgagga	ttttgattcc	tatctcgttc	naattttttgg	60
ttcatcgtca	cctcaaacctg	gatttgggat	gtcaggggaa	gaactcagtg	aatctactcc	120
agagcctcaa	aaagaaattt	ctgagtcatt	gaptgtccac	agagaccagg	atgaagatga	180
taaggctcca	gagccaaagt	gggctgatga	tctgcccgc	actacccat	ctgaggccac	240
cacacacccc	aguccactgc	tcagcaccoc	tytgatggg	gcagagggac	ctagatgttt	300
ggaaagcctt	aagcctgyaa	actgtggtga	atatgtggtt	cgatggtatt	atgacaaaca	360
ggtaaatctt	tgtgcccgat	tttggttcag	tggclgtaat	ggctcaggaa	ctagattcaa	420
cagtgaaaag	gaatgtcaag	aaacctgcac	tcaaggatga	gcaagttaaa	tggcctgtct	480
ctatcaaaag	catagaaact	cctaatllcc	acatattcac	ccaatacaaa	tacagcaacta	540
tatttgagtg	tatactgagt	atttacaact	tatacatgta	attgaattct	caclacagcc	600
ctaggatgta	catattatta	accatttata	taggttaagaa	agctgaggct	ctgagaagtt	660
tagtaacttg	tcaactgtca	cccaactaaa	aaqtttcaaa	gctgaggatt	tagaattaga	720
gctgtgttaa	ttcaatacaa	agactctata	tacttcaaaa	cctgcaatgt	gattctgatt	780
cttttaattc	ctgttgtatg	tactatgtca	gtcacaaccc	ctacccctgt	ccctgcccac	840
acctcaccoc	actcaacctc	ctaacctctc	tatgtccctc	acagtaccaa	gatgtaggtg	900
ataggaaagga	cttcgggtgtg	agaattagaa	atgatgtaaa	tggttacgca	ggagtycttg	960
gataaggatc	gggatggtga	gggtagttag	atttttgect	cacttgccct	gaaagtgtta	1020
ataggagagaa	accaatctga	attacaatta	cttaaatgta	tcaacagctg	tcacttttga	1080
ttctcccaac	atgttttgga	acaagtgtct	aatgtatgtt	aaaataaaga	aggtttttat	1140
acccctccat	taaanlatgt	cagtgggccc	ttccatttta	tygagtygaa	tgggaaggcc	1200
cttgacagcc	aggaaccact	tgaagctggc	atccactctt	gaacagggag	tattaaagac	1260
aggattccaa	ctgaanaagt	egcaccacaa	ttgaatggcg	agtaatggag	agtaacggag	1320
aatcgcttga	cctcgggaag	cagaggttgc	cgagagccgg	gattgcccac	g	1371

<210> 44

<211> 3634

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Inocyte ID No: 1911808CB1

<400> 44

ggggggcag	tggcgcgcac	aggtgattga	ctggccagct	gootgaagga	gcgcaggttc	60
ctccttgcgt	gcaggttgccg	aagcccatgt	gggggggggt	gcagaccgcy	gggggggctg	120
ggggggtctg	gtccgggagg	cgttccclgg	gcccaggcca	tygcccngcg	gcttgcagctg	180
gagcaggcgg	cctggcgctg	ggcggagacg	gtggcgcccg	aggagggtgc	gcaggagcat	240
atcgagacgg	cttacccgat	ctggctggag	ccttgcattc	gcygctgtgt	cagacgaaac	300
tcgcaaaagg	atccgaattg	cttgggttgt	atctgtgagc	atatttgggt	agggagaaata	360
gatgaaata	gttttcaata	catcgatgat	cccaactgtg	aggggggaaa	aaagaactca	420
tttgttggcc	tgaactaacct	tggagccact	tgttatgtca	acacatttct	tcaagtgtgy	480
tttctcaact	tyggagcttcg	gcaggcactc	tacttatgtc	caagcacttg	tagtgactac	540
atgctgggag	acggcatcca	agaaagaaaa	gatttatgag	ctcaaacat	ttgtggccat	600
ctccagtact	tgtttgcctt	gttgcaaaac	agtaataggg	gatacattga	tccatcaggc	660
tttgttaag	ccttgggccc	ggaactgga	caacagccagg	atgtctcaaga	attttcaaaag	720
ctctttatgt	ctctattgga	agatactttg	tctaaccaaa	agaatccaga	tgtgcgcact	780
attgttcaac	agcagttclg	tygayaattc	gcttatgtaa	ctgtttgcaa	ccagtgtggc	840
agagagctca	agcttttctg	aaaattttat	gagctggagt	tcaatatcca	agggcccaaa	900
cagttacacg	attgtatctc	ggaatttttg	aaggaagaaa	aattagaagg	agacaatcgc	960
tattttttgcg	agaaactgtca	aagcaaacag	aatgcaacaa	gaaagattcg	acttctcayc	1020
cttcccltgc	ctctgaactt	gcagctaatt	cgttttyctt	ttgacaggca	aactggacat	1080
aagaaaaagc	tgaataccta	cattggcttc	tcagaaattt	tggatatgga	gacttatgtg	1140
gaaatataag	gtgggtcttc	cgtgtatgaa	ctcagcgcag	tccatcatac	cagaggagtg	1200
agtgcattat	ctggccacta	catcgccccc	gtgaaagatc	cacagctctg	tgaattgtat	1260
aagtttaatt	atgaagacat	agaaaagatg	gaggggaaga	aattacaact	agggatctgag	1320
gaagactctag	cagaaccttc	taagtctcag	acacgtaaac	ccaagtgtgg	caagggaaat	1380
callgctctc	gaaatgcata	tatgttygtt	tatagactgc	aaactcaaga	aaagcccaac	1440
actactgttc	aagttccagc	ctttcttcaa	gagctggtag	atcgggatag	tcccaatttt	1500
gaggagtngt	gtattgaamt	ggctgagatg	cgttaagcaa	gtgtggatag	aggaaaagca	1560
aaacacgaag	aggttaagga	gctgtaccaa	aggttaacct	ctggagctgt	gocclatgag	1620
tttgtctctc	tggaatggcl	ttcaaaagtgg	tttgttgaa	caacacctac	caaacctatt	1680
gataatcagc	cttgccctgtg	ttcccatgac	aagcttcacc	cggtataaat	atcaattatg	1740
aagaggatat	ctgaatatgc	agctgaactt	ttctatatga	gattatggag	aggtccaaga	1800
ctaactytga	aagccctgtg	taaggaatgt	gtagtagaac	gttgtcccat	attgctctctg	1860
aagacccccc	laaatgaaga	ttataaaact	gttaataact	tygtgaagcc	agcagtaag	1920

```

tggttttaaca aaagagtgtg gacattttta tttttaaatt taggcaaaag tcaactatcaa 1680
atgggttgctt atttgttacc cacagccata tagtttttcc tggagggttt tggtttgttg 1740
ttgttgaaaa gatttgtctt acagctagat gaaactttct atagaaaaaa aaatttgttg 1800
aaaggtccag ttctcagtac catgtgagtc aatgatacta caactaagtt ctttttaaaa 1860
agtgaattat gtattttata aattaccctt tcacatatgc aaattctgtt tctaactaaa 1920
tggtattttt actaatgctt tatttgtgga ctcttttttg aacatctctg agtgaatata 1980
tgaatcaatt tgggtttaa actgaaagcc agttgggttg aaaggtttga aatacgtacc 2040
ccagtaaaao cattcaatcc ataattgcta aataatcttt taasaatggt ttttaatecgt 2100
atagatgaca tttttagact ttggacatgg tggttaattaa ggggcattaa ttttaactcc 2160
caaggtz

```

```

<210> 42
<211> 1826
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 1256390CB1

```

```

<220>
<221> unsure
<222> 1755
<223> a, t, c, g, or other

```

```

<400> 42
ccccggcctt tctatagcat agttctcttt aggtgggaatg attcctatna gattttctcat 60
tattaaatca tgcatttttc aagatggnaat caatcttlln ttttaataaa gctgatattc 120
tcatttgttt gaagaacac acacatgcta gagagagagg aggaatatata cccacgaccc 180
ccacagccagt tagtalccag ttggtgctgg actccagcca ggtgtctctg ctcaggttag 240
ttaaatgata tatagaaaag gtaaattttt aaagaatbat ttalttaalt atlccataaa 300
aacallttta aggtAACCAc ttaaaaaatgg ttaatttttc cattccaaag taaatgotaa 360
gcatgtttat taatgaagca gtactctctg ttagtatatg acattctgaa gtttaattaaa 420
ctcaatggca taatgtgttc tctcttggtt tagtggaggga tttgaggatt tctggttctc 480
gtagaggtgt tgcctaaagc tctgctllga accctttatc ttttggggat tctggttctc 540
ggaggtgtgg gatctgtag atccttagcc caacacagac aagagattgt ggcacngton 600
gtgaatccat ggagcctgga gacgtattcc tatcacctat accaccccat gggagagato 660
tatgagtggg tgagagagat cagtgagagc taccaggaag tggllgacaa gcatttctca 720
ggagtgacct atgagaccca ccccatgtat tatctgaaga tcagccaacc atctggtaat 780
cccaagaaaa tcatttggat ggaactgllga attcagccca gagaatggat tgcctctgtc 840
ttttgcaaat ggttcgtcaa agaaattcta caaaaccata aagacaacto aagtatacgc 900
aagctcctta ggaactgga ctctatgttc ctctcagttc ttaacataga tggttatata 960
tacatttggg caactgacg tctttggagg aatcccggtt caccocataa taalggcaca 1020
tgltlltggg agatcaaac tggaaetttc aatgcctctt ggtgtagtat tgggtcctct 1080
agaaactgoc gcttcataga agatcaaac attctgtggg acagggccag tctctgaacc agagaataaa 1140
gctgtttgca gcttcataga gagcaagaag gatgatattt tgtgttctct agagataaaa 1200
tcttatgggc agttaattct cacaccttac ggtatattt tgtgttctct aactataatc aagtaaccac 1260
ccagaaatga ttcaagttgg acagaaggca gcaaatgcat tgaagcaca gtatggcaac 1320
aattatagag ttggatcgag tgcagafalt ttatatgctt cctcaggttc cctcaggttc cagtggagac 1380
tgggcccagag acattgggat tcccttctca tatacgtttg agctgaggga catggaggct 1440
tatgggtttg ttctggcaga agctcagatc cagccacact gtgaggagac catggaggct 1500
gtgctgtcag tcttgatga tgtgtatgag aaacactggc actcggacag tctcggnaag 1560
gtgacatctg ccactatgct gctgggcttg ctggtgtact gcatgtctct tctcgaagt 1620
cattctgccc aggtttttt ctgcccagaa tttcccttta ttttctctcc tagtaagtc 1680
ttcttttgat actaattctg acattacctg tggaaatttt gctgacttcc acagattttt 1740
ttttctctcc tctntaact gtttgaacac actttaatgt aataatttac agactlgtgt 1800
agtgaatag galattacat gcccctg
1826

```

```

<210> 43
<211> 1371
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 1786774CB1

```

```

tccgtacaga taaaggaaga gatcccagtt ctgtatanata ttaggeagat tctgagttgt 900
tgctccagat acgaatgnt gtgcttgact caactgggtat tagkcccgac ctgcttccg 960
aggactttgt caggtaactgc ttctccyaga tggcccragt gtgtgcyytg gttggaggga 1020
ttttggcaca ggaattgtg aaggeootgt ctacagggga coctccotac aacacattct 1080
tetctcttga tggcctgaag gggcaatggg ttgtggagtg ccttggeccc aagtgaacte 1140
aagattttgg agccccagag atgccaactg cagcattgcc acctgtalte cctgtcccc 1200
tccttcattg aggcattctc aggcgaaggaa aactgaagtc gctgcttccc atcaccagca yctgctcgac 1260
ttcttcacac gaaggaggtg gtgcctgact ctttgttcca gcaactgttca ggtgacctgt catccccggc 1320
aaggggcgca ggggtggctgt ttgtgttcca gaagcaccoc ccttcttggg agatgectgc cttgtctctt 1380
ctgccaqcto ccttgagtg ggcctcgcca gccctctggg cctcttctga ccttcttggg attattcccc ggccccatga 1440
atgctgtccc caagctctgt tgetcgugag tcaggtggag agtaggccc gggccccatga ggcaccagtg 1500
ttatagagaa lccaagtcca gacaggtgcc accagtgagg cttagagagg aaaaaccatg caggcaaatg 1560
gaagcaccag cattctctct ggagtttgag acctgacaa ttgagttcca gctgggtttt ggcagaaagg gatctgtg 1620
gagtttctct ttgagtttgg tgttagggcg ggggcttcag gcttagggag gctgagctg cctttttaa cctgtatgtt 1680
gcaggttctc tccatctcgg ctccagtcac gtttgtgttt gttacttgtt accagttgoc tcttgcacc atttttctg ggtgatgcag 1740
ttactctggt aaccacagct tgataatcaa agaggggaat gcttccctct ccttccactt ttctagaatg tctgtctcca tctgtctaat 1800
gaagcttttg agaggggaat ttccctctct attgttccac ggtatcttcc aggtatcttc attataataa taaagggag 1860
actccagaga ttccctctct attgttccac ggtatcttcc aggtatcttc attataataa taaagggag 1920
caagagttta gataatcagt tcaaaagtga tgcctccatg gtttgccttg tttatgtaaa ttgtgtgaly 1980
tcaaaagtga gtttgccttg tttatgtaaa ttgtgtgaly 2040
ggagagctag gtttgccttg tttatgtaaa ttgtgtgaly 2100
gtgtttcttc aa 2160

```

<210> 41

<211> 2167

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 411344CB1

<400> 41

```

cgccgggtctt ggggggagtg ttccatcatg ggtccaatgc agaaacgact acagaagaa 60
ctgtttgctt tgcanaatga cccacotcct ggaatgacct taaatgagaa gagtgttcaa 120
aatteaatta cacagtggat tctagacatg gaaggtgcac caggtacott alataaggg 180
gaaaaalltc aactctctatt taattttagt agtcgatate cttttgactc tctcaggtc 240
atgtttactg ttgaaaatat tcoctgttct cctcatgttct atagcaatgg tcatatctgt 300
ttatctattc taacagaaga ctggctccca cgcctctcag tccaatcagt ttgtottago 360
attattagca tgccttccag ctgcaaggaa aagagacgac caccggatca ttctttttat 420
gttgcgaacat gtaacaagaa tccaaagaaa acaaaatggt ggtatcatga tgatacttgt 480
tgatgccact gttatcalcc tcttgcagga agatagtcct actyagaaaa tggacacttt 540
gactattcag tctttgaact ttaacotttg actggaagtg acctatagge atgaagact 600
acttcccttt actgcatttt taactygttg catcttgggc gcatgttgat cgtcggttca 660
gtccaggcaa ctgacatgct tttattagtc atacagtatt aatgcaggtg tccaggaatg 720
tcaaatataa ttccattctt tatttttatt tttttaagct ttggaaaag ctccaggtcc 780
tcattgtatt tgcataaaca atgacttcc tggcgttttt aggtacglta ttccatgatt ttccongcaa 840
tggnggttgt aacaygaaaa gttttcatta actgtttata ggtggaatat aaataaagt 900
agggcctatg aatgaactt actgtttata ggtggaatat aaataaagt 960
cattacttta aaaglcaccc caactgttta aaggactgta ctatgcactg tgatcctaag 1020
gttaacagca tttatattta ctgtcaagtt ttattggact atgaaagata attgnatatt 1080
tattgaattg gtacagtatg ttatccctat ggtgaaaata ygaagatttt caagtaacat 1140
ttcctcaalc tctgaagtta aggtatgagt aatataaggt aattaatttg ttgtatatag 1200
tttatttttg gtttatttgg aatggcagtg atgattaaat tgotgcagtc cataatttgg 1260
gcttcttatt tgcacatlaa agatcttctt caactctctg aacttctctg tttggaaacc 1320
tgcacatcag catgagccct tttgttttgc aatcttctct caactctctg tttggaaacc 1380
cogtaaacat tttgttttgc aatcttctct caactctctg tttggaaacc 1440
aatactttta ttgaaactct tttgttttgc aatcttctct caactctctg tttggaaacc 1500
tcattcttgc ctttaactct tttgttttgc aatcttctct caactctctg tttggaaacc 1560

```

<220>
 <221> misc_feature
 <223> Incyte ID No: 5432879CB1

<400> 39
 gtccgagcggc ggcggggggcg gtagcggagg agacgggttc aggcctccgg tgcgggtgca 60
 atgctgagct cccggggcgga ggcgggcgatg acgcgggccc acagggccat ccagcgcttc 120
 clcgguacgg ggccggccgt cagatataaa gtcatgaaga actggggagt tataggtgga 180
 attgctgctg ctcttgacgc agaatatat gttatttggg gtccattac agaagaaag 240
 aagcgtagaa aagggcttgt gctggcctt gttcaattag ggaacacctg ctcatgaac 300
 tccctgctac aagcctgtc tgcctgtctc gctttcataa ggtggctgga agagttcacc 360
 tccagtaact ccagggatca gaaggagccc cctccanacc agtatctate cttaacactc 420
 ttgcaccttc tgaagccctt gtcctgccaa gaagttactg atgatgaggt cttagatgca 480
 agctgcttgt tggatgtctt aagaatgtac agatggcaga tctcatcatl tgaagaaacg 540
 gatctgacg aattattcca tgtcattacc tcttcattgg aagatgagcg agaccggcag 600
 cctcgggctca cacttttgtt tgaatgtcat tccctgggag agnagtcaga aataactccc 660
 aaacaaatta cctgcgcgac aagagggtca cctcaccoca catccaatca ctggaggtct 720
 caacatctcl ttcattggaag actcactagt aatatggtct gcaaanactg tgaacaccag 780
 agtctgtgtc gatttgatac ctttgataga ctttcaactaa gtatccagc cccacactgg 840
 cctcgggctca cactgtcctt cactgtgcat caccacttca tctcatcaga atcagtgcgg 900
 gatgttgtgt gtgacaactg tacaagatt gaagccaaag gaacgttgaa cggggaaaag 960
 gtggaaacac agaggaccac ttttgttaaa cagttaaaac taggggaagt cctcagttgt 1020
 ctctgnatcc acctacagcg gclgagctgg tccagcnaag gcaagcctct gaagcggccl 1080
 gagcacgtgc agttcaatga gttcctgatg atggacattt acaagtacca cctccttgga 1140
 cataaacctn gtaaacacna ccttaactcy aacaagaacc cagggcctac actggagctg 1200
 caggatgggc cgggagcccc cacaccagtt ctgaatcagc caggggcccc caaaacacag 1260
 atttttatga atggcgcttg ctecccatct ttattgcaa cgtgtgcagc gccgatgcc 1320
 ttccctctcc cagttgttcc cgaactacagc tctccacat aactcttccg gctgatggca 1380
 gttgtctgct accatggaga catgcactct ggacactttg tcaacttaccg acggtcccca 1440
 ccttctgcca ctaactagc clcaactagc hatacgtgyc tctctcagcg cctacctgct 1500
 gtcgcgaagg ccagcctgca ggaggtcctg tectccagcg cctacctgct 1560
 cggctccttt ccaggtatgca gacccagagc caggagtgc agtctgaaga atgactgtgc 1620
 cctcctgcaa ggotagagct gatggcactg tctgcactgt ccaggaazaa agtcaactgt 1680
 tactgttgcg tgtcaagcg gccccactag agccttccag ccttctgggt tgttctaaag 1740
 gcaggctcca cclgggagcc agccccagt cacaanaac vaggctccct gaacgtctct 1800
 gttcactgtt gttaggtggt ctgttgtgtt aagaagcat tcaattatgt cggagtgtct 1860
 ttttaactcl ctgatacagg taaltaaaag aactagatt ctgaagcca cgttttcat 1920
 attgtaactgt taggtgttct cagaggggag gtacetttgt ctatcaacg tttccactta 1980
 gatcttttat ttttaataag cagggccata aaaattgttg acaagaatta atgaattat 2040
 taagggaaac aatttagaag aaaaagtgc tttaacttcc gattgtttt gtgacagtc 2100
 cattgtgaaa tattccttcc aggtacttca aaggatagca agagaacagg taaatgatgc 2160
 ctaaaagaaca ccltctttt totatg 2186

<210> 40
 <211> 2522
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5853753CB1

<400> 40
 ctccggggcgt gctgcggcg ggggtagggt gcgcgggggt ccggcggggg gttggcttga 60
 gggggaacgg agctgagya ggaagagccg ggcgcctggt ggagaaggag gagggtggcg 120
 gcggcatttag cgaggaggag ggcgcacagt atgacgggca gatccgctg tggggactgg 180
 aggcacagaa accgclggcg gctctctggg tgettcttgt cggcttgaag ggaactgggg 240
 ctgaaattgc caagaatctc atcttggcag gagtgaagg actgaccatg ctggatcag 300
 aacaggtaac tccagaagat cccggagclc agttcttggat tctgttggcc 360
 gaaatagggg tgaagcctct ttggagcgag ctcaaatct caaccccatg gtggatgtga 420
 aggtggacac tgaagctala gagaagaacc cagagtcalt ttctctctca tctcatgctg 480
 tgtgtctgac ttgtgctcc agggatgtca tagttaaagt tgaccagatc tgcacaaaa 540
 atagcatcaa gttctttaca ggaqatgttt ttggctacca tggalacaca ttgccaalc 600
 taggagagca tgagtttcta gaggagaaba cttaaagttgc caaagttagc caaggagtag 660
 aagatgggccc cgaacccag agggczaaac ttgatcttcc tgagccaacg atggtcaaaa 720
 agaaggtggt ctctgcctt gttaaagaag cctggaggt ggactggagc agtgagaaag 780
 caaaggctgc tetgaagcgc acgaacctcg actactttct ccttcaagtg ctcttaagt 840

tgttgaataa	tocagatata	atgagacaaa	ngtttggaaet	tgcacgggaat	ccagcaatga	1080
tgcagggagat	gatgaggaaac	cagggaacgag	ottttgagcaa	octagaaagc	atcccagggg	1140
qatataatgc	tttaaggcgc	atgtacacag	atattcagga	accaatgctg	agtgcctgcac	1200
aagagcagtt	tggttggtaat	ccatttggctt	cektgggtgag	caatacatcc	tctgggtgaa	1260
gtagtcaaac	ttcccgtaga	gaaaatagag	atccactacc	caatccatgg	gtccacaga	1320
cttcccagag	ttcatcagct	tccagcggca	ctgcacgcac	tgtgggtggc	actactggta	1380
gtactggcag	tggcacttct	gggcagagta	ctactgcgcg	aaatttgggtg	cttggagtag	1440
gagctagtat	gttcaacaca	ccagysaatgc	agagnttgtt	gcaacaaata	actgaaaaac	1500
cacaacttat	gcanaacatg	ttgtctgccc	octacatgag	aagcatgatg	cagtcaataa	1560
gcacagaatcc	tgacetttgt	gcacagatga	tgtgaaataa	tcccttatgt	gttgggaate	1620
ctcagettca	agaacaaatg	agcaaacago	tcccactttt	octccaaaca	atgcagaaac	1680
ctgatacaat	atcagcaatg	tcaaacctta	gagcaatgca	ggccttggta	cagattcage	1740
aggggtttacc	gacatcagca	acgggaagccc	caggnoctcat	oncagggttt	actcctggct	1800
tgggggcaat	aggaagcaat	ggaggtctct	cagggaactaa	tggatctaac	gccacaccta	1860
gtgcaaacac	aegtcacaca	gcaggaaccca	ctgaacctgg	acatcagcag	tttattcaga	1920
agatgottca	ggctcttggc	ggagtaaatc	ctcagctaca	gaatccagaa	gtcagatttc	1980
agcaacbaat	ggcaacacac	agtgcacatg	gatttttggaa	cngtgaagca	aaattgcaag	2040
ctctaatagc	aacaggaggt	gatatcaatg	cagctattga	aagggttactg	ggctcccagc	2100
catcatagca	gcatttctgt	atcttgaaaa	aactgaattt	atttttggat	acggctctta	2160
aaatttataa	tacctgcttt	atttcatttt	gaactcttgg	attctgtgat	gttataaaca	2220
aaaccaatat	gatgcatttt	aaggtggagt	acagtaagat	gtgtgggttt	ttctgtattt	2280
ttctttttctg	gaacagtggt	aatttaaggct	actgcattgca	tcacttctgc	atttatgtta	2340
attttttttaa	aacatcacct	tttatagttg	ggtgaccaga	ttttgtcctg	catctgtcra	2400
gtttattttgc	tttttaacaa	ttagcctatg	gtagttaatt	atgtagaata	aaagcattaa	2460
aaagaagcaa	atcattttgca	ctctataatt	tgtgttacag	tattgcttat	tgtgactttg	2520
gcattgcattt	ttgcaaacaa	tycttgaaga	tttatactac	tgataatttt	gttttatltg	2580
latcaaatat	agagtattgca	catttgggac	tgcatttctg	gaaacatact	gcaataggct	2640
ctctgagcaa	aacacctgta	actaaacaa	tgaagataag	aaaatactct	caagctgag	2700
tatttccctaa	ttgttatgaa	tcttacagca	tctttgacaa	acatctccca	gcaaaagtgc	2760
oggttagtca	ggtttggttg	aaatacagta	gaaaagctga	ttctgggtta	ctctttaagg	2820
acaatttaatt	gtacagacac	ataatgtaac	attgtctcaa	catctcatca	cagattgact	2880
gtaaattacc	ttaatctttg	tgcagactga	aggaacactg	tagtatcccc	caagtgcat	2940
ttgccttagga	cttctcagct	tctcccatga	gtagtgttaa	aggtattaaa	atttgtattt	3000
gaaatgtttgc	tttcaactgaa	aaagtgtctt	gabgtttcag	ttatttttaa	tcgcacataa	3060
aaaatagaac	tatctttttg	gttttatctgt	ttctctcatgc	acaggcaata	cacaaattta	3120
aaatgagttg	tyagcccaatt	gtttctgga	tgttttggtg	gltctattaa	gaatagtta	3180
aatatttgtgc	tttccagagc	ctcagagaca	gggtgacgag	gtgcgggggt	ggggcagcgg	3240
aatctgtctt	ggatgggggc	agcttaataa	atactggcaa	cnaagat		3287

<210> 31
 <211> 2412
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1299481CH1

<400> 31						
gggtgtgtgtg	cggcgccggc	ggcgccggcc	gagggggatg	gagcgagcgc	cgagccgggt	60
cagagttgaa	caatgaccat	agttgacaaa	gcttctgaat	cttcagccc	atcagcttat	120
cagaatcagc	ctggcagctc	cgagggcagtc	tcacctggag	acatggatgc	aggttctgcc	180
agctgggggtg	ctgtgtcttc	attgaatgat	gtgtcaaatc	acacactttc	tttaggacca	240
gtactctggty	ctgtagtltta	ttcgagttna	tblgtacctg	ataaatcaaa	acctcacca	300
caaaaggatc	aagccctagg	tgaatggcatc	gctcctccac	agaaagtctc	tttcccatct	360
gagaagattt	gtcttaagly	gcaacaaact	catagagttg	gagctgggcl	ccagaatttg	420
ggcaatacat	gttttgocaa	tgcagcactg	cagtgtttaa	ctcacacacc	acctcttgcc	480
aattacatgc	tatcacatga	acactccaaa	acatylcaatg	cagaaggctt	ttgtatgatg	540
tgtacaatgc	aagcacatat	taccacggca	ctcagtaatc	ctggggacgt	tattaaacca	600
atgttttgtca	tcaatlyaat	ggggcgtata	gclagpcacc	tcogttttgg	aaaccaagaa	660
gatgcccatg	aattccctta	atacactggt	gatgctatgc	agaaagcatg	cttgaatggc	720
agcaataaat	tagacagaca	caccacggcc	accactcttg	tttgcagat	atttggaggc	780
tacctaagat	ctagagtcac	atgtttcaat	tgaaggcg	tttcagctac	tttfgatcva	840
tatcttgata	tacacattgg	gataaaggct	gctcagagtg	tcacaaaggc	atttggagcag	900
tttgtgaagc	cggaacagct	tgetyggaa	aactcgtaca	agtgcagcaa	gtgtaaaaag	960
atggtlccag	cttcaaaagag	gttcaactatc	catagatcct	ctaattgtct	tacactttct	1020
ctgaacagtt	ttgcaaat	taccygtgga	aaaattgcta	aggatgtgaa	atcccttag	1080

<400> 29

```

gtgcttgccg cctgcgctgg acgactcggc cggtagtgga gatgtccggc cgggtctaagc 60
gggagtcctc cggttccact cgggggaagc gaggagtcga gtccgggggc agctccgggc 120
gggtccagcg ggagcgagat ggagcgagat ggagcgagat ggagcgagat 180
ctgtgcgctg gaagcggaag cgggagcgcg cgggagcgcg cgggagcgcg 240
tccgtttgtt cgggtgaag cgggagcgcg cgggagcgcg cgggagcgcg 300
aggtgcgagc aaagaatggc cgggagcgcg cgggagcgcg cgggagcgcg 360
acctggacac cattacacag cgggagcgcg cgggagcgcg cgggagcgcg 420
ccctccacac catcaatgct cgggagcgcg cgggagcgcg cgggagcgcg 480
gtttgaagtc tccagcctac attccagtc attccagtc attccagtc 540
tccacaccc caggttttac tgccttccag aagccccact gcatatgat 600
aggatatcac gtatgtgttg gcatatgat gcatatgat gcatatgat 660
agcaagccaa attgtccggg gcatatgat gcatatgat gcatatgat 720
tgaatcacat aaagggcaca gcatatgat gcatatgat gcatatgat 780
ctcctctccg gaactacttt ctggaagaag gtcacagcgt ctggaagaag 840
gggatatcat gttcttcttg caaggcacat gtcacagcgt ctggaagaag 900
ctcgaaatbt caaggcacat gtcacagcgt gtcacagcgt gtcacagcgt 960
gtaagaagac ttttcagatc gtcacagcgt gtcacagcgt gtcacagcgt 1020
tgaatgtctb gcaactccgt ctgggggggc agagatcttc ctcacatctg 1080
atgttttcca ggggtccatg agagcagctg gaccttctca acatctctg 1140
cagaagaaaa cctgacgctg gaccttctca acatctctg acatctctg 1200
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 1260
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 1320
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 1380
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 1440
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 1500
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 1560
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 1620
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 1680
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 1740
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 1800
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 1860
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 1920
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 1980
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 2040
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 2100
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 2160
agttctctca cctgacgctg gaccttctca acatctctg acatctctg 2220
aaaaa

```

<210> 30

<211> 3287

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1261376CB1

<400> 30

```

cagggcgctt acccgcgctg ctcggcgctg cggcgcgctg gggagcgctg ggaaggggca 60
gggagcgctt acccgcgctg ctcggcgctg cggcgcgctg gggagcgctg ggaaggggca 120
gggagcgctt acccgcgctg ctcggcgctg cggcgcgctg gggagcgctg ggaaggggca 180
cacaacccgt accggtggcc ctcggcgctg cggcgcgctg gggagcgctg ggaaggggca 240
gctgtccagg cctgcggctg ctcggcgctg cggcgcgctg gggagcgctg ggaaggggca 300
tgcttgcttg agtcacccgc ggcgcgcgcg ccacagccat gggcgagagt ggtgaaagcg 360
ggcgtccctc cggcgcgctg ggcgcgcgcg ccacagccat gggcgagagt ggtgaaagcg 420
ccgctgcctc cggcgcgctg ggcgcgcgcg ccacagccat gggcgagagt ggtgaaagcg 480
aggaattcgc cgtgcccag acatactgac caacttgtgt ggaattcagc gtcattaaa 540
ggttttaact acatactgac caacttgtgt ggaattcagc gtcattaaa 600
cacaacacag gctcaggat agtaactcta cttgcaggtc atgcccagac taacccagac 660
ctacatctac caacttgtgt ggaattcagc gtcattaaa 720
gttttaggtg cettggggga atgcccagac taacccagac taacccagac 780
ctctctgaat ccagagtcag atgcccagac taacccagac taacccagac 840
agatcatgga aaatcccttt gttcagagac taacccagac taacccagac 900
caattatggt caatccacaa atgcccagac taacccagac taacccagac 960

```

Asp	Gly	Ile	Asn	His	Asp	Val	Thr	Thr	Ala	Trp	Gly	Gly	Asp	Tyr
			650						655					660
Trp	Arg	Leu	Leu	Thr	Pro	Gly	Asp	Tyr	Met	Val	Thr	Ala	Ser	Ala
			665						670					675
Glu	Gly	Tyr	His	Ser	Val	Thr	Arg	Asn	Cys	Arg	Val	Thr	Phe	Glu
			680						685					690
Glu	Gly	Pro	Phe	Pro	Cys	Asn	Phe	Val	Leu	Thr	Lys	Thr	Pro	Lys
			695						700					705
Gln	Arg	Leu	Arg	Glu	Leu	Leu	Ala	Ala	Gly	Ala	Lys	Val	Pro	Pro
			710						715					720
Asp	Leu	Arg	Arg	Arg	Leu	Glu	Arg	Leu	Arg	Gly	Gln	Lys	Asp	
			725						730					

<210> 28

<211> 2080

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 088715CB1

<400> 28

tgaaggactt	tccaggacc	caaggccaca	cactggaagt	cttgagctg	aagggaagga	60
ctccctggcc	tccgcagccg	atcacatgaa	ggctgggtgcca	agtcctcctgc	tctccgtcct	120
cctggcacag	gtgtggctgg	lancoggett	ggcccccaagt	cttcagtcgc	cagagacccc	180
agccctcag	aaccagacca	gcagggtagt	gcaggctccc	agggagggaag	aggaagatga	240
gcaggaggcc	agcgaggaga	aggtctgtga	ggaagagaaa	gcttggtga	tgcccagcag	300
gcagcagctt	gccaaggaga	cttcaaacctt	cggtctcagc	ctgctgcgaa	agatctccat	360
gaggcagcat	ggcaacatgg	tcttctctcc	atttggcatg	tcttggcca	tgacaggett	420
gatgctgggg	gcccacaggc	cgactgaaac	ccagatcaag	agagggtccc	acttgcagge	480
cctgaagccc	accaagcccc	ggctcctgcc	tccctctttt	aagggaactca	gagagacctt	540
ctcccgcaac	ctggaaactgg	gctctctaca	ggggagtttt	gcttccatcc	acaaggattt	600
tcatgtccaa	gagactttct	tcaatttato	caagagggtat	tttgatacag	agtgcgtgoc	660
tatgaatttt	cgcaatgect	cacagyccaa	aeggtctatg	aatcattaca	ttascaasga	720
gaactggggg	aaaaltccca	aactgtttga	tgagatlaat	cctgaaccca	zattaattct	780
tgtggattac	atcttgttca	aagggaatg	gttgacccca	tttgaccctg	tcttcccgca	840
agtcagcact	tccagactgg	acaaaglacaa	gacacttaag	gtgcccataa	tgthcagttgc	900
agggcaagttt	gctccacact	ttgacaagaa	ttttcgttgt	catgtccca	aactgcctta	960
ccaaggaaat	gccaccatgc	tgggtggtct	cctggagaaa	atgggtgacc	acctcgcctt	1020
tgagaaactac	ctgaaccacag	acttggtgga	gaactggctc	agaaacatga	aaaccagaaa	1080
catgtgaagtt	ttctttccga	agttccagct	agatcagaag	tatgagatgc	atgagctgct	1140
tgggcagatg	ggaalccagaa	gaatctctc	accttttgc	gaacttctg	aactctcagc	1200
tactggaaag	aatctccaa	tatccagggt	tttacaaga	acagtgtatg	aagttgatga	1260
aaggggacct	gaggaagtgg	caggaatctt	gtcagaaatt	actgcttatt	ccatgcctcc	1320
tgctatccaa	gtggacoggc	catttcattt	catgatctat	gaagaacctt	ctggaatgct	1380
tctgtttctg	gtcagggtgg	tgaatccgac	tctcctataa	ttcaggacat	gcatagcaca	1440
cllctgtctg	tagtagatgc	tgaatctgag	gtatcaaaaca	cacacaggat	accagcaatg	1500
gatggcaggg	gagagtgttc	cttttgttct	tacttagttt	aggggtgtct	caaatcaata	1560
cagtagtccc	caattatctg	agggggtatc	atccaagac	ccccagcaga	tgcttgaaac	1620
ggtggacagt	gctgaacctt	atatataatt	ttctctacac	atccatacct	atgatcaagt	1680
ctaatttata	aattaggaac	agtaagagat	taacaataat	ancaacatta	agtaaatga	1740
gttacttgaa	cgcaagcaact	gcaataccat	aacagtcaaa	ctgattatag	agaaggctac	1800
caagtgaact	atgggcnagg	agcaatagaa	gtgtggnagc	atlgggcaag	ggggaagatc	1860
acatcctggg	tgggacagag	caggacgatg	caagattcca	tcccactact	cagaatggca	1920
tgctgcttaa	gaactttaga	ttgttttatt	ctggaalctt	tcaatttaag	tttttggacc	1980
atggttgacc	atggttaact	gagactgcag	aaagcaaaac	catggataag	ggaggactac	2040
tacaaaagca	ctaatttgat	aatattttt	taaaaaaaa			2080

<210> 29

<211> 2225

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 114551CB1

Ser Gly Leu Glu Asp Gly Asp Leu Tyr	140	Asp Gly Ala Trp Cys Ala	145	150
Glu Glu Gln Asp Ala Asp Pro Trp Phe	155	Gln Val Asp Ala Gly His	160	165
Pro Thr Arg Phe Ser Gly Val Ile Thr	170	Gln Gly Ser Asn Ser Val	175	180
Trp Arg Tyr Asp Trp Val Thr Ser Tyr	185	Lys Val Gln Phe Ser Asn	190	195
Asp Ser Arg Thr Trp Trp Gly Ser Arg	200	Asn His Ser Ser Gly Met	205	210
Asp Ala Val Phe Pro Ala Asn Ser Asp	215	Pro Glu Thr Pro Val Leu	220	225
Asn Leu Leu Pro Glu Pro Gln Val Ala	230	Arg Phe Ile Arg Leu Leu	235	240
Pro Gln Thr Trp Leu Gln Gly Gly Ala	245	Pro Cys Leu Arg Ala Glu	250	255
Ile Leu Ala Cys Pro Val Ser Asp Pro	260	Asn Asp Leu Phe Leu Glu	265	270
Ala Pro Ala Ser Gly Ser Ser Asp Pro	275	Leu Asp Phe Gln His His	280	285
Asn Tyr Lys Ala Met Arg Lys Leu Met	290	Lys Gln Val Gln Glu Gln	295	300
Cys Pro Asn Ile Thr Arg Ile Tyr Ser	305	Ile Gly Lys Ser Tyr Gln	310	315
Gly Leu Lys Leu Val Met Glu Met	320	Ser Asp Lys Pro Gly Glu	325	330
His Glu Leu Gly Glu Pro Glu Val Arg	335	Tyr Val Ala Gly Met His	340	345
Gly Asn Glu Ala Leu Gly Arg Glu Leu	350	Leu Leu Leu Leu Met Gln	355	360
Phe Leu Cys His Glu Phe Leu Arg Gly	365	Asn Pro Arg Val Thr Arg	370	375
Leu Leu Ser Glu Met Arg Ile His Leu	380	Leu Pro Ser Met Asn Pro	385	390
Asp Gly Tyr Glu Ile Ala Tyr His Arg	395	Gly Ser Glu Leu Val Gly	400	405
Trp Ala Glu Gly Arg Trp Asn Asn Gln	410	Ser Ile Asp Leu Asn His	415	420
Asn Phe Ala Asp Leu Asn Thr Pro Leu	425	Trp Glu Ala Gln Asp Asp	430	435
Gly Lys Val Pro His Ile Val Pro Asn	440	His His Leu Pro Leu Pro	445	450
Thr Tyr Tyr Thr Leu Pro Asn Ala Thr	455	Val Ala Pro Glu Thr Arg	460	465
Ala Val Ile Lys Trp Met Lys Arg Ile	470	Pro Phe Val Leu Ser Ala	475	480
Asn Leu His Gly Gly Glu Leu Val Val	485	Ser Tyr Pro Phe Asp Met	490	495
Thr Arg Thr Pro Trp Ala Ala Arg Glu	500	Leu Thr Pro Thr Pro Asp	505	510
Asp Ala Val Phe Arg Trp Leu Ser Thr	515	Val Tyr Ala Gly Ser Asn	520	525
Leu Ala Met Gln Asp Thr Ser Arg Arg	530	Pro Cys His Ser Gln Asp	535	540
Phe Ser Val His Gly Asn Ile Ile Asn	545	Gly Ala Asp Trp His Thr	550	555
Val Pro Gly Ser Met Asn Asp Phe Ser	560	Leu His Thr Asn Cys	565	570
Phe Glu Val Thr Val Glu Leu Ser Cys	575	Asp Lys Phe Pro His Glu	580	585
Asn Glu Leu Pro Gln Glu Trp Glu Asn	590	Asn Lys Asp Ala Leu Leu	595	600
Thr Tyr Leu Glu Gln Val Arg Met Gly	605	Ile Ala Gly Val Val Arg	610	615
Asp Lys Asp Thr Glu Leu Gly Ile Ala	620	Asp Ala Val Ile Ala Val	625	630
	635		640	645

Gly	Leu	Met	Val	Ser	Gly	Tyr	Ala	Val	Thr	Gly	Ala	Val	Leu	Gly	470	475
Gln	Asp	Arg	Leu	Ile	Asn	Tyr	Ala	Thr	Asn	Gly	Ala	Lys	Phe	Leu	480	485
Lys	Arg	His	Met	Phe	Asp	Val	Ala	Ser	Gly	Arg	Leu	Met	Arg	Thr	490	495
Cys	Tyr	Thr	Gly	Pro	Gly	Gly	Thr	Val	Glu	His	Ser	Asn	Pro	Pro	500	505
Cys	Trp	Gly	Phe	Leu	Glu	Asp	Tyr	Ala	Phe	Val	Val	Arg	Gly	Leu	510	515
Leu	Asp	Leu	Tyr	Glu	Ala	Ser	Gln	Glu	Ser	Ala	Trp	Leu	Glu	Trp	520	525
Ala	Leu	Arg	Leu	Gln	Asp	Thr	Gln	Asp	Arg	Leu	Phe	Trp	Asp	Ser	530	535
Gln	Gly	Gly	Gly	Tyr	Phe	Cys	Ser	Glu	Ala	Glu	Leu	Gly	Ala	Gly	540	545
Leu	Pro	Leu	Arg	Leu	Lys	Asp	Asp	Gln	Asp	Gly	Ala	Glu	Pro	Ser	550	555
Ala	Asn	Ser	Val	Ser	Ala	His	Asn	Leu	Leu	Arg	Leu	His	Gly	Phe	560	565
Thr	Gly	His	Lys	Asp	Trp	Met	Asp	Lys	Cys	Val	Cys	Leu	Leu	Thr	570	575
Ala	Phe	Ser	Glu	Arg	Met	Arg	Arg	Val	Pro	Val	Ala	Leu	Pro	Glu	580	585
Met	Val	Arg	Ala	Leu	Ser	Ala	Gln	Gln	Gln	Thr	Leu	Lys	Gln	Ile	590	595
Val	Ile	Cys	Gly	Asp	Arg	Gln	Ala	Lys	Asp	Thr	Lys	Ala	Leu	Val	600	605
Gln	Cys	Val	His	Ser	Val	Tyr	Ile	Pro	Asn	Lys	Val	Leu	Ile	Leu	610	615
Ala	Asp	Gly	Asp	Pro	Ser	Ser	Phe	Leu	Ser	Arg	Gln	Leu	Pro	Phe	620	625
Leu	Ser	Thr	Leu	Arg	Arg	Leu	Glu	Asp	Gln	Ala	Thr	Ala	Tyr	Val	630	635
Cys	Glu	Asn	Gln	Ala	Cys	Ser	Val	Pro	Ile	Thr	Asp	Pro	Cys	Glu	640	645
Leu	Arg	Lys	Leu	Leu	His	Pro			730						650	655

<210> 27

<211> 734

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5583922CD1

<400> 27

Met	Trp	Gly	Leu	Leu	Leu	Ala	Leu	Ala	Ala	Phe	Ala	Pro	Ala	Val	1	5
Gly	Pro	Ala	Leu	Gly	Ala	Pro	Arg	Asn	Ser	Val	Leu	Gly	Leu	Ala	10	15
Gln	Pro	Gly	Thr	Thr	Lys	Val	Pro	Gly	Ser	Thr	Pro	Ala	Leu	His	20	25
Ser	Ser	Pro	Ala	Gln	Pro	Pro	Ala	Glu	Thr	Ala	Asn	Gly	Thr	Ser	30	35
Glu	Gln	His	Val	Arg	Ile	Arg	Val	Ile	Lys	Lys	Lys	Lys	Val	Ile	40	45
Met	Lys	Lys	Arg	Lys	Lys	Leu	Thr	Leu	Thr	Arg	Pro	Thr	Pro	Leu	50	55
Val	Thr	Ala	Gly	Pro	Leu	Val	Thr	Pro	Thr	Pro	Ala	Gly	Thr	Leu	60	65
Asp	Pro	Ala	Glu	Lys	Gln	Glu	Thr	Gly	Cys	Pro	Pro	Leu	Gly	Leu	70	75
Glu	Ser	Leu	Arg	Val	Ser	Asp	Ser	Arg	Leu	Glu	Ala	Ser	Ser	Ser	80	85
Gln	Ser	Phe	Gly	Leu	Gly	Pro	His	Arg	Gly	Arg	Leu	Asn	Ile	Gln	90	95

<220>

<221> misc_feature

<223> Inocyte ID No: 5267783CD1

<400> 26

Met	Pro	Ala	Gly	Gly	Lys	Gly	Ser	His	Pro	Ser	Ser	Thr	Pro	Gln
1				5					10					15
Arg	Val	Pro	Asn	Arg	Leu	Ile	His	Glu	Lys	Ser	Pro	Tyr	Leu	Leu
				20					25					30
Gln	His	Ala	Tyr	Asn	Pro	Val	Asp	Trp	Tyr	Pro	Trp	Gly	Glu	Glu
				35					40					45
Ala	Phe	Asp	Lys	Ala	Arg	Lys	Glu	Asn	Lys	Pro	Ile	Phe	Leu	Ser
				50					55					60
Val	Gly	Tyr	Ser	Thr	Cys	His	Trp	Cys	His	Met	Met	Glu	Glu	Glu
				65					70					75
Ser	Phe	Gln	Asn	Glu	Glu	Ile	Gly	Arg	Leu	Leu	Ser	Glu	Asp	Phe
				80					85					90
Val	Ser	Val	Lys	Val	Asp	Arg	Glu	Glu	Arg	Pro	Asp	Val	Asp	Lys
				95					100					105
Val	Tyr	Met	Thr	Phe	Val	Gln	Ala	Thr	Ser	Ser	Gly	Gly	Gly	Trp
				110					115					120
Pro	Met	Asn	Val	Trp	Leu	Thr	Pro	Asn	Leu	Gln	Pro	Phe	Val	Gly
				125					130					135
Gly	Thr	Tyr	Phe	Pro	Pro	Glu	Asp	Gly	Leu	Thr	Arg	Val	Gly	Phe
				140					145					150
Arg	Thr	Val	Leu	Leu	Arg	Ile	Arg	Glu	Gln	Trp	Lys	Gln	Asn	Lys
				155					160					165
Asn	Thr	Leu	Leu	Glu	Asn	Ser	Gln	Arg	Val	Thr	Thr	Ala	Leu	Leu
				170					175					180
Ala	Arg	Ser	Glu	Ile	Ser	Val	Gly	Asp	Arg	Gln	Leu	Pro	Pro	Ser
				185					190					195
Ala	Ala	Thr	Val	Asn	Asn	Arg	Cys	Phe	Gln	Gln	Leu	Asp	Glu	Gly
				200					205					210
Tyr	Asp	Glu	Glu	Tyr	Gly	Gly	Phe	Ala	Glu	Ala	Pro	Lys	Phe	Pro
				215					220					225
Thr	Pro	Val	Ile	Leu	Ser	Phe	Leu	Phe	Ser	Tyr	Trp	Leu	Ser	His
				230					235					240
Arg	Leu	Thr	Gln	Asp	Gly	Ser	Arg	Ala	Gln	Gln	Met	Ala	Leu	His
				245					250					255
Thr	Leu	Lys	Met	Met	Ala	Asn	Gly	Gly	Ile	Arg	Asp	His	Val	Gly
				260					265					270
Gln	Gly	Phe	His	Arg	Tyr	Ser	Thr	Asp	Arg	Gln	Trp	His	Val	Pro
				275					280					285
His	Phe	Glu	Lys	Met	Leu	Tyr	Asp	Gln	Ala	Gln	Leu	Ala	Val	Ala
				290					295					300
Tyr	Ser	Gln	Ala	Phe	Gln	Leu	Ser	Gly	Asp	Glu	Phe	Tyr	Ser	Asp
				305					310					315
Val	Ala	Lys	Gly	Ile	Leu	Gln	Tyr	Val	Ala	Arg	Ser	Leu	Ser	His
				320					325					330
Arg	Ser	Gly	Gly	Phe	Tyr	Ser	Ala	Glu	Asp	Ala	Asp	Ser	Pro	Pro
				335					340					345
Glu	Arg	Gly	Gln	Arg	Pro	Lys	Glu	Gly	Ala	Tyr	Tyr	Val	Trp	Thr
				350					355					360
Val	Lys	Glu	Val	Gln	Gln	Leu	Leu	Pro	Glu	Pro	Val	Leu	Gly	Ala
				365					370					375
Thr	Glu	Pro	Leu	Thr	Ser	Gly	Gln	Leu	Leu	Met	Lys	His	Tyr	Gly
				380					385					390
Leu	Thr	Glu	Ala	Gly	Asn	Ile	Ser	Pro	Ser	Gln	Asp	Pro	Lys	Gly
				395					400					405
Glu	Leu	Gln	Gly	Gln	Asn	Val	Leu	Thr	Val	Arg	Tyr	Ser	Leu	Glu
				410					415					420
Leu	Thr	Ala	Ala	Arg	Phe	Gly	Leu	Asp	Val	Glu	Ala	Val	Arg	Thr
				425					430					435
Leu	Leu	Asn	Ser	Gly	Leu	Glu	Lys	Leu	Phe	Gln	Ala	Arg	Lys	His
				440					445					450
Arg	Pro	Lys	Pro	His	Leu	Asp	Ser	Lys	Met	Leu	Ala	Ala	Trp	Asn
				455					460					465

Phe	Ser	Ala	Asn	Phe	Thr	Asp	Ser	Val	Thr	Thr	Gly	Arg	Gln	Ile	
			170						175					180	
Asn	Asp	Tyr	Leu	Arg	Arg	Gln	Thr	Tyr	Gly	Gln	Val	Val	Asp	Cys	
			185						190					195	
Leu	Pro	Glu	Phe	Ser	Gln	Asp	Thr	Phe	Met	Val	Leu	Ala	Asn	Tyr	
			200						205					210	
Ile	Phe	Phe	Lys	Ala	Lys	Trp	Lys	His	Pro	Phe	Ser	Arg	Tyr	Gln	
			215						220					225	
Thr	Gln	Lys	Gln	Ala	Ser	Phe	Phe	Val	Asp	Glu	Arg	Thr	Ser	Leu	
			230						235					240	
Gln	Val	Pro	Met	Met	His	Gln	Lys	Glu	Met	His	Arg	Phe	Leu	Tyr	
			245						250					255	
Asp	Gln	Asp	Leu	Ala	Cys	Thr	Val	Leu	Gln	Ile	Glu	Tyr	Arg	Gly	
			260						265					270	
Asn	Ala	Leu	Ala	Leu	Leu	Val	Leu	Pro	Asp	Pro	Gly	Lys	Met	Lys	
			275						280					285	
Gln	Val	Glu	Ala	Ala	Leu	Gln	Pro	Gln	Thr	Leu	Arg	Lys	Trp	Gly	
			290						295					300	
Gln	Leu	Leu	Leu	Pro	Ser	Leu	Leu	Asp	Leu	His	Leu	Pro	Arg	Phe	
			305						310					315	
Ser	Ile	Ser	Gly	Thr	Tyr	Asn	Leu	Glu	Asp	Ile	Leu	Pro	Gln	Ile	
			320						325					330	
Gly	Leu	Thr	Asn	Ile	Leu	Asn	Leu	Glu	Ala	Asp	Phe	Ser	Gly	Val	
			335						340					345	
Thr	Gly	Gln	Leu	Asn	Lys	Thr	Ile	Ser	Lys	Val	Ser	His	Lys	Ala	
			350						355					360	
Met	Val	Asp	Met	Ser	Glu	Lys	Gly	Thr	Glu	Ala	Gly	Ala	Ala	Ser	
			365						370					375	
Gly	Leu	Leu	Ser	Gln	Pro	Pro	Ser	Leu	Asn	Thr	Met	Ser	Asp	Ile	
			380						385					390	
His	Ala	His	Phe	Asn	Arg	Pro	Phe	Leu	Leu	Leu	Leu	Trp	Glu	Val	
			395						400					405	
Thr	Thr	Gln	Ser	Leu	Leu	Phe	Leu	Gly	Lys	Val	Val	Asn	Pro	Val	
			410						415					420	

Ala Gly

<210> 25

<211> 114

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5208004CD1

<400> 25

Met	Arg	Trp	Arg	Gln	Arg	Ser	Phe	Leu	Leu	Arg	Leu	Phe	Leu	Gly	
1				5					10					15	
Ser	Leu	Arg	Gly	Gly	Gln	His	His	Pro	Pro	Leu	Thr	Leu	Pro	Ser	
				20					25					30	
Ala	Ser	Ser	Leu	Pro	Phe	Ser	Thr	Leu	Ser	Leu	Leu	Leu	Ala	Ser	
				35					40					45	
Ser	Leu	Ser	Cys	Cys	Leu	Val	Ser	Pro	Cys	Pro	Lys	Thr	Pro	Gly	
				50					55					60	
Ser	Phe	Val	Leu	Leu	Pro	Trp	Pro	Pro	Pro	Arg	Arg	Arg	Ser	Gln	
				65					70					75	
Ala	Pro	Ser	Pro	Pro	Arg	Gly	Ile	His	Thr	Thr	Gly	Ser	Cys	Trp	
				80					85					90	
Gly	Trp	Gly	Ser	Pro	Ala	Gly	Phe	Leu	Met	Pro	Cys	Ala	Gln	Gly	
				95					100					105	
Ser	Ala	Ala	Val	Ile	Phe	Gly	Leu	Ser							
				110											

<210> 26

<211> 742

<212> PRT

<213> Homo sapiens

Lys	Glu	Asn	Lys	Asp	Asp	Leu	Asn	His	Val	Asp	Leu	Asn	Val	Cys	
				95					100					105	
Thr	Ser	Phe	Ser	Gly	Pro	Gly	Arg	Ser	Gly	Met	Ala	Leu	Met	Glu	
				110					115					120	
Val	Asn	Leu	Leu	Ser	Gly	Phe	Met	Val	Pro	Ser	Glu	Ala	Ile	Ser	
				125					130					135	
Leu	Ser	Glu	Thr	Val	Lys	Lys	Val	Glu	Tyr	Asp	His	Gly	Lys	Leu	
				140					145					150	
Asn	Leu	Tyr	Leu	Asp	Ser	Val	Asn	Glu	Thr	Gln	Phe	Cys	Val	Asn	
				155					160					165	
Ile	Pro	Ala	Val	Arg	Asn	Phe	Lys	Val	Ser	Asn	Thr	Gln	Asp	Ala	
				170					175					180	
Ser	Val	Ser	Ile	Val	Asp	Tyr	Tyr	Glu	Pro	Arg	Arg	Gln	Ala	Val	
				185					190					195	
Arg	Ser	Tyr	Asn	Ser	Glu	Val	Lys	Leu	Ser	Ser	Cys	Asp	Leu	Cys	
				200					205					210	
Ser	Asp	Val	Gln	Gly	Cys	Arg	Pro	Cys	Glu	Asp	Gly	Ala	Ser	Gly	
				215					220					225	
Ser	His	His	His	Ser	Ser	Val	Ile	Phe	Ile	Phe	Cys	Phe	Lys	Leu	
				230					235					240	
Leu	Tyr	Phe	Met	Glu	Leu	Trp	Leu								
				245											

<210> 23
 <211> 520
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3683861CD1

<400>	23														
Met	Val	Ala	Arg	Val	Gly	Leu	Leu	Leu	Arg	Ala	Leu	Gln	Leu	Leu	
1				5					10					15	
Leu	Trp	Gly	His	Leu	Asp	Ala	Gln	Pro	Ala	Glu	Arg	Gly	Gly	Gln	
				20					25					30	
Glu	Leu	Arg	Lys	Glu	Ala	Glu	Ala	Phe	Leu	Glu	Lys	Tyr	Gly	Tyr	
				35					40					45	
Leu	Asn	Glu	Gln	Val	Pro	Lys	Ala	Pro	Thr	Ser	Thr	Arg	Phe	Ser	
				50					55					60	
Asp	Ala	Ile	Arg	Ala	Phe	Gln	Trp	Val	Ser	Gln	Leu	Pro	Val	Ser	
				65					70					75	
Gly	Val	Leu	Asp	Arg	Ala	Thr	Leu	Arg	Gln	Met	Thr	Arg	Pro	Arg	
				80					85					90	
Cys	Gly	Val	Thr	Asp	Thr	Asn	Ser	Tyr	Ala	Ala	Trp	Ala	Glu	Arg	
				95					100					105	
Ile	Ser	Asp	Leu	Phe	Ala	Arg	His	Arg	Thr	Lys	Met	Arg	Arg	Lys	
				110					115					120	
Lys	Arg	Phe	Ala	Lys	Gln	Gly	Asn	Lys	Trp	Tyr	Lys	Gln	His	Leu	
				125					130					135	
Ser	Tyr	Arg	Leu	Val	Asn	Trp	Pro	Glu	His	Leu	Pro	Glu	Pro	Ala	
				140					145					150	
Val	Arg	Gly	Ala	Val	Arg	Ala	Ala	Phe	Gln	Leu	Trp	Ser	Asn	Val	
				155					160					165	
Ser	Ala	Leu	Glu	Phe	Trp	Glu	Ala	Pro	Ala	Thr	Gly	Pro	Ala	Asp	
				170					175					180	
Ile	Arg	Leu	Thr	Phe	Phe	Gln	Gly	Asp	His	Asn	Asp	Gly	Leu	Gly	
				185					190					195	
Asp	Ala	Phe	Asp	Gly	Pro	Gly	Gly	Ala	Leu	Ala	His	Ala	Phe	Leu	
				200					205					210	
Pro	Arg	Arg	Gly	Glu	Ala	His	Phe	Asp	Gln	Asp	Glu	Arg	Trp	Ser	
				215					220					225	
Leu	Ser	Arg	Arg	Arg	Gly	Arg	Asn	Leu	Phe	Val	Val	Leu	Ala	His	
				230					235					240	
Glu	Ile	Gly	His	Thr	Leu	Gly	Leu	Thr	His	Ser	Pro	Ala	Pro	Arg	
				245					250					255	
Ala	Leu	Met	Ala	Pro	Tyr	Tyr	Lys	Arg	Leu	Gly	Arg	Asp	Ala	Leu	

Leu Ser Trp Asp	260	Val Leu Ala Val	265	Gln Ser Leu Tyr Gly	270
Asp	275	Val Ala Val Gln	280	Lys	285
Pro Leu Gly Gly	290	Val Ala Val Gln	295	Leu Pro Gly Lys Leu	300
Thr Asp Phe Glu	305	Trp Asp Ser Tyr	310	Ser Pro Gln Gly Arg	315
Pro Glu Thr Gln	320	Pro Lys Tyr Cys	325	His Ser Ser Phe Asp	330
Ile Thr Val Asp	335	Arg Gln Gln Gln Leu	340	Tyr Ile Phe Lys Gly	345
His Phe Trp Glu	350	Val Ala Ala Asp Gly	355	Asn Val Ser Glu Pro	360
Pro Leu Gln Glu	365	Arg Trp Val Gly Leu	370	Pro Asn Ile Glu Ala	375
Ala Ala Val Ser	380	Leu Asn Asp Gly Asp	385	Phe Tyr Phe Phe Lys	390
Gly Arg Cys Trp	395	Arg Phe Arg Gly Pro	400	Lys Pro Val Trp Gly	405
Pro Gln Leu Cys	410	Arg Ala Gly Gly Leu	415	Pro Arg His Pro Asp	420
Ala Leu Phe Phe	425	Pro Leu Arg Arg	430	Leu Ile Leu Phe Lys	435
Ala Arg Tyr Tyr	440	Val Leu Ala Arg Gly	445	Gly Leu Gln Val Glu	450
Tyr Tyr Pro Arg	455	Ser Leu Gln Asp Trp	460	Gly Ile Pro Glu	465
Val Ser Gly Ala	470	Leu Pro Arg Pro Asp	475	Gly Ser Ile Ile Phe	480
Arg Asp Asp Arg	485	Tyr Trp Arg Leu Asp	490	Gln Ala Lys Leu Gln	495
Thr Thr Ser Gly	500	Arg Trp Ala Thr Glu	505	Leu Pro Trp Met Gly	510
Trp His Ala Asn	515	Ser Gly Ser Ala Leu	520	Phe	

<210> 24

<211> 422

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4993873CD1

<400> 24

Met Gly Pro Ala Trp	1	Leu Trp Leu Leu Gly	10	Thr Gly Ile Leu Ala	15
Ser Val His Cys Gln	20	Pro Leu Leu Ala His	25	Gly Asp Lys Ser Leu	30
Gln Gly Pro Gln Pro	35	Pro Arg His Gln Leu	40	Ser Glu Pro Ala Pro	45
Ala Tyr His Arg Ile	50	Thr Pro Thr Ile Thr	55	Asn Phe Ala Leu Arg	60
Leu Tyr Lys Glu Leu	65	Ala Ala Asp Ala Pro	70	Gly Asn Ile Phe Phe	75
Ser Pro Val Ser Ile	80	Ser Thr Thr Leu Ala	85	Leu Leu Ser Leu Gly	90
Ala Gln Ala Asn Thr	95	Ser Ala Leu Ile Leu	100	Glu Gly Leu Gly Phe	105
Asn Leu Thr Glu Thr	110	Pro Glu Ala Asp Ile	115	His Gln Gly Phe Arg	120
Ser Leu Leu His Thr	125	Leu Ala Leu Pro Ser	130	Pro Lys Leu Glu Leu	135
Lys Val Gly Asn Ser	140	Leu Phe Leu Asp Lys	145	Arg Leu Lys Pro Arg	150
Gln His Tyr Leu Asp	155	Ser Ile Lys Glu Leu	160	Tyr Gly Ala Phe Ala	165


```
<210> 21
<211> 94
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> misc_feature  
<223> Incyte ID No: 3092341CD1
```

```
<210> 22
<211> 248
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> misc_feature  
<223> Incyte ID No: 36580340D1
```

20/44

His	Val	Gly	Leu	Met	Leu	Lys	Glu	Asn	His	Cys	Leu	Val	Ala	Leu	
				200					205					210	
His	Met	Cys	Lys	His	Asp	Ile	Lys	Asn	Ser	Gly	Ile	Gln	Gln	Leu	
				215					220					225	
Cys	Asp	Ala	Leu	Tyr	Leu	Asn	Ser	Ser	Leu	Arg	Tyr	Leu	Asp	Val	
				230					235					240	
Ser	Cys	Asn	Lys	Ile	Thr	His	Asp	Gly	Met	Val	Tyr	Leu	Ala	Asp	
				245					250					255	
Val	Leu	Lys	Ser	Asn	Thr	Thr	Leu	Glu	Val	Ile	Asp	Leu	Ser	Phe	
				260					265					270	
Asn	Arg	Ile	Glu	Asn	Ala	Gly	Ala	Asn	Tyr	Leu	Ser	Glu	Thr	Leu	
				275					280					285	
Thr	Ser	His	Asn	Arg	Ser	Leu	Lys	Ala	Leu	Ser	Val	Val	Ser	Asn	
				290					295					300	
Asn	Ile	Glu	Gly	Glu	Gly	Leu	Val	Ala	Leu	Ser	Gln	Ser	Met	Lys	
				305					310					315	
Thr	Asn	Leu	Thr	Phe	Ser	His	Ile	Tyr	Ile	Trp	Gly	Asn	Lys	Phe	
				320					325					330	
Asp	Glu	Ala	Thr	Cys	Ile	Ala	Tyr	Ser	Asp	Leu	Ile	Gln	Met	Gly	
				335					340					345	
Cys	Leu	Lys	Pro	Asp	Asn	Thr	Asp	Val	Glu	Pro	Phe	Val	Val	Asp	
				350					355					360	
Gly	Arg	Val	Tyr	Leu	Ala	Glu	Val	Ser	Asn	Gly	Leu	Lys	Lys	His	
				365					370					375	
Tyr	Tyr	Trp	Thr	Ser	Thr	Tyr	Gly	Glu	Ser	Tyr	Asp	His	Ser	Ser	
				380					385					390	
Asn	Ala	Gly	Phe	Ala	Leu	Val	Pro	Val	Gly	Gln	Gln	Pro			
				395					400						

<210> 20

<211> 372

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2754960CD1

<400> 20

Met	Ser	Lys	Ala	Phe	Gly	Leu	Leu	Arg	Gln	Ile	Cys	Gln	Ser	Ile	
1				5					10					15	
Leu	Ala	Glu	Ser	Ser	Gln	Ser	Pro	Ala	Asp	Leu	Glu	Glu	Lys	Lys	
				20					25					30	
Glu	Glu	Asp	Ser	Asn	Met	Lys	Arg	Glu	Gln	Pro	Arg	Glu	Arg	Pro	
				35					40					45	
Arg	Ala	Trp	Asp	Tyr	Pro	His	Gly	Leu	Val	Gly	Leu	His	Asn	Ile	
				50					55					60	
Gly	Gln	Thr	Cys	Cys	Leu	Asn	Ser	Leu	Ile	Gln	Val	Phe	Val	Met	
				65					70					75	
Asn	Val	Asp	Phe	Thr	Arg	Ile	Leu	Lys	Arg	Ile	Thr	Val	Pro	Arg	
				80					85					90	
Gly	Ala	Asp	Glu	Gln	Arg	Arg	Ser	Val	Pro	Phe	Gln	Met	Leu	Leu	
				95					100					105	
Leu	Leu	Glu	Lys	Met	Gln	Asp	Ser	Arg	Gln	Lys	Ala	Val	Arg	Pro	
				110					115					120	
Leu	Glu	Leu	Ala	Tyr	Cys	Leu	Gln	Lys	Cys	Asn	Val	Pro	Leu	Phe	
				125					130					135	
Val	Gln	His	Asp	Ala	Ala	Gln	Leu	Tyr	Leu	Lys	Leu	Trp	Asn	Leu	
				140					145					150	
Ile	Lys	Asp	Gln	Ile	Thr	Asp	Val	His	Leu	Val	Glu	Arg	Leu	Gln	
				155					160					165	
Ala	Leu	Tyr	Thr	Ile	Arg	Val	Lys	Asp	Ser	Leu	Ile	Cys	Val	Asp	
				170					175					180	
Cys	Ala	Met	Glu	Ser	Ser	Arg	Asn	Ser	Ser	Met	Leu	Thr	Leu	Pro	
				185					190					195	
Leu	Ser	Leu	Phe	Asp	Val	Asp	Ser	Lys	Pro	Leu	Lys	Thr	Leu	Glu	
				200					205					210	
Asp	Ala	Leu	His	Cys	Phe	Phe	Gln	Pro	Arg	Glu	Leu	Ser	Ser	Lys	

<220>

<221> misc_feature

<223> Incyte ID No: 411344CD1

<400> 14

Met	Ala	Ser	Met	Gln	Lys	Arg	Leu	Gln	Lys	Glu	Leu	Leu	Ala	Leu	
1				5					10					15	
Gln	Asn	Asp	Pro	Pro	Pro	Gly	Met	Thr	Leu	Asn	Glu	Lys	Ser	Val	
				20					25					30	
Gln	Asn	Ser	Ile	Thr	Gln	Trp	Ile	Val	Asp	Met	Glu	Gly	Ala	Pro	
				35					40					45	
Gly	Thr	Leu	Tyr	Glu	Gly	Glu	Lys	Phe	Gln	Leu	Leu	Phe	Lys	Phe	
				50					55					60	
Ser	Ser	Arg	Tyr	Pro	Phe	Asp	Ser	Pro	Gln	Val	Met	Phe	Thr	Gly	
				65					70					75	
Glu	Asn	Ile	Pro	Val	His	Pro	His	Val	Tyr	Ser	Asn	Gly	His	Ile	
				80					85					90	
Cys	Leu	Ser	Ile	Leu	Thr	Glu	Asp	Trp	Ser	Pro	Ala	Leu	Ser	Val	
				95					100					105	
Gln	Ser	Val	Cys	Leu	Ser	Ile	Ile	Ser	Met	Leu	Ser	Ser	Cys	Lys	
				110					115					120	
Glu	Lys	Arg	Arg	Pro	Pro	Asp	Asn	Ser	Phe	Tyr	Val	Arg	Thr	Cys	
				125					130					135	
Asn	Lys	Asn	Pro	Lys	Lys	Thr	Lys	Trp	Trp	Tyr	His	Asp	Asp	Thr	
				140					145					150	

Cys

<210> 15

<211> 362

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1256390CD1

<400> 15

Met	Leu	Val	Pro	Gly	Gly	Leu	Gly	Tyr	Asp	Arg	Ser	Leu	Ala	Gln	
1				5					10					15	
His	Arg	Gln	Glu	Ile	Val	Asp	Lys	Ser	Val	Ser	Pro	Trp	Ser	Leu	
				20					25					30	
Glu	Thr	Tyr	Ser	Tyr	Asn	Ile	Tyr	His	Pro	Met	Gly	Glu	Ile	Tyr	
				35					40					45	
Glu	Trp	Met	Arg	Glu	Ile	Ser	Glu	Lys	Tyr	Lys	Glu	Val	Val	Thr	
				50					55					60	
Gln	His	Phe	Leu	Gly	Val	Thr	Tyr	Glu	Thr	His	Pro	Met	Tyr	Tyr	
				65					70					75	
Leu	Lys	Ile	Ser	Gln	Pro	Ser	Gly	Asn	Pro	Lys	Lys	Ile	Ile	Trp	
				80					85					90	
Met	Asp	Cys	Gly	Ile	His	Ala	Arg	Glu	Trp	Ile	Ala	Pro	Ala	Phe	
				95					100					105	
Cys	Gln	Trp	Phe	Val	Lys	Glu	Ile	Leu	Gln	Asn	His	Lys	Asp	Asn	
				110					115					120	
Ser	Ser	Ile	Arg	Lys	Leu	Leu	Arg	Asn	Leu	Asp	Phe	Tyr	Val	Leu	
				125					130					135	
Pro	Val	Leu	Asn	Ile	Asp	Gly	Tyr	Ile	Tyr	Thr	Trp	Thr	Thr	Asp	
				140					145					150	
Arg	Leu	Trp	Arg	Lys	Ser	Arg	Ser	Pro	His	Asn	Asn	Gly	Thr	Cys	
				155					160					165	
Phe	Gly	Thr	Asp	Leu	Asn	Arg	Asn	Phe	Asn	Ala	Ser	Trp	Cys	Ser	
				170					175					180	
Ile	Gly	Ala	Ser	Arg	Asn	Cys	Gln	Asp	Gln	Thr	Phe	Cys	Gly	Thr	
				185					190					195	
Gly	Pro	Val	Ser	Glu	Pro	Glu	Thr	Lys	Ala	Val	Ala	Ser	Phe	Ile	
				200					205					210	
Glu	Ser	Lys	Lys	Asp	Asp	Ile	Leu	Cys	Phe	Leu	Thr	Met	His	Ser	
				215					220					225	

Leu Leu Phe Tyr Glu Arg Val Leu Ser Arg Met Gln His Gln Ser
 500 505 510
 Gln Glu Cys Lys Ser Glu Glu
 515

<210> 13

<211> 346

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5853753CD1

<400> 13

Met Val Glu Lys Glu Glu Ala Gly Gly Gly Ile Ser Glu Glu Glu
 1 5 10 15
 Ala Ala Gln Tyr Asp Arg Gln Ile Arg Leu Trp Gly Leu Glu Ala
 20 25 30
 Gln Lys Arg Leu Arg Ala Ser Arg Val Leu Leu Val Gly Leu Lys
 35 40 45
 Gly Leu Gly Ala Glu Ile Ala Lys Asn Leu Ile Leu Ala Gly Val
 50 55 60
 Lys Gly Leu Thr Met Leu Asp His Glu Gln Val Thr Pro Glu Asp
 65 70 75
 Pro Gly Ala Gln Phe Leu Ile Arg Thr Gly Ser Val Gly Arg Asn
 80 85 90
 Arg Ala Glu Ala Ser Leu Glu Arg Ala Gln Asn Leu Asn Pro Met
 95 100 105
 Val Asp Val Lys Val Asp Thr Glu Asp Ile Glu Lys Lys Pro Glu
 110 115 120
 Ser Phe Phe Thr Gln Phe Asp Ala Val Cys Leu Thr Cys Cys Ser
 125 130 135
 Arg Asp Val Ile Val Lys Val Asp Gln Ile Cys His Lys Asn Ser
 140 145 150
 Ile Lys Phe Phe Thr Gly Asp Val Phe Gly Tyr His Gly Tyr Thr
 155 160 165
 Phe Ala Asn Leu Gly Glu His Gln Phe Val Glu Glu Lys Thr Lys
 170 175 180
 Val Ala Lys Val Ser Gln Gly Val Glu Asp Gly Pro Asp Thr Lys
 185 190 195
 Arg Ala Lys Leu Asp Ser Ser Glu Thr Thr Met Val Lys Lys Lys
 200 205 210
 Val Val Phe Cys Pro Val Lys Glu Ala Leu Glu Val Asp Trp Ser
 215 220 225
 Ser Glu Lys Ala Lys Ala Ala Leu Lys Arg Thr Thr Ser Asp Tyr
 230 235 240
 Phe Leu Leu Gln Val Leu Leu Lys Phe Arg Thr Asp Lys Gly Arg
 245 250 255
 Asp Pro Ser Ser Asp Thr Tyr Glu Glu Asp Ser Glu Leu Leu Leu
 260 265 270
 Gln Ile Arg Asn Asp Val Leu Asp Ser Leu Gly Ile Ser Pro Asp
 275 280 285
 Leu Leu Pro Glu Asp Phe Val Arg Tyr Cys Phe Ser Glu Met Ala
 290 295 300
 Pro Val Cys Ala Val Val Gly Gly Ile Leu Ala Gln Glu Ile Val
 305 310 315
 Lys Ala Leu Ser Gln Arg Asp Pro Pro His Asn Asn Phe Phe Phe
 320 325 330
 Phe Asp Gly Met Lys Gly Asn Gly Ile Val Glu Cys Leu Gly Pro
 335 340 345

Lys

<210> 14

<211> 151

<212> PRT

<213> Homo sapiens

Tyr	Gly	Gln	Leu	Ile	Leu	Thr	Pro	Tyr	Gly	Tyr	Thr	Lys	Asn	Lys	
				230					235					240	
Ser	Ser	Asn	His	Pro	Glu	Met	Ile	Gln	Val	Gly	Gln	Lys	Ala	Ala	
				245					250					255	
Asn	Ala	Leu	Lys	Ala	Lys	Tyr	Gly	Thr	Asn	Tyr	Arg	Val	Gly	Ser	
				260					265					270	
Ser	Ala	Asp	Ile	Leu	Tyr	Ala	Ser	Ser	Gly	Ser	Ser	Arg	Asp	Trp	
				275					280					285	
Ala	Arg	Asp	Ile	Gly	Ile	Pro	Phe	Ser	Tyr	Thr	Phe	Glu	Leu	Arg	
				290					295					300	
Asp	Ser	Gly	Thr	Tyr	Gly	Phe	Val	Leu	Pro	Glu	Ala	Gln	Ile	Gln	
				305					310					315	
Pro	Thr	Cys	Glu	Glu	Thr	Met	Glu	Ala	Val	Leu	Ser	Val	Leu	Asp	
				320					325					330	
Asp	Val	Tyr	Ala	Lys	His	Trp	His	Ser	Asp	Ser	Ala	Gly	Arg	Val	
				335					340					345	
Thr	Ser	Ala	Thr	Met	Leu	Leu	Gly	Leu	Leu	Val	Ser	Cys	Met	Ser	
				350					355					360	

Ileu Leu

<210> 16
 <211> 123
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1786774CD1

<400> 16															
Met	Ser	Gly	Glu	Glu	Leu	Ser	Glu	Ser	Thr	Pro	Glu	Pro	Gln	Lys	
1				5					10					15	
Glu	Ile	Ser	Glu	Ser	Leu	Ser	Val	Thr	Arg	Asp	Gln	Asp	Glu	Asp	
				20					25					30	
Asp	Lys	Ala	Pro	Glu	Pro	Thr	Trp	Ala	Asp	Asp	Leu	Pro	Ala	Thr	
				35					40					45	
Thr	Ser	Ser	Glu	Ala	Thr	Thr	Thr	Pro	Arg	Pro	Leu	Leu	Ser	Thr	
				50					55					60	
Pro	Val	Asp	Gly	Ala	Glu	Asp	Pro	Arg	Cys	Leu	Glu	Ala	Leu	Lys	
				65					70					75	
Pro	Gly	Asn	Cys	Gly	Glu	Tyr	Val	Val	Arg	Trp	Tyr	Tyr	Asp	Lys	
				80					85					90	
Gln	Val	Asn	Ser	Cys	Ala	Arg	Phe	Trp	Phe	Ser	Gly	Cys	Asn	Gly	
				95					100					105	
Ser	Gly	Asn	Arg	Phe	Asn	Ser	Glu	Lys	Glu	Cys	Gln	Glu	Thr	Cys	
				110					115					120	

Ile Gln Gly

<210> 17
 <211> 983
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1911808CD1

<400> 17															
Met	Ala	Pro	Arg	Leu	Gln	Leu	Glu	Lys	Ala	Ala	Trp	Arg	Trp	Ala	
1				5					10					15	
Glu	Thr	Val	Arg	Pro	Glu	Glu	Val	Ser	Gln	Glu	His	Ile	Glu	Thr	
				20					25					30	
Ala	Tyr	Arg	Ile	Trp	Leu	Glu	Pro	Cys	Ile	Arg	Gly	Val	Cys	Arg	
				35					40					45	
Arg	Asn	Cys	Lys	Gly	Asn	Pro	Asn	Cys	Leu	Val	Gly	Ile	Gly	Glu	
				50					55					60	
His	Ile	Trp	Leu	Gly	Glu	Ile	Asp	Glu	Asn	Ser	Phe	His	Asn	Ile	

```

Tyr Gly Gln Leu Ile Leu Thr Pro Tyr Gly Tyr Thr Lys Asn Lys
230 235 240
Ser Ser Asn His Pro Glu Met Ile Gln Val Gly Gln Lys Ala Ala
245 250 255
Asn Ala Leu Lys Ala Lys Tyr Gly Thr Asn Tyr Arg Val Gly Ser
260 265 270
Ser Ala Asp Ile Leu Tyr Ala Ser Ser Gly Ser Ser Arg Asp Trp
275 280 285
Ala Arg Asp Ile Gly Ile Pro Phe Ser Tyr Thr Phe Glu Leu Arg
290 295 300
Asp Ser Gly Thr Tyr Gly Phe Val Leu Pro Glu Ala Gln Ile Gln
305 310 315
Pro Thr Cys Glu Glu Thr Met Glu Ala Val Leu Ser Val Leu Asp
320 325 330
Asp Val Tyr Ala Lys His Trp His Ser Asp Ser Ala Gly Arg Val
335 340 345
Thr Ser Ala Thr Met Leu Leu Gly Leu Leu Val Ser Cys Met Ser
350 355 360
Ileu Leu

```

```

<210> 16
<211> 123
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 1786774CD1

```

```

<400> 16
Met Ser Gly Glu Glu Leu Ser Glu Ser Thr Pro Glu Pro Gln Lys
1 5 10 15
Glu Ile Ser Glu Ser Leu Ser Val Thr Arg Asp Gln Asp Glu Asp
20 25 30
Asp Lys Ala Pro Glu Pro Thr Trp Ala Asp Asp Leu Pro Ala Thr
35 40 45
Thr Ser Ser Glu Ala Thr Thr Thr Pro Arg Pro Leu Leu Ser Thr
50 55 60
Pro Val Asp Gly Ala Glu Asp Pro Arg Cys Leu Glu Ala Leu Lys
65 70 75
Pro Gly Asn Cys Gly Glu Tyr Val Val Arg Trp Tyr Tyr Asp Lys
80 85 90
Gln Val Asn Ser Cys Ala Arg Phe Trp Phe Ser Gly Cys Asn Gly
95 100 105
Ser Gly Asn Arg Phe Asn Ser Glu Lys Glu Cys Gln Glu Thr Cys
110 115 120
Ile Gln Gly

```

```

<210> 17
<211> 983
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 1911808CD1

```

```

<400> 17
Met Ala Pro Arg Leu Gln Leu Glu Lys Ala Ala Trp Arg Trp Ala
1 5 10 15
Glu Thr Val Arg Pro Glu Glu Val Ser Gln Glu His Ile Glu Thr
20 25 30
Ala Tyr Arg Ile Trp Leu Glu Pro Cys Ile Arg Gly Val Cys Arg
35 40 45
Arg Asn Cys Lys Gly Asn Pro Asn Cys Leu Val Gly Ile Gly Glu
50 55 60
His Ile Trp Leu Gly Glu Ile Asp Glu Asn Ser Phe His Asn Ile

```

1	5	10	15
Pro Gly His Pro Arg	Lys Arg Ala Gly Arg	Asn Glu Pro Leu Lys	
20	25	30	
Lys Glu Arg Leu Lys	Trp Lys Ser Asp Tyr	Pro Met Thr Asp Gly	
35	40	45	
Gln Leu Arg Ser Lys	Arg Asp Glu Phe Trp	Asp Thr Ala Pro Ala	
50	55	60	
Phe Glu Gly Arg Lys	Glu Ile Trp Asp Ala	Leu Lys Ala Ala Ala	
65	70	75	
Tyr Ala Ala Glu Ala	Asn Asp His Glu Leu	Ala Gln Ala Ile Leu	
80	85	90	
Asp Gly Ala Ser Ile	Thr Leu Pro His Gly	Thr Leu Cys Glu Cys	
95	100	105	
Tyr Asp Glu Leu Gly	Asn Arg Tyr Gln Leu	Pro Ile Tyr Cys Leu	
110	115	120	
Ser Pro Pro Val Asn	Leu Leu Leu Glu His	Thr Glu Glu Glu Ser	
125	130	135	
Leu Glu Pro Pro Glu	Pro Pro Pro Ser Val	Arg Arg Glu Phe Pro	
140	145	150	
Leu Lys Val Arg Leu	Ser Thr Gly Lys Asp	Val Arg Leu Ser Ala	
155	160	165	
Ser Leu Pro Asp Thr	Val Gly Gln Leu Lys	Arg Gln Leu His Ala	
170	175	180	
Gln Glu Gly Ile Glu	Pro Ser Trp Gln Arg	Trp Phe Phe Ser Gly	
185	190	195	
Lys Leu Leu Thr Asp	Arg Thr Arg Leu Gln	Glu Thr Lys Ile Gln	
200	205	210	
Lys Asp Phe Val Ile	Gln Val Ile Ile Asn	Gln Pro Pro Pro Pro	
215	220	225	

Gln Asp

<210> 19

<211> 403

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Inocyte ID No: 2323917CD1

<400> 19

Met Glu Lys Ser Gln	Lys Ile Asn Pro Phe	Ile Leu His Ile Leu	
1	5	10	15
Gln Glu Val Asp Glu	Glu Ile Lys Lys Gly	Leu Ala Ala Gly Ile	
20	25	30	
Thr Leu Asn Ile Ala	Gly Asn Asn Arg Leu	Val Pro Val Glu Arg	
35	40	45	
Val Thr Gly Glu Asp	Phe Trp Ile Leu Ser	Lys Ile Leu Lys Asn	
50	55	60	
Cys Leu Tyr Ile Asn	Gly Leu Asp Val Gly	Tyr Asn Leu Leu Cys	
65	70	75	
Asp Val Gly Ala Tyr	Tyr Ala Ala Lys Leu	Leu Gln Lys Gln Leu	
80	85	90	
Asn Leu Ile Tyr Leu	Asn Leu Met Phe Asn	Asp Ile Gly Pro Glu	
95	100	105	
Gly Gly Glu Leu Ile	Ala Lys Val Leu His	Lys Asn Arg Thr Leu	
110	115	120	
Lys Tyr Leu Arg Met	Thr Gly Asn Lys Ile	Glu Asn Lys Gly Gly	
125	130	135	
Met Phe Phe Ala Ala	Met Leu Gln Ile Asn	Ser Ser Leu Glu Lys	
140	145	150	
Leu Asp Leu Gly Asp	Cys Asp Leu Gly Met	Gln Ser Val Ile Ala	
155	160	165	
Phe Ala Thr Val Leu	Thr Gln Asn Gln Ala	Ile Lys Ala Ile Asn	
170	175	180	
Leu Asn Arg Pro Ile	Leu Tyr Gly Glu Gln	Glu Glu Ser Thr Val	
185	190	195	

```

Leu Asn Glu Asp Tyr Lys Thr Val Asn Asn Leu Leu Lys Ala Ala
575 580
Val Lys Gly Ser Asp Gly Phe Trp Val Gly Lys Ser Ser Leu Arg
590 595
Ser Trp Arg Gln Leu Ala Leu Glu Gln Leu Asp Glu Gln Asp Gly
605 610
Asp Ala Glu Gln Ser Asn Gly Lys Met Asn Gly Ser Thr Leu Asn
620 625
Lys Asp Glu Ser Lys Glu Glu Arg Lys Glu Glu Glu Glu Leu Asn
635 640
Phe Asn Glu Asp Ile Leu Cys Pro His Gly Glu Leu Cys Ile Ser
650 655
Glu Asn Glu Arg Arg Leu Val Ser Lys Glu Ala Trp Ser Lys Leu
665 670
Gln Gln Tyr Phe Pro Lys Ala Pro Glu Phe Pro Ser Tyr Lys Glu
680 685
Cys Cys Ser Gln Cys Lys Ile Leu Glu Arg Glu Gly Glu Glu Asn
695 700
Glu Ala Leu His Lys Met Ile Ala Asn Gln Gln Lys Thr Ser Leu
710 715
Pro Asn Leu Phe Gln Asp Lys Asn Arg Pro Cys Leu Ser Asn Trp
725 730
Pro Glu Asp Thr Asp Val Leu Tyr Ile Val Ser Gln Phe Phe Val
740 745
Glu Glu Trp Arg Lys Phe Val Arg Lys Pro Thr Arg Cys Ser Pro
755 760
Val Ser Ser Val Gly Asn Ser Ala Leu Leu Cys Pro His Gly Gly
770 775
Leu Met Phe Thr Phe Ala Ser Met Thr Lys Glu Asp Ser Lys Leu
785 790
Ile Ala Leu Ile Trp Pro Ser Glu Trp Gln Met Ile Gln Lys Leu
800 805
Phe Val Val Asp His Val Ile Lys Ile Thr Arg Ile Glu Val Gly
815 820
Asp Val Asn Pro Ser Glu Thr Gln Tyr Ile Ser Glu Pro Lys Leu
830 835
Cys Pro Glu Cys Arg Glu Gly Leu Leu Cys Gln Gln Gln Arg Asp
845 850
Leu Arg Glu Tyr Thr Gln Ala Thr Ile Tyr Val His Lys Val Val
860 865
Asp Asn Lys Lys Val Met Lys Asp Ser Ala Pro Glu Leu Asn Val
875 880
Ser Ser Ser Glu Thr Glu Glu Asp Lys Glu Glu Ala Lys Pro Asp
890 895
Gly Glu Lys Asp Pro Asp Phe Asn Gln Ile Met His Ala Phe Ser
905 910
Val Ala Pro Phe Asp Gln Asn Leu Ser Ile Asp Gly Lys Ile Leu
920 925
Ser Asp Asp Cys Ala Thr Leu Gly Thr Leu Gly Val Ile Pro Glu
935 940
Ser Val Ile Leu Leu Lys Ala Asp Glu Pro Ile Ala Asp Tyr Ala
950 955
Ala Met Asp Asp Val Met Gln Val Cys Met Pro Glu Glu Gly Phe
965 970
Lys Gly Thr Gly Leu Leu Gly His
980

```

<210> 18

<211> 227

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1973875CD1

<400> 18

Met Gly Asn Cys Val Gly Arg Gln Arg Arg Glu Arg Pro Ala Ala

<400> 53
 ggcctgggttgg gcgcggtcc tctgctgccc cggcccggtg caggccctgc cgcgagccgc 60
 aggtgtctctg ggtctctggc caggacctgg cccacacagg gtcccagcag ggttagctcc 120
 tcccgggaca aggaccgag tgogacggto agtngttoag tgcocatgoc tcttggaggg 180
 aaaggaagcc atcttctatc tacacccacg agggctccca accgctgat ccacgagaag 240
 tccacatacc tccataaca tgcctacaat cctgtgact ggtacccctg gggagagaaa 300
 gctctcgaca aggccaggca ggaacaacag cggatttcc tctcagtcgg gtactccacc 360
 tgcactgggt gccacatgat ggaagaggag bcttccaga atgaggagat tggccgctg 420
 ctcagtggg actttgtgag tgtgaaggta gaccgtgagg agcggcctga cgtggacaaq 480
 gtgtacatga cgttctgtga ggcacccagg agcggcgggg gctggcccat gaatgtgtgg 540
 ctgaactcca acctccagcc otttgtcggg ggcacatatt tccctcctga ggttggcttg 600
 acccgagtcg gcttccgac agtjttgtcty agaatccag aacagtggaa acagaacaag 660
 aacacccctg tagaaaatag ccagcgtgtc accactgccc tgetggcccg atcagagatc 720
 agcgtgggtg accgccagct gccgcctctt gccgccaccg tgaacaatcg ctgcttccag 780
 cagctggatg aggcctatga tgaggatata gcttgcttcc ctgaggcccc caagtctccc 840
 accgctgtga tcttgagctt cctgttctcc tactggctca gccatcgact gactcaggat 900
 ggcctctggg cccagcagat ggccttgcct accctgaaa tgatggctaa cgggggcatc 960
 cgggaccatg tggggcaggg ctttccaccg tactccacag accgccagtg cccgtccct 1020
 cactttgaga agatgtctta tgaacaggca cagtctgtg tggcctattc gacgtctctc 1080
 cagcttctctg gtgatgaatt ctactctgac tgggcccagg gtaoctgga gtaoctggct 1140
 cggagcttga gccacccgtc cggaggcttc tatagcgag aagatgcaga ctgcgccca 1200
 gaggggggcc agcggcccaa agaggggccc tactatgtgt ggaaggtcaa agaggttcag 1260
 cagcttctcc cygagcctgt gttgggttgc acccgagccc tgacctcagg ccagctctcc 1320
 atgaagcact acggcctccc agaggctggg aacccagccc ccagtcagg ccacagggg 1380
 gagctgcagg gccagaatgt gctgaccgtc cggctactcg ttgctcaatt caggcttga tgetgccc 1440
 bttggcttgg atgtggaggc cgtgaggacc ttgctcaatt caggcttga tgetgccc 1500
 caggcccgga agcatcgccc caagccgcac ctggacagca agatgctggc tgcctggat 1560
 ggttctgatg tctcaggtca tgettctgac ggggctgtcc tgggccaaga caggtctgac 1620
 aactatgcca ccaatgttgc caagtctctg aagcgccaca tgtttgatgt ggcagttggc 1680
 cgcctgttgc ggacctgcta caccggcctt ggggggactg tggagcacag ccccccacc 1740
 tcttgggggt tcttggagga ctacgccttc gttgtgggg gctctgccc gcttgcctga 1800
 gctccacagg agagtgggtg gctcaggttg gctctgccc gctctgccc gctctgccc 1860
 ctcttcttgg actcccaggg tggcggctac ttcttcauty aggtgagct ggggcttggc 1920
 ctgcccctgc gtctgaagga gaccacaggat ggagcagagc ccagcgccaa ttcgctgta 1980
 gcccacacac tgcctcgggt tgatcgctt tcccgagccc aggactggat ggcacaggt 2040
 gtgtgctat atgttccgg cctctcagc ccccgagccc agatcgctg tctcggtggc 2100
 atgttccgg cctctcagc ccccgagccc agatcgctg tctcggtggc 2160
 cgtcagggca aggacaccaa ggccttgggt cagtggg lcc acttctgctc 2220
 aaggtgtctg ttctggctga tggggacccc tggagcttcc tgtcccgcca caltcttacc 2280
 ctgagtaacc tccgagctgt ggaagagcag gccantgcat atgtgtgtga gctgcccct 2340
 tgcctagttc tccctgagaa tccctgagaa tctacatoc tactacatoc 2400
 caacccctct ggggtggggc agaaggtgaa tgactagaga ctcagggcct 2460
 gcaggggccc atagaacctg tggccatccc gaccccccag gactcgggc 2520
 atctcactg cccctcttgg gacccactc accctagaat aaacttaac 2580
 gtaaaaaaa aaaaaaa 2597

<210> 54
 <211> 2385
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Inocyte ID No: 5583922CB1

<400> 54
 gaccgacccg ccaaccgccc tagcccgccc gccctgggca ctcaatcccc gccatgttgg 60
 ggcctcctgt cgccttggcc gcttctggcc cggccctggg ccccgctctg ggggccccca 120
 ggaactcgtt gctgggctct ggcagccccc ggaccaccaa ggtccacggc tgcgccagg 180
 ccttgcctag cagcccgcca cagccgcccg cggagacagc taacgggacc tcagaaagc 240
 atgtccggat tccagttatc aagaagaaaa aggtcattat gaagaagcgg aaggaagctaa 300
 ctctaaactc cccacaccca ctggtgactg ccgggcccc tgtgaccccc actccagcag 360
 ggaactctga ccccgctgag aaacaaagaaa caggtcttcc tcttgggtt cttggaccac 420
 tgcagatttc agatagccgg cttgagggcat ccagcagcca gtcctttggg ctgggagc 480
 accagagacg gctcaacatt cagtcagggc tggaggacgg cgalctatat gctggagctc 540
 ggtgtgtctg gtagcaggac gccgatccat ggtttcagggt ggacgctggg cacccccacc 600
 gcttctcggg tgttatccaa cagggcagta actctgtcty gaggatagac tgggtccact 660

catacaaggt	ccagttcagc	aatgacagtc	ggacctggty	gggaagttagg	uacacacaga	720
gtgggatgga	cgcaqtattt	cctgccaatt	cagaaccaga	aactccagtg	ctgaacctcc	780
tgccggagcc	ccaggtggcc	cgtttcattc	gcctgctgcc	cnagacctgg	ctccagggag	840
gcgcgccttg	cctccgggca	gagatccctg	cctgcccagt	ctcagacccc	aalgacctat	900
tccttgaggc	ccttgctgcg	ggatccctct	acctctctaga	ctttcagcat	cacaattaca	960
ggcccatgag	gaagctgatg	aagcaggtat	aagagcaalg	ccccacatc	acccgcctct	1020
acagcattgg	gaagagctac	cagggcctga	agctgtatgt	gatggaaatg	tccgacaagc	1080
ctggggagca	tgagctgung	gagcctgag	tgccttaagt	ggctggcatg	catggggaag	1140
agpccctggg	gogggagttg	cttctgctcc	tgatgcagtt	cctgtgccat	gagttcctgc	1200
gaggggaacc	acgggtgacc	cggctgctct	ctgagatggg	cattccactg	ctgcctctca	1260
tgaaacctga	tggtatagag	atgcctaac	acgggggttc	agagctggty	ggctgggcog	1320
agggcgcgtg	gaacaacctg	agcatcgatc	tbaaccataa	ttttgctgac	ctcaccacac	1380
actgtgggga	agcacaggac	gatgggaaag	tgcaccacat	cgtcccaaac	catcacctgc	1440
cattgcccac	ttactacacc	ctgcccactg	ccacctgggc	tectgaaacg	cgggcagtaa	1500
tcaggtggat	gaagcggatc	ccclttgtgc	taagtgcaca	cctccacggg	ggtgagctcg	1560
tggtgtccta	cccattcgac	atgactcgca	ccccgtgggc	tgcccgcgag	ctcagcccca	1620
caccagatga	tgatgagttt	cgtctggtca	gcactgtcta	tgtctggcag	aatctggcca	1680
tgccaggacac	cagcgcgcga	cctgcccaca	gccaggactt	ctccgtgcac	ggcaacatca	1740
tcaacggggc	tgacttggca	acggtccccc	ggagcatgaa	tgacttcaag	taacctacaa	1800
ccactgctt	tgaggtcact	gtggagctgt	cctgtgacaa	gttccctcac	gagaatgaat	1860
tgccccagga	gtgggagaa	acacaaagag	cctctctcac	ctacctggag	caggtgagca	1920
tgggcattgc	aggaagtggg	agggacaagg	acacggagct	tgggattgct	gacgctgtca	1980
ttgcctggga	tgggattaac	catgacgtga	ccacggcgtg	gggcggggat	tattggcgtc	2040
tgctgacccc	aggggactac	atggtgactg	ccagtgcoga	gggtaccat	tcagtgcac	2100
ggaactgtcg	ggtcaccttt	gaagaggggc	ccttccctcg	caetttcgtg	ctcaccaga	2160
ctcccaaac	gaggtgtgcg	gagctgctgg	cagctggggc	caaggtgccc	coggaccttc	2220
gcaggcgct	ggagcggcta	aggggacaga	aggattgata	cctgcggttt	aagagcccta	2280
gggcaggctg	gacctgtcaa	gacgggaag	ggtagatag	agaggtgagg	acaaagtga	2340
gaaaggtg	tcattaaagc	tacggggcac	cttaaaaaa	aaaaa		2385